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Abstract 
 
About 30–40% of all drugs currently in the market place target G-protein coupled 
receptors, however of the 900 plus GPCRs predicted to exist only about 30 are targeted 
by approved drugs. Two novel human GPCRs were investigated in this thesis, namely 
protease-activated receptor 2 (PAR2) and C3a receptor (C3aR). These membrane-
bound receptors are implicated in a variety of diseases in which inflammation is a 
common component, making them attractive targets for drugs that can treat such 
disorders. This thesis describes the rational design, synthesis and in vitro assay of 
ligands targeting these two GPCRs and they will become useful probes for 
investigating the pathology of inflammatory disorders and may lead to possible future 
treatments.  
Chapter 1 of this thesis summarises peptidic and non-peptidic ligands for protease-
activated receptor and C3a receptor reported in the literature to date, together with their 
known physiological effects. 
Chapter 2 examines structure-activity relationships for analogues of the only 
known potent PAR2 antagonist (GB88) discovered at IMB. The chemical features of 
GB88 were investigated separately by dividing the molecule into fragments, which 
were independently varied to study the effect of structure on agonist/antagonist 
function of the ligands. A potent and selective PAR2 agonist (132) was developed with 
EC50 of 0.4 µM in calcium release assays on HT29 cells. Agonist 132 has comparable 
agonist potency and better ligand efficiency to 2f-LIGRLO-NH2, which was previously 
the most potent PAR2 agonist prior to these studies. In addition, a new PAR2 
antagonist was developed (167), which was 2-fold more potent than GB88 in the 
calcium mobilisation assay.  
Chapter 3 describes the non-peptidic PAR2 agonist (GB110) and SAR studies for 
the truncation of this compound that led to the development of new PAR2 antagonists 
(192, 209, 211, 212). These ligands inhibited the activation of PAR2 induced by 1 µM 
2f-LIGRLO-NH2 with IC50 0.4–0.6 µM in the calcium release assay. 
Chapter 4 evaluates the anti-inflammatory properties of newly developed PAR2 
antagonists (133, 159, 167, 192 – from Chapters 2 & 3) in both in vivo and in vitro 
experiments. The most potent PAR2 antagonists (167 and 192) were stable in rat 
plasma and rat liver homogenates and were able to inhibit PAR2 activation induced by 
peptide agonist 2f-LIGRLO-NH2 as well as the endogenous activator, trypsin. These 
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antagonists have been demonstrated to be anti-inflammatory agents, inhibiting pro-
inflammatory cytokine release (IL6 and TNF-α) and were effective in relieving joint 
inflammation in rat models of arthritis.   
Chapter 5 explores various aromatic heterocycles that confer a turn conformation 
to ligands and this mimics the turn conformation observed for the C-terminus of C3a in 
its crystal structure. The study investigates how the hydrogen bonding capabilities of 
heteroatoms in each heterocycle affect the binding and functions of the ligands. 
Increasing the hydrogen bond acceptor properties of the heterocycle improves binding 
affinity for C3aR as demonstrated by imidazole and thiazole containing a heterocycle 
nitrogen. A potent and selective C3aR agonist (242, containing an imidazole ring) was 
generated with agonist potency comparable to the native peptide C3a. On the other 
hand, replacing the heterocycle with a thiophene ring, containing the non-hydrogen 
bond accepting sulfur, resulted in a potent C3aR antagonist (233) with IC50 80 nM 
(calcium mobilisation assay in HMDM).  
Chapter 6 investigates various guanidine mimetics and carboxylic acid bioisosteres 
to replace the basic arginine residue, in order to develop more drug-like agonists and 
antagonists for C3aR. Of all the guanidine mimetics investigated, the non-basic 
cyanoguanidine group retained most potency although the binding affinity was lowered 
by 8-fold. Furthermore the phenylsulfonamide moiety, which is known to be a good 
carboxylic acid bioisostere, was successfully utilised without significant loss in the 
potency. These arginine modified compounds, which conform to the reliable predictors 
of bioavailability such as “Lipinski’s rule of five”, are likely to show improved oral 
activity, however future studies are required to demonstrate this.  
Chapter 7 summarises all the key findings reported in Chapters 2–6 and indicates 
possible future directions in PAR2 and C3aR research.  
These studies have generated some potent agonists and antagonists for PAR2 and 
C3aR, that are now under patent examination, and have provided us with greater 
understanding of the structure-activity relationships of these ligands. These compounds 
will be valuable for interrogating the functions and physiological roles of these 
receptors in inflammatory diseases as well as other medical disorders.  
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1.1 Abstract 
 
Protease-activated receptors (PAR1, 2, 3, 4) and C3a receptor (C3aR) belong to 
the class A G-protein coupled receptor family. Proteins, synthetic peptides or small 
organic molecules are able to activate these receptors. Unlike other GPCRs, PARs 
have a unique mechanism of activation. The N-terminus of the receptor undergoes 
cleavage by serine proteases, such as trypsin or thrombin or tryptase, exposing a new 
N-terminal sequence (known as the tethered ligand, TL) which folds back, binds 
somewhere on the receptor and activates it. On the other hand, the C3a receptor is 
activated by a complement protein called C3a. Human complement component C3a 
is a 77-residue protein that binds to both a high affinity extracellular domain(s) and a 
low affinity transmembrane active site on C3aR. My research project has mainly 
focused on one PAR subtype, PAR2, and C3aR, which are potential drug targets for 
the treatment of inflammatory diseases. These receptors are expressed on 
inflammatory immune cells, such as mast cells, T cells, macrophages and neutrophils. 
So far the investigation of both physiological and pathological roles of PAR2 and 
C3aR has relied heavily upon synthetic peptide agonists, which lack potency, are 
unstable in vivo (cleaved by proteases) and have uncertain selectivity. This chapter 
outlines the mechanism of activation, physiological properties and all known ligands 
associated with PARs and C3aR reported in the literature to date. The primary goal of 
this research is the generation of potent new agonists and antagonists for PAR2 and 
C3aR.   
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1.2 Introduction 
 
G-protein coupled receptors (GPCRs) are a large family of integral membrane 
proteins, which mediate signal transduction from the cell surface to intracellular G 
proteins through endogenous extracellular ligands.1 GPCRs are divided into three 
main subfamilies: A, B and C, based on sequence similarity.2-3 It is estimated that as 
much as 3% of the human genome encodes GPCRs and that they are attractive targets 
for drug discovery. Some 30–40% of currently marketed drugs are suggested to target 
GPCRs.  These proteins each possess 7-membrane-spanning helices, 3 extra- and 3 
intra- cellular loops, an extracellular N-terminus and an intracellular C-terminus (e.g. 
Fig. 1.1).4 A short 8th helix appears to also exist on the intracellular side of the 
membrane.5 GPCRs are involved in a wide variety of physiological and 
pathophysiological processes, such as those that modulate cardiovascular, CNS, 
reproductive, metabolic, digestive, immuno-inflammatory, growth disorders and 
many others.6 
 
1.3 Protease-activated receptors 
 
Protease-activated receptors (PARs) are newly discovered members of the class 
A (rhodopsin-like) GPCRs family,7 and they are expressed in many types of cells, 
including endothelial and smooth muscle cells of the cardiovascular, respiratory and 
gastrointestinal systems. PARs are also expressed on cells in blood (including 
platelets), the immune system, the central nervous system (glial, astrocytes and 
neuronal cells) and in corneas, pancreas, liver, kidney, synovium, skeletal muscle and 
bone.8-9 Four sub-types of PARs have been discovered to date, PAR1, PAR2, PAR3 
and PAR4. 8 These receptors are activated by thrombin, trypsin or other serine and 
metallo proteases.8-11 
 
1.3.1 Mechanism of activation for PARs 
 
The mechanism of activation of PARs is quite different to other GPCRs. Most 
GPCRs are activated by the binding of an extracellular ligand, however PARs are 
self-activated when the extracellular N-terminus of a PAR is cleaved by a serine 
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protease at a specific site. This cleavage is followed by the binding of the newly 
exposed N-terminus (known as a tethered ligand) into conserved regions of 
extracellular loop 2 (ECL2) or in the transmembrane region of PARs (Fig. 1.1).12 The 
actual binding site has not yet been unambiguously determined. No specific function 
for the cleaved N-terminal fragment is known.8 PAR1 and PAR3 contain a Hirudin-
like sequence located further along the N-terminus from the cleavage site. It is known 
as hirudin because it resembles the leech anticoagulant hirudin domain. The 
negatively charged hirudin region on PAR1 and PAR3 is thought to bind to the 
positively charged region of α-thrombin, resulting in localisation of α-thrombin 
temporarily on the surface of the receptor for its subsequent activation.10 PAR2 on 
the other hand does not possess this thrombin-binding sequence. 
 
α β γ
COOH
Tethered Ligand
sequence NH2
Cleavage Site
G-proteins
Extracellular
Intracellular
ECL2
TM
1
TM
2
TM
3
TM
4
TM
5
TM
6
TM
7
Step 1
Step 2
 
Figure 1.1 The mechanism of activation of PARs. The tethered ligand (red), after 
exposure by protease-mediated cleavage (step 1), folds back onto conserved regions 
of extracellular loop 2 (ECL2, step 2) and/or a specific 7 transmembrane region to 
activate the receptor. 
  
After trypsin has cleaved the N-terminus of PAR2 (thrombin does not cleave 
PAR2, see Table 1.1), the tethered ligand sequence (SLIGRL- in rodent or SLIGKV- 
in human) binds to a site (currently unknown) on the receptor. The serine is thus the 
N-terminus of these activating N-termini in rodent and human PARs. Interestingly, 
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these hexapeptides (when untethered) also activate the receptor at µM concentrations 
compared to nM concentrations when tethered to PAR2.13-14 
 
Table 1.1 Properties of the four sub-types of Protease-Activated Receptors.12 
Property PAR1 PAR2 PAR3 PAR4 
Selective Enzyme 
Activator 
Thrombin Trypsin Thrombin 
Thrombin & 
Trypsin 
Other enzyme activators 
Trypsin, mast 
cell tryptase 
Mast cell 
tryptase 
- - 
Cleavage site (human) Arg41-Ser42 Arg36-Ser37 Lys38-Thr39 Arg47-Gly48 
Tethered ligand sequences 
SFLLRN (h), 
TFRIFD (x), 
SFFLRN (m,r) 
 SLIGKV (h), 
SLIGRL (m,r), 
TFRGAP (h), 
SFNGCP (m) 
GYPGQV 
(h), GYPGKF 
(m),  
h = human; m = mouse; r = rat; x = Xenopus   
 
1.3.2 Physiological and pathological roles of PAR2 
 
PAR2 is expressed in epithelial (e.g. lung, gastrointestinal tract),  endothelial 
cells, smooth muscle cells, fibroblasts, nerves and immune and inflammatory cells (T 
cells, monocytes, macrophages, neutrophils, mast cells and eosinophils).8-9 The 
activation of PAR2 is associated with many inflammatory diseases,15-17 as well as 
cancers,18-20 cardiovascular diseases,21-22 and asthma.23-24  Thus, PAR2 may be a 
putative new drug target for a number of diseases.  
There has been controversy about PAR2 activation being pro- and/or anti- 
inflammatory. The lack of potent and selective PAR2 agonists and antagonists 
available to study PAR2 activation in vitro and especially in vivo, has limited our 
understanding of the roles of PAR2 in inflammatory diseases.25 Activation of PAR2 
had been shown to induce release of inflammatory cytokines (IL6, IL8 and TNFα), 
anti-inflammatory mediators (PGE2 and NO) from a range of inflammatory and 
immune cells, and also found to induce prolonged joint swelling in rodents.12, 26-27 
Ferrell et al 26 reported that PAR2 was involved in mediating chronic inflammation 
(such as rheumatoid arthritis) by non-neurogenic mediators, possibly cytokines. 
PAR2 antagonists could potentially be useful as anti-inflammatory therapies.  
PAR2 has been implicated in various different forms of cancer as well. For 
example, Wilson et al showed that a type II transmembrane-bound serine protease 
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(TMPRSS2) was able to cleave and activate PAR2 in prostate cancer cells leading to 
tumor growth.28 Also, Darmoul et al suggested that trypsin was a potent growth 
factor for colon cancer cells by activating PAR2, subsequently also transactivating 
the epidermal growth factor receptor (EGF-R) leading to cell proliferation.29 
Recently, it was also reported in the literature that TF-fVIIa induced PAR2 activation 
leading to proliferation and migration of SW620 colon cancer cells.30 
 
Table 1.2 Roles of PAR2 in various physiological processes and inflammatory 
diseases.  
Diseases Phenomena caused by PAR2 activation References 
Colitis & 
Inflammatory 
bowel disease 
Induced colonic hyperaemia & bowel wall 
thickening. 
 
Increased intestinal wall thickness, caused 
granulocyte infiltration & bacterial translocation.  
 
Stimulated cytokine release (IL8) from colonic and 
gut epithelial cells. 
31 
 
 
32 
 
 
33 
Arthritis 
Stimulated growth, invasion & TNFα production. 
 
Induced joint swelling, synovial hyperemia, 
mechanical & thermal hyperalgesia.  
 
 
34 
 
26-27, 35 
Pancreatitis 
Mediated thermal hyperalgesia. 
 
Induced acinar cell injury and pancreatic oedema.  
36 
 
37-38 
 
Obesity & 
adipose 
inflammation 
Receptor activation by tissue factor VIIa promoted 
adipose tissue inflammation, insulin resistance and 
obesity.  
 
39 
Airway 
inflammation 
Stimulated secretion and production of IL6, IL8 in 
human peripheral blood eosinophils through 
mitogen-activated protein kinase/AP-1 pathway.  
 
Promoted infiltration of leukocytes, IgE response 
and methacoline-induced airway hyperreactivity.  
 
40 
 
 
 
41 
Cardiovascular 
diseases 
Promoted cardiac ischemia/reperfusion injury, 
hypotension and dilation of coronary arterioles.  
 
42-44 
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1.4 PAR-Activating Peptides 
 
1.4.1 PAR1-activating peptides (PAR1-APs) 
 
Most non-proteinaceous PAR agonists identified to date have been peptides 
corresponding to, or derived from, the tethered ligand (TL) sequence unique to each 
PAR. For example, the synthetic peptide corresponding to the TL sequence generated 
following cleavage of PAR1 between residues R41 and S42 (SFLLRN-NH2) 
activated this receptor with EC50 of 0.53 µM a calcium mobilisation assay using 
murine cells transfected with hPAR1.45 Structure-activity studies using synthetic 
peptide agonists with C-terminal amide caps and N-terminal free amino groups have 
identified key components important for potency and selectivity of these peptides. 
For example, these studies have shown that a minimum of 5 amino acids (e.g. 
SFLLR-NH2, EC50 0.49 µM) were required to activate PAR1, with truncation to 
tetrapeptides (e.g. SFLL-NH2) greatly reducing potency while dipeptides (e.g. SL-
NH2) were inactive.46-48 Acetylation or removal of the N-terminal amino group on the 
hexapeptides resulted in very low potency, while removing the N-terminal serine 
residue completely abolished potency, even when replaced with other charged or 
aromatic residues.47  
In addition, replacing phenylalanine at the second position of SFLLRN-NH2 with 
small residues, saturated rings, or aromatic groups other than those bearing electron-
withdrawing substituents, also reduced agonist potency.47 Furthermore, substitution 
of the fifth residue, arginine, with acidic amino acids sharply decreased the potency. 
Mao et al 49 and Vassallo and colleagues 50 also reported that phenylalanine and 
arginine at position 5 were the most important residues for PAR1 binding, while 
residues at positions 3 and 4 were only moderately important and can be replaced by 
other amino acids.49 Additionally, N-methylated amides or D-amino acids reduced 
potency, suggesting that amide NH protons and L-amino acids were important for 
receptor binding affinity.49 In summary, PAR1-activating peptides required a free 
amine group at the N-terminus, a small amino acid at position 1 (eg. serine, alanine, 
proline), an aromatic group at position 2 (eg. Phe preferably substituted with an 
electron-withdrawing group) and a basic residue (Arg/Lys) at position 5. One of the 
most potent reported PAR1-activating peptides that conforms to this general 
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description was H-Ala-Phe(p-F)-Arg-Cha-homoArg-Tyr-NH2 with EC50 of ∼10 nM 
(20-fold more potent than SFLLRN-NH2, EC50 200 nM) in a human blood platelet 
aggregation assay.47 
 
1.4.2 PAR2-activating peptides (PAR2-APs) 
  
Using a similar approach, PAR2-activating peptides (PAR2-APs) have been 
designed to mimic the natural tethered-ligand sequence from human (SLIGKV) and 
rodent (SLIGRL) receptors.51 The rodent hexapeptide sequence, SLIGRL-NH2 (2, 
Table 1.3), was reported to be 2-fold more potent than the human sequence, 
SLIGKV-NH2 (3), in a calcium mobilisation assay using a mouse lung 
myofibroblasts cells transfected with human PAR2.45 Table 1.3 lists some relevant 
peptides summarising their agonist responses. 
 
 SLIGRL-NH2 (2) 
 
As was observed for PAR1, a pentapeptide was the minimum length for agonist 
activity at low µM concentrations via PAR2.52 Substitution of serine at the N-
terminus with basic (4), acidic (5) or large hydrophobic residues like phenylalanine 
(6) reduced agonist activity. That study also showed that the N-terminal amino group 
was important, because acetylation (7–8) significantly decreased activity.45 In 
addition, although introduction of charged (9–10) or small amino acids (e.g. Ala (11), 
Gly (12)) at position 2 abolished activity, large residues such as cyclohexylalanine 
(Cha, 13) or phenylalanine (Phe, 14) or para-fluoro-phenylalanine (15–18) gave 
similar potency, but selectivity for PAR2 over PAR1 was lost. At position 3, Ile (2) 
and Cha (23) gave optimal agonist activity, while substitution with Ala (20) or Gly 
(21) or Phe (22) reduced the potency. 
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Table 1.3 Agonist activity of a diverse set of PAR1 and PAR2 synthetic peptides.45, 53-54  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assay conditions 
Compounds 1–33: calcium mobilisation assay on murine cells transfected with hPAR2 or hPAR1 
Compound 34: calcium mobilisation assay in rat KNRK cells expressing rat PAR2 
Compounds 35–38 = calcium mobilisation assay in HCT-15 cells. 
IA = inactive ; ND = not determined
Compound Peptide sequence
PAR-2 
EC50 (!M)
PAR-1 
EC50 (!M)
Compound Peptide sequence
PAR-2 
EC50 (!M)
PAR-1 EC50 
(!M)
1 SFLLRN-NH2 8.0 0.53 20 SLAGRL-NH2 20 IA
2 SLIGRL-NH2 5.7 IA 21 SLGGKV-NH2 31.2 IA
3 SLIGKV-NH2 11.8 IA 22 SLFGRL-NH2 27 IA
4 Orn-LIARK-NH2 IA IA 23 SL-Cha-ARL-NH2 4.2 IA
5 DLIARK-NH2 IA IA 24 SLIARK-NH2 4.4 IA
6 FLIGKV-NH2 IA IA 25 SL-Cha-Cha-RL-NH2 35.4 12.1
7 Ac-SLIGRL-NH2 IA IA 26 SLIGFL-NH2 8.3 IA
8 Ac-SLIGKV-NH2 IA IA 27 SLIGFV-NH2 7.4 IA
9 SDIGFL-NH2 IA IA 28 SLIGRA-NH2 5.6 IA
10 SKIGFL-NH2 IA IA 29 SLIGRY-NH2 5.3 IA
11 SAIGRL-NH2 IA IA 30 S-(D-Leu)-IGKV-NH2 IA ND
12 SGIGKV-NH2 IA IA 31 SL-(D-Ile)-GKV-NH2 IA ND
13 S-Cha-IGKV-NH2 15.2 65 32 SLIG-(D-Lys)-V-NH2 40 ND
14 SFIGKV-NH2 12.8 13.5 33 trans-cinnamoyl-LIGRLO-NH2 ~5 ND
15 S-pFPhe-IGRL-NH2 7.4 2.2 34 2-furoyl-LIGKV-OH 1.7 IA
16 S-pFPhe-Cha-Cha-RK-NH2 2 0.11 35 2-furoyl-LIGRL-OH 1.2 IA
17 S-pFPhe-IARK-NH2 3.9 0.35 36 2-furoyl-LIGKV-NH2 0.32 IA
18 S-pFPhe-Cha-ARK-NH2 2 0.06 37 2-furoyl-LIGRL-NH2 0.25 IA
19 SL-Cha-GRL-NH2 18.6 IA 38 2-furoyl-LIGRLO-NH2 0.24 IA
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 At position 4, Gly could be replaced with Ala (24) but Cha (25) also activated 
PAR1. Instead of having arginine or other positively-charged residues at position 5, it 
was surprising that this position also tolerated large hydrophobic groups like 
phenylalanine (26–27), suggesting that a pocket, comprising an acidic residue 
surrounded by a hydrophobic region, might be located at the corresponding binding 
position in the receptor. It was also demonstrated that leucine at position 6 was less 
important, as substitution with many other amino acids having small/large aliphatic 
chains, aromatic, or charged residues and amide did not show any significant change 
in agonist potency.45 
These results supported a requirement for only 5 amino acids in a PAR2 agonist, 
and a significant decrease in potency was observed when Leu2, Ile3 or Lys5 in 
SLIGKV-NH2 was replaced with D-amino acids (30–32), indicating that 
stereochemistry was also important for binding to the receptor.45 This requirement 
was similar to results obtained for PAR1 APs.  
Vergnolle’s group reported that the hexapeptide trans-cinnamoyl-LIGRLO-NH2 
(33) gave similar PAR2 agonist potency to the native SLIGRL-NH2 (2),53 but with 
low selectivity for PAR2. It was reported that trans-cinnamoyl-LIGRLO-NH2 (33) 
was an agonist for an unidentified receptor in mediating vasoconstriction of murine 
arteries in vitro.55 Interestingly, Kawabata et al reported that a 2-furoyl (2f) moiety in 
place of serine at the N-terminus substantially increased PAR2-AP potency by 10-
fold (36–37).54 In addition, 2f-LIGRLO-NH2 (38, where O is ornithine) was 25 times 
more potent than SLIGRL-NH2 at inducing intracellular calcium release in both 
cultured human and rat PAR2-expressing cells, and remained selective for PAR2 
over PAR1.56  
It was reported that addition of a seventh residue such as isoleucine to the C-
terminus of SLIGRL-NH2 increased potency by ~6 fold and replacing the 6th residue 
leucine with aromatic groups increased potency further (Table 1.4).57 Compounds 
having unsubstituted phenylalanine (40), homophenylalanine (41), 4-pyridylalanine 
(42) or 3-pyridylalanine (43) at the 6th position (X) of heptapeptide were less potent. 
In contrast, introduction of para-substituted phenyl rings increased the potency by 
~2-fold, while meta-substitution generally gave less potent compounds, apart from 
compound 56.  
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Table 1.4 Agonist activity of C-terminal amidated heptapeptides SLIGR-X-I-NH2 
with varying X residue.57 
 
 
*Intracellular calcium release assay on HT29 cells. 
 
Hydroxy, nitro, cyano, chloro, t-butyl and iodo groups (44-49) were all tolerated 
at the para position while azido, diethylphosphonomethyl and carboxy groups (50-
52) reduced potency. This suggested that the size of the substituents on the ring may 
be important regardless of the electronic effects of these groups.  In addition, 
extending the alkyl chain connecting the α-carbon to the phenyl ring by inserting an 
additional methylene group (53) or replacing the amino acid side chain with a 
Compound X EC50 (µM)*
39 Leu 0.7
40 Phe 1.0
41 HomoPhe 1.8
42 4-Pyridyl-Ala 1.9
43 3-Pyridyl-Ala 1.1
44 Tyr 0.4
45 4-Nitro-Phe 0.4
46 4-Cyano-Phe 0.9
47 4-Chloro-Phe 0.5
48 4-t-Butyl-Phe 0.6
49 4-Iodo-Phe 0.6
50 4-Azido-Phe 2.5
51 4-Diethylphosphonomethyl-Phe 1.3
52 4-COOH-Phe 5.0
53 Homo-Tyr 3.0
54 4-Nitrophenoxy-Ala 2.8
55 3-Nitro-Tyr 1.4
56 3,4-Dichloro-Phe 0.3
57 3,4-Dimethoxy-Phe 1.3
58 3,4-Dinitro-Phe 1.4
59 3-Methoxy-Phe 3.3
60 3-Cyano-Phe 1.7
61 3-Benzothienyl-Ala 0.3
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phenoxy group (54) greatly reduced the agonist potency, suggesting limited space 
within the receptor binding pocket. Four compounds from this series (44, 45, 56, 61) 
were equipotent with 2f-LIGRLO-NH2 (38), which was the most potent PAR2 
agonist reported upon commencement of these thesis studies.  
It had been reported by Kawabata’s group that replacement of the first residue 
(serine) of SLIGRL-NH2 (2) with 2-furoyl (2f) group improved agonist potency by 
10-fold.54 Barry et al 57 later performed structure-activity relationship studies at this 
position by introducing different non-peptidic aromatic and aliphatic groups (Table 
1.5).  
 
Table 1.5 Agonist activity of various N-terminal capped heptapeptides, X-LIGRLI-
NH2.57 
 
*Intracellular calcium release assay on HT29 cells.  
 
Compound X EC50 (µM)*
62 2-Furanyl 0.16
63 2-Benzofuranyl 0.25
64 2-Naphthyl 0.36
65 2-Benzothienyl 0.37
66 2-Indolyl 0.59
67 1-Isoquinolyl 14.9
68 4-Biphenyl 15.8
69 Cyclohexyl 4.80
70 Isobutyl 10.3
71 Phenyl 0.80
72 2-Pyridyl 0.26
73 3-Pyridyl 0.22
74 2-Pyrazyl 0.29
75 2-Hydroxy-phenyl 1.60
76 5-Isoxazolyl 0.22
77 4-(2-Methyloxazolyl) 0.18
78 3-[5-(4-Methylphenyl)isoxazolyl] 4.30
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It was shown in previous SAR studies that replacing the 6th residue leucine of 
SLIGRL-NH2 with 4-nitrophenylalanine group (45, Table 1.4) improved potency.57 
Therefore, it was expected that substitution of Leu with a 4-nitrophenylalanine group 
on 2f-LIGRL-NH2 peptide (79) could also improve the potency. However no 
improvement was observed for 79.57 Instead, compound 79 showed similar potency 
to 2f-LIGRL-NH2 (37) with EC50 of 0.2 µM in an intracellular calcium release assay 
on HT29 cells.  Surprisingly, the Ile truncated peptide (80) gave similar potency to 79 
(EC50 0.2 µM), but it was reported previously that addition of a seventh residue 
(isoleucine) to the C-terminus of SLIGRL-NH2 (e.g. SLIGRLI-NH2) can increase 
potency by ~6 fold.57  
 
These results support the well accepted view that ligand binding fragments bind 
cooperatively, and are not always additive, because their protein targets adjust pocket 
sizes and residue locations in response to the ligand. This is the well known “induced 
fit” concept58 which was first reported by Koshland in 1958 and replaced the previous 
“lock and key” concept first proposed by Fischer in 1894.59 Essentially the “lock” and 
“key” are both flexible and changes to each cooperatively affect one another.  
Recently Boitano et al reported two peptides (2-aminothiazol-4-yl-LIGRL-NH2 
and 6-aminonicotinyl-LIGRL-NH2) with reported agonist activity comparable to that 
for 2f-LIGRLO-NH2 (38). The serine residue of SLIGRL-NH2 (2) was replaced with 
a range of heterocycles and the peptides that gave comparable potency to 2f-
LIGRLO-NH2 (38) were 2-aminothiazol-4-yl-LIGRL-NH2 (2-at-LIGRL-NH2) and 6-
aminonicotinyl-LIGRL-NH2 (6-an-LIGRL-NH2).60 This work really did not add to 
the previous report from Barry et al in which multiple heterocycles were examined as 
replacements for 2-furoyl.57 
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In summary, these key potency and selectivity findings for PAR2-APs indicated 
that, in terms of the activity of the rodent tethered ligand sequence (SLIGRL-NH2): 
Ser1 or small replacements like a small heterocycle enhanced PAR2-APs potency; 
Leu2 was optimally replaced with Cha, while aromatic residues gave similar potency 
but with diminished selectivity for PAR2 over PAR1; either Ile or Cha at the third 
position was optimal; Gly4 and Leu6 were not crucial for potency and can be 
substituted; Arg5 was possibly binding to a negatively-charged residue in PAR2, 
although substitution with large hydrophobic groups did not significantly reduce 
agonist potency, suggesting that this may be for affinity rather than agonist activity 
per se. It was also possible that Arg5 may be involved in a cation-π interaction with 
an aromatic residue (such as Phe or Tyr) in the binding pocket; addition of a seventh 
residue to the C-terminus may or may not improve potency, depending on the moiety 
at N-terminus. 
 
1.4.3 Non-peptidic and peptidomimetic PAR2 agonists 
 
Although some potent PAR2 peptide agonists have been developed, the typically 
poor bioavailability of these peptides have been a significant limitation for in vivo 
studies. To overcome this shortcoming, recent studies have attempted to develop non-
peptidic PAR2 agonists.8 For example, non-peptidic PAR2 agonists (81a–b) were 
reported in 2008 from a screen of over 250,000 drug-like compounds using a high 
throughput receptor selection and amplification technology (R-SAT) cell-based 
functional assay.61 
  
       AC-55541 (81a)          AC-98170 (81b)  AC-264613 (81c) 
 
While compound 81a was a full agonist (EC50 200–1000 nM, in cellular 
proliferation, phosphatidylinositol hydrolysis and Ca2+ mobilisation assays) of 
PAR2,62 compound 81b was a partial agonist with respect to intracellular Ca2+ release 
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in human PAR2 expressed in HEK293T cells. Further studies on the more potent 
agonist (81a) suggested that the methyl substituent on the hydrazone was crucial for 
agonist activity, since replacing it with hydrogen or larger alkyl groups significantly 
reduced agonist activity. Although this compound possessed good metabolic stability 
in human and rat microsomes, it was highly insoluble in aqueous phosphate buffer as 
well as organic solvents.61  
Superposition of compounds 81a and 81b led to identification of the more potent 
PAR2 agonist (81c) with an EC50 of 30–100 nM (same assay conditions for 81a). 
Structure-activity relationships studies on 81c indicated that meta substitution of the 
bromine was prefered, since ortho and para substitutions reduced activity by 50-fold. 
Also, the N-methylated hydrazone did not show any activity, suggesting that the NH 
proton may act as a hydrogen bond donor to PAR2. Importantly, both 81a and 81c 
were more potent agonists than the PAR2 activating peptide SLIGRL-NH2, and were 
selective for PAR2 over other PAR-subtypes. These molecules demonstrated good 
stability, but poor solubility,61-62 and the hydrazone was not a drug-like moiety as it 
was readily metabolised. 
Barry et al had found that truncation of 2f-LIGRLI-NH2 to two residues (X1-
X2), with a 2-furoyl cap at the dipeptide N-terminus maintained relatively good 
potency in the Ca2+ release assay performed on HT29 cells (Table 1.6).63 
 
Table 1.6 Single concentration agonist activity of “dipeptide” PAR2 agonists.63 
Compound  X1 X2 
% relative activity                
(50 µM) a 
82 Leu Ile 38 
83 Leu Cha 43 
84 Leu  Phe 22 
85 Leu Phe (p-F) 19 
86 Cha Ile 58 
87 Phe Ile 67 
88 Chg Ile 12 
a Ca2+ release assay on HT-29 cells, expressed as % Ca2+ efflux for 2f-LIGRLI-NH2. 
 
From the furoyl-dipeptide, optimisation of the 2nd and 3rd residues led to the 
findings of phenylalanine or cyclohexylalanine at position 2 and isoleucine at 
  16 
position 3 with the greatest potencies. However, compound 87 with Phe at position 2 
was not selective for PAR2 over PAR1, whereas 86 did retain PAR2 selectivity.  
Replacing serine at position 1 with small aromatic heterocycles improved potency. 
Therefore, the promising dipeptide analogue (2-furoyl-Cha-Ile-NH2, 86) was further 
optimised by replacing 2-furoyl with other small heterocycles. Pyrazole, isoxazole 
and methyloxazole were examined, leading to the most potent agonist (89) (EC50 1.0–
4.0 µM).63 The nitrogen of the isoxazole group in 89 may form a H-bonding 
interaction with the receptor that is responsible for the improved agonist activity.   
                             
   89        90 
Linking this fragment (89) to different groups (R, 90) generated a library of 
compounds with variable agonist/antagonist activities. One potent and selective 
agonist was 91 (also called GB110, EC50 0.28 µM), which was subsequently 
modified to develop PAR2 antagonists (see section 1.5.2).63 It was hypothesised that 
the “dipeptide” fragment (89) could be used to target ligands to PAR2, while C-
terminal appendages (R in 90) might influence agonist or antagonist activity. Such an 
approach led to several potent antagonists (described in section 1.5.2). 
 
 
 
  
     GB110 (91) 
 
1.4.4 PAR3 and PAR4-activating peptides 
 
Unlike other PAR subtypes, the synthetic tethered ligand sequences for PAR3, 
TFRGAP-NH2 (human) and SFNGGP-NH2 (murine), were not able to activate PAR3 
itself but did activate PAR1 and PAR2. It remains unclear why PAR3 was not 
activated by its own tethered ligand. It was proposed that the PAR3 tethered ligand 
may serve as a co-factor to regulate PAR1 signaling.64 As a result, PAR3 activating 
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peptides (PAR3-APs) that mimicked the natural tethered ligand were non-specific.65 
For example, TFRGAP-NH2 triggered hPAR1 and activated MAPK signaling. A 
selective PAR1 antagonist RWJ56110 was able to block the TFRGAP-induced 
MAPK activation. It was proposed that PAR3 may act as a co-factor to modulate 
PAR1 signalling.64 Also, it was shown that PAR3 human and murine tethered 
sequences activated PAR1 and PAR2, but not PAR3 in both Jurkat and over-
expressing HEK-293 cells, probably due to the identity of the T/S-F residues of 
PAR1 and PAR3-APs.66 
Similar to PAR1 and PAR2, PAR4 can be activated by peptides that mimic the 
tethered ligand sequences: GYPGQV-NH2 (human) and GYPGKF-NH2 (murine). 
Both of these peptides were selective and did not activate PAR1 or PAR2.67 A PAR4-
activating peptide: AYPGKF-NH2 was reported to be 10-fold more potent than 
GYPGKF and was almost equipotent as thrombin for PAR4 activation. It is by far the 
most potent PAR4-AP to date. SAR studies on this peptide revealed that substitution 
of the second residue (tyrosine) with alanine abolished the agonist response, while 
substitution with phenylalanine or p-fluorophenylalanine induced PAR1 and PAR4 
activation. Pro3 and Gly4 were found to be crucial for potency, as alanine substitution 
led to a significant decrease in agonist potency.68 
 
1.5 PAR Antagonists 
 
1.5.1 PAR1 antagonists 
 
PAR1 is thought to be the principal receptor for the serine protease thrombin, 
which is involved in thrombosis, inflammation, atherosclerosis and fibroproliferative 
disorders.69 Therefore, the development of PAR1 antagonists could potentially be 
beneficial in treating the above diseases. Antagonists for PAR1 were designed based 
on the SAR information of the PAR1 activating peptides. The first potent and 
selective PAR1 antagonist (BMS-200261, 92, IC50 ~ 20 nM for inhibition of 
SFLLRNP-NH2-induced platelet aggregation) was designed based on modifications 
of the potent pentapeptide agonist (S-pFPhe-p-guanidinoPhe-Leu-Arg-NH2, EC50 
~0.04 µM).70 The N-terminus of serine was systematically replaced with neutral 
hydrophobic secondary amide groups and resulted in partial agonists or antagonists. 
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Substitution of serine with a trans-cinnamoyl or 3-phenyl-2-propynoyl group gave 
potent antagonists. In addition, the antagonist potency was improved by introducing a 
positive charge at position 3 and extending the C-terminus with another arginine 
residue.70  
      
                              
 
 
 
 
 
 
 
 
In 1998, Johnson Pharmaceuticals71 developed azole compounds as PAR1 
inhibitors. N-terminal amines, an aromatic ring at the 2nd position, and a positive-
charged residue at the 5th position, were integrated into the structures, some of which 
had a heterocylic ring (e.g. thiazole or oxazole) between the 2nd and 3rd residue in 
order to constrain the peptide backbone. However the compounds showed only 
moderate potency (IC50 ~20 µM, inhibition of platelet aggregation induced by α-
thrombin).71 Later, they designed PAR1 antagonists de novo72 using a ‘three-point 
pharmacophore model’ (Fig. 1.2) based on distances between three important 
functional groups, i.e. the N-terminal ammonium group, the centre of the benzene 
ring of the 2nd residue, and the guanidino group on the Arg5.  
N
N N
NH3
8-20 Å
6-8 Å 6-18 Å
               
Figure 1.2 The ‘Three Point Pharmacophoric Model’ and the chemical structures of 
RWJ-56110 (93a, X=CH) and RWJ-58259 (93b, X=N).72   
 
These three key residues were attached to rigid scaffolds like 6-aminoindole. 
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RWJ-56110 (93a) was a potent and selective PAR1 antagonist (IC50 0.34 µM against 
thrombin; IC50 0.16 µM against SFLLRN-NH2, for the inhibition of platelet 
aggregation).72 It was selective, binding to PAR1 but not to PAR2, PAR3 or PAR4. It 
inhibited platelet aggregation stimulated by both thrombin and SFLLRN-NH2, but 
caused moderate hypotensive responses in guinea pigs at a dose of 7 mg/kg/i.v.72 An 
indazole was used to replace the indole moiety to give RWJ-58259 (93b),73 which 
showed similar selectivity and potency in inhibiting platelet aggregation as RWJ-
56110 (93a), but had higher binding affinity and no side effects in guinea pigs at a 
dose of 7 mg/kg/i.v.   
A few non-peptidic PAR1 antagonists have also been reported in the literature. 
The first was FR171113 (94),74 which was more potent (IC50 0.29 µM) than the 
peptide PAR1 antagonist 3-mercapto-propionyl-Phe-Cha-Cha-RNPNDKY, C186-65 
(15 µM) in inhibiting thrombin-induced platelet aggregation and it was a competitive 
antagonist for the PAR1 receptor. 
 
FR171113 (94) 
 
Another potent PAR1 antagonist 95 (IC50 0.6 µM, inhibition of platelet 
aggregation) was discovered by screening combinatorial libraries. Further modication 
by incorporating several constrained moieties led to piperidine derivative (96) with 
similar antagonist activity (IC50 0.5 µM). Reduction of the piperidine ring size and 
introduction of an oxygen atom to the ring (morpholine) substantially reduced the 
potency. However, introduction of a 5-membered ring (e.g. proline) substituted with 
OH or NH groups was tolerated, suggesting that the hydroxyl group on the piperidine 
ring in 96 could be a H-bond donor to, or acceptor for, a residue in PAR1.75 A novel 
isoxazole compound 97 (IC50 9 µM) was also discovered through library sceening, 
which was further optimised leading to the discovery of a 100-fold more potent 
antagonist 98 (IC50 0.09 µM, inhibition of platelet aggregation).76  
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  95                 96 
 
                                             
 97                                              98  
 
In 2004, Kawahara et al reported a very potent PAR1 antagonist, ER129614-06 
(99) with IC50 of 14 nM and 28 nM against thrombin and SFLLRN-induced platelet 
aggregation, respectively. This compound showed a dose-dependent antithrombotic 
effect in a guinea pig thrombosis model and was orally bioavailable.77  
 
 
                   ER-129614-06 (99) 
 
In 2009, two small molecule compounds (100b–c) were discovered as PAR1 
antagonists, inhibiting SFLLR-induced human platelet aggregation and showing 
antithrombotic activity in a rat model after i.v. or oral administration. Most 
importantly, these compounds did not present any bleeding side effects, which were 
often seen for other antiplatelet drugs.78  
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 100a    100b                100c 
 
Compound 100a was discovered after optimisation of a hit obtained from 
screening a library.78 The compound was further optimised by introducing various 
substituents and different substitution patterns on both phenyl rings. It was reported 
that substitution at the ortho-position of the styrene phenyl ring gave optimal activity 
compared to substitution at the meta or para-position. On the other hand, the 
aryl/benzylpiperazine phenyl ring could be replaced with heterocycles, saturated 
rings, or other substituted phenyl in particular a 3-chlorophenyl or 
cycloheptylcarbonyl, which slightly improved the antagonist potency.  As for the 
linker, the unsaturated carbon chain was favoured  compared to an alkane and alkyne. 
A few other piperazine derivatives were also introduced, such as 2,5-
dimethylpiperazine, piperazine-2-one, homopiperazine and 4-aminopiperidine, but 
none of these improved antagonist potency. Combining all the SAR information, a 
few analogues were synthesised and their antithrombotic potential in vivo was 
evaluated in an arteriovenous extracorporal shunt model in anesthetised rats. Both 
compounds 100b and 100c inhibited Ca2+ release (induced by 1 µM SFLLR-NH2 in 
CHO cells) by >90% at 10 µM concentrations and displayed potent antithrombotic 
effects in a rat shunt model. However, compound 100b displayed better activity after 
oral administration at 40 mg/kg (59%) compared to 1.25 mg/kg i.v. (28%), while 
compound 100c showed similar results (54% p.o. vs 58% i.v.) at the same doses as 
compound 100b. These two compounds were also highly selective for PAR1 and did 
not show any agonist activity at other PAR-subtypes.78 However, it was unknown 
which parts of the molecule contributed to the PAR1 selectivity. Nonetheless, these 
small molecules may also target other G protein-coupled receptors since piperazines 
are a common fragment in GPCR ligands. These compounds are also potentially 
substrates for Michael addition which may compromise development.  
High throughput screening of thioether compounds identified a “hit” compound 
which displayed 96% antagonism at 10 µM of 1 µM SFLLR agonist peptide in CHO 
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cells (Ca2+ assay). Further lead optimisation resulted in two compounds (101a–b) that 
showed strong antithrombotic activity in vivo. These two compounds were not 
metabolically stable against rat liver microsomes but were relatively stable against 
human liver microsomes.79 
 101a: X = H    101b: X = Cl  
 
The Schering-Plough Research Institute developed analogues of the natural 
product himbacine into potent orally active PAR1 antagonists. Compound 102a was 
the first orally active PAR1 antagonist with high potency (IC50 11 nM, PAR1 binding 
assay using purified human platelet membrane). Synthetic himbacine analogues were 
racemic mixtures.  After enantiomeric resolution by using a chiral HPLC column, the 
(+) enantiomer, which had opposite absolute stereochemistry to the natural product 
himbacine, showed 10 times greater potency than its (–) counterpart.80 Compound 
102a was further optimised to compound 102b (IC50 6.3 nM in binding assay using 
purified human platelet membrane), which had little activity in an  ex vivo  model of 
platelet aggregation in cynomolgus monkey, probably due to rapid clearance of the 
compound.81  To improve the inhibitory potency in the above ex vivo model, 102c 
was synthesised and it inhibited agonist-induced ex vivo platelet aggregation with Ki 
= 4.5 nM. Most importantly, this compound was orally active in monkeys (F = 
62%).82   
         
102a  102b    102c            102d             102e 
           (SCH530348, 
             Vorapaxar) 
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Structure-activity relationships studies around the vinyl pyridine region of 
himbacine (102d) led to the finding that substitution at the 5- or 6-position of the 2-
vinyl pyridyl ring was important for binding to PAR1.83 In addition, substitution of 
an aryl or a heteroaryl group at the 5th position was well-tolerated and also gave a 
reasonably favourable cLogP (3.7).83 Further optimisation at C-7 of the tricyclic 
motif improved in vivo metabolism profiles,84 and eventually led to a stable and 
orally active drug SCH530348 (102e, also known as Vorapaxar). The latter 
compound inhibited platelet aggregation for 24 hours (IC50 47 nM, thrombin-
induced; 25 nM, PAR1-AP-induced platelet aggregation) and was selective over 
other GPCRs including PAR2, PAR3 and PAR4. This compound succesfully 
progressed to phase-III clinical studies for acute coronary syndrome (ACS).85-86 
However, Vorapaxar (102e) recently failed the ACS studies due to a significantly 
increased risk of bleeding in patients, although recently this compound has been 
groomed for FDA registration with a warning label.87 
Other compounds in clinical development include compound E5555 (103, also 
called Atopaxar), which in addition to inhibiting PAR1, also inhibited platelet 
function through actions on PECAM-I, GP IIb/IIIa antigen, and activity with PAC-1, 
GPIb, thrombospondin, vitronectin receptor expression, and formation of platelet-
monocyte aggregates.88-89  
 
E5555 (103, Atopaxar) 
 
Atopaxar (103) was able to inhibit human platelet aggregation induced by 
thrombin (IC50 64 nM) and thrombin receptor activating peptide (IC50 31 nM). In 
addition, Atopaxar (103) also inhibited platelet aggregation in guinea pigs without 
prolonging bleeding times even at the highest dosage of 1000 mg/kg.90 Two phase II 
studies were recently performed on patients with acute coronary syndrome and 
coronary artery disease and demonstrated that Atopaxar was effective in platelet 
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inhibition.91-92 Atopaxar (103) will be tested in a larger group of patients in phase III 
to confirm the efficacy and safety of the drug. 
Early in 2012, a new PAR1 antagonist (104, ML161) was identified by high-
throughput screening of a large library of compounds. 104 was reported as an 
allosteric antagonist for PAR1 (IC50 0.26 µM), inhibiting platelet aggregation induced 
by PAR1 peptide agonist (SFLLRN-NH2) as well as thrombin. SAR studies revealed 
a few essential requirements contributing to the activity of this compound. A 3-
carbon chain at the left hand end of the molecule was optimal and intolerant to 
substitution with a phenyl ring. The 1,3-substitution pattern on the middle scaffold 
was preferred. For the phenyl ring at the right of the molecule, ortho substitution was 
more favorable and electron-withdrawing or neutral lipophilic groups were the 
prefered substituents. Additionally, the two amide bonds were essential for potency, 
as methylating either of the amide NHs led to inactive compounds.93  
 
     ML161 (104) 
 
1.5.2 PAR2 antagonists  
 
Currently, there are only a few PAR2 antagonists reported in the scientific 
literature. The first discovered PAR2 antagonist was ENMD-1068 (105), which was 
reportedly selective for PAR2 in vitro but only with low millimolar IC50 potency.27  
 
ENMD-1068 (105) 
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K-12940 (106) and K-14585 (107) were more recently discovered 
peptidomimetic PAR2 antagonists. While they did not antagonise endogenous PAR2 
activators like trypsin, they were competitive inhibitors of the binding of 
radiolabelled 3H-2f-LIGRL-NH2 to human PAR2, giving Ki values of 1.9 and 0.6 µM 
(NCTC2544-PAR2 cells) respectively and they were selective for PAR2 over other 
PARs. The inhibitory effects in an NFκB-luciferase reporter gene assay were also 
examined, giving IC50 2.9 and 1.1 µM respectively, in which the NCTC2544-PAR2 
cells were stimulated with SLIGKV-NH2. The inhibitory effects of these compounds 
were found to be concentration-dependent. SAR studies revealed that some moieties 
were strictly required for PAR2 antagonism: an N-terminal heteroaromatic urea, a 
basic amino side chain and hydrophobic groups at the C-terminus. These two 
compounds were water-insoluble due to high molecular weight and bulky 
hydrophobic groups.94 
 
K-12940 (106)           K-14585 (107) 
 
The more potent compound, K-14585 (107), was used to further investigate the 
mechanism of inhibiton in a number of intracellular signalling pathways. It was 
reported that K-14585 (107) had dual effects (agonism and antagonism) on certain 
signalling events, such as PAR2 mediated phosphorylation of ERK and p38 MAP 
kinase and Gq/11 pathways. At low-micromolar concentrations, this compound was 
able to inhibit distinct signalling parameters induced by SLIGKV-NH2, but it became 
an agonist at higher concentrations. For instance, K-14585 (107) was able to inhibit 
PAR2 mediated Gq/11–dependent pathways but it also activated Gq/11–independent 
events including activation of p38 MAP kinase. This phenomenon is called agonist-
directed signalling, also known as stimulus trafficking or biased agonism.95  
A natural diterpenoid from Tripterygium wilfordii Hook F, triptolide (108), used 
in Chinese medicine, inhibited (IC50 14 nM, in A549/NF-κB-luc cells) NFκB 
activation by 10 µM 2f-LIGRLO-NH296 but also inhibited substance P-induced 
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neurokinin receptor 1 (NK1) mediated production of IL8 (IC50 23 nM, in A549/Tacr1 
cells).96 Previous studies proposed this natural product for the treatment of arthritis 
and other inflammatory diseases,97-100 although it was toxic after oral administration 
to rats, some of which died.101 
 
 
108     109     GB88 (110) 
 
The morpholine compound (109, IC50 57 µM) and spiroindene derivatives 
(GB88, 110, IC50 1–2 µM in Ca2+ release assay) were derived from the non-peptidic 
PAR2 agonist (89, section 1.4.3), with the latter being the most potent PAR2 
antagonist.63, 102 GB88 (110) was a novel PAR2 antagonist with a bulky C-terminal 
spiroindenepiperidine.63, 102 It was the first PAR2 antagonist (IC50 ∼2 µM) to inhibit 
PAR2 activation reversibly by endogenous (e.g. trypsin), synthetic peptide (e.g. 2f-
LIGRLO-NH2) and nonpeptide (91) agonists at low concentrations and in multiple 
cell types.101 In addition, GB88 was a pathway-selective antagonist, inhibiting PAR2-
induced intracellular Ca2+ release, cAMP stimulation, receptor internalisation, and 
proinflammatory cytokine release without affecting PAR2 mediated ERK 
phosphorylation.103-104 It was also a surmountable (competitive) antagonist of 2f-
LIGRLO-NH2, but an insurmountable antagonist of both trypsin and PAR2 agonist 
91, making it a valuable PAR silencing tool for mechanistic studies. Furthermore, 
GB88 was serum stable and orally active and had been investigated for PAR2 
modulation in vivo in a range of animal models of human inflammatory and 
proliferative diseases. Given orally at 5 mg/kg/p.o. this antagonist inhibited rat paw 
oedema elicited by PAR2 agonists but not PAR1 agonists,102 and substantially 
inhibited collagen-induced arthritis in rats.105 However, GB88 (110) only showed 
potency at micromolar concentrations in all the in vitro assays and thus a high 
concentration of GB88 is required for inhibition. Development of more potent PAR2 
antagonists would therefore be extremely beneficial. More potent PAR2 ligands will 
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be useful in further characterizing PAR2 modulation in vitro and in vivo as a 
promising therapeutic target in inflammatory and other diseases.  
 
1.5.3 PAR4 antagonists 
   
PAR4 antagonist development has significantly lagged behind PAR1. Trans-
cinnamoyl-YPGKF (tc-YGPKF), a TL derived peptide, was first shown to prevent 
PAR4-AP and thrombin-mediated platelet aggregation and was also able to block 
platelet aggregation induced by AYPGKH-NH2, GYPGKF-NH2, as well as thrombin, 
at concentrations up to 400 µM.106 The most promising PAR4 antagonist developed 
to date was YD-3 (111) [1-benzyl-3(ethoxycarbonylphenyl)-indazole], which 
inhibited thrombin stimulated platelet aggregation in mice (IC50 21 µM). However, 
for human platelets it was able to block aggregation induced by GYPGKF-NH2 but 
not by thrombin.107-108 
 
 
YD-3 (111) 
 
1.6 Human Complement System and C3a Receptor 
 
Human complement plays a crucial role in the innate immune system to defend 
against infectious organisms (viruses/bacteria) as well as tissue injuries and cancers. 
The complement activation cascade is very complex, involving many soluble and 
membrane-bound proteins.109-111 Three major pathways are implicated in complement 
activation: classical, lectin and alternative pathways, as shown in figure 1.3. The 
classical and alternative pathways converged at C3, with two C3 convertases cleaving 
C3 to produce anaphylatoxin C3a and opsonin C3b, then C5 convertases cleaving C5 
to give anaphylatoxin C5a and C5b. The C5b fragment then joined C6-C9 to 
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MAC 
complete a membrane attack complex (MAC), which caused lysis and death of 
bacteria and infected cells.109, 112  
C3a and C5a are small proteins that bind to their respective anaphylatoxin 
receptors C3aR and C5aR, which are G protein-coupled receptors.  Similar to 
protease-activated receptor 2 described above, C3a receptor (C3aR) is also implicated 
in numerous inflammatory disorders such as asthma,113-114 arthritis,115-116 ischemia-
reperfusion injury117 118 and many others. There were also reports suggesting that C3a 
can be pro-inflammatory119-120 or anti-inflammatory.121-122  
The biological roles of C3a in diseases remain to be fully elucidated and there 
are no effective small molecules as selective and potent C3aR agonists and 
antagonists for studies in vivo. Therefore, development of potent agonists and 
antagonists targeting this receptor could provide valuable new tools for investigation 
of C3aR functions in various inflammatory processes and disease models.  
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Figure 1.3 Human complement cascade. Antigen/antibody complexes trigger the 
classical pathway and bacteria or foreign materials activate the alternative pathway. 
Both pathways merge at C3 leading to the formation of C3a and C3b and eventually 
the formation of the membrane attack complex that causes cell lysis.112 
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1.6.1 Mechanism of activation for C3aR 
 
Human anaphylatoxin C3a is a 77 amino acid protein that binds to its 
corresponding C3aR with high affinity.123 Common to other GPCRs, C3a receptor 
contains seven transmembrane helices but with a very large extracellular loop 2. 
Thislarge extracellular loop was proposed to interact with a helical region of C3a at 
Site 1 (Fig. 1.4), which is the non-effector binding site for C3a. A second binding site 
on C3aR, known as the effector binding site, was thought to possibly interact with the 
C-terminal sequence (LGLAR) of C3a within the transmembrane region of the 
receptor (Site 2, Fig. 1.4).  
 
Figure 1.4 Schematic for binding to C3aR. There are two binding sites on C3a, non-
effector (site 1) and effector sites (site 2). The C-terminus (LGLAR) sequence of C3a 
was thought to bind with low (mM) affinity to site 1 while other regions of C3a bind 
to the large extracellular loop of the receptor.112 
 
The guanidine and carboxylate groups on the C-terminal arginine residue were 
both reported to be crucial for activity,124 and may form electrostatic interactions with 
the receptor. In addition, site-directed receptor mutagenesis studies have suggested 
that charged residues Arg 161 (on helix 4), Arg 340 (on helix 5) and Asp 417 (on 
helix 6) in C3aR were important for binding. This also supported electrostatic 
interactions at this site being important for receptor activation. It have been proposed 
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that the guanidine group on Arg 77 of C3a may make a charged interaction with the 
carboxyl group on Asp 417 (from helix 6), while the carboxyl group on Arg 77 may 
interact with the guanidine group of either Arg 161 or Arg 340.125 
 
1.6.2 Physiological and pathological roles of C3aR 
 
The C3a receptor is expressed on many different cell types including immune 
and inflammatory cells (monocytes, neutrophils, macrophages, T cell, mast cell and 
eosinophils),126  epithelial,127 glia, neuron,128 astrocytes,129 and adipocytes130 cells. 
Depending on the disease mode, activation of C3aR can be either pro-inflammatory 
or anti-inflammatory and therefore drugs that either block or activate C3aR could 
both potentially have benefits for the treatment of various diseases depending upon 
the condition and cell type involved.  
 
Table 1.7 Roles of C3aR in various physiological processes and inflammatory 
diseases.  
Diseases Phenomena caused by C3aR activation References 
Arthritis 
Promoted joint swelling and expression of 
IL-1β in synovial tissue. 
 
115-116 
Renal inflammation 
Caused renal leukocyte infiltration, tubular 
dilation, and expression of CXC 
chemokines. 
131-132 
 
Obesity & adipose 
inflammation 
Promoted macrophage infiltration, secretion 
of pro-inflammatory cytokines, insulin 
resistance and increased body weight in 
mice model treated with high fat diet.  
130 
Dermatitis 
C3a-induced calcium fluxes in T-
lymphocytes isolated from birch pollen-
sensitised patients with atopic dermatitis. 
133 
Airway 
inflammation/asthma 
Promoted TH2 cytokine production, lung 
inflammtion and airway 
hyperresponsiveness.  
 
Stimulated the production of Th17 cytokines 
in RSV-infected wild-type mice. 
 
Mediated secretion of IL-23 and IL-17A  
134 
 
 
 
135 
 
 
136 
Cardiovascular 
diseases 
Caused inflammatory response in aortic 
valve myofibroblasts.  
 
Activated coronary plaques. 
137 
 
 
138 
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1.7 C3aR peptide agonists and antagonists 
 
The natural ligand for C3aR, anaphylatoxin C3a, is a 77-residue peptide. It had 
been demonstrated that a minimum sequence of 5 amino acid residues (LGLAR) at 
the C-terminus were essential for activity.139 This C-terminal pentapeptide is present 
in human,140 pig,141 rat142 and mouse143 C3a. However, a synthetic C-terminal 
octapeptide (C3a-(70–77), ASHLGLAR) showed much less biological activity (1–
2%) than the full length C3a (100%, activity for contraction of smooth muscle strips 
isolated from guinea pig ileum).139 Further studies also had shown that the activity 
was proportional to the length of the peptide.144 A C-terminal 21-residue peptide 
(C3a-(57–77)) had been shown to possess comparable agonist activity to native C3a 
(based on guinea pig ileal assays145).146 An α-helical conformation (41% helicity, in 
aqueous buffer containing 25% (v/v) TFE) was observed for this peptide and this 
may have contributed to the full activity of this peptide.146 In addition, amino acid 
substitution on this peptide with helix-enhancing amino acids, such as alanine, 2-
aminobutyric acid or 2-aminobutyric acid, increased the helicity and produced higher 
agonist activity than either native C3a or C3a-(57–77). Incorporating helix-breaking 
residues, such as proline, led to a reduction of potency. All of the above suggested 
that a secondary structure at the C-terminus was important for potency.146 Also, the 
C-terminal arginine residue was particularly important in C3a, since cleavage of this 
basic residue to give C3a-desArg by carboxypeptidase N, completely abolished the 
activity of C3a.147-148 
A series of N-terminal acylated peptides was reported about two decades ago, 
showing that capping the N-terminus with large complex aromatic groups like 
fluorenylmethoxycarbonyl (Fmoc) or naphthyl groups enhanced activity in an ATP 
release assay (in guinea pig platelet) compared to the non-acylated ones. The addition 
of an amino-hexyl (Ahx) linker between the aromatic cap group and the peptide 
sequence further improved activity by 2-fold.149 Later, a 15-residue peptide, having 
two tryptophan groups at the N-terminus (WWGKKYRASKLGLAR) was found to 
be a 15-fold more potent agonist than C3a in a guinea pig platelet assay. It was 
proposed that the hydrophobic group at the N-terminus bound to the non-effector site 
of C3aR, while the crucial LGLAR sequence might bind to the effector site. Both of 
these groups were important contributors to the potency of the peptide.150 
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A few pentapeptide analogues of LGLAR were synthesised and their 
anaphylatoxin activities were evaluated in a smooth muscle (guinea pig ileum) 
contraction assay.151 The results of these peptides showed that replacement of Leu-73 
in C3a with aromatic groups such as phenylalanine and tyrosine increased the smooth 
muscle contractions, and larger aliphatic groups (isoleucine or valine) were also 
tolerated with no significant loss of potency. As for Gly-74, substitution with polar 
amino acid residues (Ser, Gln, Glu) or slightly larger aliphatic residues (valine, 
isoleucine) reduced the potency. Therefore only a small group like glycine was 
tolerated at this position in C3a.151 In addition, proline was also tolerated as shown by 
the peptide WPLPR. The pentapeptide WPLPR was derived from Oryzatensin and 
showed some C3aR activating activity in ileum contraction assay.152-153 This peptide 
possessed guinea pig ileum-contracting activity, anti-analgesia and anti-amnesia 
properties when administered orally at 300 mg/kg.153 Leu-75 was substituted with 
alanine, valine, isoleucine, methionine and phenylalanine but all showed dramatic 
loss of activity, which implied that leucine was the optimal residue at this position. 
Similar to Leu-75, Ala-76 was also intolerant of substitution by other amino acids. It 
was replaced with proline, glutamine, serine and glycine but none of them was 
tolerated.151 The last residue arginine was crucial for activity. The carboxylic acid 
and guanidine groups of arginine can both make strong interactions with the C3a 
receptor at the effector site.124 Also, L-Arg was more favorable than the D-
enantiomer.151 
Recently, our group published a library of C3a hexapeptides with varying 
binding potencies and agonist/antagonist functions.154 These compounds were by far 
the most potent known small peptide agonists for human C3aR reported to date. The 
binding affinity and intracellular calcium release activity of these peptides were 
assayed using the human promonocytic cell line U937, which was differentiated with 
Bt2-cAMP.154 C3aR and C5aR are structurally similar to each other. They each 
contain an effector and a non-effector binding sites. Both the C-terminus of C3a and 
C5a showed a turn conformation.146, 154-158 Peptides that mimic the C-terminal 
sequence of C3a and C5a were quite similar so the potent C5aR peptide agonist, 
FKP(dCha)(Cha)R was modified by replacing the last three residues with the C3a C-
terminal sequence (LAR) to give the peptide FKPLAR, which activated C3aR with 
EC50 of 33 µM in a calcium release assay. Replacing lysine and proline with leucine 
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and threonine respectively resulted in a much more potent peptide agonist (FLTLAR, 
EC50 0.37 µM) that was selective for C3aR over C5aR.154 SAR studies around 
FLTLAR demonstrated that substitution of phenylalanine with tyrosine, 
homophenylalanine or capping the N-terminus with an acetyl group reduced the 
potency. The optimal fifth residue from the C-terminus was leucine and it could only 
be replaced by norleucine. Replacing threonine with glycine or serine displayed 
similar agonist activity but potency decreased 4-fold with alanine substitution. In 
addition, the LAR sequence was essential and could not be replaced with other amino 
acids. However, substitution of the leucine of LAR with cyclohexylalanine resulted 
in a peptide with antagonist activity in intracellular calcium release assays (IC50 1.5 
µM). This peptide, FLTChaAR, was selective for C3aR over C5aR in a 125I-
radiolabelled C3a binding assay and was an insurmountable antagonist. The 
carboxylic acid group on the arginine again proved to be important since amidation 
of the C-terminal acid reduced the potency.154  
Similar to the C-terminus of C3a, the most potent peptide agonist, FLTLAR, 
showed a turn-like or bend structure by proton NMR spectroscopy in DMSO 
solution, suggesting that a turn conformation might be important for binding to the 
C3a receptor.146, 154, 157 Although these peptides showed relatively good potency in 
binding to C3aR, they were not very drug-like and were likely degraded by proteases 
in vivo. Therefore, development of less peptidic molecules, perhaps incorporating a 
turn conformation, was anticipated to lead to the discovery of more potent and 
selective ligands for human C3aR.  
 
1.8 C3aR non-peptidic agonists and antagonists 
 
The most potent, non-peptidic C3aR antagonist reported to date is N2-[(2,2-
diphenylethoxy)acetyl]-L-arginine (SB290157, 113). This compound was discovered 
by high throughput screening of compounds from SmithKline Beecham.115 The first 
hit generated from the screening was compound SKF63649 (112) and further 
optimisation yielded SB290157 (113).  
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The binding affinities (IC50) of SKF63649 (112) and SB290157 (113) were 3000 
nM and 200 nM respectively, which were determined from 125I SPA binding assays 
using membranes from rat basophilic leukemia cells (RBL 2H3) expressing the C3aR 
(RBL-C3aR). Consistent with the binding assay results, the calcium release assay 
(with the same cell line) also showed that SB290157 (113, IC50 28 nM) was more 
efficient than SKF63649 (112, IC50 350 nM) in blocking the calcium response 
induced by 1 nM C3a. This compound also blocked the C3a induced-calcium release 
in RBL 2H3 cells expressing mouse and guinea pig C3aRs with low nanomolar 
antagonist potency. Also, SB290157 (113) was selective for C3aR over C5aR as it 
did not inhibit calcium release induced by C5a, nor indeed five other chemotatic 
GPCRs (leukotriene B4, fMLP, platelet-activating factor, CXCR1 and CXCR2) as 
well. SB290157 (113) was evaluated on whole cells (human monocyte-drived 
macrophages, Chapter 5) and it inhibited the calcium response induced by 100 nM 
(EC80) C3a with IC50 of 1.3 µM. In addition, this compound blocked the activating 
effect of C3a in a contractile response to field stimulation of the perfused rat caudal 
artery and inhibited C3a-induced ATP release from guinea pig platelets. In vivo 
experiments demonstrated that SB290157 (113) (at high doses – 30mg/kg/i.p.) was 
able to inhibit recruitment of neutrophils in a LPS-induced guinea pig airway 
neutrophilia model,115 reduced paw swelling and IL-1β secretion in a rat arthritis 
model.115-116 
However, SB290157 (113) had also been reported to show full agonist activity in 
other assays, especially for cells that had over-expression of C3aR. This compound 
showed comparable agonist potency to C3a in a calcium release assay using both 
human and mouse transfected RBL cells, and an enzyme-release assay in 
differentiated U937 cells.159 It also showed agonist activity in a β-lactamase assay in 
CHO-NFAT-bla-Gα16 cells although the agonist response was much lower than for 
C3a. For cells that had a low density of C3aR, such as guinea pig platelets, SB290157 
(113) behaved as a C3aR antagonist with negligible agonist activity.159 
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Constraining the alkyl ether chain of SB290157 (113) into a furan ring gave 
compounds with variable agonist/antagonist activities.160 Most of the furan analogues 
displayed relatively good binding to C3aR (pIC50 6.0–7.0) as determined by 125I-C3a 
binding assays with membranes prepared from HMC-1 cells. It is well known 
however that affinities for C3aR and C5aR in isolated membrane preparations are 10-
fold or more higher than in isolated but intact cells. The best furan containing C3aR 
antagonist was compound 114a (pIC50 6.8) in a calcium mobilisation assay induced 
by 5 nM C3a. Compound 114a was re-synthesised and evaluated in our group. It was 
a C3aR antagonist with pIC50 5.7 in calcium mobilization assay induced by 100 nM 
C3a on human monocyte-derived macrophages (Chapter 5).  Surprisingly, two other 
similar furan compounds (114b–c) having chlorophenyl groups on one side of the 
molecule switched the function of the molecules to agonists with pEC50 7.7 and 6.9 
respectively. When the furan ring was replaced with phenyl or thiazole rings, the 
binding potency reduced by 1–2 log units.160 Unfortunately, none of these C3aR 
ligands were orally bioavailable, possibly due to the carboxylate and basic guanidine 
groups on the arginine and very low logD values.  
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In an attempt to obtain more orally bioavailable ligands, Grant et al 161 reported a 
diiminoisoindoline compound (115) and Denonne et al 162 synthesised some amino-
piperidine derivatives without the arginine side chain. Compound 115 bound to C3aR 
with micromolar affinity and was a C3aR antagonist at µM concentrations in calcium 
mobilisation assays on human neutrophils. Compound 116 containing a dichloro-
xanthene group was a C3aR antagonist with IC50 of 0.6 µM in the calcium 
mobilisation assay. On the other hand, the cyclohexyl-bearing compound (117) was 
found to be a full agonist (EC50 0.2 µM) for the C3a receptor. The pyridyl ring was 
important for potency as replacement with a phenyl ring significantly reduced the 
activity. However, a poor DMPK profile (poor bioavailability, rapid elimination in 
vivo) was observed for all compounds containing the amino-piperidine linker.162 
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In summary, SB290157 (113) remained the most potent, non-peptidic C3aR 
antagonist reported in the literature to date, with micromolar potency in a calcium 
release assay on whole cells (Chapter 5). Similar to antagonist 114a, SB290157 (113) 
possessed a basic arginine moiety on the molecule, which contributed to a poor 
pharmacokinetic profile and thus studies in animals required very large doses of this 
compound (>25 mg/kg) to exert any appreciable activity. At such doses, the 
compound undoubtedly binds to many different receptors and further chemical 
foliage is likely required to generate true receptor specificity in vivo. As a result, 
there is a need for the development of more potent and more selective C3aR 
antagonists for the treatment of human inflammatory diseases. Having potent C3aR 
agonists would also be useful to evaluate the biological functions of the C3aR 
receptor and such agonists may have valuable immunostimulatory properties for 
treating immune disorders and immune-compromised patients.  
 
1.9 Thesis Objectives  
 
Anti-inflammatory drugs on the market nowadays used to treat inflammatory 
disorders are either not very effective or are compromised by high cost, safety 
concerns, or decreasing effectiveness over time. Therefore, the general aim of this 
thesis was to design, develop and synthesise more effective anti-inflammatory drugs 
by targeting two human G-protein-coupled receptors (Protease-activated receptor 2 
and C3a receptor) that are implicated in a large range of inflammatory diseases.  
Currently no highly potent agonists or antagonists are available to target these 
two receptors. As a result, the determination of both physiological and pathological 
roles of PAR2 and C3aR have relied heavily on synthetic peptide agonists that mimic 
the N- and C-terminal sequences respectively of the natural ligands. Such peptides 
lack potency, have poor pharmacokinetics and uncertain GPCR selectivity. To 
overcome these problems, rational design of potent, orally bioavailable and more 
target-selective nonpeptidic compounds was implemented along with optimisation of 
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the compounds reported in the literature. Due to the lack of crystal structures of these 
receptors, structure activity relationship studies had to be conducted to gain more 
information on ligand-receptor interactions.  
Recently, our group reported a PAR2-selctive antagonist (GB88, 110), effective 
against both protease and peptide agonists of PAR2 in vitro.63, 102 In order to develop 
more potent PAR2 antagonists or agonists, further structure-activity relationship 
studies (SAR) and lead optimisation strategies were implemented. First, the SAR 
around the putative binding pocket of each fragment (isoxazole, cyclohexylalanine, 
isoleucine) on the PAR2 antagonist GB88 (110) was investigated followed by 
optimisation of the C-terminal spiroindene piperidine fragment. Then we determined 
which fragments were able to control the activation/inhibition of the receptor. In 
addition, the successfully developed new PAR2 agonists/antagonists were evaluated 
in in vitro and in vivo experiments to validate the potential of these ligands in 
regulating inflammatory conditions.  
For the development of potent agonists or antagonists for C3a receptor (C3aR), a 
heterocycle such as oxazole was incorporated into a C3aR antagonist (SB290157, 
113) to mimic a turn conformation. The poor pharmacokinetics caused by the 
irreplaceable arginine residue also limit in vivo applications of current C3aR ligands. 
My aims here were to: a) incorporate a heterocycle that can mimic a turn structure 
and at the same time confer strong hydrogen bonding properties and potency; b) 
replace the arginine residue in C3aR ligands with less basic and more drug-like 
arginine mimetics.  
All of these newly discovered non-peptidic PAR2 and C3aR agonists and 
antagonists could be useful for the future development of druggable regulators for 
these receptors. All of these discoveries are reported in Chapters 2-6. My 
experimental program was a 50:50 mix of medicinal chemistry and molecular 
pharmacology. Thus, I designed, synthesised and characterized 113 new compounds, 
90% of which were also evaluated by me in human cells for PAR2 agonist/antagonist 
activity, C3aR affinity and C3aR agonist/antagonist potency. In addition I also 
pharmacologically screened and characterized 33 compounds prepared by others (as 
expressly indicated in each Chapter). In all cases, I drive ligand design for PAR2 and 
C3aR. My results thus include both my own synthetic compounds, and those 
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prepared on my behalf by others. This has enabled a more complete analysis of the 
agonist/antagonist pharmacophores for two GPCRs. 
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2.1 Abstract 
 
Activation of PAR2 is thought to be either pro-inflammatory or anti-
inflammatory. The availability of a potent and selective agonist and antagonist for 
PAR2 could help to verify these claims in vivo in inflammatory models. The most 
potent PAR2 antagonist known is GB88 (110, IC50 1–2 µM), a nonpeptidic compound 
developed in our laboratories from the native tethered ligand (SLIGRL-NH2). This 
hexapeptide was initially truncated to three amino acid residues (SLI-NH2) and 
further developed through structure-activity relationship (SAR) studies leading to 
isoxazole-Cha-Ile-NH2 (89, Chapter 1, section 1.4.3) with agonist potency at sub-
micromolar concentrations. By using a privileged fragment approach, a spiroindene 
piperidine moiety was appended to the C-terminus of this dipeptide analogue (89), 
resulting in a PAR2 antagonist, GB88 (110, Chapter 1, section 1.5.2) that maintained 
sub-micromolar activity and was selective for PAR2 over PAR1. However, there was 
little SAR around GB88 (110). This chapter explores SAR around each component of 
GB88 (110). It was found that changes to the isoxazole, isoleucine or C-terminal 
moieties influenced ligand function (agonist/antagonist activity). Compound 132 was 
an agonist with comparable potency to 2f-LIGRLO-NH2 (the most potent PAR2 
peptide agonist, EC50 0.2–0.4 µM) but had higher ligand efficiency, while 167 (also 
known as AY117) was an antagonist with slightly higher potency than GB88 (110). 
AY117 (167) inhibited PAR2 activation induced by either 2f-LIGRLO-NH2 or the 
endogenous activator trypsin, and it was selective for PAR2 over PAR1. The 
pharmacological properties of these compounds were evaluated and are detailed in 
Chapter 4. The agonist 132 and antagonist AY117 (167) may be valuable chemical 
probes for evaluating the functions of PAR2 in inflammatory disorders and cancer.  
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2.2 Introduction 
 
Protease-activated receptor 2 (PAR2) has been implicated in inflammatory 
conditions and cancers, but it has not yet been convincingly established whether 
PAR2 activation is pro-inflammatory or anti-inflammatory, or whether it is both and 
context dependent.1 A lack of potent and selective PAR2 agonists and antagonists has 
limited our understanding of the roles of PAR2 in vivo in inflammatory diseases. It 
has been reported that PAR2 activation can lead to inflammatory diseases, such as 
arthritis,2-5 and inflammatory bowel diseases.6-8 Developing drugs to antagonize the 
receptor could therefore be an important objective to realize a potential treatment for 
these diseased states. However, only a few PAR2 antagonists have been reported to 
date and, although they each have selectivity for PAR2 over PAR1, they each have 
significant deficiencies that limit their usefulness.  
The small water-soluble compound ENMD-1068 (105, Fig. 2.1) was the first 
compound reported to exhibit PAR2 antagonism, but this compound only displayed 
activity at millimolar concentrations and its small size undoubtedly led to 
nonselective action at such high concentrations.4  
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Figure 2.1 Chemical structures and activities of PAR2 antagonists. ENMD-1068 
(105) inhibited calcium release with IC50 of ~10 mM (elicited by 200 µM of 
SLIGKV-NH2 in murine Lewis lung carcinoma (LLC) cells)4 or IC50 of ~5 mM 
(calcium release induced by 1 μM 2f-LIGRLO-NH2) in human colon adenocarcinoma 
cells (HT29). K14585 (107) inhibited luciferase expression stimulated by SLIGKV-
NH2 (IC50 1.1 μM) in NCTC2544-PAR2 cells.9 GB88 (110) inhibited calcium release 
(IC50 of 1–2 μM) induced by 1 μM 2f-LIGRLO-NH2 in HT29 cells.10  
 
The compound K14585 (107, Fig. 2.1) has been reported to block the action of 
PAR2 agonist peptides at low µM concentrations, but it did not antagonize PAR2 
activation by endogenous protease agonists such as trypsin and it was too insoluble in 
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water.9 Further studies indicated that it had dual functions due either to partial agonist 
action or possibly to agonist-directed signaling.11  
Recently our group reported a PAR2-selective antagonist GB88 (110), which was 
effective at low micromolar concentrations against both protease and peptide agonists 
of PAR2 in vitro, while also being orally bioavailable in rodents. This set it apart as 
the most potent and useful PAR2 antagonist reported to date.10, 12 In order to develop 
even more potent PAR2 antagonists or agonists, further structure-activity relationship 
(SAR) studies and optimisation strategies have been examined in this chapter.  
 
2.3 Results and Discussion 
 
2.3.1 Approach to ligand optimisation 
 
The plan was to attempt to optimise agonist and antagonist potency against PAR2 
by first investigating structure-activity relationships (SAR) through changes to each 
of the component fragments (isoxazole, cyclohexylalanine, isoleucine) of the PAR2 
antagonist GB88 (110), followed by optimisation of the C-terminal spiroindene 
piperidine fragment (Fig. 2.2).   
 
Figure 2.2 Sites of modification (A, B, C and D) for optimisation of lead antagonist 
GB88. 
 
The agonist and antagonist activities of compounds (at 1–100 µM) were measured 
by fluorescence-based detection of intracellular Ca2+ release in HT29 cells that 
express PAR2 on plasma membrane. The Ca2+ released from the endoplasmic 
reticulum was captured by the cell permeable dye, Fluo-3, which then emits 
fluorescence at 520 nm (excitation 495 nm)13 due to the action of a known PAR2 
agonist. The detailed assay protocol is described in the experimental section 2.5.7.  
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There were some available SAR studies, based on peptide analogues of tethered 
ligands, that had led to discovery of potent agonists including 2f-LIGRLO-NH2 
(Chapter 1, section 1.4.2). PAR2 agonist peptides seemed to require an N-terminal 
heterocycle for potency at the head position corresponding to position-A in GB88 
(Fig. 2.2).14-15 For position-B, changes from Cha or Leu to aromatic groups (such as 
Phe) introduced some additional activation of PAR1 in agonist peptides examined.16 
However, the Ile group corresponding to position-C was found to be optimal.16 It was 
not clear whether all such compounds bound to PAR2 necessarily in the same way 
but, without clear evidence to the contrary, we considered this information to be 
valuable in making initial changes to the structure of GB88 (110) in order to increase 
antagonist potency and, through truncation, to increase agonist potency.  
It was hypothesised that fragments A–D bound to four distinct binding pockets in 
the receptor. The interactions between each of the four fragments and the receptor 
may separately influence activation or antagonism of PAR2 and it was a goal to 
identify how each fragment affected these properties. Our group had previously 
demonstrated that truncation of hexapeptide ligands to an N-terminal capped 
“dipeptide” structure, isoxazole-Cha-Ile (89), maintained crucial selectivity and 
binding affinity, and that appending a spiroindene-piperidine at the C-terminus of this 
unit switched the ligand to become an antagonist.10, 12 Therefore, by mapping 
influences of each component we considered that it should be possible to derive 
superior antagonists and agonists for PAR2, while mapping both a pharmacophore 
and a reciprocal receptor model. Retaining the spiroindene-piperidine fragment D, 
followed by stepwise scanning of the first three residues A, B and C, was expected to 
produce more potent antagonists. On the other hand, removing fragment D was 
expected to enable improvements to the agonist unit isoxazole-Cha-Ile. We, planned 
to probe the spiroindene-piperidine fragment for enhanced antagonist potency, while 
mapping the antagonist-determining pharmacophore. Finally, the therapeutic potential 
was to be investigated using a PAR2-induced rat paw oedema model, which is 
described in Chapter 4.  
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2.3.2 Optimisation of the “dipeptide” fragment (isoxazole-Cha-Ile-NH2, 89) 
 
NH2
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N
O
N
H
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89 
 
A previous investigation conducted by our group showed that truncation of the 
hexapeptide SLIGRL-NH2 to give isoxazole-Cha-Ile-NH2 (89), produced a 
micromolar PAR2 agonist (EC50 4 µM).12 However this “dipeptide” (89) was not fully 
optimised since not many analogues were examined. To begin the structure-activity 
relationship studies (SAR) for PAR2, the importance of the C-terminal amide was 
investigated since having amide at this position may not be optimal. The terminal 
amide was replaced by an ester (119) or a carboxylic acid group (118) in attempts to 
vary the H-bonding properties of the carbonyl oxygen at the C-terminus (Table 2.1). 
Also, introduction of a primary amine (120) could inform about any charge 
interaction with the receptor and the importance of the presence of the carbonyl 
group. Relocation of the carbonyl oxygen 2-atom further at the C-terminus (121), 
while at the same time maintaining the H-bonding donor character of the amide NH at 
that position (a reverse amide), may improve the potency.  
 
Table 2.1 Activity of “dipeptides” with different moiety at the C-terminus, as 
measured by calcium release assay in human colon adenocarcinoma cells (HT29). 
  
 
 
  
 
 
 
 
a % Calcium efflux in HT29 cells induced by compounds at 10 µM relative to 100% for 2f-LIGRLO-
NH2 at 100 µM (n = 1). b % inhibition of the calcium efflux in HT29 cells elicited by 1 µM 2f-
LIGRLO-NH2  (n = 1). N.A. Not applicable 
 
Compound R % activation at 10 µM a % inhibition at 10 µM b 
89 CONH2 87 N.A. 
118 COOH 8 3 
119 CO2Me 62 N.A. 
120 CH2NH2 10 3 
121 CH2NHCOCH3 10 5 
R
H
N
O
N
H
O
N O
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“Dipeptides” with carboxylic acid (118), methylene amine (120) and reverse 
amide (121) at the C-terminus were significantly less potent than the amide (89), 
while the ester (119) slightly reduced the activity, suggesting that the position and the 
hydrogen bond donating ability of the amide carbonyl group were important for 
potency (Table 2.1). The order of potency (amide > ester > carboxylic acid) was 
consistent with the order for H-bonding acceptor strength of the respective carbonyl 
oxygen atoms as reported in the literature.17 None of these compounds was an 
antagonist (Table 2.1) and the amide group had to be attached to the α-carbon of 
isoleucine. As a result, the amide was retained at the C-terminus in successive 
compound series below.  
Many SAR studies had been performed around PAR2 hexapeptides and reported 
in the literature.15-16 However, our compounds do not necessarily bind PAR2 in a 
similar fashion to the hexapeptides and so the hexapeptide SAR information may not 
directly translate to our compounds. Therefore the effect of changes to the Cha and Ile 
residues was systematically investigated by replacing them with polar and unnatural 
amino acids in order to improve the potency of these compounds (Table 2.2). 
H
N
O
N
H
O
N O
O
NH2
R2
R3  
 
Table 2.2 Activity of  “dipeptides” at 10 µM, as measured by calcium release assay in 
human colon adenocarcinoma cells (HT29).   
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a % Calcium efflux in HT29 cells induced by compounds at 10 µM relative to 100% for 2f-LIGRLO-
NH2 at 100 µM (n = 1).  
b % Inhibition of the calcium efflux in HT29 cells elicited by 1 µM 2f-LIGRLO-NH2 (n = 1). N.A. Not 
applicable 
Compound R2 R3 % activation 
at 10 µM a
% inhibition 
at 10 µM b
89 L-Cha L-Ile 87 N.A.
122 L-Tyr L-Ile 0.1 0
123 L-Trp L-Ile 0.1 3
124 D-Phe L-Ile 4 9
125 D-Cha L-Ile 0.2 2
126 L-Phe(4-Me) L-Ile 0.1 5
127 L-Phe(4-NH2) L-Ile 0.1 0
128 L-Cha L-tBuAla 40 40
129 L-Cha L-Val 40 N.A.
130 L-Cha L-nVal 80 N.A.
131 L-Cha D-nVal 2 2
132 L-Cha L-Chg 92 N.A.
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Similar to what had been reported in the literature,16 our data confirmed that D-
amino acids were not tolerated (130 vs 131 and 89 vs 125, Table 2.2) at the 2nd and 3rd 
positions. Aromatic groups introduced at the Cha position did not show any activity, 
suggesting that a saturated ring was preferred at this site. Amino acid 
cyclohexylglycine had been previously introduced at this position, but was also less 
potent than Cha.12 Therefore, Cha was the best substituent at this position for 
promoting agonist activity. On the other hand, isoleucine at the 3rd position could be 
replaced by L-norvaline (130) without loss in potency, or by L-cyclohexylglycine 
(132) but with 3-fold improved potency (EC50 0.4 µM for 132 vs 1.2 µM for 89, Fig. 
2.3). The cyclohexylglycine group, which is more bulky than isoleucine, may fit into 
a receptor binding pocket better, leading to improved potency. 
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Figure 2.3 Agonist responses of compounds 130, 132, 89 and 2f-LIGRLO-NH2 in 
calcium release assay (in HT29 cells) expressed as % Ca2+ response relative to 100 
µM 2f-LIGRLO-NH2. EC50 values for 130, 132, 89 and 2f-LIGRLO-NH2 were 1.7 
µM, 0.4 µM, 1.2 µM and 0.5 µM respectively. Each data point represents mean ± 
SEM. 
 
2.3.3 Determining PAR2 selectivity for compound 132 
 
The PAR2 selectivity for compounds 89 and 132 can be determined from 
desensitisation experiments18-19. In this experiment, HT29 cells, which expressed both 
PAR1 and PAR2 receptors, were first exposed to a PAR2 selective agonist (20 µM, 
2f-LIGRLO-NH2) and the release of calcium response was observed due to the 
activation of PAR2. A selective PAR2 agonist (2f-LIGRLO-NH2) at 20 µM was 
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sufficient to activate all PAR2 on the cell membrane and led to desensitisation of the 
receptor’s response to the agonist and therefore no calcium response was observed 
from the 2nd treatment of 2f-LIGRLO-NH2 (Fig. 2.4A). However, other receptor 
agonists, such as PAR1 agonist (TFLLR-NH2), were still able to activate their 
corresponding receptor and trigger a second calcium response after desensitisation of 
PAR2 by 2f-LIGRLO-NH2, as shown in figure 2.4B. Both compounds 89 and 132 at 
100 µM (Fig. 2.4C–D) did not trigger a second calcium signal after PAR2 
desensitisation, consistent with these compounds being selective for PAR2 over 
PAR1.   
100 μM 89
100 μM TFLLR-NH2 
20 μM 2f-LIGRLO-NH2 
100 μM 2f-LIGRLO-NH2 
20 μM 2f-LIGRLO-NH2 20 μM 2f-LIGRLO-NH2 
20 μM 2f-LIGRLO-NH2 
100 μM TFLLR-NH2 
100 μM 132
(R
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)
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)
(R
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Figure 2.4 Desensitisation assays for compounds 89 and 132. (A) Control: HT29 
cells were treated with 2f-LIGRLO-NH2 (20 µM) at t0 to desensitise the PAR2 
receptor. 2f-LIGRLO-NH2 (100 µM) was then injected at t300 (s) to confirm PAR2 
desensitisation. (B) 2nd Control: HT29 cells were first desensitised with 2f-LIGRLO-
NH2 (20 µM), then a PAR1 agonist (TFLLR-NH2 at 100 µM) was added to induce a 
second Ca2+ release thus confirmed that only PAR2 was desensitised. (C–D) Cells 
were first desensitised by 2f-LIGRLO-NH2 (20 µM) at t0, then compound at 100 µM 
was administered at t300 (s). Compounds 89 and 132 did not stimulate a further release 
of Ca2+ following desensitisation of the PAR2 receptor by 2f-LIGRLO-NH2 and 
therefore they were selective to PAR2 at 100 µM. 
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The above experiments showed that compound 132 was the most potent, 
selective (up to 100 µM as determined from desensitisation assay, Fig. 2.4) and the 
smallest ‘peptide-like’ PAR2 agonist to date, with superior ligand efficiency to the 
previous most potent PAR2 peptide agonist 2f-LIGRLO-NH2.  
 
2.3.4 Substitution of isoxazole ring (Fragment A) 
 
 
GB88 
The isoxazole ring has been found to be unstable under certain conditions, 
decomposing either chemically under mild basic conditions or metabolically in the 
case of some compounds, depending upon the structural environment of the 
isoxazole.20-21 Kalgutkar et al 21 and Grunanger et al 20 reported that isoxazoles 
underwent ring opening in the presence of base, and isoxazoles were chemically 
unstable to reduction (e.g. hydrogenation) and to reactions with nucleophiles. This 
was due to the reactivity of the N-O bond. Kalgutkar et al 21 reported that ring 
opening of isoxazole was also mediated by cytochrome P450 enzymes in some in 
vitro studies. Although the isoxazole ring of GB88 has been reported to be stable 
under the calcium mobilisation assay condition and in serum,10, 12 it may not be very 
stable in other assay or in vivo experiment conditions.    
In order to avoid the possibility of instability and to probe the effects of substituents at 
this site (fragment A), the isoxazole ring in GB88 was replaced with different cyclic 
or acyclic moieties varying in hydrophobicity, size, saturation and polar substituents 
(Fig. 2.5A). A large batch of H2N-Cha-Ile-spiroindene-[1,4]-piperidine was prepared 
using solution phase synthesis from Boc-protected amino acids. The stock solution 
was split and coupled in parallel to a panel of acids/reagents to produce a focused 
library. Antagonist/agonist potency was assessed by calcium release in HT29 cells 
(Fig. 2.5B–D). All potential antagonists were assessed for agonist activity (Fig. 2.5C) 
to eliminate the possibility of the observed antagonist activity (i.e. low calcium 
response, Fig. 2.5B) was caused by desensitisation of the receptor following receptor 
activation stimulated by the agonist effect of the compound.12  
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Figure 2.5 (A) Chemical structures of ligands with changes at the isoxazole 
(Fragment A, R1). Compounds 133, 135, 139–142 and 151 were synthesised by Dr. 
Ligong Liu (The University of Queensland). (B) % inhibition of Ca2+ efflux by 
compounds at 10 µM against 1 µM 2f-LIGRLO-NH2 in HT29 cells (n = 1). (C) % 
calcium efflux induced by compounds at 10 µM relative to 100% for 2f-LIGRLO-
NH2 at 100 µM in HT29 cells (n = 1). (D) Concentration dependent responses of 
selected antagonists, 133 (♦), 134 (ο), 137 () and GB88 () based on the inhibition 
of Ca2+ release induced by 1 µM 2f-LIGRLO-NH2 (n ≥ 3) in HT29 cells. Each data 
point represents mean ± SEM.  
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Replacing isoxazole with small aromatic heterocycles, such as furan (140), 
pyridine (141), or pyrazine (142), completely abolished the activity; while triazole 
(139), oxazole (138), 5-methyl-3-isoxazole (136), or imidazole (137) (IC50 3 µM, Fig. 
2.5D) retained antagonist activity but with reduced potency. The commonly used 
PAR2 agonist 2f-LIGRLO-NH2 has a furan ring to replace the serine of the tethered 
ligand (SLIGRL), which led to improved agonist activity in peptide ligands. 
However, reduction in potency was observed when isoxazole was replaced by furan 
(140, Fig. 2.5B), which supported the possibility that antagonist GB88 may bind 
differently to peptide agonists. Switching the relative position of oxygen/nitrogen 
from isoxazole (GB88 vs 136) was detrimental (~5-fold less potent), although such an 
effect could be caused by the extra methyl substitution in 136.  
A homology model of PAR2 was generated by Dr. Praveen Madala (The 
University of Queensland) based on the crystal structure of bovine rhodopsin. Bovine 
rhodopsin was the only GPCR crystal structure available at the time of this SAR study 
and it shares just 20% sequence identity with PAR2. This homology model was used 
for docking of PAR2 ligands. The best-fitting binding poses of ligands were chosen 
based on the highest score calculated from the GOLD modeling software. Docking 
studies of GB88, SLIGRL-NH2 and 2f-LIGRLO-NH2 in this homology model 
proposed that all of them share the same binding domain in the receptor. It was 
reported that GB88 is a surmountable and competitive antagonist of 2f-LIGRLO-
NH2.10 As all the compounds discussed in this chapter are analogues of GB88, it was 
hypothesised that these compounds and GB88 are binding at the same site in the 
receptor. The model indicated the presence of two Asp residues (ASP121 in 
transmembrane helix 2 (TM2) and ASP340 in transmembrane helix 7 (TM7)) within 
close proximity to the isoxazole ring of GB88. Thus an amino group was introduced 
on the isoxazole ring (compounds 133, 134) in order to interact with the Asp residue 
through an ionic/polar interaction (Fig. 2.6A). However, these compounds did not 
improve the antagonist potency.  
 
 
 
 
 
 
 69 
 
A      B 
          
Figure 2.6 Homology model of PAR2 with docked GB88 antagonist (green). (A) The 
isoxazole ring of GB88 was located close to two aspartic acid residues (D121 and 
D340, cyan) in the putative binding pocket. (B) Proposed H-bond interactions 
between the isoxazole ring of GB88 (green), a serine (S162) and a asparagine (N336) 
residues (cyan). (The original PAR2 homology model was generated by Dr. Praveen 
Madala, The University of Queensland). 
 
The amino-isoxazole derivative of GB88 (133) resulted in comparable 
antagonism potency (IC50 1 µM) to GB88. On the other hand, introduction of an 
amino-methyl group (134) led to reduction in antagonist potency (IC50 9 µM, Fig. 
2.5D). Replacement of the oxygen of amino-isoxazole (133) with a hydrogen bond 
donor (NH) resulted in an amino-pyrazole compound (135), which switched to 
become a weak agonist. The diazoles (135 and 137) and triazole (139) can exist in 
tautomeric forms, with the nitrogen at the 2nd position of the ring able to act as either 
a H-bond donor or acceptor. Regardless of that, compounds 135, 137 and 139 showed 
reasonable antagonist potency (IC50 ~ 3–15 µM). Furthermore, removal of the H-bond 
donor/acceptor (NH or N) at the 2nd position of the ring resulted in complete loss of 
potency, as demonstrated by the furan analogue (140). These data suggested that a 
hydrogen bond acceptor at the 2nd  position of the 5-membered heterocyclic ring may 
be critical for high affinity. These were supported by a docking study using a PAR2 
homology model, the nitrogen of the isoxazole ring acting as a H-bond acceptor to 
interact with Asn336 (TM7), while the oxygen interacted with Ser162 (TM3) 
(Fig.2.6B). These interactions showed that both the nitrogen and oxygen of isoxazole 
could be important for maintaining the antagonist activity of the ligand.  
Sterically bulky bicyclic moieties, such as 3-methyl-5-p-tolylisoxazole (143) and 
dimethoxyphenyl (145), were not tolerated at this site (position A) except for indole 
(144). The activity of the indole derivative may be due to a hydrogen bonding 
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interaction with the receptor through the indole NH since there was no corresponding 
hydrogen bond donor in dimethoxyphenyl and 3-methyl-5-p-tolylisoxazole. 
Bernatowicz22 previously reported that incorporation of a cinnamoyl group into the N-
terminus of a PAR1 peptide agonist resulted in PAR1 antagonist activity. A pyridine 
cinnamoyl group (146) was therefore introduced at the N-terminus of GB88 but this 
resulted in complete loss of activity. The loss of activity could be due to limited space 
in the PAR2 binding site.  
Other non-polar and polar/charged groups, including serine mimetics and non-
aromatic heterocycles, in derivatives of GB88 (147-152) were either inactive or 
displayed less antagonist activity than GB88.  This suggested that aromaticity may be 
important for potency. It is also possible that the loss of activity was due to the change 
in compound conformation. In general, aromatic heterocycles were tolerated better 
than bulky groups, non-polar groups and non-aromatic heterocycles.  
Of the 9 small aromatic heterocylces compared at the N-terminus, only amino-
isoxazole (133, also called LL13C) and imidazole (137) gave compounds with 
relatively potent antagonist activity (IC50 ~1–5 µM, Fig. 2.5D). They are 
metabolically and chemically more stable than isoxazole and showed better water 
solubility based on shorter HPLC retention times.  
In summary, a minimum of two heteroatoms (nitrogen or oxygen) were required 
on aromatic heterocycles, with one acting as a H-bond acceptor preferred for high 
ligand agonist/antagonist potency. Hydrophobic substitution on the ring was not 
tolerated due to steric hindrance. Although none of the substituents displayed better 
potency than isoxazole, replacements such as amino-isoxazole (133) or imidazole 
(137) may be valuable for improving metabolic stability and water solubility if 
potency can be enhanced by changes elsewhere in GB88. Since other heterocycles 
were not as potent as isoxazole, the stability of the heterocycles was not investigated.  
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2.3.5 Substitution of cyclohexylalanine (Fragment B) 
 
GB88 
 
In hexapeptide agonists, it had been reported that changes from Leu-2 in SLIGRL 
to phenylalanine led to PAR1 binding as well and thus loss of selectivity for PAR2 
over PAR1.26 For this reason aromatic rings were excluded as replacements for the 
cyclohexyl ring in fragment B in GB88. The size of the corresponding binding pocket 
on PAR2 was probed using hydrophobic alkyl groups in GB88 analogues, such as 
homo-cyclohexylalanine (hCha) with an extra methylene group (154) and tert-butyl 
glycine (tBuG, 153), which is shorter but more bulky (Fig. 2.7B). Both variations 
almost completely abolished both antagonist and agonist potencies (Fig. 2.7C–D). 
These steric restraints were clearly not tolerated, thus Cha was retained at this 
position. Given the presence of two Ser residues (Ser124 at TM2, Ser337 at TM7) 
around this binding site in a homology model (Fig. 2.7A), a morpholine group (155) 
was incorporated with intentions to maintain the space requirement and improve 
potency by having polar or H-bond interactions with the receptor. However the 
antagonist activity was reduced (Fig. 2.7C). In combination with knowledge obtained 
from peptide agonists,12, 16 the Cha group was the best substituents examined at this 
site and a hydrophobic space-filling interaction with the receptor seemed to be 
important for this binding site in PAR2 with a different requirement for aromaticity in 
ligands for PAR1. 
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Figure 2.7 (A) Two serine residues (cyan) were located closed to the Cha residue of 
GB88 (green) in PAR2 homology model (The original PAR2 homology model was 
generated by Dr. Praveen Madala, The University of Queensland.). (B) Chemical 
structures of ligands by changing cyclohexylalanine (Fragment B, R2). Compound 
155 was synthesised by Dr. Ligong Liu (The University of Queensland). (C) % 
inhibition of Ca2+ efflux by compounds at 10 & 100 µM in HT29 cells against 1 µM 
2f-LIGRLO-NH2 (n = 1). (D) % calcium efflux induced by compounds at 10, 30 & 
100 µM relative to 100% for 2f-LIGRLO-NH2 at 100 µM in HT29 cells (n = 1). Each 
data point represents mean ± SEM.  
 
2.3.6 Substitution of isoleucine (Fragment C) 
 
 
GB88 
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GB88 153 154 155
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According to SAR studies of hexapeptide agonists,16 the corresponding position 
to fragment C was intolerant of substitution with all natural amino acids except Ile 
and the unnatural residue Cha. These residues also gave the best binding to PAR2.16 
Therefore, in our antagonist selection, small alkyl groups (gem-dimethyl 156), 
branched alkyl group (t-butyl glycine, 157) and Cha (158) were separately introduced 
to GB88 (Fig. 2.8A) but all showed reduced potency compared to GB88 (Ile at this 
position, Fig. 2.8B–C). Compounds 156–157 were synthesised and assessed in the 
intracellular calcium release assay (iCa2+) by Dr. Grant Barry, thus the data are not 
shown in Fig. 2.8B–C. Given that the corresponding binding pocket has two polar 
residues (Tyr296 and Asn304) in the homology model of PAR2 (Fig. 2.8D), some 
polar groups were incoporated, such as threonine (163), O-methylated threonine (159, 
also called LL115), asparagine (161), histidine (162) and aminoethyl (160) (Fig. 
2.8A), to investigate the potential polar or H-bond or ionic interactions, while 
maintaining a spacefilling size close to that of Ile. However, these modifications 
triggered activation of PAR2 (Fig. 2.8C). These polar groups possibly form H-
bonding interaction with the two highligted residues (cyan, Fig. 2.8D) and these 
interactions could trigger receptor activation.  
The methylated threonine (159, LL115) compound had similar antagonist activity 
to GB88, but also showed a higher agonist response than for isoleucine at this position 
in GB88 at higher concentrations (Fig. 2.8E). All the SAR results supported the fact 
that isoleucine was optimal for antagonist activity, possibly because the Ile side chain 
fitted well in a receptor binding pocket without triggering activation of PAR2. The 
results also showed that this binding site could act as a switch between agonism and 
antagonism. The PAR2 receptor was activated if a polar side chain was inserted at this 
position, as shown in compounds 159, 161–163. 
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Figure 2.8 (A) Chemical structures of ligands by changing the isoleucine (Fragment 
C, R3). Compounds 156–157 were synthesised by Dr. Grant Barry and compounds 
159–163 were synthesised by Dr. Ligong Liu (The University of Queensland). (B) % 
inhibition of Ca2+ efflux by compounds at 10 µM in HT29 cells against 1 µM 2f-
LIGRLO-NH2 (n = 1). (C) % calcium efflux induced by compounds at 10 µM relative 
to 100% for 2f-LIGRLO-NH2 at 100 µM in HT29 cells (n = 1). (D) Two polar 
residues (N304 and Y296, cyan) were located closed to the isoleucine residue of 
GB88 (green) in PAR2 homology model. (The original PAR2 homology model was 
generated by Dr. Praveen Madala, The University of Queensland.) (E) Compound 
159 inhibited calcium release in HT29 cells with IC50 of 1 µM (pIC50 5.96 ± 0.06) but 
induced calcium release at high concentrations. (B–C & E) Each data point represents 
mean ± SEM.  
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2.3.7 Optimisation of the C-terminus moiety (Fragment D)  
 
 
GB88 
 
It had been suggested that PAR2 may have a hydrophobic pocket that can 
accommodate the 5th and 6th residue of a tethered hexapeptide ligand.15-16 Therefore, 
the spiroindene piperidine (Fragment D) was replaced with different hydrophobic 
groups, such as aliphatic and aromatic rings, that allow a better understanding of the 
structure-activity relationships and to discover more potent PAR2 antagonists. 
Importantly, the spiroindenepiperidine fragment in GB88 was responsible for 
conferring antagonism to GB88. To map variations at this position, a divergent, 
solution-phase parallel synthesis approach was implemented (Scheme 2.1). The C-
terminal amines, either obtained commercially or synthesised in house, were first 
coupled to Boc-Ile-OH followed by deprotection of the Boc group and subsequent 
coupling of Boc-Cha-OH and isoxazole-5-carboxylic acid under conditions specified 
in scheme 2.1. 
Scheme 2.1 Synthesis of GB88 analogues with different groups at the C-terminus. 
NH
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2.3.7.1 Replacement of spiroindene piperidine with piperazine and piperidine 
derivatives.  
 
Substituted piperazines are common fragments found in various GPCR ligands.23  
Modification of the piperazine ring through chemistry involving the second ring 
nitrogen not part of piperidine could provide fast entry to a diverse library. In 
addition, the extra nitrogen can change electronic properties of the ring and provides 
extra polar interaction with the receptor. Three aryl-substituted analogues (164, 165 
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and 166, Fig 2.9A) were initially prepared and assessed but all switched the function 
of these ligands from antagonist to agonist (Fig. 2.9C). The apparent antagonist 
activity (i.e. low calcium response, Fig. 2.9B) for compounds 164–166 was caused by 
desensitisation of the receptor following receptor activation stimulated by the agonist 
property of the compound.19 Introduction of a methylene group between the 
piperazine and phenyl rings (166) reduced the agonist activity (Fig. 2.9C), suggesting 
that the preferred hydrophobic interaction possibly involved an optimal orientation or 
restricted rotation of the aryl group.  
A 
R4
OH
N
O
N
H
O
N O
 
GB
8816
4
16
5
16
6
16
7
16
8
16
9
17
0
17
1
17
2
17
3
17
4
0
20
40
60
80
100
%
 in
hi
bi
tio
n 
ag
ai
ns
t
 1
 µ
M
 2
f-L
IG
R
LO
-N
H
2
16
4
16
5
16
6
16
7
16
8
16
9
17
0
17
1
17
2
17
3
17
4
0
20
40
60
80
100
%
 C
a2
+  
re
sp
on
se
 re
la
tiv
e 
to
 
2f
-L
IG
R
LO
-N
H
2 
at
 1
00
 µ
M
B CAntagonist activity Agonist activity
 
Figure 2.9 (A) Chemical structures of ligands by changing fragment D (R4) at the C-
terminus. Compounds 164 was synthesised by Dr. Grant Barry (The University of 
Queensland). (B) % inhibition of Ca2+ efflux by compounds at 10 µM against 1 µM 
2f-LIGRLO-NH2 in HT29 cells (n = 1). (C) % calcium efflux induced by compounds 
at 10 µM relative to 100% for 2f-LIGRLO-NH2 at 100 µM in HT29 cells (n = 1). 
Agonists 164–166 and 174 showed 100% inhibition of calcium release is due to 
receptor desensitisation. Each data point represents mean ± SEM.  
 
As the piperazine group induced agonist activity, piperidine was retained in  
attempts to create potent antagonists. The aromatic group was also retained with the 
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expectation of hydrophobic, π-stacking or/and π-H interactions 24-25 with the receptor, 
which has four hydrophobic Tyr residues (Y210-TM4, Y156-TM3, Y160-TM3, 
Y326-TM6) in the transmembrane region where the ligand was thought to bind (Fig. 
2.10A).  
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Figure 2.10 (A) The presence of four tyrosine residues (cyan) located closed to the 
spiroindene piperidine ring of GB88 (green) in PAR2 homology model. (The PAR2 
homology model was generated by Dr. Praveen Madala, The University of 
Queensland.) (B) Alignment of energy minimised conformations of compound 164 
(green), 167 (magenta) and GB88 (orange) using Openeye software – Omega2 and 
ROCS. (C) Concentration dependent responses for 167 () and GB88 () based on 
the inhibition of Ca2+ release in HT29 cells induced by 1 µM 2f-LIGRLO-NH2 (n ≥ 
3). (D) Agonist responses of compound 164 and 167 in calcium release assay 
expressed as % Ca2+ response relative to 100 µM 2f-LIGRLO-NH2 in HT29 cells (n ≥ 
3). Each data point represents mean ± SEM.  
 
Removal of the 5-membered spiro ring in GB88 resulted in a phenyl-piperidine 
analogue (167, also called AY117) with improved antagonist potency (IC50 0.7 µM, 
Fig. 2.10C). Compared to phenyl-piperazine analogue 164 (an agonist), it was 
assumed that this antagonist-agonist switch was caused by either the electronic effect 
of the extra nitrogen, which increased electron density of the aromatic ring, or the 
protonated charged state of piperazine, or a slightly different space orientation of the 
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aryl substituent caused by sp3 geometry of nitrogen vs carbon. An alternative 
explanation was that the nitrogen in piperazine could potentially participate in H-bond 
interaction with the receptor that triggers receptor activation. Alignment of energy-
minimised conformations of compound 164, compound 167 (AY117) and GB88 
using Sybyl showed that the phenyl rings from 167 (AY117) and GB88 were 
superimposable, while the phenyl piperazine (164) adopted a different orientation 
(Fig. 2.10B). These conformational differences might account for the opposing 
functions of compounds 164 and 167 (AY117).  
Relaxation of conformational strain with an extra methylene group between 
piperidine and phenyl rings, as illustrated in benzyl-piperidine 168, retained 
antagonist activity but with ~2-fold reduced potency. The more potent phenyl-
piperidine compound (167, AY117) was further derivatised by incorporating electron-
donating (methoxy, 170 and 171) or electron-withdrawing (chloro, 169, 
trifluoromethyl, 172 and 173) groups, but all of them gave a slight reduction in 
antagonist potency (Fig. 2.9B). This could be due to limited space in the binding 
pocket in PAR2. The size of this binding pocket was also investigated and will be 
discussed later in section 2.3.7.2. In addition, introduction of an acetamide group 
(174) switched the role to an agonist. The acetamide group in 174, containing a H-
bond donor NH and a H-bond acceptor carbonyl oxygen, could possibly interact with 
PAR2 through H-bonding interactions and these may induce conformational change 
of the receptor by interfering with the interactions between transmembrane helices of 
PAR2 and lead to receptor activation. 
 
2.3.7.2 Extensions to Fragment D 
 
To probe the allowable size of the C-terminal fragment D, an extra phenyl ring 
was placed at the ortho (175), meta (176), or para (177) positions of phenyl 
piperidine (Fig 2.11A).  
The ortho substitution (175) showed better activity than meta (176) or para (177) 
substitution, suggesting that more space was available for ortho substitution. A phenyl 
ring at this position may be too hindered and thus confer less potency than the 
unsubstituted phenyl-piperidine (167). A more flexible phenoxy group (178) was 
therefore attached to the para position of phenyl-piperidine resulting in the loss of 
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activity presumably due to steric hindrance. Other substituted phenyl piperidine 
analogues were shown in section 2.3.7.1 and none of them showed greater antagonist 
potency than the unsubstituted phenyl (167). These findings indicated that the space 
around the phenyl ring of piperidine was limited and that an unsubstituted phenyl 
group may be optimal.  
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Figure 2.11 (A) Chemical structures of substituted phenyl piperidine analogues. (B) 
% inhibition of Ca2+ efflux by compounds at 10 µM against 1 µM 2f-LIGRLO-NH2 in 
HT29 cells (n = 1). (C) % calcium efflux induced by compounds at 10 µM relative to 
100% for 2f-LIGRLO-NH2 at 100 µM in HT29 cells (n = 1). Each data point 
represents mean ± SEM.  
 
 
2.3.7.3 Replacement of spiroindene piperidine with bicyclic and spiro derivatives.  
 
 
Bicyclic and spiro moieties are commonly found in GPCR ligands.23 Therefore 
incorporating these groups into the C-terminus might have increased PAR2 antagonist 
potency (Fig 2.12A). Compound 179 (cis-decahydroisoquinoline), with two fused 
saturated rings, displayed only moderate antagonist potency (Fig. 2.12B). However, 
removal of one cyclohexane ring to give compound 180 (also with a tert-butyl amide 
group at position-2 of piperidine) improved potency (IC50 8.6 µM, Fig. 2.12D). This 
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suggested that there was space available in PAR2 close to where the second position 
of the piperidine fits.  
Compound 181 incorporating the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
unit showed an agonist response in the calcium release assay. It was suspected that 
one of the two methoxy groups was presented in a position such that the methoxy 
oxygen participated in a H-bond interaction with the receptor, and thus induced partial 
agonist activity. On the other hand, all other spiropiperidine analogues (182, 184, 
185) displayed potent agonist activity (EC50 ~1  µM, Fig. 2.12C). By comparison with 
GB88, they all possess an oxygen atom in a location that could possibly form a 
hydrogen bond with the receptor. It was speculated that the carbonyl on the 
spirochroman ring of compound 182 could be involved in a H-bonding interaction 
with the receptor. The results showed that removal of the carbonyl group to give 
compound 183 completely restored antagonist activity with similar potency (IC50 1.8 
µM) to GB88. This indicated that the carbonyl oxygen was interacting with the 
receptor and led to receptor activation. Similar to other antagonists, including GB88, 
antagonist 183 also triggered a Ca2+ response at high concentrations, which was 
attributed to either an off-target effect or PAR2 agonist activity. Previously our group 
had synthesised some spiro derivatives of GB88 containing the C-OH on the ring and 
all of those compounds were agonists. Thus, it was suspected that introduction of C-
OH or even alkyl ether on spiro derivatives of GB88, possessing H-bond 
donor/acceptor properties, was likely to activate the receptor.  
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Figure 2.12 (A) List of substituents introduced at the C-terminus. Compounds 182–
185 were synthesised by Dr. Ligong Liu (The University of Queensland). (B) % 
inhibition of Ca2+ efflux by compound at 10 µM against 1 µM 2f-LIGRLO-NH2 in 
HT29 cells (n = 1). (C) % calcium efflux induced by compounds at 10 µM relative to 
100% for 2f-LIGRLO-NH2 at 100 µM in HT29 cells (n = 1). (D) Concentration 
dependent responses of compounds 167 (), 180 (), 183 () and the reference 
GB88 () for the inhibition of Ca2+ release induced by 1 µM 2f-LIGRLO-NH2 (n ≥ 
3). (E) Agonist responses of compound 182 and 183 in calcium release assay 
expressed as % Ca2+ response relative to 100 µM 2f-LIGRLO-NH2 (n ≥ 3). Each data 
point represents mean ± SEM.  
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In summary, all of the results supported a hypothesis where the C-terminal 
moiety was important for controlling agonism/antagonism. All the piperazine 
compounds were agonists, while piperidines retained antagonism for the receptor. The 
phenyl ring on piperidine was found to be crucial for maintaining potency, possibly 
due to a π-stacking interaction with the receptor, and the phenyl ring had to be 
directly attached to the piperidine ring. The phenyl piperidine compound (167, 
AY117) was the most potent PAR2 antagonist in this series and its synthesis was 
much easier than for spiroindene piperidines.  
 
2.3.8 Conversion of compound 132 agonist to PAR2 antagonist 
 
The PAR2 agonist 132 with cyclohexylglycine as the fragment C was a better 
agonist than when isoleucine was at this position. SAR studies on site D indicated that 
phenylpiperidine was preferred for potent PAR2 antagonism. Therefore, the 
phenylpiperidine moiety was linked to the “dipeptide” fragment of 132 to seek a more 
potent antagonist than the phenyl piperidine compound (167, AY117), namely 186.  
Compound 186 was synthesised using a solution phase chemistry approach and 
examined in the calcium mobilisation assay on HT29 cells. Unfortunately, this 
compound did not improve the antagonist potency (Fig. 2.13B). It was suspected that 
the cyclohexylglycine group, being adjacent to the bulky phenylpiperidine, may have 
sterically hindered access by the piperidine to the desired space in PAR2 resulting in 
reduced antagonist potency.  
A      B 
 
 
 
 
 
  
 
 
Figure 2.13 (A) Chemical structure of compound 186. (B) Concentration dependent 
Ca2+ release induced by 1 µM 2f-LIGRLO-NH2 inhibited by compound 186 () 
versus GB88 ()(n = 3) in HT29 cells. Each data point represents mean ± SEM.  
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2.3.9 Variable temperature NMR spectra data for compound 167  
 
The proton NMR spectra of all compounds containing a piperidine ring displayed 
extensive rotatory isomerism due to the constrained rotation of the tertiary piperidine 
amide bond. For compound 167 in deuterated DMSO, most of the signals in the 13C 
NMR spectrum were duplicated, with a separation of ~0.5-2 ppm. Assignments of 
proton and carbon NMR spectra resonances for compound 167 (in section 2.6), the 
most potent PAR2 antagonist reported in this chapter, were determined using various 
one- and two-dimensional NMR experiments (JMOD, gCOSY, gHSQC, gHMBC). 
To distinguish the possibility of rotational isomers rather than epimers, NMR spectra 
were recorded at elevated temperatures and some signal coalescences were observed 
(Figure 2.14). For example, at 298K, the amide NHb split into 2 sets of doublets (8.94 
ppm, appeared as triplet due to overlapping signals), amide NHd into 2 sets of 
doublets (8.20 ppm), isoxazole proton Ha into 2 sets of doublets (8.75 ppm), and  Ile-
α-CH (He) was multiplet at 4.64 ppm. All these signals were simplified at 318K with 
Ha appearing as one broad singlet, Hb as a sharp doublet (coupling with Hc) and He as 
a triplet (coupling with Hd and Ile-β-CH). Hd, at 318K, was still appearing as 2 sets of 
doublets but the signals were getting closer to each other. Also, at this temperature, 
two distinguished methylene pairs (Haxial and Hequatorial) of s-syn (4.55, 2.60 ppm) and 
s-anti (4.19, 3.10 ppm) NCH2 of the piperidine ring were still observed. The presence 
of two rotamers rather than epimers was further evidenced by varying NMR solvent, 
where the ratio of two isomers was 1:1 in CDCl3 but changed to 3:2 in DMSO-d6. 
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Figure 2.14 1H NMR spectra of compound 167 in DMSO-d6 at three different 
temperatures – 298K, 308K and 318K. As temperature increases, the signals of two 
rotamers (a, b and c) slowly coalesced to become one set of signals.   
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2.4 Summary and Conclusions 
 
In summary, this chapter has reported the discovery of the smallest known PAR2 
agonist (isoxazole-Cha-Chg-NH2 132, EC50 0.4 µM; iCa2+, HT29 cells) and the most 
potent known PAR2 antagonist (167, also called AY117, IC50 0.7 µM; iCa2+, HT29 
cells), as determined by intracellular calcium (iCa2+) mobilisation assay. Both 
compounds have lower molecular weights than previously available agonists or 
antagonists. AY117 (167) was easier to synthesise and derivatise than derivatives of 
GB88 or spiroindene piperidines. The pharmacological properties of AY117 (167) 
were evaluated elsewhere, but preliminary data are reported in Chapter 4.  
The SAR study based on modifying individual fragments of antagonist GB88 was 
not as successful as expected. Although a panel of antagonists was discovered with 
activities at low micro- and sub-micromolar concentrations, this was not dramatically 
different to the potency of GB88. It was found that changes to the heterocycle, 
cyclohexylalanine, isoleucine resulted in comparable effects to these components, but 
that the heterocycle and the isoleucine could be altered to switch function from 
agonist to antagonist. On the other hand, changes to the cyclohexylalanine largely 
affected PAR2 specificity over PAR1 with aromatic groups permitting PAR1 
activation. The agonist/antagonist switching was postulated to affect interactions in 
the transmembrane region of PAR2 and a homology model seemed to account for 
most of the SAR observations made.  The C-terminus preferred an aromatic ring to 
maintain potency and antagonist activity, and ligand docking studies with the 
homology modeling supported possible π-stacking/ π-H interactions with the receptor 
that may disrupt helix-helix interactions in PAR2. Overall, we suspected that the 
failure to substantially enhance antagonist potency may be due to an inherent 
stereochemical constraint imposed on all of these ligands by the three central amide 
bonds (isoxazole-Cha-Ile-NH2) linking the four fragments A–D. These amides should 
perhaps be removed or replaced with amine-bond isosteres, such as thioamide, alkene, 
fluoroalkene or aza analogues, in future studies aimed at further enhancing antagonist 
potency. 
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2.5 Experimental Methods 
 
General Methods 
 
All amino acids were purchased from Novabiochem. Diisopropylethylamine 
(DIPEA), DMF and TFA were obtained from Auspep Pty Ltd., Australia. Other 
chemicals were obtained from Aldrich. All reagents were used as received. 
Hydrogenation reactions were conducted using a medium pressure Parr hydrogenator 
apparatus. Preparative-scale rpHPLC separations were performed on a Phenomenex 
Luna C18 15 µm, 250 × 21.2 mm column. Standard conditions were used for elution 
of all compounds unless otherwise indicated at a flow rate of 20 mL/min: 50% to 
100% B linear gradient over 10 min followed by a further 10 min at 100% B where 
solvent B was 90% MeCN, 10% H2O + 0.1% TFA and solvent A was H2O + 0.1% 
TFA. Detection was by UV and pure fractions were lyophilised. Analytical rpHPLC 
was used to assess compound purity (Phenomenex Luna C18 column, 15 µm, 90 Å, 
4.6 × 250 mm, λ 214, 230 and 254 nm) at three different wavelengths. Four standard 
conditions were used for all compounds unless otherwise indicated at a flow rate of 1 
mL/min. Method I: 20% to 100% B linear gradient over 10 min followed by a further 
10 min at 100% B; Method II: 50% to 100% B linear gradient over 10 min followed 
by a further 10 min at 100% B; Method III: 90% B isocratic for 10 min; Method IV: 
20% to 100% B linear gradient over 15 min followed by a further 10 min at 100% B. 
Solvent conditions were the same as preparative-scale rpHPLC.  
Electrospray ionisation mass spectra (ESI-MS) measurements were obtained on 
Micromass LCT and high-resolution mass spectra (ESI-HRMS) measurements were 
obtained on a Bruker microTOF mass spectrometer equipped with a Dionex LC 
system (Chromeleon) in positive ion mode by direct infusion in MeCN at 100 µL/h 
using sodium formate clusters as an internal calibrant. Data was processed using 
Bruker Daltonics DataAnalysis 3.4 software. Mass accuracy was better than 1 ppm 
error.  
1H and 13C NMR spectra were recorded on either a Varian 400 or Bruker Avance 
600 spectrometers at 298 K in the deuterated solvents indicated. 1H NMR spectra 
were referenced to the residual 1H signals; DMSO-d6 2.50, CD3OD 3.31 ppm except 
CDCl3 solutions were referenced to internal TMS. 13C NMR resonances were 
referenced to the residual solvent peak (DMSO-d6 40.4, CDCl3 77.0 ppm).  
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2.5.1 Synthesis of Dipeptides 89, 118-132 
 
Scheme 2.2 Synthesis of Fmoc-protected L-isoleucine methylene amine (4)  
 
IFmocHNOHFmocHN
O
OHFmocHN NH2
FmocHNa b c, d
1 2 3 4
OMsFmocHN
e
N3
FmocHNf
g
Route A
Route B
 
 
Reagents and conditions: a) (i) ClCOOiBu, NMM, DME; (ii) NaBH4, H2O; b) PPh3, 
I2, Imidazole, DCM; c) NaN3/DMF; d) H2, 10% Pd/C, MeOH, 40 psi; e) MsCl, TEA, 
DCM, 0°C to RT; f) NaN3, DMF; g) H2, 10% Pd/C, THF, 40 psi. 
 
The synthesis of 4 via route A gave higher yield compared to route B. Step f in route 
B gave very low yield (20%) of the azide product. The synthetic procedures for route 
A are described below:  
 
Synthesis of Fmoc-protected L-isoleucine alcohol (2).26 The starting material 
Fmoc-L-Ile-OH (2.02 g, 5.71 mmol) in DME (11 mL) was stirred at -15 °C under N2. 
To this solution, N-methylmorpholine (NMM, 0.6 mL, 5.71 mmol) was added 
dropwise followed by dropwise addition of isobutyl chloroformate (0.7 mL, 5.71 
mmol). The reaction mixture was stirred at -15 °C for an hour. After 1 h, the reaction 
mixture was filtered and the filtrate was cooled to -15 °C and then NaBH4 (0.32 g, 
8.56 mmol) in H2O (2.8 mL) was added in one portion followed by H2O (140 mL). A 
white precipitate was observed to form upon addition of water. The mixture was 
filtered, washed with H2O (50 mL) and petroleum ether (50 mL) and dried under 
vacuum to give 1.74 g of 2 as a white solid (90%). Rt = 12.1 min (Method I); ESI-
MS: m/z 340.2 [MH]+; 1H NMR (600 MHz, CDCl3), δ 0.88–0.95 (m, 6 H), 1.10–1.18 
(m, 1 H), 1.46–1.54 (m, 1 H), 3.51–3.57 (m, 1 H), 3.62–3.67 (m, 1 H), 3.69–3.75 (m, 
1 H), 4.22 (t, 1 H, J = 6.7 Hz), 4.41–4.50 (m, 2 H), 4.87 (d, 1 H, J = 8.1 Hz), 7.32 (t, 2 
H, J = 7.4 Hz), 7.40 (t, 2 H, J = 7.4 Hz), 7.59 (d, 2 H, J = 7.5 Hz), 7.76 (d, 2 H, J = 
7.5 Hz). 
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Synthesis of Fmoc-protected L-isoleucine iodide (3). A mixture of 
triphenylphosphine (2.34 g, 8.94 mmol), imidazole (1.01 g, 14.9 mmol) and iodine 
(1.01 g, 8.94 mmol) were dissolved in anhydrous DCM (12 mL). To this stirred 
mixture, the alcohol 2 (1.01 g, 2.98 mmol) in anhydrous DCM (7 mL) was added and 
stirred at RT overnight. The reaction mixture was concentrated in vacuo and purified 
by flash column chromatography (SiO2, 10% EtOAc in petroleum ether, Rf product 
0.3) to yield product (3) as a white solid (1.06 g, 79%). Rt = 13.0 min (Method I); 
ESI-MS: m/z 450.2 [MH]+; 1H NMR (600 MHz, CDCl3), δ 0.87–0.94 (m, 6 H), 1.14–
1.22 (m, 1 H), 3.12–3.23 (m, 1 H), 3.32 (dd, 1 H, J = 4.6, 10.3 Hz), 3.44 (dd, 1 H, J = 
3.7, 10.5 Hz), 4.24 (t, 1 H, J = 6.8 Hz), 4.39–4.49 (m, 2 H), 4.77 (d, 1 H, J = 9.4 Hz), 
7.30–7.34 (m, 2 H), 7.40 (t, 2 H, J = 7.6 Hz), 7.59–7.63 (m, 2 H), 7.77 (d, 2 H, J = 7.6 
Hz).  
 
Synthesis of Fmoc-protected L-isoleucine methylene amine (4). To the 
solution of 3 (1.04 g, 2.31 mmol) in DMF (9 mL), sodium azide (0.45 g, 6.93 mmol) 
was added. H2O (1 mL) was added to solubilise the NaN3. The reaction mixture was 
stirred at RT for 6 h. The reaction mixture was diluted with EtOAc (10 mL) and 
washed with saturated NaHCO3 (2 × 10 mL) and H2O (1 × 10 mL). The organic phase 
was dried over MgSO4, filtered and evaporated to give a pale yellow solid (ESI-MS: 
m/z 365.2 [MH]+). The resulting solid in MeOH (40 mL) with 10% Pd/C (60 mg) was 
hydrogenated at 40 psi for 1 h. The Pd/C catalyst was removed by filtering the 
mixture through celite and the filtrate was evaporated to dryness in vacuo to yield 4 
(ESI-MS: m/z 339.2 [MH]+). The crude product (4, 0.51 g, 1.51 mmol) was loaded 
onto TCP-resin (0.32 g, 1.1 mmol/g) followed by subsequent amino acid coupling to 
give dipeptide 120. Dipeptide 120 was fully characterized and the data were reported 
in section 2.6.   
 
Solid & solution phase synthesis of dipeptides 89, 118-132. Dipeptides 89, 118, 
120-132 were synthesised on solid phase following standard Fmoc SPPS procedures. 
To synthesise dipeptide 89, 122-132, Rink-amide resin (100–300 mg, 0.70 mmol/g) 
was used and for dipeptide 118, Wang resin (200 mg, 1.10 mmol/g) was used. To 
synthesise dipeptide 120, the Fmoc-protected L-Isoleucine methylene amine (4, 0.47 
g, 1.39 mmol) was loaded onto TCP-resin (0.31 g, 1.12 mmol) followed by 
subsequent amino acid coupling. Upon cleavage, dipeptide 120 (40 mg) was obtained 
 89 
and acetylation of 120 (16 mg, 0.04 mmol) with acetic anhydride (8.3 µL, 0.08 mmol) 
in DCM (0.15 mL) containing Et3N (24.5 µL, 0.16 mmol), gave dipeptide 121 (4 mg) 
after HPLC purification. The methyl ester dipeptide (119) was synthesised via 
solution phase chemistry approach using Boc-protected amino acids. The unprotected 
L-Ile-OH (1.02 g, 7.77 mmol) was first esterified using acetyl chloride (1.1 mL, 15.5 
mmol) in anhydrous MeOH (30 mL) and then coupled to subsequent amino acids to 
yield 119. Dipeptides 89, 118-132 were fully characterized and the data were reported 
in section 2.6.   
 
2.5.2 Synthesis of compound 134 
 
Scheme 2.3 Synthesis of compound 134.27 
BocHN O BocHN NH OH
a
N O
CO2Et
NHBoc
b c, d, e
N
OH
N
O
N
H
O
N O
NH2
5 6 7
134  
Reagents and conditions: a) NH2OH.HCl, pyridine, MeOH; b) NCS, ≡CO2Et, Et3N, 
DMF; c) LiOH, THF/H2O; d) NH2-Cha-Ile-spiroindenepiperidine, HBTU/DIPEA, 
DMF; e) 20% TFA, DCM. 
 
Synthesis of oxime 6. A mixture of N-Boc-2-aminoacetaldehyde 5 (0.51 g, 3.14 
mmol), hydroxylamine hydrochloride (0.32 g, 4.71 mmol) and pyridine (2.5 mL) in 
MeOH (18 mL) was stirred at RT overnight. The reaction mixture was concentrated 
in vacuo and the residue was re-dissolved in DCM (20 mL) and washed with H2O (1 
× 20 mL). The aqueous phase was extracted with DCM (2 × 20 mL). All organic 
extracts were combined, dried over MgSO4, filtered, evaporated in vacuo and used for 
next step without purification. ESI-MS: m/z 175.2 [MH]+. 
 
Synthesis of 7. To a solution of oxime 6 (0.54 g, 3.14 mmol) in DMF (18 mL) 
was added solid N-chlorosuccinimide (0.67 g, 5.21 mmol) at RT. After addition, the 
reaction mixture was heated at 60 °C for an hour. Then the reaction mixture was 
cooled to 0°C and propynoic acid ethyl ester (0.91 mL, 8.81 mmol) was added 
followed by dropwise addition of Et3N (0.5 mL in 4 mL DMF). The colour of the 
reaction mixture slowly turned from colourless to bright orange colour during 
addition of Et3N. After complete addition of Et3N, the reaction mixture was warmed 
to RT, diluted with EtOAc (20 mL) and H2O (20 mL) and then the layers were 
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separated. The aqueous phase was extracted with EtOAc (2 × 15 mL) and the 
combined organic extracts were washed with H2O (1 × 20 mL), brine (1 × 20 mL), 
dried over MgSO4, filtered and evaporated to dryness in vacuo. The crude product 
was purified by flash column chromatography (SiO2, Petroleum ether/EtOAc, 1:1, Rf 
product 0.6) and gave desired product (7) as an orange syrup (0.39 g, 46% yield after 
2 steps). ESI-MS: m/z 271.3 [MH]+; 1H NMR (600 MHz, CDCl3), δ 1.34 (t, 3 H, J = 
7.1 Hz), 1.40 (s, 9 H), 4.34–4.39 (m, 4 H), 5.30 (br s, 1 H), 6.90 (s, 1 H). 
  
Ester hydrolysis of 7. To a cooled solution of 7 (0.20 g, 0.74 mmol) in THF (2.5 
mL), 1 M LiOH solution (0.7 mL, 0.74 mmol) was added and the reaction mixture 
was stirred at 0°C for 1 h. The THF was evaporated and the residual was acidified 
with 2 M HCl (0.2 mL) and extracted with DCM (3 × 3 mL). The organic phase was 
dried over MgSO4, filtered and evaporated to dryness in vacuo. The crude product 
was used for the next step without purification. ESI-MS: m/z 243.1 [MH]+.  
 
Synthesis of 134. The 3-(N-Boc-aminomethyl)isoxazole-5-carboxylic acid (32 
mg, 0.13 mmol) in DMF (0.3 mL) was activated with HBTU (49 mg, 0.13 mmol) and 
DIPEA (23 µL, 0.13 mmol) for 15 min. After that, NH2-Cha-Ile-
spiroindenepiperidine (50 mg, 0.11 mmol) was added and the reaction mixture was 
stirred at RT for 6 h. The reaction mixture was diluted with EtOAc (2 mL) and 
washed with saturated NaHCO3 twice (2 × 2 mL). The organic phase was dried over 
MgSO4, filtered and evaporated to dryness in vacuo. The crude was then purified by 
HPLC. 10 mg of the purified compound was treated with 20% TFA in DCM (0.5 mL) 
to remove the Boc group yielded the desired product 134 (6 mg). Compound 134 was 
characterized and the data were reported in section 2.6.   
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2.5.3 Synthesis of Phenyl-Piperidine amines using 1-Boc-4-Piperidone 
 
Scheme 2.4 Synthesis of phenyl-piperidine amines (9a–b) 
 
BrBocN
O
BocN OH HNa
R R
8a, R = H
8b, R = Cl
9a, R = H
9b, R = Cl
R
b or c
 
 
Reagents and conditions: a) Mg/THF, reflux; b) (i) H2, 10% Pd/C, HCl/EtOH, 50 psi; 
(ii) 4 M HCl/THF; c) (i) 100% TFA; (ii) H2, PtO2, EtOH, 10 psi.  
 
Grignard Reaction (Synthesis of 8a and 8b).28-29 To a dry nitrogen filled 2-
necked round bottom flask was loaded magnesium turnings (0.49 g, 20.1 mmol), a 
small crystal of iodine and dry THF (3.8 mL). While stirring in a warm water bath 
(55–65 °C), a solution of bromobenzene (2.2 mL, 20.1 mmol) in anhydrous THF (5 
mL) was loaded into a dried syringe and 1/3 of the solution was slowly transferred to 
the flask to initiate the reaction (Note: the colour slowly changed from dark brown to 
light brown). When the mixture began to reflux, the warm water bath was removed 
and the mixture was diluted with dry THF (5 mL).  The remaining bromobenzene 
solution was slowly added to the flask. After refluxing for 20 min the mixture was 
cooled in an ice-water bath and a solution of 1-Boc-4-piperidone (2.01 g, 10.1 mmol) 
in dry THF (5 mL) was added dropwise (a white solid was formed during addition). 
After addition, the mixture was allowed to stir at room temperature for 30 min.  A 
chilled solution of 10% citric acid (10 mL) was added and the mixture was stirred for 
1 min upon which solids were formed. Diethyl ether (10 mL) and H2O (10 mL) were 
added to dissolve the solid and the layers were separated. The aqueous layer was 
extracted with ether (2 × 15 mL) and the combined organic extracts were washed with 
H2O (15 mL), dried over anhydrous MgSO4, filtered and evaporated in vacuo. The 
crude product was purified by silica gel column chromatography eluting with 
petroleum ether/EtOAc (4:1) to give a white crystalline product (8a, 0.96 g, 35%; 8b, 
1.26 g, 41%). A di-piperidine by-product was formed in this reaction and thus led to a 
low yield of the desired product. The formation of this by-product can be avoided if 
N-Bn-4-piperidone and n-BuLi were used.  
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N
Boc
O
NBoc
HO
           by-product from step (a) 
 
8a: Rt = 4.9 min (80B isocratic); ESI-MS: m/z 278.2 [MH]+; 1H NMR (400 MHz, 
CDCl3), δ 1.47 (s, 9 H), 1.62–1.68 (m, 2 H), 1.87–1.95 (m, 1 H), 2.39 (t, 1 H, J = 6.2 
Hz), 3.20-3.23 (m, 1 H), 3.40 (d, 2 H, J = 3.2 Hz), 3.68 (t, 1 H, J = 6.2 Hz), 7.27–7.37 
(m, 2 H), 7.40–7.45 (m, 2 H), 7.55–7.58 (m, 1 H). 
 
8b: Rt = 5.9 min (80B isocratic); ESI-MS: m/z 312.1 [MH]+; 1H NMR (400 MHz, 
CDCl3), δ 1.48 (s, 9 H), 1.63–1.70 (m, 2 H), 1.96 (dd, 2 H, J= 9.3, 12.0 Hz), 2.17 (br 
s, 1 H), 3.24 (m, 2 H), 4.01 (m, 2 H), 7.33 (d, 2 H, J = 6.8 Hz), 7.43 (d, 2 H, J = 6.8 
Hz).  
 
Synthesis of 9a. A mixture of 8a (0.20 g, 0.72 mmol), 10% Pd/C (50 mg), and 
catalytic amount of concentrated HCl (1.2 mL) in EtOH (20 mL) was hydrogenated at 
50 psi for an hour. The Pd/C catalyst was removed by filtering the mixture through 
celite, and the filtrate was evaporated in vacuo. The resulting crude product (0.19 g) 
was treated with 4 M HCl (4 mL) in THF (4 mL) for an hour. The THF solvent and 
HCl were evaporated and the residue was dissolved in CH2Cl2 (5 mL) and washed 
with saturated NaHCO3 (2 × 4 mL). The organic extracts were dried over MgSO4, 
filtered, and evaporated in vacuo. The residue amine (9a, ESI-MS: m/z 162.1 [MH]+) 
was coupled to Boc-protected isoleucine as described in the procedures under section 
2.5.6. without further purification (>95% pure by analytical rpHPLC, Rt = 5.7 min 
(Method I)).  
 
Synthesis of 9b. 8b (0.19 g, 0.63 mmol) was treated with 100% TFA (5 mL) and 
stirred overnight to dehydrate the tertiary alcohol to give an olefin with concomitant 
loss of the Boc group. The reaction mixture was dried under N2 to remove all the TFA 
and the crude was then treated with PtO2 (15 mg, 0.1 eq) and hydrogenated at 10 psi 
for 1 h in EtOH (5 mL). (Note: The chlorine on phenyl ring was removed under 10% 
Pd/C at 50 psi. Thus PtO2 was used.). After filtration, the filtrate was evaporated. The 
residue was dissolved in DCM (5 mL) and washed with saturated NaHCO3 (2 × 4 
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mL). The DCM extracts were dried over MgSO4, filtered and evaporated to dryness in 
vacuo. The resulting crude product was purified by HPLC (Method I) and lyophilised 
to give 68.1 mg (54%) of 9b as a pale-yellow amorphous powder. Rt = 6.9 min 
(Method I); ESI-MS: m/z 196.3 [MH]+; 1H NMR (400 MHz, CDCl3), δ 1.99–2.12 (m, 
4 H), 2.72–2.80 (m, 1 H), 2.97–3.06 (m, 2 H), 3.53 (d, 2 H, J = 12.8 Hz), 7.14–7.17 
(m, 2H), 7.27–7.32 (m, 2H), 9.25 (br s), 9.75 (br s).  
 
2.5.4 Synthesis of Phenyl-Piperidine amines (13c–j) using N-Bn-4-piperidone 
 
Scheme 2.5 Synthesis of phenyl-piperidine amines (13c–j).30  
BrBnN
O
BnN OH BnN HNa b c
 11 c-j
R R R
12 c-i 13 c-i (X = H)      j (X = OH)
R
X
 
R = (c) p-OMe, (d) o-phenyl, (e) m-phenyl, (f) p-phenyl, (g) p-O-phenyl, (h) 2,5-
dimethoxy, (i) o-CF3, (j) 2,4-di-trifluoromethyl  
Reagents and conditions: a) n-BuLi, THF, -78 °C; b) conc. HCl; c) H2, 10% Pd/C, 
HCOOH/MeOH.  
 
Synthesis of 11c–j (General Procedure). The aryl bromide (1 eq.) in dry THF (3 
mL/mmol) was stirred at -78 °C under N2 and a solution of n-BuLi in hexanes (1.6 M, 
1.1 eq.) was added to give a suspension. The mixture was stirred at -78 °C for 30 
minutes. N-Bn-4-piperidone (1 eq.) in dry THF (0.8 mL/mmol) was slowly added to 
the above mixture over 30 minutes and then stirred for 3 h at -78 °C under N2. After 
that the cold reaction mixture was poured into ice-cold solution of NH4Cl in H2O and 
extracted with ether (2 ×). The organic phase was washed with H2O (2 ×) and brine (1 
×), and then dried over MgSO4, filtered and evaporated to dryness in vacuo. The 
crude was purified by silica gel column chromatography eluting with petroleum 
ether/EtOAc (~1:3) to give a white solid (11c = 15%; 11d = 46%; 11e = 22%; 11f = 
35%; 11g = 13%; 11h = 17%; 11i = 29%; 11j = 19%). The side product shown 
previously in section 2.5.3 (under synthesis of 8a, 8b), was not observed when n-BuLi 
was used. The yields for 11c-j varied from 13–46% because different substrates were 
used. 
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11c: ESI-MS: m/z 298.3 [MH]+; 1H NMR (400 MHz, CDCl3), δ 1.71–1.77 (m, 2 H), 
2.14 (td, 2 H, J = 4.4, 13.2 Hz), 2.43–2.50 (m, 2 H), 2.73–2.79 (m, 2 H), 3.58 (s, 2 H), 
3.80 (s, 3 H), 6.86–6.89 (m, 2 H), 7.23–7.28 (m, 1 H), 7.30–7.37 (m, 4 H), 7.41–7.45 
(m, 2 H).  
 
11d–f: ESI-MS: m/z 344.3 [MH]+; 1H NMR (400 MHz, CDCl3), δ 1.82–1.85 (m, 2 
H), 2.25 (td, 2 H, J = 4.0, 13.2 Hz), 2.39–2.45 (m, 2 H), 2.70–2.72 (m, 2 H), 3.55 (s, 2 
H), 7.13–7.63 (m, 14 H). 
  
11g: ESI-MS: m/z 360.2 [MH]+; 1H NMR (400 MHz, CDCl3), δ 1.73 (d, 2 H, J = 12 
Hz), 2.14 (td, 2 H, J = 4.4, 13.6 Hz), 2.42–2.50 (m, 2 H), 2.71–2.78 (m, 2 H), 3.57 (s, 
2 H), 6.95–7.00 (m, 4 H), 7.06–7.10 (t, 1 H, J = 7.2 Hz), 7.23–7.35 (m, 7 H), 7.45 (d, 
2 H, J = 8.4 Hz). 
 
11h: ESI-MS: m/z 328.3 [MH]+; 1H NMR (400 MHz, CDCl3), δ 1.97–2.00 (m, 2 H), 
2.09 (td, 2 H, J = 4.0, 12.8 Hz), 2.54–2.60 (m, 2 H), 2.72–2.75 (m, 2 H), 3.57 (s, 2 H), 
3.73 (s, 3 H), 3.82 (s, 3 H), 6.72 (dd, 1 H, J = 2.8, 8.8 Hz), 6.82 (d, 1 H, J = 8.8 Hz), 
6.88 (d, 1 H, J = 3.2 Hz), 7.29–7.36 (m, 5 H). 
 
11i: ESI-MS: m/z 352.4 [MH]+; 1H NMR (400 MHz, CDCl3), δ 1.86–1.89 (m, 2 H), 
2.27 (td, 2 H, J = 4.6, 13.0 Hz), 2.53–2.58 (m, 2 H), 2.77–2.82 (m, 2 H), 3.59 (s, 2 H), 
7.26–7.29 (m, 1 H), 7.31–7.38 (m, 5 H), 7.48–7.52 (m, 1 H), 7.59–7.62 (m, 1 H), 7.79 
(d, 1 H, J = 8 Hz). 
  
11j: ESI-MS: m/z 404.4 [MH]+; 1H NMR (400 MHz, CDCl3), δ 1.85 (d, 2 H, J = 13.6 
Hz), 2.22–2.30 (m, 2 H), 2.48–2.55 (m, 2 H), 2.79–2.82 (m, 2 H), 3.58 (s, 2 H), 7.23–
7.35 (m, 5 H), 7.74–7.75 (m, 2 H), 8.03 (s, 1 H). 
 
Synthesis of 13c. 11c (50 mg) in MeOH (5 mL) was treated with 20% HCOOH 
(1 mL) and 10% Pd/C (15 mg) was slowly added to it. The mixture was stirred at 
room temperature for 2 h. The mixture was then transferred to a hydrogenation 
reactor with addition of conc. HCl (1 mL) and hydrogenated at 40 psi for 1 h. The 
reaction mixture was filtered, solvent was evaporated, and then neutralised with 1 M 
NaOH (10 mL), and then extracted with DCM (3 × 3 mL). The organic phase was 
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dried over MgSO4, filtered and evaporated to dryness in vacuo to give 20.7 mg (64%) 
of 13c. Rt = 6.05 min (Method I); ESI-MS: m/z 192.2 [MH]+; 1H NMR (CDCl3), δ 
1.96–2.11 (m, 4 H), 2.66–2.69 (m, 1 H), 2.93–2.95 (m, 2 H), 3.52–3.53 (m, 2 H), 3.77 
(s, 3 H), 6.86 (d, 2 H, J = 8.4 Hz), 7.15 (d, 2 H, J = 8.8 Hz), 8.66 (br s, NH). 
  
Synthesis of 12d–i (General Procedure). Unlike 11c, the OH group of  11d–
11h was harder to dehydrate and required harsher conditions. 11d–11j (0.91 mmol) 
were treated with 100% conc. HCl (10 mL) and heated using heat gun for 5–15 
minutes. However no reaction was observed for 11i and 11j.  Thus, 11i was refluxed 
in 100% conc. HCl (10 mL) for 5 h and 11j did not dehydrate at all under this 
condition. So 11j was used directly for the next reaction. When reaction went to 
completion, it was cooled down, neutralised with 2 M NaOH solution (40 mL) and 
extracted with EtOAc (2 × 30 mL). The organic phase was dried over MgSO4, filtered 
and evaporated to dryness in vacuo. The crude product was used for the next step 
without purification. 12d–f, ESI-MS: m/z 326.2 [MH]+; 12g, ESI-MS: m/z 342.2 
[MH]+; 12h, ESI-MS: m/z 310.1 [MH]+; 12i, ESI-MS: m/z 318.2 [MH]+; 11j, ESI-
MS: m/z 404.2 [MH]+.  
 
Synthesis of 13d–13j (General Procedure). Compounds 12d–j (0.60 mmol) 
were first dissolved in MeOH (18 mL) containing 20% HCOOH (6 mL) and then 
10% Pd/C (50 mg) was slowly added to it. The reaction mixture was stirred at room 
temperature for 1–2 h and then it was transferred to a hydrogenation vessel and shake 
under H2 at 50 psi for an hour. The organic solvent was evaporated and the remaining 
acidic aqueous solution was neutralised with 2 M NaOH (20 mL) and extracted with 
EtOAc (2 × 20 mL). The organic phase was dried over MgSO4, filtered and 
evaporated to dryness in vacuo. All the crude product, except 13g (Rt = 8.1 min, 
Method I, ESI-MS: m/z 253.3) and 13i (Rt = 7.0 min, Method I, ESI-MS: m/z 229.2), 
were purified by HPLC (Method I) to give 13c (50%), 13d (40%), 13e (50%), 13f 
(79%), 13g (56%), 13h (53%), 13i (60%) and 13j (92%). 13g and 13i were used for 
the next step without purification.  
13c: Rt = 6.10 min (Method I); ESI-MS: m/z 191.2 [MH]+; 1H NMR (400 MHz, 
CDCl3), δ 1.96–2.14 (m, 4 H), 2.66–2.72 (m, 1 H), 2.93–2.98 (m, 2 H), 3.52 (d, 2 H, J 
= 10.8 Hz), 3.79 (s, 3 H), 6.85 (d, 2 H, J = 8.4 Hz), 7.15 (d, 2 H, J = 8.8 Hz), 8.66 (br 
s, 1 H). 
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13d: Rt = 7.86 min (Method I); ESI-MS: m/z 238.4 [MH]+; 1H NMR (400 MHz, 
CDCl3), δ 1.87 (d, 2 H, J = 14.0 Hz), 2.03–2.15 (m, 2 H), 2.72–2.81 (m, 2 H), 2.85–
2.93 (m, 1 H), 3.38 (d, 2 H, J = 11.6 Hz), 7.18–7.30 (m, 5 H), 7.36–7.44 (m, 4 H), 
9.10 (br s), 9.61 (br s). 
13e: Rt = 8.03 min (Method I); ESI-MS: m/z 238.4 [MH]+; 1H NMR (400 MHz, 
CDCl3), δ 2.05–2.19 (m, 4 H), 2.80–2.85 (m, 2 H), 3.02–3.10 (m, 1 H), 3.55 (d, 2 H, J 
= 10.8 Hz), 7.20 (d, 1 H, J = 7.6 Hz), 7.32–7.49 (m, 6 H), 7.56–7.58 (m, 2 H), 9.16 
(br s), 9.61 (br s). 
13f: Rt = 8.17 min (Method I); ESI-MS: m/z 238.4 [MH]+; 1H NMR (400 MHz, 
CDCl3), δ 2.06–2.17 (m, 4 H), 2.80–2.86 (m, 1 H), 3.03–3.07 (m, 2 H), 3.56 (d, 2 H, J 
= 12.8 Hz), 7.29–7.39 (m, 3 H), 7.43–7.46 (m, 2 H), 7.56–7.59 (m, 4 H), 9.25 (br s), 
9.73 (br s). 
13h: Rt = 6.37 min (Method I); ESI-MS: m/z 222.3 [MH]+; 1H NMR (400 MHz, 
CDCl3), δ 1.97–2.05 (m, 4 H), 2.98–3.10 (m, 2 H), 3.14–3.22 (m, 1 H), 3.51 (d, 2 H, J 
= 12.4 Hz), 3.76 (s, 3 H), 3.79 (s, 3 H), 6.72–6.81 (m, 3 H), 9.12 (br s), 9.65 (br s). 
13j: Rt = 7.53 min (Method I); ESI-MS; m/z 314.2 [MH]+; 1H NMR (400 MHz, 
CDCl3), δ 2.10 (d, 2 H, J = 14.4 Hz), 2.60 (t, 2 H, J = 12.8 Hz), 3.34–3.42 (m, 2 H), 
3.50–3.62 (m, 2 H), 7.77 (d, 1 H, J = 8.8 Hz), 7.85 (d, 1 H, J = 8.0 Hz), 8.06 (s, 1 H), 
9.47 (br s), 9.57 (br s). 
 
2.5.5 Synthesis of 1-(4-fluorobenzyl)piperazine 
 
Scheme 2.6 Synthesis of 1-(4-fluorobenzyl)piperazine (14d) 
 
NHHN NHBocN
a F
NBocN
F
Br
F
NHN
b c
14a 14b 14c 14d  
Reagents and conditions: a) Boc2O, tBuOH/NaOH/H2O; b) Et3N, DCM; c) 20% TFA 
in DCM.  
 
Synthesis of 14b. To a solution of piperazine (10.3 g, 0.12 mol) in water (120 
mL) and tert-butanol (140 mL), a solution of 4 M NaOH (23 mL) was added. The 
mixture was cooled to 0°C and then di-tert-butyl-dicarbonate (13.1 g, 0.06 mmol) was 
added in portions. After addition, the reaction mixture was stirred at room 
temperature for 45 minutes and then tert-butanol was evaporated. The precipitate in 
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water (diBOC-piperazine) was filtered. The filtrate was extracted with DCM (2 × 80 
mL). The organic phase was then dried over MgSO4, filtered and then evaporated to 
dryness in vacuo to give the desired product (14b) as a white solid (4.73 g, 22%). 
ESI-MS: m/z 187.2 [MH]+; 1H NMR (400 MHz, CDCl3), δ 1.46 (s, 9 H), 2.81 (t, 4 H, 
J = 5.2 Hz), 3.38 (t, 4 H, J = 4.8 Hz).  
 
Synthesis of 14c. To mono-Boc protected piperazine (14b, 0.50 g, 2.68 mmol) in 
anhydrous DCM (10 mL), triethylamine (0.56 mL, 2.95 mmol) and 4-
fluorobenzylbromide (0.4 mL, 4.02 mmol) were added under N2. The mixture was 
stirred at room temperature overnight. After this time, the mixture was diluted with 
water (10 mL), and extracted with DCM (2 × 10 mL). The organic phase was dried 
over MgSO4, filtered and evaporated to dryness in vacuo.  The crude product was 
purified by flash column chromatography (SiO2, Petroleum Ether/EtOAc 1:1) to yield 
0.64 g of product (14c, 81.3%). ESI-MS: m/z 295.2 [MH]+; 1H NMR (400 MHz, 
CDCl3), δ 1.36 (s, 9 H), 2.26 (t, 4 H, J = 5.2 Hz), 3.28 (t, 4 H, J = 4.8 Hz), 3.43 (s, 2 
H), 7.08–7.13 (m, 2 H), 7.28–7.32 (m, 2 H). 
 
Synthesis of 1-(4-fluorobenzyl)piperazine (14d). The Boc group on 14c (0.59 g, 
2.01 mmol) was then removed with 20% TFA in DCM (10 mL). The reaction was 
completed after stirring for an hour at room temperature. The solvent and TFA were 
evaporated and the residue was re-dissolved in DCM (10 mL) and washed with 
saturated NaHCO3 (2 × 10 mL). The organic phase was dried over MgSO4, filtered 
and evaporated to dryness in vacuo.  The crude product (ESI-MS: m/z 195.2 [MH]+) 
was coupled to Boc-Ile-OH followed by Boc-deprotection and subsequent coupling 
with Boc-Cha-OH and isoxazole-COOH to give compound 166. Compound 166 was 
characterized and the data were reported in section 2.6.   
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2.5.6 General procedures for solution phase amino acid coupling 
 
Scheme 2.7 General synthetic scheme for the synthesis of compounds 133–186. 
 
NH
R1
R2
O
BocHN OH
O
H2N N
R1
R2
OH
N N
R1
R2O
N
H
O
N O
a, b c, b, d
 
 
Reagents and conditions: a) HBTU, DIPEA, DMF; b) 20% TFA, DCM; c) Boc-Cha-
OH, HBTU, DIPEA, DMF; d) isoxazole-5-carboxylic acid, HBTU, DIPEA, DMF. 
 
Compounds (133–186) were synthesised via solution phase chemistry approach 
using Boc-protected amino acids. Firstly, the amino acid (1.2–1.5 eq.) was activated 
with HBTU (1.5 eq.) and DIPEA (1.5 eq.) as 0.2–0.5 M solutions in DMF for 10 
minutes. Then the reaction mixture was added to an amino bearing C-terminal moiety 
and the mixture was stirred overnight at room temperature. The reaction mixture was 
diluted with EtOAc and washed with saturated NaHCO3 (2 ×). The organic extracts 
were dried over MgSO4, filtered and evaporated in vacuo. The crude product was then 
treated with 20% TFA in DCM and stirred for 1–2 h to remove the Boc group. TFA 
was removed by evaporating the reaction mixture under N2. The residue was 
dissolved in DCM and washed with saturated NaHCO3 (2 ×).  DCM phase was dried 
with MgSO4, filtered and evaporated in vacuo. Subsequent N-Boc-amino acids and 
amines were sequentially coupled under the same condition. Each coupling reactions 
were monitored by ESI-MS, with most reactions went to completion overnight.  
 
2.5.7 Intracellular calcium release assay10, 12  
 
Assay Protocol. Adherent human colon adenocarcinoma cells (HT29) were 
plated at ~2 x 104 cells/well in a 96-well cleared-bottom black-wall assay plate 
(Corning) with equal amounts of medium (Dulbecco’s modified essential serum 
(DMEM from Gibco), penicillin (10 U/mL) and streptomycin (10 U/mL)) added and 
incubated overnight at 37oC. Before assay, the medium was removed and cells were 
incubated with dye-loading buffer (12 mL assay buffer, 4 µM Fluo-3 AM, 25 µL 
Pluronic acid F-127 and 1% fetal bovine serum) for 1 h at 37oC. After that, cells were 
washed once with the same assay buffer (HBSS supplemented with 2.5 mM 
probenecid and 20 mM HEPES, pH 7.4). 
 
 99 
Sample Preparation. Stock solutions of compounds were prepared by dissolving 
the compound in DMSO solution to give a 10 mM stock solution. The 10 mM stock 
solutions were then diluted with assay buffer (described in assay protocol) to give the 
concentrations required for the assay.  
 
Preliminary Assessment of Compounds. For the antagonist assay, the cells 
were pre-incubated with desired concentrations of the synthesised compounds (50 µL, 
20 µM) for 30 min before the addition of PAR2 agonist (2f-LIGRLO-NH2). The 96-
well plate was placed into fluorescence plate reader (Fluostar Optima – BMG 
Labtechnologies or FLIPRTETRA) and then 2f-LIGRLO-NH2 (50 µL, 2 µM) was added 
to give a final agonist concentration of 1 µM. The final concentration of compounds 
was 10 µM). After addition of agonist, the intracellular release of Ca2+ was monitored 
via fluorescence measurement for at least 60 s (excitation 495 nm, emission 520 nm). 
The agonist assay was conducted in a similar manner, except that assay buffer (50 µL) 
was added to the cells first and the intracellular Ca2+ release was monitored 
immediately after the injection of the desired concentration of the synthesised 
compounds. 
 
Concentration Dependent Inhibition Assay. To assess a potential antagonist in 
more detail, a range of concentrations of the compound (50 µL) was pre-incubated 
with the cells for 30 min prior to the addition of 2f-LIGRLO-NH2 (50 µL, 2 µM). 
After addition of agonist, the intracellular release of Ca2+ was monitored via 
fluorescence measurement for at least 60 s (excitation 495 nm, emission 520 nm). 
Duplicate measurements were made for each data point, mean ± SEM were reported 
from multiple experiments as indicated. Changes in fluorescence (% response) were 
plotted against logarithmic compound concentrations. The half maximal inhibitory 
concentration (IC50) values were derived from the concentration response curve using 
a nonlinear regression curve in Graphpad Prism v5. 
 
Concentration Dependent Response Curves. To assess a potential agonist in 
more detail, a range of concentrations of the compound (50 µL) was added to the cells 
containing 50 µL assay buffer. The intracellular Ca2+ release was monitored for at 
least 60 s (excitation 495 nm, emission 520 nm) immediately after the injection of the 
desired concentration of the synthesised compounds. Duplicate measurements were 
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made for each data point, mean ± SEM were reported from multiple experiments as 
indicated. Changes in fluorescence (% response) were plotted against logarithmic 
compound concentrations. The half maximal effective concentration (EC50) values 
were derived from the concentration response curve using a nonlinear regression 
curve in Graphpad Prism v5. 
 
2.6 Characterization data for all final compounds 
 
General Methods  
 
All purified final compounds were characterized by ESI-HRMS and 1H NMR 
(Varian 400 or Bruker Avance 600), and the purities were assessed via analytical 
rpHPLC (Phenomenex C18 column, 15 µm, 90 Å, 4.6 × 250 mm, λ 214, 230 and 254 
nm). All compounds were ≥95% pure. Four standard HPLC conditions were used for 
all compounds unless otherwise indicated at a flow rate of 1 mL/min. Method I: 20% 
to 100% B linear gradient over 10 min followed by a further 10 min at 100% B; 
Method II: 50% to 100% B linear gradient over 10 min followed by a further 10 min 
at 100% B; Method III: 90% B isocratic for 10 min; Method IV: 20% to 100% B 
linear gradient over 15 min followed by a further 10 min at 100% B where solvent B 
was MeCN + 0.1% TFA and solvent A was H2O + 0.1% TFA. HPLC was performed 
using an Agilent 1200 Series with a diode-array detector on a Phenomenex Luna 5 
µm, C18 or C8 250 × 4.60 mm column. All compounds were analysed on NMR 
(Varian 400 or Bruker Avance 600) at 298 K in the deuterated solvents indicated and 
were referenced to the residual 1H signals; DMSO-d6 2.50, CD3OD 3.31 ppm except 
CDCl3 solutions were referenced to internal TMS. 13C NMR resonances were 
referenced to the residual solvent peak (DMSO-d6 40.4, CDCl3 77.0 ppm). 
Electrospray ionisation high-resolution mass spectra (ESI-HRMS) measurements 
were obtained on a Bruker microTOF mass spectrometer equipped with an Agilent 
1100 Series LC/MSD mass detector in positive ion mode by direct infusion in MeCN 
at 100 µL/h using sodium formate clusters as an internal calibrant.  
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Compound Dipeptide sequence Analytical data 
89 Isox–Cha–Ile–NH2 
 
Rt = 8.9 min (Method I); HRMS: [MH]+ 
379.2340 (calc. for C19H31N4O4+) 379.2340 
(found); 1H NMR (600 MHz, DMSO–d6), δ 
0.78–0.84 (m, 6 H), 0.84–0.95 (m, 2 H), 
1.02–1.13 (m, 3 H), 1.13–1.22 (m, 1 H), 
1.27–1.35 (m, 1 H), 1.39–1.47 (m, 1 H), 
1.51–1.60 (m, 2 H), 1.60–1.73 (m, 6 H), 4.12 
(dd, 1 H, J = 7.6, 8.8 Hz), 4.52–4.57 (m, 1 
H), 7.02 (s, 1 H), 7.15 (d, 1 H, J = 1.9 Hz), 
7.37 (s, 1 H), 7.82 (d, 1 H, J = 9 Hz), 8.74 
(d, 1 H, J = 1.9 Hz), 8.97 (d, 1 H, J = 7.9 
Hz).  
118 Isox–Cha–Ile–OH 
 
 
Rt = 10.1 min (Method I); HRMS: [MH]+ 
380.2180 (calc. for C19H30N3O5+) 380.2176 
(found); 1H NMR (600 MHz, DMSO–d6), δ 
0.82–0.87 (m, 6 H), 0.87–0.95 (m, 2 H), 
1.07–1.14 (m, 2 H), 1.14–1.24 (m, 2 H), 
1.30–1.38 (m, 1 H), 1.39–1.46 (m, 1 H), 
1.52–1.61 (m, 2 H), 1.61–1.67 (m, 3 H), 
1.67–1.74 (m, 2 H), 1.75–1.82 (m, 1 H), 4.17 
(dd, 1 H, J = 6, 8.3 Hz), 4.58–4.63 (m, 1 H), 
7.16 (d, 1 H, J = 1.9 Hz), 8.11 (d, 1 H, J = 
8.2 Hz), 8.74 (d, 1 H, J = 2 Hz), 8.92 (d, 1 H, 
J = 8.5 Hz).  
119 Isox–Cha–Ile–CO2Me 
 
Rt = 8.5 min (Method I); HRMS: [MNa]+ 
416.2156 (calc. for C20H31NaN3O5+) 
416.2155 (found); 1H NMR (600 MHz, 
CDCl3), δ 0.85–0.92 (m, 6 H), 0.92–1.01 (m, 
2 H), 1.10–1.27 (m, 4 H), 1.34–1.44 (m, 2 
H), 1.60–1.82 (m, 8 H), 1.86–1.93 (m, 1 H), 
3.75 (s, 3 H), 4.58 (q, 1 H, J = 4.9 Hz), 4.66–
4.71 (m, 1 H), 6.55 (d, 1 H, J = 8.6 Hz), 6.94 
(d, 1 H, J = 1.8 Hz), 7.10 (d, 1 H, J = 8.2 
Hz), 8.33 (d, 1 H, J = 1.8 Hz).  
120 Isox–Cha–Ile–CH2NH2 
 
Rt = 9.3 min (100A to 100 B in 10 min); 
HRMS: [MH]+ 365.2547 (calc. for 
C19H33N4O3+) 365.2543 (found); 1H NMR 
(600 MHz, DMSO–d6), δ 0.77–0.82 (m, 6 
H), 0.82–0.95 (m, 2 H), 1.03–1.11 (m, 3 H), 
1.12–1.18 (m, 1 H), 1.25–1.40 (m, 2 H), 
1.48–1.55 (m, 1 H), 1.55–1.60 (m, 1 H), 
1.60–1.70 (m, 5 H), 1.70–1.75 (m, 1 H), 
2.75–2.83 (m, 1 H), 2.90–2.97 (m, 1 H), 
3.80–3.86 (m, 1 H), 4.46–4.50 (m, 1 H), 7.14 
(d, 1 H, J = 1.9 Hz), 7.73 (br s, 2 H), 7.83 (d, 
1 H, J = 8.8 Hz), 8.73 (d, 1 H, J = 1.9 Hz), 
9.03 (d, 1 H, J = 8.1 Hz).  
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121 Isox–Cha–Ile–
CH2NHCOCH3 
 
 
Rt = 9.4 min (Method I); HRMS: [MH]+ 
407.2653 (calc. for C21H35N4O4+) 407.2653 
(found); 1H NMR (600 MHz, DMSO–d6), δ 
0.78–0.83 (m, 6 H), 0.84–0.95 (m, 2 H), 
1.03–1.19 (m, 4 H), 1.26–1.35 (m, 1 H), 
1.37–1.43 (m, 1 H), 1.45–1.52 (m, 1 H), 
1.54–1.72 (m, 7 H), 1.74 (s, 3 H), 3.07–3.13 
(m, 2 H), 3.66–3.72 (m, 1 H), 4.40–4.45 (m, 
1 H), 7.15 (d, 1 H, J = 1.7 Hz), 7.59 (d, 1 H, 
J = 8.9 Hz), 7.64 (t, 1 H, J = 6 Hz), 8.72 (d, 
1 H, J = 1.9 Hz), 8.90 (d, 1 H, J = 8 Hz).  
122 Isox–Tyr–Ile–NH2 
 
 
Rt = 6.7 min (Method I);HRMS: [MNa]+ 
411.1639 (calc. for C19H24NaN4O5+) 
411.1636 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.79–0.88 (m, 6 H), 1.04–1.11 
(m, 1 H), 1.41–1.48 (m, 1 H), 1.68–1.75 (m, 
1 H), 2.84 (dd, 1 H, J = 10.8, 13.9 Hz), 2.97 
(dd, 1 H, J = 3.9, 14 Hz), 4.17 (dd, 1 H, J = 
7.2, 8.9 Hz), 4.65–4.70 (m, 1 H), 6.61 (d, 1 
H, J = 8.5 Hz), 7.04 (s, 1 H), 7.07 (d, 1 H, J 
= 1.9 Hz), 7.10 (d, 2 H, J = 8.5 Hz), 7.39 (s, 
1 H), 7.99 (d, 1 H, J = 9 Hz), 8.71 (d, 1 H, J 
= 1.9 Hz), 8.95 (d, 1 H, J = 8.5 Hz).  
123 Isox–Trp–Ile–NH2 
 
Rt = 8.0 min (Method I); HRMS: [MNa]+ 
434.1799 (calc. for C21H25NaN5O4+) 
434.1798 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.80–0.84 (m, 6 H), 1.03–1.13 
(m, 1 H), 1.41–1.48 (m, 1 H), 1.69–1.75 (m, 
1 H), 3.12 (dd, 1 H, J = 10.5, 14.9 Hz), 3.19 
(dd, 1 H, J = 4.4, 14.9 Hz), 4.17 (dd, 1 H, J = 
7.2, 8.9 Hz), 4.75–4.82 (m, 1 H), 6.92–6.95 
(m, 1 H), 7.00–7.06 (m, 3 H), 7.15 (d, 1 H, J 
= 2 Hz), 7.28 (d, 1 H, J = 8.1 Hz), 7.40 (br s, 
1 H), 7.65 (d, 1 H, J = 8.0 Hz), 8.03 (d, 1 H, 
J = 9.0 Hz), 8.68 (d, 1 H, J = 1.9 Hz), 8.94 
(d, 1 H, J = 8.3 Hz), 10.77 (s, 1 H).  
124 Isox–D(Phe)–Ile–NH2 
 
 
Rt = 8.2 min (Method I); HRMS: [MNa]+ 
395.1690 (calc. for C19H24NaN4O4+) 
395.1694 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.73–0.80 (m, 6 H), 0.97–1.05 
(m, 9 H), 1.29–1.36 (m, 1 H), 1.66–1.74 (m, 
1 H), 2.96 (dd, 1 H, J = 10.3, 13.4 Hz), 3.05 
(dd, 1 H, J = 5.0, 13.9 Hz), 4.14 (dd, 1 H, J = 
6.8, 8.9 Hz), 4.81–4.87 (m, 1 H), 7.04 (br s, 
1 H), 7.12–7.16 (m, 1 H), 7.22 (t, 2 H, J = 
7.5 Hz), 7.32 (d, 2 H, J = 7.4 Hz), 7.37 (br s, 
1 H), 8.24 (d, 1 H, J = 9.2 Hz), 8.68 (d, 1 H, 
J = 1.8 Hz), 9.05 (d, 1 H, J = 8.8 Hz).  
125 Isox–D(Cha)–Ile–NH2 
 
Rt = 8.9 min (Method I); HRMS: [MNa]+ 
401.2159 (calc. for C19H30NaN4O4+) 
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 401.2162 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.78–0.84 (m, 6 H), 0.85–0.94 
(m, 2 H), 1.04–1.20 (m, 4 H), 1.26–1.34 (m, 
1 H), 1.34–1.42 (m, 1 H), 1.52–1.60 (m, 2 
H), 1.60–1.67 (m, 3 H), 1.68–1.80 (m, 3 H), 
4.13 (dd, 1 H, J = 7.1, 8.9 Hz), 4.59–4.64 
(m, 1 H), 7.06 (br s, 1 H), 7.16 (d, 1 H, J = 
1.9 Hz), 7.33 (br s, 1 H), 8.14 (d, 1 H, J = 
9.4 Hz), 8.73 (d, 1 H, J = 1.9 Hz), 8.94 (d, 1 
H, J = 8 Hz).  
126 Isox–Phe(4–Me)–Ile–
NH2 
 
Rt = 8.4 min (Method I); HRMS: [MNa]+ 
409.1876 (calc. for C20H26NaN4O4+) 
409.1876 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.80–0.86 (m, 6 H), 1.04–1.13 
(m, 1 H), 1.41–1.49 (m, 1 H), 1.69–1.76 (m, 
1 H), 2.22 (s, 3 H), 2.92 (dd, 1 H, J = 10.9, 
13.6 Hz), 3.04 (dd, 1 H, J = 4.4, 14.2 Hz), 
4.17 (dd, 1 H, J = 7.2, 8.6 Hz), 4.71–4.76 
(m, 1 H), 7.04–7.05 (m, 3 H), 7.07 (d, 1 H, J 
= 1.8 Hz), 7.20 (d, 2 H, J = 7.9 Hz), 7.37 (br 
s, 1 H), 8.02 (d, 1 H, J = 9.1 Hz), 8.70 (d, 1 
H, J = 2.0 Hz), 9.01 (d, 1 H, J = 8.6 Hz).  
127 Isox–Phe(4–NH2)–Ile–
NH2 
 
 
Rt = 7.3 min (100A to 100B in 10 min); 
HRMS: [MNa]+ 410.1799 (calc. for 
C19H25NaN5O4+) 410.1800 (found); 1H NMR 
(600 MHz, DMSO–d6), δ 0.80–0.86 (m, 6 
H), 1.04–1.13 (m, 1 H), 1.41–1.49 (m, 1 H), 
1.69–1.76 (m, 1 H), 2.92 (dd, 1 H, J = 10.9, 
13.9 Hz), 3.07 (dd, 1 H, J = 3.8, 13.9 Hz), 
4.17 (dd, 1 H, J = 6.9, 8.8 Hz), 4.72–4.77 
(m, 1 H), 7.00 (d, 2 H, J = 8.4 Hz), 7.04 (br 
s, 1 H), 7.07 (d, 1 H, J = 1.6 Hz), 7.31 (d, 2 
H, J = 8.7 Hz), 7.41 (br s, 1 H), 8.04 (d, 1 H, 
J = 8.7 Hz), 8.71 (d, 1 H, J = 1.9 Hz), 9.03 
(d, 1 H, J = 8.6 Hz).  
128 Isox–Cha–tBuAla–NH2 
 
Rt = 9.4 min (Method I); HRMS: [MH]+ 
393.2496 (calc. for C20H33N4O4+) 393.2493 
(found); 1H NMR (600 MHz, DMSO–d6), δ 
0.85 (s, 9 H), 0.87–0.95 (m, 1 H), 1.06–1.20 
(m, 3 H), 1.26–1.33 (m, 1 H), 1.43–1.51 (m, 
1 H), 1.52–1.58 (m, 2 H), 1.58–1.70 (m, 6 
H), 4.23 (td, 1 H, J = 3.8, 8.9 Hz), 4.43–4.48 
(m, 1 H), 6.97 (br s, 1 H), 7.12 (br s, 1 H), 
7.13 (d, 1 H, J = 2 Hz), 8.02 (d, 1 H, J = 9 
Hz), 8.72 (d, 1 H, J = 1.9 Hz), 8.93 (d, 1 H, J 
= 8.5 Hz).  
129 Isox–Cha–Val–NH2 
 
 
Rt = 8.5 min (Method I); HRMS: [MH]+ 
365.2183 (calc. for C18H29N4O4+) 365.2185 
(found); 1H NMR (600 MHz, DMSO–d6), δ 
0.83 (t, 6 H, J = 7.6 Hz), 0.86–0.96 (m, 2 H), 
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1.06–1.13 (m, 2 H), 1.13–1.22 (m, 1 H), 
1.28–1.36 (m, 1 H), 1.53–1.61 (m, 2 H), 
1.61–1.73 (m, 5 H), 1.90–1.97 (m, 1 H), 4.11 
(dd, 1 H, J = 6.8, 9.4 Hz), 4.53–4.58 (m, 1 
H), 7.03 (br s, 1 H), 7.15 (d, 1 H, J = 1.8 
Hz), 7.38 (br s, 1 H), 7.81 (dd, 1 H, J = 8.9 
Hz), 8.75 (d, 1 H, J = 2.0 Hz), 8.99 (d, 1 H, J 
= 8.4 Hz).  
130 Isox–Cha–nVal–NH2 
 
 
Rt = 8.6 min (Method I); HRMS: [MH]+ 
365.2183 (calc. for C18H29N4O4+) 365.2185 
(found); 1H NMR (600 MHz, DMSO–d6), δ 
0.82 (t, 3 H, J = 7.4 Hz), 0.85–0.94 (m, 2 H), 
1.04–1.34 (m, 6 H), 1.44–1.52 (m, 1 H), 
1.53–1.59 (m, 3 H), 1.59–1.72 (m, 6 H), 
4.14–4.19 (m, 1 H), 4.47–4.51 (m, 1 H), 7.0 
(br s, 1 H), 7.14 (d, 1 H, J = 1.9 Hz), 7.25 (br 
s, 1 H), 7.94 (d, 1 H, J = 8.7 Hz), 8.72 (d, 1 
H, J = 2 Hz), 8.94 (d, 1 H, J = 8.8 Hz).  
131 Isox–Cha–D(nVal)–
NH2 
 
 
Rt = 8.9 min (Method I); HRMS: [MH]+ 
365.2183 (calc. for C18H29N4O4+) 365.2186 
(found); 1H NMR (600 MHz, DMSO–d6), δ 
0.83 (t, 3 H, J = 7.4 Hz), 0.85–0.92 (m, 2 H), 
1.04–1.17 (m, 3 H), 1.17–1.34 (m, 3 H), 
1.45–1.52 (m, 1 H), 1.53–1.75 (m, 8 H), 
4.11–4.17 (m, 1 H), 4.47–4.52 (m, 1 H), 7.04 
(br s, 1 H), 7.14 (d, 1 H, J = 1.9 Hz), 7.21 (br 
s, 1 H), 8.27 (d, 1 H, J = 8.6 Hz), 8.72 (d, 1 
H, J = 2.0 Hz), 8.95 (d, 1 H, J = 7.7 Hz).  
132 Isox–Cha–ChaGly–NH2 
 
 
Rt = 9.4 min (Method I); HRMS: [MH]+ 
405.2496 (calc. for C21H33N4O4+) 405.2498 
(found); 1H NMR (600 MHz, DMSO–d6), δ 
0.82–1.20 (m, 9 H, cyclohexyl H), 1.25–1.33 
(m, 1 H, cyclohexyl CH), 1.50–1.59 (m, 5 H, 
cyclohexyl H), 1.59–1.71 (m, 9 H, 
cyclohexyl H), 4.08 (t, 1 H, J = 7.7 Hz, Chg-
α-CH), 4.51–4.56 (m, 1 H, Cha-α-CH), 7.00 
(br s, 1 H, C-terminal NH2), 7.14 (d, 1 H, J = 
1.9 Hz, isoxazole-4-CH), 7.36 (br s, 1 H, C-
terminal NH2), 7.77 (d, 1 H, J = 9.4 Hz, 
Chg-NH), 8.73 (d, 1 H, J = 1.7 Hz, 
isoxazole-3-CH), 8.97 (d, 1 H, J = 8.5 Hz, 
Cha-NH). 13C NMR (150 MHz, DMSO-d6), 
δ 25.9 (cHex-CH2), 26.0 (cHex-CH2), 26.1 
(cHex-CH2), 26.2 (cHex-CH2), 26.4 (cHex-
CH2), 28.4 (cHex-CH2), 29.6 (cHex-CH2), 
32.1 (cHex-CH2), 33.6 (cHex-CH2), 34.1 
(cHex-CH), 39.1 (Cha-β-CH2), 51.4 (Cha-α-
CH), 57.3 (Chg-α-CH), 106.6 (isoxazole-4-
CH), 152.2 (isoxazole-3-CH), 155.8 
(isoxazole-C), 162.8 (isoxazole-CO), 171.5 
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(Cha-CO), 173.0 (Chg-CO). 
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Compound R1 Analytical data 
133 
N O
H2N
 
Rt = 15.0 min (Method IV); HRMS: [MH]+ 562.3388 
(calc. for C32H44N5O4+) 562.3388 (found); 1H NMR (400 
MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 0.84–1.04 
(m, 8 H), 1.08–2.24 (m, 18 H), 3.05–3.16 (m, 1 H), 3.44–
3.59 (m, 1 H), 4.19–4.26 (m, 1 H), 4.60–4.77 (m, 2 H), 
4.93–5.01 (m, 1 H), 6.47 (s, 1 H), 6.82–6.87 (m, 2 H), 
7.18–7.49 (m, 6 H). 
134 
N O
NH2
 
Rt = 6.2 min (Method II); HRMS: [MH]+ 576.3544 (calc. 
for C33H46N5O4+) 576.3544 (found); 1H NMR (600 MHz, 
DMSO–d6) (two rotamers in a ratio of 2:1), δ 0.80–0.97 
(m, 8H), 1.04–1.21 (m, 5H), 1.22–1.38 (m, 2H), 1.47–
1.62 (m, 3H), 1.62–1.77 (m, 5H), 1.77–1.99 (m, 3H), 
2.99–3.10 (m, 1 H), 3.46 (t, 1 H, J = 13 Hz), 4.17 (t, 1 H, 
J = 14 Hz), 4.24–4.30 (m, 2H), 4.43 (d, J = 13 Hz, minor) 
and 4.50 (d, J = 13 Hz, major, 1 H), 4.54–4.62 (m, 1 H), 
4.64–4.70 (m, 1 H), 6.84 (d, J = 5.6 Hz, major) and 7.06 
(d, J = 5.6 Hz, minor, 1 H), 7.13–7.20 (m, 1 H), 7.21–7.28 
(m, 2H), 7.32–7.36 (m, 1 H), 8.16 (d, J = 8.8 Hz, minor) 
and 8.31 (d, J = 8.8 Hz, major, 1 H), 8.50 (br s, 2H), 9.12 
(d, J = 8.0 Hz, minor) and 9.14 (d, J = 8.0 Hz, major, 1 H) 
135 
N NH
H2N
 
Rt = 9.6 min (Method I) or 13.7 (Method IV); HRMS: 
[MH]+ 561.3548 (calc. for C32H45N6O3+) 561.3548 
(found); 1H NMR (400 MHz, CDCl3) (two rotamers in a 
ratio of 1:1), δ 0.80–1.04 (m, 8 H), 1.06–2.20 (m, 18 H), 
3.04–3.16 (m, 1 H), 3.46–3.56 (m, 1 H), 4.17–4.24 (m, 1 
H), 4.76–4.81 (m, 2H), 5.01–5.08 (m, 1 H), 6.04 (br s, 1 
H), 6.80–6.85 (m, 2H), 7.18–7.35 (m, 5H), 7.78 (br s, 1 
H), 8.40 (br s, 1 H). 
136 
O N  
Rt = 11.4 min (Method II); HRMS: [MH]+ 561.3435(calc. 
for C33H45N4O4+) 561.3428 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.86–0.97 (m, 5 
H), 0.99–1.02 (m, 2 H), 1.08–1.27 (m, 4 H), 1.36–1.56 (m, 
4 H), 1.62–1.75 (m, 5 H), 1.77–1.87 (m, 3 H), 1.91–2.09 
(m, 2 H), 2.12–2.20 (m, 1 H), 2.48 (s, 3 H), 3.03–3.17 (m, 
1 H), 3.42–3.57 (m, 1 H), 4.16–4.25 (m, 1 H), 4.59–4.71 
(m, 2 H), 4.89–4.96 (m, 1 H), 6.44 (s, 1 H), 6.82–6.86 (m, 
2H), 7.10–7.29 (m, 5 H), 7.33–7.36 (m, 1 H).  
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137 N
HN  
Rt = 6.58 min (Method II); HRMS: [MH]+ 546.3439 (calc. 
for C32H44N5O3+) 546.3437 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.78–0.99 (m, 8 
H), 1.10–1.25 (m, 4 H), 1.38–1.50 (m, 4 H), 1.60–1.62 (m, 
2 H), 1.70–1.89 (m, 6 H), 1.93–2.11 (m, 2 H), 3.00–3.10 
(m, 1 H), 3.47 (t, 1 H, J = 12.8 Hz), 4.25 (d, 1 H, J = 12.4 
Hz), 4.57–4.66 (m, 1 H), 4.70–4.90 (m, 1 H), 5.02 (q, 1 H, 
J = 8.0 Hz), 6.77–6.82 (m, 2 H), 7.19–7.26 (m, 5 H), 
7.31–7.35 (m, 1 H), 7.90–8.00 (br s, 1 H), 8.40–8.48 (br s, 
1 H), 8.49–8.62 (br s, 1 H).  
138 N
O  
Rt = 9.7 min (Method II); HRMS: [MH]+ 547.3206 (calc. 
for C32H43N4O3+) 547.3278 (found); 1H NMR (600 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.86–0.97 (m, 5 
H), 1.01 (d, 2 H, J = 6.8 Hz), 1.1–1.28 (m, 4 H), 1.28–1.6 
(m, 4 H), 1.61–1.78 (m, 5 H), 1.78–1.90 (m, 2 H), 1.91–
2.07 (m, 2 H), 2.09–2.16 (m, 1 H), 3.05–3.16 (m, 1 H), 
3.44–3.56 (m, 2 H), 4.14–4.22 (m, 1 H), 4.61–4.76 (m, 2 
H), 4.93 (q, 1 H, J = 7.2 Hz), 6.83–6.92 (m, 2 H), 7.09 
(dd, 1 H, J = 8.8, 18 Hz), 7.18–7.36 (m, 5 H), 7.76 (s, 1 
H), 7.95 (s, 1 H).  
139 N
HN N  
Rt = 8.92 min (Method II); HRMS: [MH]+ 547.3391 (calc. 
for C31H43N6O3+) 547.3391 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.80–1.01 (m, 9 
H), 1.10–1.26 (m, 5 H), 1.40–1.58 (m, 5 H), 1.66–1.88 (m, 
5 H), 1.98–2.18 (m, 2 H), 3.16 (t, 1 H, J = 12.4 Hz), 3.56 
(q, 1 H, J = 13.6 Hz), 4.78–4.85 (m, 1 H), 5.10–5.20 (m, 1 
H), 5.21–5.40 (m, 1 H), 6.84–6.88 (m, 2 H), 7.21–7.37 (m, 
4 H), 8.02–8.21 (m, 2 H), 8.80–8.85 (m, 1 H).  
140 
O  
Rt = 10.92 min (Method II); HRMS: [MH]+ 546.3326 
(calc. for C33H44N3O4+) 546.3330 (found); 1H NMR (400 
MHz, CDCl3), δ 0.85–0.94 (m, 4 H), 0.97–1.0 (m, 2 H), 
1.05–1.28 (m, 4 H), 1.37–1.58 (m, 4 H), 1.62–1.74 (m, 4 
H), 1.75–1.85 (m, 6 H), 1.91–2.14 (m, 2 H), 3.00–3.02 (m, 
1 H), 3.41–3.52 (m, 1 H), 4.12–4.18 (m, 1 H), 4.61–4.75 
(m, 2 H), 4.88–4.95 (m, 1 H), 6.51 (dd, 1 H, J = 2.0, 3.4 
Hz), 6.77–6.87 (m, 4 H), 7.14 (d, 1 H, J = 3.2 Hz), 7.19–
7.36 (m, 4 H), 7.46 (br s, 1 H).  
141 
N  
Rt = 7.26 min (Method II); HRMS: [MH]+ 557.3486 (calc. 
for C34H45N4O3+) 557.3494 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.85–0.95 (m, 4 
H), 0.98–1.04 (m, 2 H), 1.05–1.08 (m, 4 H), 1.38–1.58 (m, 
4 H), 1.64–1.85 (m, 10 H), 1.91–2.14 (m, 2 H), 3.03–3.12 
(m, 1 H), 3.41–3.51 (m, 1 H), 4.12–4.18 (m, 1 H), 4.63–
4.71 (m, 1 H), 4.75–4.83 (m, 1 H), 4.91–4.97 (m, 1 H), 
6.82–6.93 (m, 4 H), 7.19–7.29 (m, 3 H), 7.33–7.40 (m, 2 
H), 8.11–8.15 (m, 1 H), 8.73 (dt, J = 1.6, 4.8 Hz), 9.03 (t, 
J = 2.4 Hz). 
142 N
N  
Rt = 11.6 min (Method II); HRMS: [MH]+ 558.3439 (calc. 
for C33H44N5O3+) 558.3440 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.86–1.05 (m, 7 
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H), 1.12–1.28 (m, 4 H), 1.40–1.57 (m, 4 H), 1.66–1.89 (m, 
9 H), 1.91–2.21 (m, 2 H), 3.04–3.17 (m, 1 H), 3.44–3.58 
(m, 1 H), 4.18–4.26 (m, 1 H), 4.62–4.78 (m, 2 H), 4.91–
4.97 (m, 1 H), 6.83–6.87 (m, 2 H), 7.13–7.30 (m, 4 H), 
7.34–7.37 (m, 1 H), 8.17–8.20 (m, 1 H), 8.60 (br s, 1 H), 
8.78 (br s, 1 H), 9.41 (br s, 1 H). 
143 
O N  
Rt = 14.98 min (Method I); HRMS: [MH]+ 637.3748 
(calc. for C39H49N4O4+) 637.3752 (found); 1H NMR (400 
MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 0.86–1.06 
(m, 7H), 1.09–1.30 (m, 4 H), 1.36–1.55 (m, 4 H), 1.61–
1.76 (m, 5 H), 1.80–1.89 (m, 3 H), 1.94–2.20 (m, 3 H), 
2.41 (s, 3 H), 3.02–3.16 (m, 1 H), 3.42–3.55 (m, 1 H), 
4.13–4.23 (m, 1 H), 4.60–4.76 (m, 2 H), 4.90–4.98 (m, 1 
H), 6.83–6.86 (m, 2 H), 6.92–7.04 (m, 4 H), 7.19–7.36 (m, 
6H), 7.66–7.70 (m, 1 H).  
144 
N
H  
Rt = 12.1 min (Method I); HRMS:  [MH]+ 595.3643 (calc. 
for C37H47N4O3+) 595.3644 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.86 (t, 2 H, J = 
7.2 Hz), 0.89–0.95 (m, 4 H), 0.96–1.08 (m, 3 H), 1.10–
1.30 (m, 4 H), 1.36–1.67 (m, 5 H), 1.68–2.07 (m, 9 H), 
3.04–3.14 (m, 1 H), 3.43–3.54 (m, 1 H), 4.14–4.24 (m, 1 
H), 4.61–4.74 (m, 1 H), 4.80–4.89 (m, 1 H), 4.91–4.98 (m, 
1 H), 6.66–6.74 (m, 1 H), 6.81–6.88 (m, 2 H), 7.17–7.24 
(m, 2 H), 7.26–7.30 (m, 3 H), 7.30–7.36 (m, 2 H), 7.41–
7.46 (m, 1 H), 7.86 (t, 1 H, J = 3.2 Hz), 7.98–8.03 (m, 1 
H), 8.65 (br s, 1 H).  
145 MeO
OMe  
Rt = 12.8 min (Method I); HRMS: [M+Na]+ 638.3564 
(calc. for C37H49NaN3O5+) 638.3573 (found); 1H NMR 
(400 MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 
0.85–1.03 (m, 9 H), 1.08–1.28 (m, 5 H), 1.37–1.52 (m, 4 
H), 1.61–1.89 (m, 5 H), 1.92–2.13 (m, 2 H), 3.30–3.13 (m, 
1 H), 3.41–3.52 (m, 1 H), 3.83 (s, 6 H), 4.10–4.19 (m, 1 
H), 4.62–4.78 (m, 2 H), 4.89–4.96 (m, 1 H), 6.58–6.63 (m, 
2 H), 6.82–6.92 (m, 3 H), 7.19–7.36 (m, 6 H).  
146 
N  
Rt = 10.25 min (Method I); HRMS: [MH]+ 583.3643 
(calc. for C36H47N4O3+) 583.3645 (found); 1H NMR (400 
MHz, DMSO–d6) (two rotamers in a ratio of 1:1), δ 0.80–
0.96 (m, 8 H), 1.03–1.32 (m, 7 H), 1.47–1.70 (m, 7 H), 
1.74–2.00 (m, 4 H), 2.97–3.10 (m, 1 H), 3.45 (t, 1 H, J = 
12.8 Hz), 4.13–4.20 (m, 1 H), 4.40 (d, 1 H, J = 14 Hz), 
4.48–4.60 (m, 1 H), 4.63–4.67 (m, 1 H), 6.82 (d, 1 H, J = 
5.6 Hz), 6.89 (d, 1 H, J = 16 Hz), 7.11–7.34 (m, 5 H), 7.49 
(d, 1 H, J = 15.6 Hz), 7.59 (dd, 1 H, J = 5.2, 7.6 Hz), 8.15 
(d, 1 H, J= 8.0 Hz), 8.22 (d, 1 H, J = 9.2 Hz), 8.29–8.36 
(m, 1 H), 8.61 (s, 1 H), 8.84 (s, 1 H). 
147  Rt = 12.18 min (Method I); HRMS: [MH]
+ 522.3696 
(calc. for C32H48N3O3+) 522.3698 (found); 1H NMR (400 
MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 0.87–1.01 
(m, 8 H), 1.07–1.33 (m, 4 H), 1.37–1.58 (m, 3 H), 1.64–
1.72 (m, 5 H), 1.78–2.11 (m, 11 H), 2.18–2.23 (m, 2 H), 
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3.02–3.12 (m, 1 H), 3.41–3.51 (m, 1 H), 4.11–4.17 (m, 1 
H), 4.50–4.71 (m, 2 H), 4.86–4.92 (m, 1 H), 5.94 (t, 1 H, J 
= 6.4 Hz), 6.78–6.87 (m, 2 H), 7.20–7.35 (m, 5 H). 
148 H2N  Rt = 5.4 min (Method II); HRMS: [MH]
+ 509.3486 (calc. 
for C30H45N4O3+) 509.3492 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.81–0.95 (m, 7 
H), 1.06–1.19 (m, 4 H), 1.25–1.46 (m, 4 H), 1.56–1.71 (m, 
7 H), 1.75–2.10 (m, 4 H), 2.97–3.04 (m, 1 H), 3.37–3.47 
(m, 1 H), 3.72–3.76 (m, 1 H), 3.97–4.02 (m, 1 H), 4.15–
4.20 (m, 1 H), 4.51–4.60 (m, 2 H), 4.83–4.92 (m, 1 H), 
6.78 (d, 2 H, J = 2 Hz), 7.13–7.34 (m, 6 H), 7.55 (br s, 1 
H), 8.28–8.46 (br d, 1 H).  
149 H2N
HO  
Rt = 9.7 min (Method I); HRMS: [MH]+ 539.3592 (calc. 
for C31H47N4O4+) 539.3589 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.81–0.96 (m, 7 
H), 1.06–1.27 (m, 4 H), 1.28–1.43 (m, 4 H), 1.55–1.86 (m, 
7 H), 1.90–2.15 (m, 4 H), 2.93–3.07 (m, 1 H), 3.36–3.54 
(m, 1 H), 3.92–4.17 (m, 3 H), 4.28–4.55 (m, 3 H), 4.80–
4.89 (m, 1 H), 6.71–6.86 (m, 2 H), 7.12–7.29 (m, 6 H), 
7.34–7.47 (m, 2 H).  
150 
NH  
Rt = 5.6 min (Method II); HRMS: [MH]+ 549.3799 (calc. 
for C33H49N4O3+) 549.3792 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.83–0.98 (m, 9 
H), 1.07–1.23 (m, 4 H), 1.37–1.50 (m, 4 H), 1.60–1.75 (m, 
7 H), 1.88–2.14 (m, 6 H), 2.40–2.53 (m, 2 H), 3.00–3.09 
(m, 1 H), 3.40–3.50 (m, 3 H), 4.11–4.21 (m, 1 H), 4.52–
4.69 (m, 2 H), 4.71–4.80 (m, 1 H), 4.87–4.99 (m, 1 H), 
6.80–6.85 (m, 2 H), 7.17–7.29 (m, 4 H), 7.29–7.36 (m, 1 
H), 7.37–7.47 (m, 1 H), 7.90–8.0 (m, 1 H).  
151 
NH
O  
Rt = 8.30 min (Method II); HRMS: [MH]+ 563.3573 (calc. 
for C33H47N4O4+) 563.3598 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.87–1.03 (m, 7 
H), 1.09–1.31 (m, 5 H), 1.38–1.57 (m, 4 H), 1.58–1.84 (m, 
7 H), 1.90–2.04 (m, 2 H), 2.06–2.30 (m, 2 H), 2.39–2.59 
(m, 3 H), 3.04–3.14 (m, 1 H), 3.44–3.55 (m, 1 H), 4.15–
4.28 (m, 2 H), 4.53–4.68 (m, 2 H), 4.90–4.95 (m, 1 H), 
6.81–6.86 (m, 2 H), 6.99–7.01 (m, 1 H), 7.20–7.39 (m, 6 
H).  
152 
HN  
Rt = 9.79 min (Method I); HRMS: [MH]+ 563.3956 (calc. 
for C34H51N4O3+) 563.3956 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.85–0.99 (m, 7 
H), 1.15–1.27 (m, 7 H), 1.33–1.55 (m, 4 H), 1.88–2.17 (m, 
12 H), 2.50–2.63 (m, 1 H), 2.98–3.04 (m, 3 H), 3.40–3.57 
(m, 3 H), 4.13–4.19 (m, 1 H), 4.53–4.65 (m, 2 H), 4.89 (q, 
1 H, J = 8.4 Hz), 6.73–6.77 (m, 1 H), 6.80–6.85 (m, 2 H), 
7.17–7.35 (m, 6 H).  
N
OH
N
O
N
H
R2O
N O
 
 109 
Compound R2 Analytical data 
153 
 
Rt = 9.15 min (Method II); HRMS: [MH]+ 507.2966 (calc. 
for C29H39N4O4+) 507.2965 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 57:43), δ 0.86–0.95 (m, 
5 H), 1.00 (d, 1 H, J = 6.8 Hz), 1.06 (s, 4 H), 1.12–1.13 (s, 
5 H), 1.39–1.60 (m, 2 H), 1.79–1.88 (m, 1 H), 1.90–2.04 
(m, 2 H), 2.10–2.20 (m, 2 H), 3.02–3.17 (m, 1 H), 3.43–
3.57 (m, 1 H), 4.12–4.27 (m, 1 H), 4.50–4.75 (m, 2 H), 
4.92–4.98 (m, 1 H), 6.83–6.88 (m, 2 H), 6.97–6.98 (m, 1 
H), 7.20–7.35 (m, 6 H), 8.34 (d, 1 H, J = 2.0 Hz).  
154 
 
Rt = 11.37 min (Method II); HRMS: [MH]+ 561.3435 
(calc. for C33H45N4O4+) 561.3438 (found); 1H NMR (400 
MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 0.84–0.96 
(m, 6 H), 1.02 (d, 1 H, J = 6.4 Hz), 1.09–1.32 (m, 7 H), 
1.40–1.57 (m, 3 H), 1.60–1.76 (m, 5 H), 1.78–1.87 (m, 2 
H), 1.90–2.05 (m, 3 H), 2.10–2.18 (m, 1 H), 3.04–3.16 (m, 
1 H), 3.44–3.57 (m, 1 H), 4.15–4.23 (m, 1 H), 4.58–4.73 
(m, 2 H), 4.92–4.98 (m, 1 H), 6.83–6.87 (m, 2 H), 6.94 (t, 
1 H, J = 2.0 Hz), 7.03 (dd, 1 H, J = 8.8 Hz, 16.6 Hz), 
7.20–7.36 (m, 6 H), 8.34–8.35 (m, 1 H).  
155 
N
O
 
Rt = 9.96 min (0% to100% B in 10 min, then 100%B for 
extra 5min); HRMS: [MH]+ 550.3024 (calc. for 
C30H40N5O5+) 550.3022 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.85–1.54 (m, 
10 H), 1.80–2.22 (m, 3 H), 3.06–3.13 (m, 1 H), 3.37 (br s, 
4 H), 3.45–3.55 (m, 1 H), 3.65–3.71 (m, 1 H), 3.83–3.92 
(m, 1 H), 3.99 (s, 4 H), 4.14 (d, 1 H, J = 12 Hz), 4.58–
4.66 (m, 1 H), 4.80–4.85 (m, 1 H), 5.26–5.34 (m, 1 H), 
6.81–6.86 (m, 2H), 6.99 (d, J = 1.6 Hz, 1 H), 7.19–7.37 
(m, 4H), 7.96 (d, 1 H, J = 6.8 Hz), 8.34 (d, J = 1.6 Hz, 1 
H), 8.77–8.82 (m, 1 H). 
N
O
N
H
O
N O
R3
 
Compound R3 Analytical data 
158 H
N
O
 
Rt = 11.89 min (Method II); HRMS: [MH]+ 587.3592 
(calc. for C35H47N4O4+) 587.3588 (found); 1H NMR (400 
MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 0.84–1.07 
(m, 4 H), 1.08–1.28 (m, 6 H), 1.30–1.56 (m, 5 H), 1.57–
1.91 (m, 12 H), 1.95–2.20 (m, 3 H), 3.01–3.15 (m, 1 H), 
3.40–3.56 (m, 1 H), 4.04–4.12 (m, 1 H), 4.58–4.75 (m, 1 
H), 5.07–5.15 (m, 1 H), 6.82–6.86 (m, 1 H), 6.94–6.95 (m, 
1 H), 6.99–7.04 (m, 1 H), 7.10–7.15 (m, 1 H), 7.20–7.36 
(m, 4 H), 8.34 (dd, 1 H, J = 0.8,1.6 Hz). 
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159 H
N
O
O
 
Rt = 9.24 min (Method II); HRMS: [MH]+ 549.3071 (calc. 
for C31H41N4O5+) 549.3072 (found); 1H NMR (400 MHz, 
CDCl3)(two rotamers in a ratio of 1:1), δ 0.88–1.32 (m, 8 
H), 1.36–1.50 (m, 3 H), 1.63–2.16 (m, 9 H), 3.07–3.17 (m, 
1 H), 3.35 (s, 3 H), 3.44–3.53 (m, 1 H), 3.66 (m, 1 H), 
4.17 (br s, 1 H), 4.65–4.72 (m, 1 H), 4.72–4.79 (m, 1 H), 
5.12 (dd, 1 H, J = 4.0, 8.0 Hz), 6.83 (d, 1 H, J = 6.0 Hz), 
6.85 (d, 1 H, J = 6.0 Hz), 6.96 (d, 1 H, J = 1.6 Hz), 7.40–
7.19 (m, 6 H), 8.35 (d, 1 H, J = 2.0 Hz). 
160 H
N
O
NH2  
Rt = 10.1 min (Method I); HRMS: [MH]+ 534.3075 (calc. 
for C30H40N5O4+) 534.3070 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.82–1.22 (m, 5 
H), 1.32–1.48 (m, 2 H), 1.54–1.82 (m, 8 H), 1.92–2.08 (m, 
3 H), 2.20–2.38 (m, 1 H), 2.82–3.20 (m, 3 H), 3.38–3.46 
(m, 1 H), 3.90–4.08 (m, 1 H), 4.46–4.74 (m, 2 H), 5.04–
5.14 (m, 1 H), 6.74–6.83 (m, 2 H), 6.91 (br s, 1 H), 7.14–
7.33 (m, 4 H), 8.0–8.17 (br m, 5 H), 8.27 (s, 1 H). 
161 H
N
O
NH2
O
 
Rt = 10.1 min (Method I); HRMS: [MH]+ 548.2867 (calc. 
for C30H38N5O5+) 548.2869 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.82–2.30 (m, 
17 H), 2.56–2.90 (m, 2 H), 3.05–3.12 (m, 1 H), 3.43–3.54 
(m, 1 H), 4.06–4.12 (m, 1 H), 4.48–4.64 (m, 2 H), 5.26–
5.34 (m, 1 H), 6.06 (br s, 1 H) and 6.17 (br s, 1 H), 6.74–
6.86(m, 3 H), 6.93 (d, 1 H, J = 1.2 Hz), 7.14–7.63 (m, 
6H), 8.35 (d, 1 H, J = 1.2 Hz). 
162 H
N
O
HN
N  
Rt = 9.1 min (Method I); HRMS: [MH]+ 571.3027 (calc. 
for C32H39N6O4+) 571.3026 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.80–1.20 (m, 5 
H), 1.30–1.80 (m, 10 H), 1.95–2.12 (m, 2 H), 2.92–3.30 
(m, 3 H), 3.44–3.58 (m, 1 H), 3.96–4.12 (m, 1 H), 4.48–
4.71 (m, 2 H), 5.24–5.33 (m, 1 H), 6.77–7.00 (m, 3 H), 
7.14–7.35 (m, 5 H), 7.85 (d, 1 H, J = 7.6 Hz), 8.01–8.09 
(m, 1 H), 8.32 (d, 1 H, J = 1.6 Hz), 8.51 (br s, 1 H). 
163 H
N
O
HO  
Rt = 11.1 min (Method II); HRMS: [MH]+ 535.2915(calc. 
for C30H39N4O5+) 535.2915 (found); 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1), δ 0.86–1.28 (m, 8 
H), 1.34–2.14 (m, 12 H), 2.84–3.33 (m, 2 H), 3.42–3.64 
(m, 1 H), 4.06–4.13 (m, 1 H), 4.52–4.62 (m, 1 H), 4.91––
4.97 (m, 1 H), 5.16–5.22 (m, 1 H), 6.80–6.94 (m, 2 H), 
6.96 (d, 1 H, J = 2.0 Hz), 7.11–7.67 (m, 6 H), 8.35 (d, 1 
H, J = 2.0 Hz). 
R4
OH
N
O
N
H
O
N O
 
Compound R4 Analytical data 
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165 N
N
F  
Rt = 8.2 min (Method II); HRMS: [MH]+ 542.3137 
(calc. for C29H41FN5O4+) 542.3137 (found); 1H NMR 
(400 MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 
0.85–1.02 (m, 7 H), 1.09–1.26 (m, 4 H), 1.30–1.40 
(m, 1 H), 1.46–1.55 (m, 1 H), 1.62–1.81 (m, 9 H), 
3.15–3.32 (m, 4 H), 3.66–3.73 (m, 1 H), 3.80–3.87 
(m, 1 H), 4.01–4.16 (m, 1 H), 4.59–4.65 (m, 1 H), 
4.80 (d, J = 8.0 Hz) and 4.82 (d, J = 8.0 Hz, 1 H), 
6.91 (d, 1 H, J = 2.0 Hz), 7.03–7.07 (m, 4 H), 7.13–
7.17 (m, 2 H), 8.34 (d, 1 H, J = 2.0 Hz). 
166 N
N
F
 
Rt = 5.65 min (Method II); HRMS: [MH]+ 556.3294 
(calc. for C30H43FN5O4+) 556.3291 (found); 1H NMR 
(400 MHz, DMSO–d6) (two rotamers in a ratio of 
1:1), δ 0.94–1.09 (m, 10 H), 1.14–1.31 (m, 5 H), 
1.38–1.48 (m, 1 H), 1.54–1.58 (m, 3 H), 1.70–1.82 
(m, 7 H), 1.86–1.94 (m, 1 H), 3.00–3.18 (m, 2 H), 
4.38–4.58 (m, 4 H), 4.59–4.64 (m, 1 H), 4.67 (t, 1 H, 
J = 8.4Hz), 7.27 (s, 1 H), 7.43–7.45 (m, 2 H), 7.65–
7.67 (m, 2 H), 8.28 (d, 1 H, J = 8.0 Hz), 8.88 (s, 1 H), 
9.05 (br s, 1 H).  
167 N
 
Rt = 10.02 min (Method II); HRMS: [MH]+ 523.3279 
(calc. for C30H43N4O4+) 523.3280 (found); 1H NMR 
1H NMR (600 MHz, DMSO-d6) (two rotamers in a 
ratio of 60:40) δ 0.78–0.95 (m, 8 H), 0.99–1.21 (m, 4 
H), 1.25–1.44 (m, 2 H), 1.44–1.90 (m, 12 H), 2.59–
2.68 (m, 1 H, Hax of s-syn amide piperidine NCH2), 
2.75–2.83 (m, 1 H, piperidine-CHPh), 3.09 (t, J = 
12.0 Hz, minor) and 3.14 (t, J = 12.0 Hz, major, 1 H, 
Hax of s-anti amide piperidine NCH2), 4.19 (d, 1 H, J 
= 13.2 Hz, Heq of s-anti amide piperidine NCH2), 
4.53–4.59 (m, 2 H, Cha-α-CH and Heq of s-syn amide 
piperidine NCH2), 4.60–4.65 (m, 1 H, Ile-α-CH), 
7.14–7.41 (m, 6 H, 5 × Ar-H, isoxazole-4-CH), 8.14 
(d, J = 8.4 Hz, minor) and 8.28 (d, J = 9.0 Hz, major, 
1 H, Ile-NH), 8.74 (d, J = 1.8 Hz, major) and 8.75 (d, 
J = 1.8 Hz, minor, 1 H, isoxazole-3-CH), 8.94 (d, J = 
7.2 Hz, minor) and 8.95 (d, J = 7.8 Hz, major, 1 H, 
Cha-NH); 13C NMR (150 MHz, CDCl3): 11.5/11.7 
(CH3, Ile-δ-CH3), 16.0/16.3 (CH3, Ile-γ-CH3), 
24.3/24.4 (CH2, Ile-γ-CH2), 26.0(8)/26.1(7) (CH2), 
26.2(5)/26.3(0) (CH2), 26.5 (CH2), 32.1(8)/32.2(0) 
(CH2), 33.3(8)/33.4(4) (CH2), 33.6(7)/33.7(0) (CH2), 
34.1 (CH, Cha-γ-CH), 34.2 (CH2), 36.6/36.9 (CH, Ile-
β-CH), 39.3/39.5 (CH2, Cha-β-CH2), 42.0/42.2 (CH, 
piperidine CHPh), 42.6/42.7 (CH2, s-syn amide 
piperidine NCH2), 46.1/46.3 (CH2, s-anti amide 
piperidine NCH2), 51.3/51.4 (CH, Cha-α-CH), 
52.5/52.6 (CH, Ile-α-CH), 106.6/106.7 (CH, 
isoxazole-4-CH), 126.7 (Ar-CH), 127.0(9)/127.1(3) 
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(Ar-CH), 128.9/129.0 (Ar-CH), 145.9/146.0 (Ar-C), 
152.2 (CH, isoxazole-3-CH), 155.8 (isoxazole-C), 
162.8 (isoxazole-CO), 169.6/169.7 (C, Ile-CO), 
171.6/171.7 (C, Cha-CO). 
168 N
 
Rt = 12.18 min (Method II); HRMS: [MH]+ 537.3435 
(calc. for C31H45N4O4+) 537.3449 (found); 1H NMR 
(400 MHz, DMSO–d6) (two rotamers in a ratio of 
58:42), δ 0.76–1.40 (m, 15 H), 1.40–1.82 (m, 12 H), 
2.32–2.50 (m, 1 H), 2.50 (CH2Ph, overlapped with the 
solvent peak), 2.89–2.98 (m, 1 H), 4.02 (d, 1 H, J = 
12.8 Hz), 4.31–4.38 (m, 1 H), 4.50–4.60 (m, 2 H), 
7.12–7.30 (m, 6 H), 8.04 (d, J = 8.8 Hz, minor) and 
8.16 (d, J = 9.2 Hz, major, 1 H, NH) 8.74 (s, minor) 
and 8.76 (s, major, 1 H), 8.89–8.95 (m, 1 H).  
169 N
Cl  
Rt = 12.68 min (Method II); HRMS: [MH]+ 577.2889  
(calc. for C30H42ClN4O4+) 577.2894 (found); 1H NMR 
(400 MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 
0.84–1.03 (m, 8 H), 1.07–1.38 (m, 6 H), 1.44–1.61 
(m, 3 H), 1.62–1.73 (m, 6 H), 1.74–1.81 (m, 3 H), 
2.66–2.79 (m, 2 H), 3.15–3.24 (m, 1 H), 4.12–4.19 
(m, 1 H), 4.65–4.71 (m, 1 H), 4.74–4.79 (m, 1 H), 
4.86–4.91 (m, 1 H), 6.74–6.79 (m, 1 H), 6.93 (d, 1 H, 
J = 1.6 Hz), 7.04–7.08 (m, 1 H), 7.10–7.14 (m, 2 H), 
7.27–7.30 (m, 2 H), 8.33 (d, 1 H, J = 2.0 Hz).  
170 N
OMe  
Rt = 11.73 min (Method II); HRMS: [MH]+ 553.3384 
(calc. for C31H45N4O5+) 553.3384 (found); 1H NMR 
(400 MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 
0.84–1.03 (m, 8 H), 1.06–1.36 (m, 5 H), 1.43–2.00 
(m, 13 H), 2.71–2.78 (m, 2 H), 3.17–3.22 (m, 1 H), 
3.79 (s, 3 H), 4.15–4.17 (m, 1 H), 4.66–4.78 (m, 2 H), 
4.90 (q, 1 H, J = 7.2 Hz), 6.84–6.87 (m, 3 H), 6.93 (d, 
1 H, J = 2.0 Hz), 7.08–7.12 (m, 3 H), 8.33 (d, 1 H, J = 
2.0 Hz).  
171 N OMe
OMe  
Rt = 11.39 min (Method II); HRMS: [MH]+ 583.3490 
(calc. for C32H47N4O6+) 583.3492 (found); 1H NMR 
(600 MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 
0.84–0.93 (m, 6 H), 0.93–1.01 (m, 3 H), 1.05–1.27 
(m, 6 H), 1.30–1.38 (m, 1 H), 1.45–1.53 (m, 2 H), 
1.53–1.84 (m, 13 H), 1.86–2.00 (m, 4 H), 2.72–2.76 
(m, 1 H), 3.14–3.25 (m, 2 H), 3.75 (d, 3 H, J = 5.4 
Hz), 3.79 (s, 3 H), 4.09–4.16 (m, 1 H), 4.65–4.70 (m, 
1 H), 4.74–4.76 (m, 1 H), 4.87–4.90 (m, 1 H), 6.71–
6.73 (m, 2 H), 6.78–6.80 (m, 1 H), 6.89 (dd, 1 H, J = 
9.0, 14.4 Hz), 6.93 (d, 1 H, J = 1.8 Hz), 7.08–7.11 (m, 
1 H), 8.34 (s, 1 H).  
172 N CF3
 
Rt = 12.8 min (Method II); HRMS: [MH]+ 591.3153 
(calc. for C31H42F3N4O4+) 591.3156 (found); 1H NMR 
(600 MHz, CDCl3) (two rotamers in a ratio of 59:41), 
δ 0.86–1.07 (m, 8 H), 1.08–1.59 (m, 7 H), 1.61–2.01 
(m, 9 H), 2.70–2.78 (m, 1 H, Hax of s-syn amide 
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piperidine NCH2), 3.19–3.28 (m, 2 H, piperidine-
CHAr and Hax of s-anti amide piperidine NCH2), 
4.16–4.23 (m, 1 H, Heq of s-anti amide piperidine 
NCH2), 4.66–4.74 (m, 1 H, Cha-α-CH), 4.81 (d, J = 
13.0 Hz, 1 H, Heq of s-syn amide piperidine NCH2), 
4.89–4.94 (m, 1 H, Ile-α-CH), 6.83 (d, J = 8.4 Hz, 
minor) and 6.92 (d, J = 9.0 Hz, major, 1H), 6.95 (d, 1 
H, J = 1.8 Hz, isoxazole-CH), 7.08–7.13 (m, 1 H), 
7.31–7.42 (m, 2 H), 7.51–7.56 (m, 1 H), 7.64–7.67 
(m, 1 H), 8.36 (d, 1 H, J = 1.8 Hz, isoxazole-CH).  
173 N CF3
CF3
OH
 
Rt = 11.99 min (Method II); HRMS: [MH]+ 675.2976 
(calc. for C32H41F6N4O5+) 675.2976 (found); 1H NMR 
(600 MHz, CDCl3) (two rotamers in a ratio of 2:1), δ 
0.86–0.94 (m, 6 H), 0.94–1.03 (m, 2 H), 1.08–1.28 
(m, 5 H), 1.31–1.40 (m, 1 H), 1.47–1.54 (m, 1 H), 
1.61–1.73 (m, 6 H), 1.73–1.84 (m, 4 H), 1.95–2.05 
(m, 3 H), 2.08–2.19 (m, 2 H), 2.23–2.30 (m, 1 H), 
3.17–3.22 (m, 1 H), 3.66–3.71 (m, 1 H), 4.00 (dd, 1 
H, J = 13.2 Hz), 4.61–4.68 (m, 2 H), 4.87–4.91 (m, 1 
H), 6.78 & 6.86 (2 sets of d, 1 H, J = 8.4 Hz), 6.92 & 
6.94 (2 sets of d, 1 H, J = 1.8 Hz), 7.06 (dd, 1 H, J = 
7.8 Hz), 7.71 (d, 1 H, J = 9.0 Hz), 7.80 (t, 1 H, J = 9.0 
Hz), 8.05 (s, 1H), 8.34 (d, 1 H, J = 1.8 Hz).  
174 N NHCOMe
 
Rt = 8.34 min (Method II); HRMS: [MH]+ 580.3493 
(calc. for C32H46N5O5+) 580.3493 (found); 1H NMR 
(600 MHz, DMSO–d6) (two rotamers in a ratio of 
62:38), δ 0.79–0.84 (m, 7 H), 0.85–0.93 (m, 1 H), 
1.01–1.20 (m, 4 H), 1.25–1.33 (m, 1 H), 1.46–1.53 
(m, 2 H), 1.53–1.58 (m, 1 H), 1.58–1.77 (m, 7 H), 
1.77–1.85 (m, 1 H), 1.88 & 1.91 (2 sets of s, 3 H), 
2.38–2.45 (m, 2 H), 2.83–2.90 (m, 1 H), 3.24–3.32 
(m, 1 H), 4.00 (t, 2 H, J = 13.2 Hz), 4.27 & 4.34 (2 
sets of d, 2 H, J = 13.2 Hz), 4.52–4.58 (m, 2 H), 7.13 
& 7.16 (2 sets of d, 1 H, J = 1.8 Hz), 7.18–7.22 (m, 1 
H), 7.26–7.34 (m, 4 H), 8.06 (d, 1 H, J = 5.4 Hz), 
8.15 & 8.28 (2 sets of d, 1 H, J = 9.0 Hz), 8.74 (2 sets 
of d, 1 H, J = 1.8 Hz), 8.92 (t, 1 H, J = 8.4 Hz). 
175 N Ph
 
Rt = 14.34 min (Method II); HRMS: [MH]+ 599.3592 
(calc. for C36H47N4O4+) 599.3597 (found); 1H NMR 
(400 MHz, CDCl3) (two rotamers in a ratio of 56:44), 
δ 0.79–1.54 (m, 14 H), 1.54–1.86 (m, 12 H), 2.45–
2.51 (m, 1 H), 2.91–2.99 (m, 2 H), 4.05 (d, 1 H, J = 
13.2 Hz), 4.65–4.72 (m, 2 H), 4.82–4.90 (m, 1 H), 
6.86 (d, J = 9.2 Hz) and 6.92 (d, J = 9.2 Hz, 1 H), 
6.93 (d, J = 1.8 Hz, minor) and 6.94 (d, J = 1.8 Hz, 
major, 1 H), 7.11 (d, J = 8.8 Hz) and 7.16 (d, J = 8.4 
Hz), 7.19–7.45 (m, 9 H), 8.33 (d, J = 1.8 Hz, major) 
and 8.34 (d, J = 1.8 Hz, major, 1 H). 
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176 N
Ph
 
Rt = 14.3 min (Method II); HRMS: [MH]+ 599.3592 
(calc. for C36H47N4O4+) 599.3590 (found); 1H NMR 
(400 MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 
0.84–2.09 (m, 26 H), 2.72–2.89 (m, 2 H), 3.20–3.26 
(m, 1 H), 4.18–4.25 (m, 1 H), 4.66–4.72 (m, 1 H), 
4.79 (d, 1 H, J = 12.8 Hz), 4.88–4.96 (m, 1 H), 6.92 
(d, J = 2.0 Hz) and 6.94 (d, J = 2.0 Hz, 1 H), 6.99–
7.04 (m, 1 H), 7.14–7.60 (m, 10 H), 8.33 (d, J = 2.0 
Hz) and 8.34 (d, J = 2.0 Hz, 1 H).  
177 N
Ph  
Rt = 13.6 min (Method II); HRMS: [MH]+ 599.3592 
(calc. for C36H47N4O4+) 599.3594 (found); 1H NMR 
(400 MHz, CDCl3) (two rotamers in a ratio of 1:1), δ 
0.85–2.07 (m, 26 H), 2.70–2.88 (m, 2 H), 3.18–3.27 
(m, 1 H), 4.14–4.20 (m, 1 H), 4.65–4.72 (m, 1 H), 
4.79 (d, 1 H, J = 11.6 Hz), 4.88–4.94 (m, 1 H), 6.75 
(t, 1 H, J = 9.6 Hz), 6.93–6.94 (m, 1 H), 7.07 (t, 1 H, 
J = 9.6 Hz), 7.26–7.58 (m, 9 H), 8.33–8.34 (m, 1 H).  
178 N
OPh  
Rt = 13.21 min (Method II); HRMS: [MH]+ 615.3541 
(calc. for C36H47N4O5+) 615.3546 (found); 1H NMR 
(400 MHz, DMSO-d6) (two rotamers in a ratio of 
64:36), δ 0.88–2.00 (m, 26 H), 2.69–2.78 (m, 1 H), 
2.87–2.94 (m, 1 H), 3.16–3.27 (m, 1 H), 4.28 (d, 1 H, 
J = 12.8 Hz), 4.62–4.75 (m, 3 H), 7.00–7.58 (m, 10 
H), 8.21 (d, J = 9.6 Hz, minor) and 8.34 (d, J = 9.6 
Hz, major, 1 H), 8.83 (d, J = 1.8 Hz, major) and 8.85 
(d, J = 1.8 Hz, minor, 1 H), 9.02 (d, 1 H, J = 8.4 Hz). 
179 
N
OHN
H
H
 
Rt = 13.59 min (Method II); HRMS: [MH]+ 600.4119 
(calc. for C33H54N5O5+) 600.4118 (found); 1H NMR 
(400 MHz, DMSO–d6) (two rotamers in a ratio of 
1:1), δ 0.76–0.91 (m, 8 H), 0.97–1.36 (m, 18 H), 
1.40–1.70 (m, 15 H), 1.77–1.84 (m, 1 H), 1.91–1.95 
(m, 1 H), 3.25–3.29 (s, 9 H, rotamer of the tBu–amide 
group), 3.50 (t, 1 H, J = 12.4 Hz), 3.64 (dd, 1 H, J = 
4.4, 13.2 Hz), 4.41–4.54 (m, 2 H), 4.65 (t, 1 H, J = 
8.8 Hz), 4.78–4.81 (m, 1 H), 7.12 (s, 1 H), 7.13 (d, 1 
H, J = 1.6 Hz), 8.11 (d, 1 H, J = 8.8 Hz), 8.72 (d, 1 H, 
J = 1.6 Hz), 8.91 (d, 1 H, J = 8.4 Hz).  
180 
N
OHN
 
Rt = 9.29 min (Method II); HRMS: [MH]+ 546.3650 
(calc. for C29H48N5O5+) 546.3653 (found); 1H NMR 
(400 MHz, DMSO–d6) (two rotamers in a ratio of 
2:1), δ 0.76–0.92 (m, 10 H), 0.97–1.23 (m, 6 H), 
1.16–1.26 (m, 11 H), 1.27–1.44 (m, 5 H), 1.47–1.67 
(m, 12 H), 1.76–1.81 (m, 1 H), 1.95–1.98 (m, 1 H), 
3.92 (br d, 1 H, J = 13.2 Hz), 4.49–4.55 (m, 2 H), 
4.64 (t, 1 H, J = 8.4 Hz), 4.92–4.94 (m, 1 H), 7.04 (s, 
1 H), 7.13 (d, 1 H, J = 2.0 Hz), 8.06 (d, 1 H, J = 2.0 
Hz), 8.72 (d, 1 H, J = 2.0 Hz), 8.91 (d, 1 H, J = 8.4 
Hz).  
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181 N OMe
OMe  
Rt = 9.13 min (Method II); HRMS: [MH]+ 555.3177 
(calc. for C30H43N4O6+) 555.3179 (found); 1 H NMR 
(400 MHz, DMSO–d6) (two rotamers in a ratio of 
58:42), δ 0.89–1.98 (m, 22 H), 2.75–2.95 (m, 2 H), 
3.64–3.97 (m, 8 H, including MeO singlets at δ 3.82 
and 3.84), 4.54–4.87 (m, 4 H), 6.83 (s)/6.87 (s)/6.89 
(s, 2 H), 7.26 (d, J = 2.0 Hz, minor) and 7.27 (d, J = 
2.0 Hz, major, 1 H),  8.29 (d, J = 8.8 Hz, minor) and 
8.32 (d, J = 8.8 Hz, major, 1 H), 8.86 (d, 1 H, J = 2.0 
Hz), 9.00 (d, J = 8.0 Hz, minor) and 9.01 (d, J = 8.0 
Hz, major, 1 H). 
182 N
O
O
 
Rt = 10.4 min (Method II); HRMS: [MH]+ 579.3177 
(calc. for C32H43N4O6+) 579.3178 (found); 1H NMR 
(400 MHz, DMSO–d6), δ 0.85–1.08 (m, 8 H), 1.03–
1.40 (m, 5 H), 1.43–1.84 (m, 11 H), 2.11–2.24 (m, 2 
H), 2.71-2.82 (m, 2 H), 3.10–3.26 (m, 1 H), 3.56–3.69 
(m, 1 H), 3.93–4.06 (m, 1 H), 4.37–4.47 (m, 1 H), 
4.62–4.72 (m, 1 H), 4.85 (t, 1 H, J = 8.6 Hz), 6.94 (d, 
J = 2.0 Hz) and 6.96 (d, J = 2.0 Hz, 1 H), 6.99–7.08 
(m, 2 H), 7.18 (d, J = 7.6 Hz, major) and 7.23 (d, J = 
8.0 Hz, minor, 1 H), 7.36 (d, J = 9.2 Hz, minor) and 
7.44 (d, J = 8.8 Hz, major, 1 H), 7.50–7.56 (m, 1 H), 
7.87–7.91 (m, 1 H), 8.35 (d, 1 H, J = 2.0 Hz).  
183 N
O
 
Rt = 10.6 min (Method II); HRMS: [MH]+ 565.3384 
(calc. for C32H45N4O5+) 565.3385 (found); 1H NMR 
(400 MHz, CDCl3) (two rotamers in a ratio of 1:1) δ 
0.85–1.00 (m, 8 H), 1.11–1.24 (m, 6 H), 1.49–2.22 
(m, 14 H), 2.77–2.82 (m, 2 H), 3.15–3.28 (m, 1 H), 
3.57–3.69 (m, 1 H), 3.92–4.00 (m, 1 H), 4.40–4.47 
(m, 1 H), 4.68–4.76 (m, 1 H), 4.90 (t, 1 H, J = 8.4 
Hz), 6.82–7.14 (m, 5 H), 7.31–7.58 (m, 2 H), 8.34 (d, 
1 H, J = 1.2 Hz).  
184 N
O
O  
Rt = 9.6 min (Method II); HRMS: [MNa]+ 587.2840 
(calc. for C31H40N4NaO6+) 587.2843 (found); 1H 
NMR (400 MHz, CDCl3) (two rotamers in a ratio of 
72:28) δ 0.88–1.90 (m, 24 H), 2.00–2.16 (m, 1 H), 
2.29–2.37 (m, 1 H), 3.14–3.24 (m, 1 H), 3.63–3.71 
(m, 1 H), 4.17–4.21 (m, 1 H), 4.66–4.76 (m, 2 H), 
4.89–4.94 (m, 1 H), 6.95 (d, 1 H, J = 2.0 Hz), 6.88 (d, 
0.28 H, J = 8.8Hz) and 7.03 (d, 0.72 H, J = 8.8 Hz), 
7.16–7.21 (m, 1 H), 7.35 (d, 0.28 H, J = 8.0Hz) and 
7.45 (d, 0.72 H, J = 8.0 Hz), 7.54–7.60 (m, 1 H), 
7.68–7.73 (m, 1 H), 7.90–7.95 (m, 1 H), 8.35 (d, 0.28 
H, J = 2.0 Hz) and 8.36 (d, 1 H, 0.72 H, J = 2.0 Hz). 
185 N
N
SO2Me  
Rt = 9.9 min (Method II); HRMS: [MNa]+ 650.2983 
(calc. for C32H45N5NaO6S+) 650.2985 (found); 1H 
NMR (400 MHz, CDCl3) (two rotamers in a ratio of 
2:1) δ 0.85–1.03 (m, 8 H), 1.09–2.10 (m, 18 H), 
2.80–2.93 (m, 1 H), 2.94(s)/2.93(s, 3H, SO2Me), 
3.24–3.41 (m, 1 H), 3.86–3.93 (m, 2 H), 4.14–4.24 
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(m, 1 H), 4.56–4.74 (m, 2 H), 4.87–4.91 (m, 1 H), 
6.95 (d, J = 2.0 Hz, major) and 6.96 (d, J = 2.0 Hz, 
minor, 1 H), 7.05–7.31 (m, 4 H), 7.37–7.42 (m, 1 H), 
7.45 (d, J =8.8 Hz, minor) and 7.55 (d, J = 8.8 Hz, 
major, 1 H), 8.35 (d, 1 H, J = 2.0 Hz). 
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3.1 Abstract 
 
Many GPCR antagonists have been derived from their respective endogenous 
peptide agonists, often through minor changes. This chapter sought to use information 
reported for two PAR2 agonists, the heptapeptide 2f-LIGRLO-NH2 and the non-
peptidic GB110 (91) (both with EC50 of 200–300 nM in an intracellular calcium 
mobilization assay (iCa2+) using HT29 cells), to generate non-peptidic antagonists 
selective for PAR2 over PAR1. An already known PAR2 antagonist GB88, shares 
some of the same structure as GB110, but has a C-terminal spiroindene phenyl ring 
which confers antagonism. This chapter therefore set out to investigate replacements 
for this spiroindene piperidine towards optimising a more potent antagonist. Firstly, 
GB110 (91) was truncated by removing the piperidine and replacing the benzyl ring 
with one of around 40 different benzylamines which was attached to the C-terminus 
of isoxazolyl-Cha-Ile. Compounds which were found to be antagonists included 192 
(AY265), 209, 211 and 212 (IC50 ~400–600 nM) that all inhibited PAR2 activation in 
a concentration-dependent manner. However, as the compound concentration 
increased, some agonist response was observed. This is quite common for GPCRs. 
Further investigation revealed that compound 192 (AY265) was able to inhibit PAR2 
activation induced by both 2f-LIGRLO-NH2 and trypsin in cells and in PAR2-induced 
rat paw oedema (Chapter 4). This confirms that PAR2 activation is pro-inflammatory 
and that PAR2 antagonism is anti-inflammatory, at least in these settings. 
	   122 
3.2 Introduction 	  
Prior to the current studies, the most potent agonists for PAR2 were GB110 (91, 
EC50 0.28 µM; iCa2+, HT29 cells)1 and 2f-LIGRLO-NH2 (EC50 0.2 µM; iCa2+, HT29 
cells).2 However, peptides like 2f-LIGRLO-NH2 tend to be cleaved by peptidases in 
vivo. Therefore, the non-peptidic GB110 (91) was chosen in this study to evaluate the 
structure activity relationships (SAR) around this agonist, with the aim to transform it 
to a PAR2 antagonist.                                
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GB110 (91) was the most potent non-peptidic PAR2 agonist (EC50 0.28 µM; 
iCa2+, HT29 cells) previously discovered by our group.1 It was a hybrid molecule, 
combining peptidic and non-peptidic fragments. Our initial plan was to modify it to 
maintain or improve the binding affinity with an expectation of being able to switch 
its function to an antagonist. Previous studies by Barry et al had suggested that the 
benzyl and piperidine rings in the C-terminus of GB110 (91) act as linkers, while the 
primary amine at the end of the C-terminus may contribute to the agonist activity of 
GB110.1 Removal of the C-terminal primary amine and replacement with a 
morpholine moiety led to a weak antagonist 109 (IC50 57 µM; iCa2+, HT29 cells).1 
The terminal amine in GB110 (91) may contribute to binding and possibly 
confers agonist activity. Comparing to GB88 (110) and SAR studies reported in 
Chapter 2, the C-terminal aromatic ring could be involved in a π-stacking interaction 
at the corresponding binding pocket. A homology model of PAR2 indicated that this 
putative binding site has several hydrophobic residues including four tyrosine 
residues (Fig. 2.10A in Chapter 2). As this site was not well defined or understood, 
various substituted benzylamines were incorporated into analogues of antagonist 
GB88 (110) to probe this binding site.  	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3.3 Results and Discussion 
3.3.1 Truncation of GB110 and incorporation of various benzylamines 	  
As the chemical structures of GB110 (91) and GB88 (110) are similar, it is 
possible that the phenyl ring of GB110 (91) binds to the same receptor pocket as the 
spiroindene phenyl ring of GB88 (110) . Furthermore, the middle benzylamine core of 
GB110 (91) replaces the cyclic piperidine structure of GB88 (110), while presenting a 
phenyl ring closer to the amide linker than that in GB88 (110). The commercial 
availability of benzylamine derivatives provided diverse building blocks that allowed 
fast entry to a diverse library of compounds featuring the common core, shared by 
both GB88 (110) and GB110 (91), anchored to benzylamines. 
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The first modification was to truncate the compound GB110 (91) by removing 
the piperidine methylamine (e.g. 187, Fig. 3.1), then various substituents were 
introduced onto the aromatic ring. It was assumed that the phenyl ring of GB110 (91) 
could bind to the same receptor pocket as the spiroindene phenyl ring of GB88 (110). 
Thus, the truncated GB110 (91), possessing a benzyl ring at the C-terminus, may 
become an antagonist. In addition, the interaction of different substituents on the 
benzyl ring with PAR2 was also investigated.  
Diverse functional groups were attached to the benzyl ring with varied electronic 
and steric properties (Fig. 3.1). Fluorine was introduced at ortho (188), meta (189) 
and para (190) positions of the benzyl moiety respectively to potentially improve the 
activity, since fluorine is known to be capable of making weak H-bonding 
interactions. Fluorine is also capable of inducing electron withdrawing and inductive 
effects. In addition, fluorine is able to stabilise the phenyl ring from metabolic 
oxidation.3 In addition, other than fluorine, methoxy groups were also incorporated on 
the aromatic ring, as the methoxy oxygen atom is a better H-bond acceptor than 
fluorine, due to the low polarizability and tightly contracted lone pairs of the latter 
and in spite of its greater electronegativity. Pyridines and benzimidazole have a ring 
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nitrogen that could be involved in H-bonding, while electron withdrawing groups 
such as chlorine, nitro, trifluoromethyl and trifluoromethoxy were also introduced to 
vary the electronic properties of the aromatic ring.  
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Figure 3.1 Benzylamines appended at the C-terminus of the N-terminal isoxazoyl-
capped dipeptide Cha-Ile. 
 
Compound 187, the truncated GB110 (91), possessing an amide NH adjacent to 
the benzyl ring, was a partial PAR2 agonist. Three fluorinated benzyl analogues (188-
190) of 187 were also partial agonists and the phenylhydrazide (191) also showed 
some agonist activity (Fig. 3.2B). However, a methoxy group at the ortho position 
(192, also called AY265) showed more potent antagonist activity (IC50 500 nM, Fig. 
3.3A) than GB88 (IC50 1–2 µM, Fig. 3.3A).  
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Figure 3.2 Calcium mobilisation assay on HT29 cells. (A) % inhibition of Ca2+ efflux 
by compounds at 1 µM against 1 µM 2f-LIGRLO-NH2 (n = 1). (B) % calcium efflux 
induced by compounds at 10 µM relative to 100% for 2f-LIGRLO-NH2 at 100 µM (n 
= 1). Each data point represents mean ± SEM.  
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Figure 3.3 (A) Concentration dependent responses for compound 192 (blue) and the 
reference GB88 antagonist (red) for the inhibition of Ca2+ release in HT29 cells 
induced by 1 µM 2f-LIGRLO-NH2 (n ≥ 3). (B) Ca2+ release of compound 192 vs 2f-
LIGRLO-NH2, relative to 100% for 2f-LIGRLO-NH2 at 100 µM (n ≥ 3) in HT29 
cells. (C) Overlay of antagonist (from A) and agonist (from B) activity of compound 
192. (D) Ca2+ release of compound 196 vs 2f-LIGRLO-NH2 in HT29 cells, relative to 
100% for 2f-LIGRLO-NH2 at 100 µM (n = 1). Each data point represents mean ± 
SEM.  
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It was speculated that the methoxy group on the benzyl ring of 192 (AY265) 
could either make a H-bonding interaction with the receptor or bind into a small 
pocket in PAR2. It was also possible that the electron-donating methoxy enhanced a 
π-stacking interaction between the benzylamine phenyl ring and an aromatic residue 
from the receptor. Superimposition of compound 192 (AY265) with GB88 (110) 
showed that the o-methoxy benzylamine group of 192 (AY265) can potentially 
occupy the same position as the spiroindene piperidine ring (Fig. 3.4). However, this 
compound also showed some agonist activity in the calcium release assay at high 
concentrations (Fig. 3.3B & C), in which the agonist activity could be caused by the 
neighbouring amide NH behaving as H-bond donor. Therefore, to remove the 
hydrogen bond donor, an attempt was made to N-methylate the amide and this will be 
discussed in section 3.3.2.  
 
Figure 3.4 Superimposition of energy minimised conformations of compound 192 
(AY265) (cyan) and GB88 (in green) using Openeye software – Omega2 and ROCS. 
 
Introduction of flexibility, while increasing the distance between the dipeptide 
and the aromatic ring, led to compound 193 with no increase in antagonist potency 
(Fig. 3.2). On the other hand, incorporation of aromatic heterocycles, such as 
pyridines (194, 195) and benzimidazole (196), resulted in full agonists (Fig. 3.2B). A 
concentration dependent calcium assay was performed on compound 196 (Fig. 3.3D), 
and it was found to be 5-fold less potent than the reported PAR2 agonist (2f-
LIGRLO-NH2). In addition, compounds containing electron-withdrawing groups on 
the benzyl ring, such as chloro, nitro, trifluoromethyl and trifluoromethoxy (197–
200), were not antagonists as all displayed agonist responses up to 40% at 10 µM. It 
was important that all potential antagonists were assessed for agonist activity to 
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eliminate the possibility of the observed antagonist activity (i.e. low calcium 
response) being caused by desensitisation of the receptor resulting from receptor 
activation stimulated by agonist.1, 4  
 
3.3.2 Investigation of the agonist properties of benzylamines 	  
The agonist activity observed for some benzylamine derivatives above may be 
contributed by the amide NH proton adjacent to the benzylamine moiety. It was 
assumed that the NH proton acted as a hydrogen bond donor and may form a H-bond 
interaction with the receptor. Therefore removing that NH proton may abolish the 
agonist response. When the NH proton was replaced by a methyl group, compounds 
201 and 202 (Fig. 3.5A) became antagonists with very weak agonist activity (Fig. 
3.5B–C). This suggested that the amide NH proton was the main cause of the 
observed agonist activity. However, the antagonist activities of the N-methylated 
compounds (201 and 202) also significantly reduced at the same time. 
Superimposition of compound 202 with 192 (AY265) indicated that the N-methylated 
compound (202) projected the aromatic ring to another position (Fig. 3.5D), and so it 
probably did not bind to PAR2 in a similar fashion to the compound that retained the 
NH donor (192) - therefore the potency decreased. As a result, the NH of amide was 
retained in later ligand design in order to maintain antagonist potency.   
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Figure 3.5 (A) Chemical structures of two N-methylated benzylamines (201–202). 
(B) % inhibition of Ca2+ efflux by compounds at 1 µM against 1 µM 2f-LIGRLO-NH2 
(n = 1) in HT29 cells. (C) % calcium efflux induced by compounds at 10 µM relative 
to 100% for 2f-LIGRLO-NH2 at 100 µM (n = 1) in HT29 cells. Each data point 
represents mean ± SEM. (D) Superimposition of energy minimised conformations of 
compound 192 (cyan) and 202 (in magenta) using Openeye software – Omega2 and 
ROCS. 
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3.3.3 Introduction of bulky groups at the C-terminus 	  
The size of the o-methoxybenzylamine group in compound 192 is smaller than 
the spiroindene piperidine of GB88 (110). Therefore, it was assumed that even bulkier 
benzylamines might be tolerated. Bulky groups such as ortho, meta, para biphenyl 
and naphthalene compounds were synthesised (203–206, Fig. 3.6A) but they were not 
very potent PAR2 antagonists (Fig. 3.6B), suggesting that there might be limited  
space in the receptor binding pocket to accommodate the extra phenyl ring. The 
reduction in potency observed for compounds 203–206 may also be due to the 
electronic effects induced by the extra phenyl ring. 
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Figure 3.6  (A) Chemical structures of compounds 203–208. (B) % inhibition of Ca2+ 
efflux by compounds at 1 µM against 1 µM 2f-LIGRLO-NH2 (n = 1) in HT29 cells. 
(C) % calcium efflux induced by compounds at 10 µM relative to 100% for 2f-
LIGRLO-NH2 at 100 µM (n = 1) in HT29 cells. Each data point represents mean ± 
SEM.  
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To contrast with these aromatic substituents, some bulky aliphatic groups were 
also introduced to the putative antagonists. Di-isobutyl amine at the C-terminus (207, 
Fig. 3.6A) proved to be inactive, suggesting that an aromatic ring was preferred at the 
C-terminus possibly to make a π-stacking interaction with the receptor. This was 
supported by SAR studies from Chapter 2, in which an aromatic ring was also found 
to be essential at the C-terminus for activity, as shown by the phenyl piperidine 
compound (167). However, an adamantyl amine substituent in 208 was able to 
antagonise PAR2 activation but with less potency than GB88 (Fig. 3.6B). The 
inhibition by this compound may instead be due to its space filling properties and not 
a π-stacking interaction. 
 
3.3.4 Optimisation of Compound 192 	  
Since compound 192, with an o-methoxybenzyl group at the C-terminus, 
displayed promising antagonist activity, a methoxy group was introduced at the meta 
or para position of the ring (Fig. 3.7A) to examine if relocation of the methoxy group 
could improve the antagonist activity. The calcium release results indicated that the 
ortho- (192), meta- (209) and para-methoxy (210) compounds gave similar antagonist 
potency (IC50 500–600 nM) (Fig. 3.7B), but the para-methoxy (210) analogue showed 
higher undesirable agonist activity at 10 µM (Fig. 3.7C). Since the ortho- and meta-
methoxy analogues were tolerated, two methylenedioxyphenyl analogues (217, 218) 
were synthesised and these compounds showed similar antagonist potencies to 
compound 209, as well as displaying partial agonist activity.  
In order to determine whether the oxygen from o-methoxybenzyl of 192 was 
involved a H-bond interaction, the methyl derivative 212 was assessed and it showed 
a similar antagonist profile as the methoxy analogue (192, Fig. 3.7D). This confirmed 
that the oxygen from the methoxy group was not participating in any H-bonding 
interaction. Thus the methoxy or methyl group at the ortho position of the benzyl ring 
could be just filling space in the corresponding binding pocket on PAR2. Therefore, 
larger substituents were introduced at the ortho position of the benzyl ring to map the 
space. Previous studies had shown that an ortho-biphenyl substituent was not 
tolerated (section 3.3.3), therefore smaller groups like O-ethyl, O-propyl, O-butyl, etc, 
were introduced to explore the available space. Incorporating substituents with 
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appropriate size could possibly lock the molecule into the binding pocket and might 
be able to abolish the residual agonist activity observed for compound 192, as well as 
to improve binding affinity of the ligand.   
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Figure 3.7 (A) Chemical structures of compounds 209–218. (B) % inhibition of Ca2+ 
efflux by compounds at 1 µM against 1 µM 2f-LIGRLO-NH2 (n = 1) in HT29 cells. 
(C) % calcium efflux induced by compounds at 10 µM relative to 100% for 2f-
LIGRLO-NH2 at 100 µM (n = 1) in HT29 cells. (D) Concentration dependent 
responses of 212 (red, n = 3), 192 (blue, n ≥ 3), compound 209 (green, n = 2) and 211 
(orange, n ≥ 3), and for the inhibition of Ca2+ release induced by 1 µM 2f-LIGRLO-
NH2 in HT29 cells. (E) Concentration dependent responses of compound 215 (purple, 
n = 3), GB88 (red, n ≥ 3) and 192 (blue, n ≥ 3) for the inhibition of Ca2+ release 
induced by 1 µM 2f-LIGRLO-NH2 in HT29 cells. Each data point represents mean ± 
SEM.  
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To probe the small hydrophobic pocket around the methoxy binding site, a 
homologous series of alkyl groups , smaller than a phenyl ring, such as ethoxy (211), 
n-propyl (213), n-butyl (214), sec-butyl (215) and isopropyl (216) was introduced. 
Assay results indicated that having ethoxy (211), n-propyl (213), n-butyl (214), sec-
butyl (215) and isopropyl (216) on the benzyl ring did not improve the antagonist 
potency relative to the o-methoxy compound 192 (Fig. 3.7B & D) while the n-butyl 
(214) almost abolished antagonist activity. However, it was surprising that n-propyl 
(213) and sec-butyl (215) were not partial agonists (Fig. 3.7C).  
In summary, these SAR results suggested that the binding pocket around the 
ortho position of the benzyl ring was relatively small and that a methoxy or a methyl 
group was better.  
 
3.3.5 Multi-substituted benzylamines 	  
Instead of a mono-substituted phenyl ring, di-substituted compounds were 
assessed with some examples taken from known NK2 receptor ligands (e.g. 225, 226, 
227, Fig. 3.8A). As ortho- and meta-methoxy benzylamines had similar potency, it 
was thought that having two methoxy groups on the ring may be beneficial. However, 
all di-methoxy substituted compounds were agonists and the tri-substituted analogue 
(224) was not active, presumably due to the bulkiness of the ring (Fig. 3.8B & C). 
Compounds 225 and 227 were also not active, which could be due to limited space 
around the OCF3 or meta CF3 region. Compound 226 was an antagonist, nearly 
devoid of agonist activity. A concentration response curve showed that the inhibitory 
activity of 226 (IC50 1.4 µM) was comparable to that for GB88 (IC50 1.0 µM, Fig. 
3.8C).  
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Figure 3.8 (A) Chemical structures of compounds 219–227. (B) % inhibition of Ca2+ 
efflux by compounds at 1 µM against 1 µM 2f-LIGRLO-NH2 (n = 1). (C) % calcium 
efflux induced by compounds at 10 µM relative to 100% for 2f-LIGRLO-NH2 at 100 
µM (n = 1). (D) Concentration dependent responses of compound 226 (, n = 2) and 
GB88 (, n = 2) for the inhibition of Ca2+ release induced by 1 µM 2f-LIGRLO-NH2. 
Each data point represents mean ± SEM.  
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3.4 Summary and Conclusions 	  
Truncation of GB110 (91) has led to a few compounds with variable 
agonist/antagonist activities at micromolar concentrations and has generated some 
useful SAR information. The amide NH proton adjacent to the benzyl group did 
contribute to PAR2 agonist activity, removing the proton by N-methylation 
significantly reduced the agonist activity. Also, an aromatic ring was required at the 
C-terminus, possibly to maintain a π-stacking interaction with the receptor. Smaller 
substituents were tolerated at ortho, meta and para positions of the aromatic ring. 
Interestingly, ortho-methoxy (192, also called AY265), meta-methoxy (209), ortho-
ethoxy (211) and ortho-methyl (212) substituted benzyl compounds were PAR2 
antagonists at nM concentrations (IC50 400–600 nM; iCa2+, HT29 cells, Fig. 3.7D). 
All these compounds possessed lower molecular weight (<500) and lower cLogP 
(3.3–4.0) than GB88 (MW 546, cLogP 4.3), which are usually beneficial for oral 
bioavailability according to Lipinski’s rule of 5. The pharmacokinetic profile and 
anti-inflammatory activity of compound 192 (AY265) was determined and is reported 
in Chapter 4. 	  	  
3.5 Experimental Methods 
 
General Methods 
 
All amino acids were purchased from Novabiochem. Diisopropylethylamine 
(DIPEA), DMF and TFA were obtained from Auspep Pty Ltd., Australia. Other 
chemicals were obtained from Aldrich. All reagents were used as received. 
Hydrogenation reactions were conducted using a medium pressure Parr hydrogenator 
apparatus. Preparative-scale rpHPLC separations were performed on a Phenomenex 
Luna C18 15 µm, 250 × 21.2 mm column. Standard conditions were used for all 
compounds unless otherwise indicated at a flow rate of 20 mL/min: 50% to 100% B 
linear gradient over 10 min followed by a further 10 min at 100% B where solvent B 
was 90% MeCN, 10% H2O + 0.1% TFA and solvent A was H2O + 0.1% TFA. 
Analytical rpHPLC were used to assess compound purity (Phenomenex Luna C18 
column, 15 µm, 90 Å, 4.6 × 250 mm, λ 214, 230 and 254 nm) at three different 
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wavelengths. Standard conditions (same as preparative-scale rpHPLC) were used for 
all compounds unless otherwise indicated at a flow rate of 1 mL/min. Solvent 
conditions were the same as preparative-scale rpHPLC.  
Electrospray ionization mass spectra (ESI-MS) measurements were obtained on 
Micromass LCT and high-resolution mass spectra (ESI-HRMS) measurements were 
obtained on a Bruker microTOF mass spectrometer equipped with a Dionex LC 
system (Chromeleon) in positive ion mode by direct infusion in MeCN at 100 µL/h 
using sodium formate clusters as an internal calibrant. Data was processed using 
Bruker Daltonics DataAnalysis 3.4 software. Mass accuracy was better than 1 ppm 
error.  
1H and 13C NMR spectra were recorded on either a Varian 400 or Bruker Avance 
600 spectrometer at 298 K in the deuterated solvents indicated. 1H NMR spectra were 
referenced to the residual 1H signals; DMSO-d6 2.50, CD3OD 3.31 ppm except CDCl3 
solutions were referenced to internal TMS. 13C NMR resonances were referenced to 
the residual solvent peak (DMSO-d6 40.4, CDCl3 77.0 ppm).  
 
3.5.1 Synthesis of Compounds 187-227 
 
Scheme 3.1 Synthesis of compounds 187–227 
Route A: 
OH
N
O
N
H
O
N O
OH NH
R1
R2
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N
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O
N O
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Route B: 
NH
O
BocHN OH
O
H2N N
R1 OH
N N
R1
O
N
H
O
N O
R1 a, b c, b, d
R2
R2 R2  
Reagents and conditions: a) HBTU, DIPEA, DMF; b) 20% TFA, DCM; c) Boc-Cha-
OH, HBTU, DIPEA, DMF; d) isoxazole-5-carboxylic acid, HBTU, DIPEA, DMF. 
 
Synthetic route A was initially used to synthesise compounds 187–227. However, 
coupling of the “dipeptide”-like isoxazoyl-Cha-Ile-carboxylic acid with amine (step a) 
resulted in epimerisation of the α-C centre of L-isoleucine. Various coupling agents 
(BOP, HATU, DIC) and mild, low temperature conditions (HBTU, -40 °C to rt) were 
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tried, but none of these conditions prevented the epimerisation. Therefore, route B, 
where no epimerisation was observed, was used for the synthesis of compounds 187–
227.  
 
General procedures for Route B. Compounds were synthesised via solution 
phase chemistry approach using Boc-protected amino acids. Firstly, the amino acid 
(1.2–1.5 eq) was activated with HBTU (1.5 eq) and DIPEA (1.5 eq) as 0.2–0.5 M 
solutions in DMF for 10 minutes. Then the solution was added to an amino group 
bearing C-terminal moiety (R1R2NH) and the mixture was stirred for a minimum of 1 
h at room temperature. The reaction mixture was diluted with EtOAc and washed 
with saturated NaHCO3 (2 ×). The organic extracts were dried over MgSO4, filtered 
and evaporated in vacuo. The crude was then treated with 20% TFA in DCM and 
stirred for 1–2 h to remove the Boc group. TFA was removed by evaporating the 
reaction mixture under N2.  The residue was dissolved in DCM and washed with 
saturated NaHCO3 (2 ×).  DCM phase was dried with MgSO4, filtered and evaporated 
in vacuo. Subsequent N-Boc-amino acids and amines were sequentially coupled under 
the same conditions. Each coupling reaction was monitored by ESI-MS, with most 
reactions going to completion overnight. Compounds 187–227 were characterized and 
the data were reported in section 3.6. 
 
3.5.2 Synthesis of benzylamine building blocks 	  	  
Scheme 3.2 Preparation of ortho-alkoxybenzylamines (4) 	  
O
OH
O
O O
N OH
O
NH2
R R R
1 2a, R = n-butyl2b, R = sec-butyl
2c, R = n-propyl
2d, R = isopropyl
a b c
3a, R = n-butyl
3b, R = sec-butyl
3c, R = n-propyl
3d, R = isopropyl
4a, R = n-butyl
4b, R = sec-butyl
4c, R = n-propyl
4d, R = isopropyl  
RX = n-butyl bromide, sec-butyl bromide, n-propyl bromide, isopropyl iodide.  
Reagents and conditions: a) RX, DBU, DMF, microwave 140°C, 10 min; b) 
NH2OH.HCl, NaOH, MeOH/H2O (1:1); c) H2, 10% Pd/C, EtOH. 
 
General procedures for synthesis of 2-alkoxybenzaldehydes (2a–d). In a 
microwave reaction vial was loaded salicylaldehyde (1, 1 eq.), DMF (0.2 mL/mmol), 
DBU (1 eq.) and the corresponding bromide/iodide (2 eq.). The vessel was sealed and 
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the mixture was irradiated in Biotage Initiator microwave reactor (140 °C, 10 min). 
The progress of the reaction was monitored by TLC (Petroleum ether/EtOAc 4:1, 
product Rf ~0.5–0.6). Upon completion, the reaction mixture was allowed to cool 
down, diluted with EtOAc and H2O, and washed with sat. Na2CO3 (3 ×) to remove 
starting material salicylaldehyde. The organic phase was dried over MgSO4, filtered 
and evaporated to dryness to the give product (2a–d) as a yellow liquid (70–90% 
yield). This reaction was initially conducted by mixing starting material 
salicylaldehyde, the corresponding bromide, K2CO3 in acetone and refluxed 
overnight. However, the yield of product under this condition was low (~10%). The 
yield of this reaction was significantly improved when the reaction was heated in 
microwave using DBU as base and DMF as the reaction solvent.  
 
2a: Rt = 12.7 min (20–100% B 10 min gradient plus 100% B for further 10 min); ESI-
MS: m/z 179.2 [MH]+; 1H NMR (400 MHz, CDCl3), δ 1.03 (t, 3 H, J = 7.2 Hz), 1.53–
1.59 (m, 2 H), 1.83–1.90 (m, 2 H), 4.10 (t, 2 H, J = 6.4 Hz), 6.97–7.03 (m, 2 H), 
7.50–7.55 (m, 1 H), 7.82 (dd, 1 H, J = 1.6, 7.6 Hz), 10.50 (s, 1 H).  
 
2b: Rt = 12.4 min (20–100% B 10 min gradient plus 100% B for further 10 min); 
ESI-MS: m/z 179.2 [MH]+; 1H NMR (400 MHz, CDCl3), δ 0.95 (t, 3 H, J = 13.3 Hz), 
1.29 (d, 3 H, J = 6.0 Hz), 1.60–1.67 (m, 1 H), 1.71–1.78 (m, 1 H), 4.37–4.43 (m, 1 H), 
6.89–6.94 (m, 2 H), 7.43–7.46 (m, 1 H), 7.77 (dd, 1 H, J = 1.8, 7.7 Hz), 10.48 (s, 1 
H).  
 
2c: Rt = 11.8 min (20–100% B 10 min gradient plus 100% B for further 10 min); ESI-
MS: m/z 165.3 [MH]+; 1H NMR (400 MHz, CDCl3), δ 0.93 (t, 3 H, J = 7.4 Hz), 1.69–
1.75 (m, 2 H), 3.86 (t, 2 H, J = 6.4 Hz), 6.80–6.86 (m, 2 H), 7.35–7.39 (m, 1 H), 7.68 
(dd, 1 H, J = 1.8, 7.7 Hz), 10.39 (s, 1 H). 
  
2d: Rt = 12.0 min (20–100% B 10 min gradient plus 100% B for further 10 min); 
ESI-MS: m/z 165.3 [MH]+; 1H NMR (400 MHz, CDCl3), δ 1.21 (s, 3 H), 1.23 (s, 3 
H), 4.46–4.52 (m, 1 H), 6.76–6.82 (m, 2 H), 7.29–7.33 (m, 1 H), 7.63 (dd, 1 H, J = 
2.0, 8.0 Hz), 10.32 (s, 1 H).  
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General procedures for synthesis of 2-alkoxybenzaldehyde oximes (3a–d). 
The 2-alkoxybenzaldehydes (2a–d, 1 eq.) was treated with hydroxylamine 
hydrochloride (2 eq.) and NaOH (4 eq.) in MeOH/H2O (1:1) and stirred at room 
temperature for 2 h. After completion, the reaction solution was evaporated to dryness 
and then re-dissolved in EtOAc, washed with 1 M HCl (2 ×), sat. NaHCO3 (2 ×) and 
brine (1 ×). The organic phase was dried over MgSO4, filtered and concentrated in 
vacuo to give a waxy solid (3). Oximes 3a–d were used for the next step without 
purification. 3a–b, ESI-MS: m/z 194.1 [MH]+; 3c–d, ESI-MS: m/z 180.1 [MH]+. 
 
General procedures for reduction of oximes (3a–d) to amines (4a–d). To 
starting material oximes (3a–d, ~3.30 mmol) in EtOH (50 mL) and glacial AcOH (10 
mL), 10% Pd/C (50 mg) was added and the reaction mixture was hydrogenated at 50 
psi overnight. The Pd/C catalyst was removed by filtering the mixture through celite, 
washed with EtOH (10 mL) and the filtrate was evaporated to reduce the volume of 
solvent. The resulting solution was basified with 5 M NaOH (10 mL) solution and 
extracted with EtOAc (3 × 10 mL). The organic phase was dried over MgSO4, 
filtered, and concentrated in vacuo to give the desired amines (4a–d). 4a–b, ESI-MS: 
m/z 180.1 [MH]+; 4c–d, ESI-MS: m/z 166.1 [MH]+. The amines were coupled to Boc-
Ile-OH followed by Boc-deprotection and subsequent coupling with Boc-Cha-OH and 
isoxazole-COOH to give compounds 213–216. Compounds 213–216 were 
characterized and the data were reported in section 3.6. 
 
Scheme 3.3 Preparation of benzo[d][1,3]dioxol-4-ylmethanamine.5 
 
OH
OHO O
O
O
H2N
O
O
5 6 7
a b
 
Reagents and conditions: a) Dibromomethane, CuO, K2CO3, DMF, 153 °C overnight; 
b) H2, 10% Pd/C, EtOH 
 
Synthesis of benzo[d][1,3]dioxol-4-ylmethanamine (7). In a round-bottomed 
flask containing DMF (16 mL), 2,3-dihydroxybenzaldehyde (2.01 g, 14.5 mmol), 
dibromomethane (1.4 mL, 17.4 mmol), cupric oxide (0.11 g, 1.45 mmol), K2CO3 (2.4 
g, 17.4 mmol) were added and the reaction mixture was refluxed at 153 °C overnight. 
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The Pd/C catalyst was removed by filtering the mixture through celite. The filtrate 
was washed with H2O (3 × 20 mL). The organic extract was dried over MgSO4, 
filtered and evaporated to dryness to give dark brown oil. The oil was distilled using a 
Kugelrohr distillation apparatus (b.p. 120 °C / 0.1 mm) to give product (6) as a yellow 
oil (1.5 g, 69%). Rt = 8.9 min (20–100% B 10 min gradient plus 100% B for further 
10 min); ESI-MS: m/z 151.1 [MH]+; 1H NMR (400 MHz, CDCl3): δ 6.09 (s, 2 H), 
6.89 (t, 1 H, J = 7.8 Hz), 6.98 (d, 1 H, J = 7.6 Hz), 7.23 (d, 1 H, J = 8.4 Hz), 10.08 (s, 
1 H). The aldehyde 6 was converted to oxime followed by hydrogenation to give the 
primary amine (7) (procedures described in section 3.5.2). The amine (7) was coupled 
to Boc-Ile-OH followed by Boc-deprotection and subsequent coupling with Boc-Cha-
OH and isoxazole-COOH to give compound 218. Compound 218 was characterized 
and the data were reported in section 3.6. 
 
3.5.3 Intracellular calcium release assay1, 6  
 
Assay Protocol. Adherent human colon adenocarcinoma cells (HT29) were 
plated at ~2 x 104 cells/well in a 96-well cleared-bottom black-wall assay plate 
(Corning) with equal amounts of medium (Dulbecco’s modified essential serum 
(DMEM from Gibco), penicillin (10 U/mL) and streptomycin (10 U/mL)) added and 
incubated overnight at 37oC. Before assay, the medium was removed and cells were 
incubated with dye-loading buffer (12 mL assay buffer, 4 µM Fluo-3 AM, 25 µL 
Pluronic acid F-127 and 1% fetal bovine serum) for 1 h at 37oC. After that, cells were 
washed once with the same assay buffer (HBSS supplemented with 2.5 mM 
probenecid and 20 mM HEPES, pH 7.4). 
 
Sample Preparation. Stock solutions of compounds were prepared by dissolving 
the compound in DMSO solution to give a 10 mM stock solution. The 10 mM stock 
solutions were then diluted with assay buffer (described in assay protocol) to give the 
concentrations required for the assay.  
 
Preliminary Assessment of Compounds. For the antagonist assay, the cells 
were pre-incubated with desired concentrations of the synthesised compounds (50 µL, 
20 µM) for 30 min before the addition of PAR2 agonist (2f-LIGRLO-NH2). The 96-
well plate was placed into fluorescence plate reader (Fluostar Optima – BMG 
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Labtechnologies or FLIPRTETRA) and then 2f-LIGRLO-NH2 (50 µL, 2 µM) was added 
to give a final agonist concentration of 1 µM. The final concentration of compounds 
was 10 µM). After addition of agonist, the intracellular release of Ca2+ was monitored 
via fluorescence measurement for at least 60 s (excitation 495 nm, emission 520 nm). 
The agonist assay was conducted in a similar manner, except that assay buffer (50 µL) 
was added to the cells first and the intracellular Ca2+ release was monitored 
immediately after the injection of the desired concentration of the synthesised 
compounds. 
 
Concentration Dependent Inhibition Assay. To assess a potential antagonist in 
more detail, a range of concentrations of the compound (50 µL) was pre-incubated 
with the cells for 30 min prior to the addition of 2f-LIGRLO-NH2 (50 µL, 2 µM). 
After addition of agonist, the intracellular release of Ca2+ was monitored via 
fluorescence measurement for at least 60 s (excitation 495 nm, emission 520 nm). 
Duplicate measurements were made for each data point, mean ± SEM were reported 
from multiple experiments as indicated. Changes in fluorescence (% response) were 
plotted against logarithmic compound concentrations. The half maximal inhibitory 
concentration (IC50) values were derived from the concentration response curve using 
a nonlinear regression curve in Graphpad Prism v5. 
 
Concentration Dependent Response Curves. To assess a potential agonist in 
more detail, a range of concentrations of the compound (50 µL) were added to the 
cells containing 50 µL assay buffer. The intracellular Ca2+ release was monitored for 
at least 60 s (excitation 495 nm, emission 520 nm) immediately after the injection of 
the desired concentration of the synthesised compounds. Duplicate measurements 
were made for each data point, mean ± SEM were reported from multiple experiments 
as indicated. Changes in fluorescence (% response) were plotted against logarithmic 
compound concentrations. The half maximal effective concentration (EC50) values 
were derived from the concentration response curve using a nonlinear regression 
curve in Graphpad Prism v5. 
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3.6 Characterization data for all final compounds 	  
General Methods  
 
All purified final compounds were characterized by ESI-HRMS and 1H NMR 
(Varian 400 or Bruker Avance 600), and the purities were assessed via analytical 
rpHPLC (Phenomenex C18 column, 15 µm,	  90 Å, 4.6 × 250 mm, λ 214, 230 and 254 
nm). All compounds were ≥ 95% pure. Four standard HPLC conditions were used for 
all compounds unless otherwise indicated at a flow rate of 1 mL/min. Method I: 20% 
to 100% B linear gradient over 10 min followed by a further 10 min at 100% B; 
Method II: 50% to 100% B linear gradient over 10 min followed by a further 10 min 
at 100% B; Method III: 90% B isocratic for 10 min where solvent B was MeCN + 
0.1% TFA and solvent A was H2O + 0.1% TFA. HPLC was performed using an 
Agilent 1200 Series with a diode-array detector on a Phenomenex Luna 5 µm, C18 or 
C8 250 × 4.60 mm column. All compounds were analysed on NMR (Varian 400 or 
Bruker Avance 600) at 298 K in the deuterated solvents indicated and were referenced 
to the residual 1H signals; DMSO-d6 2.50, CD3OD 3.31 ppm except CDCl3 solutions 
were referenced to internal TMS. 13C NMR resonances were referenced to the 
residual solvent peak (DMSO-d6 40.4, CDCl3 77.0 ppm).	   Electrospray ionization 
high-resolution mass spectra (ESI-HRMS) measurements were obtained on a Bruker 
microTOF mass spectrometer equipped with an Agilent 1100 Series LC/MSD mass 
detector in positive ion mode by direct infusion in MeCN at 100 µL/h using sodium 
formate clusters as an internal calibrant.  
R4
OH
N
O
N
H
O
N O
 
 Structure Analytical data 
187 N
H  
Rt = 9.36 min (Method II); HRMS: [MH]+ 469.2809 (calc. 
for C26H37N4O4+) 469.2818 (found); 1H NMR (400 MHz, 
CDCl3), δ 0.82–1.00 (m, 9 H), 1.05–1.25 (m, 5 H), 1.30–1.35 
(m, 1 H), 1.42–1.53 (m, 1 H), 1.63–1.78 (H’s overlap with 
H2O peak), 1.82–1.92 (m, 1 H), 4.27–4.31 (m, 1 H), 4.35–
4.41 (m, 1 H), 4.48 (dd, 1 H, J = 6.0, 14.8 Hz), 4.68–4.76 (m, 
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1 H), 6.48 (br s, 1 H), 6.85 (br s, 1 H), 6.88–6.89 (m, 1 H), 
7.24–7.34 (m, 6 H), 8.30–8.31 (m, 1 H). 
188 
N
H
F
 
Rt = 9.51 min (Method II); HRMS: [MH]+ 487.2715 (calc. 
for C26H36FN4O4+) 487.2718 (found); 1H NMR (400 MHz, 
CDCl3), δ 0.79–0.86 (m, 8 H), 0.88–0.98 (m, 1 H), 1.01–1.23 
(m, 5 H), 1.27–1.37 (m, 1 H), 1.39–1.49 (m, 1 H), 1.63–1.77 
(H’s overlap with H2O peak), 1.81–1.88 (m, 1 H), 4.43 (dd, 1 
H, J = 5.6, 14.8 Hz), 4.55 (dd, 1 H, J = 6.0, 14.8 Hz), 4.70–
4.76 (m, 1 H), 6.63 (br s, 1 H), 6.88 (br s, 1 H), 6.91 (d, 1 H, 
J = 2.0 Hz), 7.00–7.10 (m, 2 H), 7.22–7.36 (m, 3 H), 8.30 (d, 
1 H, J = 1.6 Hz). 
189 
N
H
F
 
Rt = 9.45 min (Method II); HRMS: [MH]+ 487.2715 (calc. 
for C26H36FN4O4+)  487.2712 (found); 1H NMR (400 MHz, 
CDCl3), δ 0.80–0.84 (m, 4 H), 0.88–0.90 (m, 4 H), 0.93–0.98 
(m, 1 H), 1.03–1.20 (m, 5 H), 1.28–1.35 (m, 1 H), 1.42–1.51 
(m, 1 H), 1.60–1.77 (H’s overlap with H2O peak), 1.86–1.92 
(m, 1 H), 4.30 (t, 1 H, J = 8 Hz), 4.38 (dd, 1 H, J = 5.2, 15.2 
Hz), 4.48 (dd, 1 H, J = 6, 15.2 Hz), 4.70–4.76 (m, 1 H), 6.73 
(br s, 1 H), 6.91–6.96 (m, 3 H), 7.02 (d, 1 H, J = 7.6 Hz), 
7.23–7.29 (m, 1H), 7.37 (br s, 1H), 8.30 (d, 1 H, J = 2.0 Hz).  
190 
N
H
F  
Rt = 9.47 min (Method II); HRMS: [MH]+ 487.2715 (calc. 
for C26H36FN4O4+) 487.2719 (found); 1H NMR (400 MHz, 
CDCl3), δ 0.81–0.90 (m, 7 H), 0.91–0.99 (m, 2 H), 1.04–1.21 
(m, 5 H), 1.28–1.38 (m, 1 H), 1.42–1.52 (m, 1 H), 1.60–1.78 
(H’s overlap with H2O peak), 1.86–1.92 (m, 1 H), 4.26 (t, 1 
H, J = 8.4 Hz), 4.34 (dd, 1 H, J = 5.2, 14.8 Hz), 4.45 (dd, 1 
H, J = 6.0, 14.8 Hz), 4.66–4.74 (m, 1 H), 6.53 (br s, 1 H), 
6.82 (br s, 1 H), 6.90 (d, 1 H, J = 2.0 Hz), 6.97–7.01 (m, 2 
H), 7.20–7.27 (m, 3 H), 8.31 (d, 1 H, J = 2.0 Hz). 
191 
N
H
H
N
 
Rt = 8.59 min (Method II); HRMS: [MH]+ 470.2762 (calc. 
for C25H36N5O4+) 470.2761 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.85–0.95 (m, 9 H), 1.16–1.24 (m, 5 H), 1.31–
1.39 (m, 1 H), 1.50–1.57 (m, 2 H), 1.57–1.62 (m, 1 H), 1.62–
1.76 (m, 6 H), 1.76–1.83 (m, 1 H), 4.22 (t, 1 H, J = 8.4 Hz), 
4.59–4.63 (m, 1 H), 6.69–6.76 (m, 4 H), 7.10 (t, 2 H, J = 7.8 
Hz), 7.18 (s, 1H), 8.13 (d, 1 H, J = 8 Hz), 8.77 (d, 1 H, J = 
1.2 Hz), 8.98 (d, 1 H, J = 8.4 Hz), 9.84 (s, 1 H). 
192 
N
H
OMe
 
Rt = 9.31 min (Method II); HRMS: [MH]+ 499.2915 (calc. 
for C27H39N4O5+) 499.2915 (found); 1H NMR (600 MHz, 
CDCl3), δ 0.82–0.86 (m, 7 H, Cha/Ile H), 0.88–1.00 (m, 2 H, 
Cha/Ile H), 1.04–1.22 (m, 1 H, Cha/Ile H), 1.25–1.37 (m, 2 
H, Cha/Ile H), 1.40–1.46 (m, 1 H, Cha/Ile H), 1.59–1.73 (m, 
7 H, Cha/Ile H), 1.77–1.84 (m, 2 H, Cha/Ile H), 3.86 (s, 3 H, 
OCH3), 4.21 (t, 1 H, J = 7.2 Hz, Ile-α-CH), 4.39 (dd, 1 H, J = 
6.0, 14.4 Hz, Bn-CH2), 4.48 (dd, 1 H, J = 6.0, 14.4 Hz, Bn-
CH2), 4.60–4.65 (m, 1 H, Cha-α-H), 6.20 (t, 1 H, J = 5.6 Hz, 
Bn-NH), 6.51 (d, 1 H, J = 8.8 Hz, Ile-NH), 6.87–6.93 (m, 3 
H, Ar-H, isoxazole-4-CH), 7.00 (d, 1 H, J = 7.2 Hz, Cha-
NH), 7.23–7.29 (m, 2 H), 8.33 (d, 1 H, J = 1.6 Hz, isoxazole-
3-CH). 13C NMR (150 MHz, CDCl3), δ 11.2 (Ile-δ-CH3), 
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15.2 (Ile-γ-CH3), 25.0 (Ile-γ-CH2), 25.9 (Cha-CH2), 26.1 
(Cha-CH2), 26.3 (Cha-CH2), 32.7 (Cha-δ-CH2), 33.6 (Cha-δ-
CH2), 34.1 (Cha-γ-CH), 37.6 (Cha-β-CH2), 39.7 (Bn-CH2), 
40.1 (Bn-CH2), 51.2 (Cha-α-CH), 55.3 (OCH3), 57.9 (Ile-α-
CH), 106.8 (Ar-CH), 110.2 (Ar-CH), 120.6 (Ar-CH), 125.6 
(Ar-C-CH2), 129.1 (isoxazole-4-CH), 129.8 (Ar-CH), 151.0 
(isoxazole-3-CH), 155.5 (Ar-C-OCH3), 157.5 (isoxazole-C), 
162.4 (isoxazole-CO), 170.3 (Cha-CO), 171.1 (Ile-CO). 
193 
N
H
OMe
OMe
 
Rt = 8.39 min (Method II); HRMS: [MNa]+ 565.2999 (calc. 
for C29H43N4Na1O6+) 565.2997 (found); 1H NMR (400 MHz, 
DMSO–d6), δ 0.85–0.90 (m, 7 H), 0.94–1.04 (m, 2 H), 1.06–
1.16 (m, 1 H), 1.19–1.35 (m, 3 H), 1.42–1.52 (m, 2 H), 1.62–
1.80 (m, 9 H), 2.74 (t, 2 H, J = 7.2 Hz), 3.31–3.37 (m, 1 H), 
3.42 (br s, 6 H), 3.82 (s, 3 H), 3.85 (s, 3 H), 4.23 (t, 1 H, J = 
8.4 Hz), 4.64–4.70 (m, 1 H), 6.80 (dd, 1 H, J = 1.6, 8.4 Hz), 
6.91–6.96 (m, 2 H), 7.27 (d, 1 H, J = 2.0 Hz), 7.98 (d, 1 H, J 
= 9.2 Hz), 8.13 (t, 1 H, J = 5.6 Hz), 8.86 (d, 1 H, J = 2.0 Hz), 
9.07 (d, 1 H, J = 8.4 Hz).  
194 
N
H
N  
Rt = 7.45 min (Method I); HRMS: [MH]+ 470.2762 (calc. for 
C25H36N5O4+)  470.2763 (found); 1H NMR (400 MHz, 
DMSO–d6), δ 0.93–1.05 (m, 9 H), 1.19–1.29 (m, 5 H), 1.38–
1.48 (m, 1 H), 1.56–1.69 (m, 3 H), 1.74–1.81 (m, 3 H), 1.86–
1.92 (m, 1 H), 4.30 (t, 1 H, J = 8.4 Hz), 4.54 (dd, 1 H, J = 
6.0, 17.2 Hz), 4.61 (dd, 1 H, J = 6.0, 17.2 Hz), 4.66–4.72 (m, 
1 H), 7.27 (d, 1 H, J = 1.6 Hz), 7.74 (d, 2 H, J = 6.0 Hz), 
8.20 (d, 1 H, J = 8.0 Hz), 8.83 (dd, 2 H, J = 1.2, 5.2 Hz), 
8.87–8.90 (m, 2 H), 9.06 (d, 1 H, J = 8.0 Hz). 
195 
N
H
N
 
Rt = 7.65 min (Method I); HRMS: [MH]+ 470.2762 (calc. for 
C25H36N5O4+) 470.2759 (found); 1H NMR (400 MHz, 
DMSO–d6), δ 0.92–1.05 (m, 9 H), 1.17–1.29 (m, 5 H), 1.38–
1.48 (m, 1 H), 1.54–1.68 (m, 4 H), 1.73–1.81 (m, 3 H), 1.85–
1.91 (m, 1 H), 4.32 (t, 1 H, J = 8.4 Hz), 4.52 (dd, 1 H, J = 
5.6, 16.4 Hz), 4.58 (dd, 1 H, J = 5.6, 16.4 Hz), 4.66–4.72 (m, 
1 H), 7.27 (d, 1 H, J = 2.0 Hz), 7.53 (d, 1 H, J = 8.0 Hz), 
7.58 (t, 1 H, J = 5.6 Hz), 8.09 (t, 1 H, J = 6.4 Hz), 8.16 (d, 1 
H, J = 8.8 Hz), 8.71 (dd, 1 H, J = 0.8, 5.2 Hz), 8.78 (t, 1 H, J 
= 5.6 Hz), 8.86 (d, 1 H, J = 2.0 Hz), 9.07 (d, 1 H, J = 8.0 
Hz).  
196 
N
H N
H
N
 
Rt = 8.27 min (Method I); HRMS: [MH]+ 509.2871 (calc. for 
C27H37N6O4+) 509.2872 (found); 1H NMR (400 MHz, 
DMSO–d6), δ 0.90–1.01 (m, 9 H), 1.17–1.26 (m, 5 H), 1.34–
1.44 (m, 1 H), 1.50–1.57 (m, 1 H), 1.61–1.66 (m, 2 H), 1.70–
1.77 (m, 3 H), 1.86–1.94 (m, 1 H), 4.37 (t, 1 H, J = 8.0 Hz), 
4.66–4.74 (m, 2 H), 4.78 (q, 1 H, J = 5.6 Hz), 7.25–7.26 (m, 
1 H), 7.56–7.58 (m, 2 H), 7.83–7.85 (m, 2 H), 8.18 (d, 1 H, J 
= 8.4 Hz), 8.86–8.87 (m, 1 H), 9.03 (t, 1 H, J = 4.8 Hz), 9.10 
(d, 1 H, J = 8.4 Hz).  
197 
N
H
Cl
 
Rt = 8.49 min (Method II); HRMS: [MNa]+ 525.2239 (calc. 
for C26H35ClN4Na1O4+) 525.2239 (found); 1H NMR (600 
MHz, DMSO–d6), δ 0.80–0.84 (m, 6 H), 0.86–0.93 (m, 2 H), 
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1.05–1.12 (m, 3 H), 1.12–1.20 (m, 1 H), 1.28–1.35 (m, 1 H), 
1.42–1.49 (m, 1 H), 1.50–1.56 (m, 1 H), 1.56–1.60 (m, 1 H), 
1.60–1.72 (m, 5 H), 1.72–1.79 (m, 1 H), 4.21 (t, 1 H, J = 8.4 
Hz), 4.30 (dd, 1 H, J = 6.0, 16.2 Hz), 4.35 (dd, 1 H, J = 6.0, 
16.2 Hz), 4.55–4.60 (m, 1 H), 7.16 (d, 1 H, J = 1.8 Hz), 
7.26–7.31 (m, 1 H), 7.41–7.44 (m, 1 H), 8.04 (d, 1 H, J = 8.4 
Hz), 8.51 (t, 1 H, J = 6.0 Hz), 8.74 (d, 1 H, J = 1.8 Hz), 8.96 
(d, 1 H, J = 7.8 Hz).  
198 
N
H
CF3
 
Rt = 8.93 min (Method II); HRMS: [MNa]+ 559.2503 (calc. 
for C27H35F3N4Na1O4+) 559.2502 (found); 1H NMR (600 
MHz, DMSO–d6), δ 0.83–0.86 (m, 6 H), 0.87–0.94 (m, 2 H), 
1.06–1.22 (m, 4 H), 1.29–1.37 (m, 1 H), 1.45–1.51 (m, 1 H), 
1.52–1.62 (m, 2 H), 1.62–1.74 (m, 5 H), 1.75–1.82 (m, 1 H), 
4.23 (t, 1 H, J = 8.4 Hz), 4.42 (dd, 1 H, J = 5.4, 16.2 Hz), 
4.50 (dd, 1 H, J = 5.4, 16.2 Hz), 4.58–4.62 (m, 1 H), 7.18 (d, 
1 H, J = 1.8 Hz), 7.48–7.50 (m, 1 H), 7.63 (t, 1 H, J = 7.8 
Hz), 7.72 (d, 1 H, J = 7.8 Hz), 8.09 (d, 1 H, J = 8.4 Hz), 8.59 
(t, 1 H, J = 5.4 Hz), 8.76 (d, 1 H, J = 1.8 Hz), 8.98 (d, 1 H, J 
= 7.8 Hz).  
199 
N
H
OCF3  
Rt = 11.41 min (Method II); HRMS: [MH]+ 553.2632 (calc. 
for C27H36F3N4O5+) 553.2632 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.79–0.81 (m, 6 H), 0.83–0.92 (m, 2 H), 1.05–
1.20 (m, 4 H), 1.27–1.35 (m, 1 H), 1.40–1.48 (m, 1 H), 1.49–
1.55 (m, 1 H), 1.55–1.60 (m, 1 H), 1.61–1.77 (m, 6 H), 4.18 
(t, 1 H, J = 8.4 Hz), 4.29–4.35 (m, 2 H), 4.53–4.59 (m, 1 H), 
7.16 (d, 1 H, J = 1.8 Hz), 7.21–7.23 (m, 2 H), 7.26 (d, 1 H, J 
= 7.8 Hz), 7.43 (t, 1 H, J = 7.8 Hz), 8.03 (d, 1 H, J = 9.0 Hz), 
8.61 (t, 1 H, J = 6.0 Hz), 8.74 (d, 1 H, J = 1.8 Hz), 8.94 (d, 1 
H, J = 8.4 Hz). 
200 
N
H
NO2
 
Rt = 7.78 min (Method II); HRMS: calc. for C26H35N5Na1O6+ 
536.2480 [MNa]+, found 536.2481; 1H NMR (600 MHz, 
DMSO–d6), δ 0.81–0.84 (m, 6 H), 0.87–0.95 (m, 2 H), 1.06–
1.21 (m, 4 H), 1.29–1.35 (m, 1 H), 1.42–1.48 (m, 1 H), 1.50–
1.57 (m, 1 H), 1.58–1.62 (m, 1 H), 1.63–1.78 (m, 6 H), 4.22 
(t, 1 H, J = 8.4 Hz), 4.56–4.61 (m, 3 H), 7.17 (d, 1 H, J = 1.8 
Hz), 7.51–7.57 (m, 2 H), 7.69 (t, 1 H, J = 7.8 Hz), 8.04–8.08 
(m, 2H), 8.59 (t, 1 H, J = 6.0 Hz), 8.76 (d, 1 H, J = 1.8 Hz), 
8.96 (d, 1 H, J = 8.4 Hz).  
201 N
 
Rt = 10.17 min (Method II); HRMS: [MH]+ 483.2966 (calc. 
for C27H39N4O4+) 483.2970 (found); 1H NMR (600 MHz, 
CDCl3), δ 0.80–0.88 (m, 5 H), 0.93–0.99 (m, 3 H), 1.06–1.25 
(m, 5 H), 1.26–1.40 (m, 1 H), 1.48–1.58 (m, 1 H), 1.62–1.82 
(m, 10 H), 2.17 (s, 1 H, rotamer), 2.94 (s, 1 H), 3.04 (s, 2 H), 
4.49–4.61 (m, 1 H), 4.65–4.73 (m, 2 H), 4.84–4.95 (m, 1 H), 
6.70 (t, 1 H, J = 8.8 Hz), 6.93 (d, 1 H, J = 1.2 Hz), 7.07 (d, 1 
H, J = 8.0 Hz), 7.18–7.21 (m, 2 H), 7.26–7.38 (m, 3 H), 8.33 
(d, 1 H, J = 1.2 Hz). 
202 
N
OMe
 
Rt = 10.80 min (Method II); HRMS: [MH]+ 513.3071 (calc. 
for C28H41N4O5+), 513.3071 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.75 (d, 1 H, J = 6.6 Hz), 0.80 (t, 1 H, J = 7.2 
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Hz), 0.86–0.89 (m, 4 H), 0.90–0.97 (m, 2 H), 1.00–1.17 (m, 
3 H), 1.17–1.26 (m, 1 H), 1.31–1.40 (m, 1 H), 1.49–1.60 (m, 
2 H), 1.60–1.65 (m, 1 H), 1.65–1.77 (m, 5 H), 1.80–1.90 (m, 
1 H), 2.80 (s, 1 H), 3.09 (s, 2 H), 3.82 (s, 3 H), 4.45 (dd, 1 H, 
J = 16.8 Hz), 4.57–4.67 (m, 2 H), 4.70–4.77 (m, 1 H), 6.87 
(t, 1 H, J = 7.2 Hz), 6.94–6.97 (m, 1 H), 7.02–7.11 (m, 1 H), 
7.19–7.20 (m, 1 H), 7.26–7.33 (m, 1 H). 8.34 (d, 1 H, J = 9 
Hz), 8.78–8.79 (m, 1 H), 8.97 (t, 1 H, J = 7.8 Hz).  
203 
N
H  
Rt = 11.52 min (Method II); HRMS: [MH]+ 545.3122 (calc. 
for C32H41N4O4+) 545.3121 (found); 1H NMR (400 MHz, 
CDCl3), δ 0.80–0.83 (m, 7 H), 0.87–1.05 (m, 4 H), 1.09–1.25 
(m, 4 H), 1.28–1.42 (m, 2 H), 1.62–1.70 (H’s overlap with 
H2O peak), 1.74–1.83 (m, 2 H), 4.17 (dd, 1 H, J = 6.8, 8.4 
Hz), 4.37 (dd, 1 H, J = 5.6, 14.8 Hz), 4.44 (dd, 1 H, J = 5.6, 
14.8 Hz), 4.63–4.69 (m, 1H), 6.04–6.07 (m, 1H), 6.68 (d, 1 
H, J = 8.4 Hz), 6.87 (d, 1 H, J = 2.0 Hz), 7.16 (d, 1 H, J = 8.0 
Hz), 7.24–7.44 (m, 9 H), 8.30 (d, 1 H, J = 2.0 Hz). 
204 
N
H  
Rt = 11.45 min (Method II); HRMS: [MH]+ 545.3122 (calc. 
for C32H41N4O4+) 545.3125 (found); 1H NMR (400 MHz, 
CDCl3), δ 0.83–0.87 (m, 4 H), 0.90–0.92 (m, 4 H), 0.93–1.00 
(m, 1 H), 1.07–1.21 (m, 5 H), 1.26–1.36 (m, 1 H), 1.46–1.54 
(m, 1 H), 1.59–1.77 (H’s overlap with H2O peak), 1.88–1.96 
(m, 1 H), 4.28 (dd, 1 H, J = 7.2, 8.6 Hz), 4.47 (dd, 1 H, J = 
5.6, 14.6 Hz), 4.57 (dd, 1 H, J = 5.6, 14.6 Hz), 4.63–4.68 (m, 
1 H), 6.36 (t, 1 H, J = 5.6 Hz), 6.66 (d, 1 H, J = 8.4 Hz), 6.87 
(d, 1 H, J = 2.0 Hz), 7.10 (d, 1 H, J = 8.0 Hz), 7.22–7.27 (m, 
1 H), 7.33–7.38 (m, 1 H), 7.39–7.46 (m, 3 H), 7.48–7.52 (m, 
2 H), 7.55–7.58 (m, 2 H), 8.30 (d, 1 H, J = 1.6 Hz).  
205 N
H
 
Rt = 11.35 min (Method II); HRMS: [MH]+ 545.3122 (calc. 
for C32H41N4O4+) 545.3123 (found); 1H NMR (400 MHz, 
CDCl3), δ 0.84–0.88 (m, 4 H), 0.91–0.94 (m, 4 H), 0.97–1.00 
(m, 1 H), 1.07–1.25 (m, 5 H), 1.31–1.39 (m, 1 H), 1.47–1.55 
(m, 1 H), 1.61–1.79 (H’s overlap with H2O peak), 1.89–1.98 
(m, 1 H), 4.27–4.31 (m, 1 H), 4.42–4.47 (m 1 H), 4.52 (dd, 1 
H, J = 6.0, 14.8 Hz), 4.64–4.72 (m, 1 H), 6.42 (br s, 1 H), 
6.75 (br s, 1 H), 6.88 (d, 1 H, J = 1.2 Hz), 7.18 (br s, 1 H), 
7.27–7.37 (m, 3 H), 7.41–7.45 (m, 2 H), 7.52–7.57 (m, 4 H), 
8.30 (s, 1 H).  
206 
N
H  
Rt = 10.79 min (Method II); HRMS: [MH]+ 519.2966 (calc. 
for C30H39N4O4+) 519.2968 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.78–0.82 (m, 6 H), 0.85–0.95 (m, 2 H), 1.03–
1.21 (m, 4 H), 1.29–1.37 (m, 1 H), 1.42–1.49 (m, 1 H), 1.50–
1.56 (m, 1 H), 1.57–1.62 (m, 1 H), 1.62–1.78 (m, 6 H), 4.23 
(t, 1 H, J = 8.4 Hz), 4.56–4.60 (m, 1 H), 4.71 (dd, 1 H, J = 
5.4, 15.0 Hz), 4.78 (dd, 1 H, J = 5.4, 15.0 Hz), 7.17 (d, 1 H, J 
= 1.8 Hz), 7.43–7.47 (m, 2 H), 7.51–7.56 (m, 2 H), 7.86 (d, 1 
H, J = 7.8 Hz), 7.95–7.97 (m, 1 H), 8.03–8.07 (m, 2 H), 8.54 
(t, 1 H, J = 6.0 Hz), 8.76 (d, 1 H, J = 1.8 Hz), 8.97 (d, 1 H, J 
= 8.4 Hz).  
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207 
N
H  
Rt = 12.99 min (Method II); HRMS: [MH]+ 513.3435 (calc. 
for C29H45N4O4+) 513.3435 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.80–0.85 (m, 6 H), 0.86–0.97 (m, 2 H), 1.01–
1.09 (m, 1 H), 1.10–1.24 (m, 3 H), 1.27–1.34 (m, 1 H), 1.42–
1.48 (m, 1 H), 1.55–1.75 (m, 15 H), 1.91 (s, 6 H), 2.00 (br s, 
3 H), 4.10 (t, 1 H, J = 8.4 Hz), 4.53–4.57 (m, 1 H), 7.17 (d, 1 
H, J = 1.8 Hz), 7.35 (s, 1 H), 7.81 (d, 1 H, J = 9.0 Hz), 8.76 
(d, 1 H, J = 1.8 Hz), 8.98 (d, 1 H, J = 7.8 Hz).  
208 
N
 
Rt = 12.88 min (Method II); HRMS: [MH]+ 491.3592 (calc. 
for C27H47N4O4+) 491.3595 (found); 1H NMR (600 MHz, 
DMSO–d6), contains rotamers, δ 0.87–1.03 (m, 30 H), 1.11–
1.30 (m, 6 H), 1.39–1.49 (m, 1 H), 1.55–1.64 (m, 3 H), 1.69–
1.77 (m, 9 H), 1.90–1.96 (m, 1 H), 1.99–2.07 (m, 3 H), 3.12 
(q, 1 H, J = 8.0 Hz), 3.22 (dd, 2 H, J = 7.6, 12.8 Hz), 3.45–
3.51 (m, 6 H), 4.65–4.71 (m, 2 H), 7.26 (d, 1 H, J = 2.0 Hz), 
8.24 (d, 1 H, J = 9.6 Hz), 8.85 (d, 1 H, J = 2.0 Hz), 9.00 (d, 1 
H, J = 8.4 Hz).  
209 N
H
OMe
 
Rt = 9.32 min (Method II); HRMS: [MH]+ 499.2915 (calc. 
for C27H39N4O5+) 499.2918 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.83–0.86 (m, 6 H), 0.87–0.98 (m, 2 H), 1.07–
1.16 (m, 3 H), 1.17–1.24 (m, 1 H), 1.30–1.38 (m, 1 H), 1.46–
1.53 (m, 1 H), 1.54–1.64 (m, 2 H), 1.64–1.80 (m, 6 H), 3.76 
(s, 3 H), 4.22 (t, 1 H, J = 8.4 Hz), 4.28 (d, 2 H, J = 6.0 Hz), 
4.58–4.62 (m, 1 H), 6.82–6.84 (m, 3 H), 7.19 (d, 1 H, J = 1.8 
Hz), 7.23 (t, 1 H, J = 7.8 Hz), 8.03 (d, 1 H, J = 9.0 Hz), 8.51 
(t, 1 H, J = 6.0 Hz), 8.78 (d, 1 H, J = 1.8 Hz), 8.99 (d, 1 H, J 
= 7.8 Hz).  
210 N
H
OMe  
Rt = 9.32 min (Method II); HRMS: [MH]+ 499.2915 (calc. 
for C27H39N4O5+) 499.2918 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.83–0.86 (m, 6 H), 0.87–0.98 (m, 2 H), 1.07–
1.16 (m, 3 H), 1.17–1.24 (m, 1 H), 1.30–1.38 (m, 1 H), 1.46–
1.53 (m, 1 H), 1.54–1.64 (m, 2 H), 1.64–1.80 (m, 6 H), 3.76 
(s, 3 H), 4.22 (t, 1 H, J = 8.4 Hz), 4.28 (d, 2 H, J = 6.0 Hz), 
4.58–4.62 (m, 1H), 6.82–6.84 (m, 3H), 7.19 (d, 1 H, J = 1.8 
Hz), 7.23 (t, 1 H, J = 7.8 Hz), 8.03 (d, 1 H, J = 9.0 Hz), 8.51 
(t, 1 H, J = 6.0 Hz), 8.78 (d, 1 H, J = 1.8 Hz), 8.99 (d, 1 H, J 
= 7.8 Hz).  
211 
N
H
O
 
Rt = 10.96 min (Method II); HRMS: [MH]+ 513.3071 (calc. 
for C28H41N4O5+) 513.3071 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.80–0.84 (m, 6 H), 0.85–0.94 (m, 2 H), 1.03–
1.12 (m, 3 H), 1.12–1.21 (m, 1 H), 1.28–1.36 (m, 4 H), 1.42–
1.49 (m, 1 H), 1.50–1.60 (m, 2 H), 1.61–1.78 (m, 6 H), 4.02 
(q, 2 H, J = 7.2 Hz), 4.19–4.26 (m, 3 H), 4.55–4.59 (m, 1 H), 
6.83–6.85 (m, 1 H), 6.93 (d, 1 H, J = 7.8 Hz), 7.11 (dd, 1 H, 
J = 1.8, 7.8 Hz), 7.16 (d, 1 H, J = 1.8 Hz), 7.18–7.21 (m, 1 
H), 8.00 (d, 1 H, J = 9.0 Hz), 8.25 (t, 1 H, J = 5.4 Hz), 8.74 
(d, 1 H, J = 1.8 Hz), 8.97 (d, 1 H, J = 7.8 Hz).  
212 
N
H
Me
 
Rt = 9.93 min (Method II); HRMS: [MH]+ 483.2966 (calc. 
for C27H39N4O4+) 483.2965 (found); 1H NMR (600 MHz, 
CDCl3), δ 0.81 (t, 3 H, J = 7.2 Hz), 0.88 (d, 1 H, J = 6.6 Hz), 
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0.90–0.98 (m, 1 H), 1.02–1.11 (m, 1 H), 1.11–1.22 (m, 3 H), 
1.29–1.35 (m, 1 H), 1.45–1.52 (m, 1 H), 1.58–1.63 (m, 1 H), 
1.63–1.72 (m, 5 H), 1.72–1.79 (m, 1 H), 1.83–1.89 (m, 1 H), 
2.29 (s, 3 H), 4.31 (t, 1 H, J = 8.4 Hz), 4.36 (dd, 1 H, J = 5.4, 
15 Hz), 4.45 (dd, 1 H, J = 5.4, 15 Hz), 4.74–4.78 (m, 1 H), 
6.52–6.57 (m, 1 H), 6.86 (d, 1 H, J = 1.8 Hz), 7.07 (d, 1 H, J 
= 8.4 Hz), 7.12–7.20 (m, 4 H), 7.45 (d, 1 H, J = 8.4 Hz), 8.26 
(d, 1 H, J = 1.8 Hz).  
213 
N
H
O
 
Rt = 11.44 min (Method II); HRMS: [MH]+ 527.3228 (calc. 
for C29H43N4O5+) 527.3227 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.79–0.84 (m, 6 H), 0.84–0.93 (m, 2 H), 0.99 
(t, 3 H, J = 7.5 Hz), 1.03–1.12 (m, 3 H), 1.12–1.21 (m, 1 H), 
1.27–1.35 (m, 1 H), 1.42–1.49 (m, 1 H), 1.50–1.60 (m, 2 H), 
1.60–1.70 (m, 5 H), 1.70–1.78 (m, 3 H), 3.92 (t, 1 H, J = 6.0 
Hz), 4.20–4.28 (m, 3 H), 4.55–4.59 (m, 1 H), 6.84 (t, 1 H, J = 
7.2 Hz), 6.93 (d, 1 H, J = 7.8 Hz), 7.11 (d, 1 H, J = 6.6 Hz), 
7.15 (d, 1 H, J = 1.8 Hz), 7.18–7.21 (m, 1 H), 8.01 (d, 1 H, J 
= 9.0 Hz), 8.25 (t, 1 H, J = 5.4 Hz), 8.74 (d, 1 H, J = 1.8 Hz), 
8.96 (d, 1 H, J = 8.4 Hz).  
214 
N
H
O
 
Rt = 12.70 min (Method II); HRMS: [MH]+ 541.3384 (calc. 
for C30H45N4O5+) 541.3388 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.79–0.85 (m, 6 H), 0.85–0.92 (m, 2 H), 0.93 
(t, 3 H, J = 7.8 Hz), 1.04–1.12 (m, 3 H), 1.13–1.21 (m, 1 H), 
1.28–1.35 (m, 1 H), 1.42–1.50 (m, 3 H), 1.51–1.60 (m, 2 H), 
1.60–1.78 (m, 8 H), 3.97 (t, 2 H, J = 6.6 Hz), 4.21–4.24 (m, 3 
H), 4.55–4.60 (m, 1 H), 6.84 (t, 1 H, J = 7.2 Hz), 6.94 (d, 1 
H, J = 8.4 Hz), 7.11 (d, 1 H, J = 7.8 Hz), 7.16 (d, 1 H, J = 1.8 
Hz), 7.18–7.21 (m, 1 H), 8.01 (d, 1 H, J = 9.0 Hz), 8.25 (t, 1 
H, J = 6.0 Hz), 8.74 (d, 1 H, J = 1.8 Hz), 8.96 (d, 1 H, J = 8.4 
Hz).  
215 
N
H
O
 
Rt = 11.85 min (Method II); HRMS: [MH]+ 541.3384 (calc. 
for C30H45N4O5+) 541.3387 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.80–0.85 (m, 6 H), 0.85–0.90 (m, 2 H), 0.92 
(t, 3 H, J = 7.2 Hz), 1.04–1.12 (m, 3 H), 1.12–1.20 (m, 1 H), 
1.22 (t, 3 H, J = 6.0 Hz), 1.28–1.36 (m, 1 H), 1.43–1.50 (m, 1 
H), 1.51–1.60 (m, 3 H), 1.60–1.70 (m, 6 H), 1.70–1.79 (m, 1 
H), 4.17–4.28 (m, 3 H), 4.37–4.41 (m, 1 H), 4.56–4.60 (m, 1 
H), 6.82 (t, 1 H, J = 7.2 Hz), 6.94 (d, 1 H, J = 8.4 Hz), 7.10 
(d, 1 H, J = 7.8 Hz), 7.15–7.19 (m, 2 H), 8.01 (d, 1 H, J = 9.0 
Hz), 8.22–8.25 (m, 1 H), 8.74 (d, 1 H, J = 1.8 Hz), 8.97 (d, 1 
H, J = 7.8 Hz).  
216 
N
H
O
 
Rt = 8.96 min (Method II); HRMS: [MH]+ 527.3228 (calc. 
for C29H43N4O5+) 527.3231 (found); 1H NMR (600 MHz, 
CDCl3), δ 0.81–0.87 (m, 6 H), 0.87–1.01 (m, 2 H), 1.06–1.34 
(m, 6 H), 1.37 (t, 6 H, J = 6.0 Hz), 1.40–1.49 (m, 1 H), 1.63–
1.73 (m, 6 H), 1.76–1.84 (m, 1 H), 4.20 (dd, 1 H, J = 6.6, 9.0 
Hz), 4.40 (dd, 1 H, J = 6.0, 14.4 Hz), 4.46 (dd, 1 H, J = 6.0, 
14.4 Hz), 4.59–4.65 (m, 2 H), 6.22 (t, 1 H, J = 6.0 Hz), 6.59 
(d, 1 H, J = 9.6 Hz), 6.86–6.89 (m, 2 H), 6.91 (d, 1 H, J = 1.8 
Hz), 7.02 (d, 1 H, J = 9.0 Hz), 7.22–7.24 (m, 1 H), 8.33 (d, 1 
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H, J = 1.8 Hz).  
217 N
H
O
O
 
Rt = 8.96 min (Method II); HRMS: [MH]+ 513.2708 (calc. 
for C27H37N4O6+) 513.2708 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.79–0.83 (m, 6 H), 0.83–0.94 (m, 2 H), 1.02–
1.21 (m, 4 H), 1.26–1.34 (m, 1 H), 1.41–1.48 (m, 1 H), 1.49–
1.55 (m, 1 H), 1.55–1.60 (m, 1 H), 1.60–1.76 (m, 6 H), 4.14–
4.20 (m, 3 H), 4.54–4.58 (m, 1 H), 5.97 (s, 2 H), 6.70 (dd, 1 
H, J = 1.8, 8.4 Hz), 6.77–6.78 (d, 1 H, J = 1.2 Hz), 6.81 (d, 1 
H, J = 7.8 Hz), 7.16 (d, 1 H, J = 1.8 Hz), 7.98 (d, 1 H, J = 9.0 
Hz), 8.41 (t, 1 H, J = 5.4 Hz), 8.74 (d, 1 H, J = 2.4 Hz), 8.95 
(d, 1 H, J = 8.4 Hz).  
218 
N
H
O
O
 
Rt = 9.39 min (Method II); HRMS: [MNa]+ 535.2527 (calc. 
for C27H36N4Na1O6+) 535.2528 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.84–0.90 (m, 6 H), 0.90–1.01 (m, 2 H), 1.05–
1.23 (m, 4 H), 1.29–1.37 (m, 1 H), 1.43–1.50 (m, 1 H), 1.60–
1.75 (m, 6 H), 1.76–1.81 (m, 1 H), 1.84–1.92 (m, 1 H), 4.26 
(dd, 1 H, J = 7.2, 9.0 Hz), 4.40 (dd, 1 H, J = 6.0, 15 Hz), 4.48 
(dd, 1 H, J = 6.0, 15 Hz), 4.62–4.66 (m, 1 H), 5.96–5.97 (m, 
2 H), 6.19–6.24 (m, 1 H), 6.52–6.58 (m, 1 H), 6.74–6.80 (m, 
3 H), 6.91 (d, 1 H, J = 1.8 Hz), 7.03–7.08 (m, 1 H), 8.33 (d, 1 
H, J = 1.8 Hz).  
219 
N
H
OMe
OMe  
Rt = 9.49 min (Method II); HRMS: [MH]+ 529.3021 (calc. 
for C28H41N4O6+) 529.3022 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.79–0.82 (m, 6 H), 0.83–0.95 (m, 2 H), 1.01–
1.20 (m, 4 H), 1.26–1.34 (m, 1 H), 1.38–1.46 (m, 1 H), 1.49–
1.55 (m, 1 H), 1.56–1.60 (m, 1 H), 1.60–1.75 (m, 6 H), 3.73 
(s, 3 H), 3.76 (s, 3 H), 4.10–4.16 (m, 2 H), 4.16–4.21 (m, 1 
H), 4.54–4.58 (m, 1 H), 6.42 (dd, 1 H, J = 2.4, 8.4 Hz), 6.52 
(d, 1 H, J = 2.4 Hz), 7.03 (d, 1 H, J = 8.4 Hz), 7.15 (d, 1 H, J 
= 1.8 Hz), 7.96 (d, 1 H, J = 9.0 Hz), 8.15 (t, 1 H, J = 5.4 Hz), 
8.75 (d, 1 H, J = 1.8 Hz), 8.96 (d, 1 H, J = 8.4 Hz).  
220 
N
H
OMe
OMe  
Rt = 9.54 min (Method II); HRMS: [MH]+ 529.3021 (calc. 
for C28H41N4O6+) 529.3021 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.80–0.84 (m, 6 H), 0.85–0.93 (m, 2 H), 1.03–
1.20 (m, 4 H), 1.26–1.34 (m, 1 H), 1.42–1.60 (m, 3 H), 1.60–
1.77 (m, 6 H), 3.66 (s, 3 H), 3.73 (s, 3 H), 4.16–4.25 (m, 3 
H), 4.55–4.58 (m, 1 H), 6.75–6.77 (m, 2 H), 6.88 (d, 1 H, J = 
8.4 Hz), 7.16 (d, 1 H, J = 1.8 Hz), 7.98 (d, 1 H, J = 9.0 Hz), 
8.30 (t, 1 H, J = 6.0 Hz), 8.75 (d, 1 H, J = 1.8 Hz), 8.95 (d, 1 
H, J = 7.8 Hz).  
221 N
H
OMe
OMe  
Rt = 8.35 min (Method II); HRMS: [MH]+ 529.3021 (calc. 
for C28H41N4O6+) 529.3022 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.90 (t, 3 H, J = 7.4 Hz), 0.95 (d, 4 H, J = 6.8 
Hz), 0.96–1.04 (m, 1 H), 1.11–1.30 (m, 5 H), 1.33–1.40 (m, 
1 H), 1.49–1.56 (m, 1 H), 1.67–1.84 (m, 6 H), 1.91–1.99 (m, 
1 H), 3.90 (s, 3 H), 3.91 (s, 3 H), 4.28 (dd, 1 H, J = 6.6, 8.4 
Hz), 4.34 (dd, 1 H, J = 5.4, 15.0 Hz), 4.50 (dd, 1 H, J = 6.0, 
15 Hz), 4.67–4.71 (m, 1 H), 6.22 (t, 1 H, J = 5.4 Hz), 6.65 (d, 
1 H, J = 8.4 Hz), 6.83–6.86 (m, 3 H), 6.94 (d, 1 H, J = 1.8 
Hz), 7.10 (d, 1 H, J = 7.8 Hz), 8.37 (d, 1 H, J = 1.8 Hz).  
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222 
N
H
OMe
OMe
 
Rt = 9.63 min (Method II); HRMS: [MH]+ 529.3021  (calc. 
for C28H41N4O6+) 529.3021 (found); 1H NMR (600 MHz, 
CDCl3), δ 0.81–0.86 (m, 6 H), 0.87–0.99 (m, 2 H), 1.02–1.26 
(m, 4 H), 1.28–1.35 (m, 1 H), 1.40–1.48 (m, 1 H), 1.59–1.63 
(m, 1 H), 1.63–1.71 (m, 5 H), 1.71–1.80 (m, 4 H), 1.80–1.87 
(m, 1 H), 3.85 (s, 3 H), 3.86 (s, 3 H), 4.25 (dd, 1 H, J = 7.2, 
9.0 Hz), 4.42 (dd, 1 H, J = 6.0, 15.0 Hz), 4.50 (dd, 1 H, J = 
6.0, 15.0 Hz), 4.66–4.70 (m, 1 H), 6.43 (t, 1 H, J = 6.0 Hz), 
6.72 (d, 1 H, J = 9.0 Hz), 6.84–6.87 (m, 2 H), 6.91 (d, 1 H, J 
= 1.8 Hz), 6.98–7.01 (m, 1 H), 7.20 (d, 1 H, J = 8.4 Hz), 8.31 
(d, 1 H, J = 1.8 Hz).  
223 
N
H
OMe
MeO  
Rt = 10.15 min (Method II); HRMS: [MH]+ 529.3021 (calc. 
for C28H41N4O6+) 529.3021 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.76–0.80 (m, 6 H), 0.84–0.94 (m, 2 H), 0.97–
1.04 (m, 1 H), 1.07–1.20 (m, 3 H), 1.26–1.33 (m, 1 H), 1.36–
1.43 (m, 1 H), 1.48–1.54 (m, 1 H), 1.57–1.72 (m, 8 H), 3.74 
(s, 6 H), 4.16–4.20 (m, 2 H), 4.27 (dd, 1 H, J = 4.8, 12.6 Hz), 
4.51–4.55 (m, 1 H), 6.64 (d, 2 H, J = 8.4 Hz), 7.15 (d, 1 H, J 
= 1.8 Hz), 7.24 (t, 1 H, J = 8.4 Hz), 7.61 (t, 1 H, J = 4.8 Hz), 
7.86 (d, 1 H, J = 9.0 Hz), 8.74 (d, 1 H, J = 1.8 Hz), 8.97 (d, 1 
H, J = 8.4 Hz).  
224 N
H
OMe
OMe
OMe  
Rt = 12.04 min (Method II); HRMS: [MH]+ 559.3126 (calc. 
for C29H43N4O7+) 559.3125 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.79–0.83 (m, 6 H), 0.85–0.94 (m, 2 H), 1.03–
1.20 (m, 4 H), 1.26–1.34 (m, 1 H), 1.43–1.50 (m, 1 H), 1.51–
1.55 (m, 1 H), 1.56–1.60 (m, 1 H), 1.60–1.77 (m, 6 H), 3.61 
(s, 3 H), 3.73 (s, 6 H), 4.17–4.24 (m, 3 H), 4.54–4.58 (m, 1 
H), 6.55 (s, 2 H), 7.15 (d, 1 H, J = 1.8 Hz), 7.97 (d, 1 H, J = 
8.4 Hz), 8.47 (t, 1 H, J = 5.4 Hz), 8.74 (d, 1 H, J = 1.8 Hz), 
8.94 (d, 1 H, J = 8.4 Hz).  
225 
N
H
OMe
OCF3  
Rt = 11.60 min (Method II); HRMS: [MH]+ 583.2738 (calc. 
for C28H38F3N4O6+) 583.2739 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.79–0.83 (m, 6 H), 0.84–0.94 (m, 2 H), 1.03–
1.12 (m, 3 H), 1.12–1.20 (m, 1 H), 1.26–1.34 (m, 1 H), 1.41–
1.49 (m, 1 H), 1.50–1.55 (m, 1 H), 1.56–1.60 (m, 1 H), 1.60–
1.68 (m, 4 H), 1.68–1.77 (m, 2 H), 4.16–4.30 (m, 3 H), 4.55–
4.59 (m, 1 H), 7.05 (d, 1 H, J = 9.0 Hz), 7.08 (d, 1 H, J = 1.8 
Hz), 7.15 (d, 1 H, J = 1.8 Hz), 7.22 (dd, 1 H, J = 3.0, 9.0 Hz), 
8.02 (d, 1 H, J = 9.0 Hz), 8.45 (t, 1 H, J = 6.0 Hz), 8.73 (d, 1 
H, J = 1.8 Hz), 8.94 (d, 1 H, J = 8.4 Hz).  
226 N
H
Cl
Cl  
Rt = 13.37 min (Method II); HRMS: [MH]+ 537.2030 (calc. 
for C26H35Cl2N4O4+) 537.2028 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.79–0.82 (m, 6 H), 0.85–0.91 (m, 2 H), 1.03–
1.16 (m, 4 H), 1.23–1.29 (m, 1 H), 1.40–1.47 (m, 1 H), 1.48–
1.53 (m, 1 H), 1.56–1.76 (m, 7 H), 4.16 (t, 1 H, J = 8.4 Hz), 
4.22–4.30 (m, 2 H), 4.54–4.58 (m, 1 H), 7.15 (d, 1 H, J= 1.8 
Hz), 7.22 (dd, 1 H, J = 1.8, 7.8 Hz), 7.47 (d, 1 H, J = 1.8 Hz), 
7.55 (d, 1 H, J = 8.4 Hz), 8.04 (d, 1 H, J = 8.4 Hz), 8.59 (t, 1 
H, J = 6.0 Hz), 8.75 (d, 1 H, J = 1.8 Hz), 8.93 (d, 1 H, J = 8.4 
Hz).  
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227 N
H
CF3
CF3  
Rt = 13.98 min (Method II); HRMS: [MH]+ 605.2557 (calc. 
for C28H35F6N4O4+) 605.2556 (found); 1H NMR (600 MHz, 
DMSO–d6), δ 0.78–0.82 (m, 6 H), 0.82–0.92 (m, 2 H), 1.01–
1.17 (m, 4 H), 1.25–1.34 (m, 1 H), 1.40–1.46 (m, 1 H), 1.47–
1.52 (m, 1 H), 1.54–1.59 (m, 1 H), 1.59–1.71 (m, 5 H), 1.72–
1.78 (m, 1 H), 4.19 (t, 1 H, J = 8.4 Hz), 4.43 (dd, 1 H, J = 
6.0, 15.6 Hz), 4.55–4.59 (m, 1 H), 7.15 (d, 1 H, J = 2.4 Hz), 
7.94 (s, 2 H), 7.97 (s, 1 H), 8.07 (d, 1 H, J = 8.4 Hz), 8.74–
8.76 (m, 2 H), 8.91 (d, 1 H, J = 7.8 Hz).  	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4.3 Results and Discussion 
4.3.1 Physiochemical properties of LL13C (133), LL115 (159) AY117 (167) and 
AY265 (192) 	  
Lipinski’s ‘rule of five’ provides guidelines to improve oral absorption (and 
likely membrane permeability) of compounds to make them more drug-like.13 No 
PAR2 antagonists listed in Table 4.1, except AY265 (192), fully obey all of these 
guidelines. All compounds have calculated octanol-water partition coefficient LogP < 
5, number of H-bond donor < 5 and number of H-bond acceptor < 10. However, all 
compounds in Table 4.1 except AY265 (192) have molecular weight greater than 500 
Daltons. 
Another common property correlating with drug-likeness was identified by Veber 
et al,14 correlating molecules with ≤ 10 rotatable bonds and ≤ 140 Å2 polar surface 
area (PSA) with good oral bioavailability in rats. All PAR2 antagonists listed in Table 
4.1 met the PSA and rotatable bonds guidelines except for AY265 (192), which has 
12 rotatable bonds.  Although the PAR2 antagonists did not fully obey the criteria 
proposed by Lipinski and Veber, this could not rule out the possibility that these 
compounds are not drug-like in practice. For example, there are drugs on the market, 
such as atorvastatin (Lipitor) and montelukast (Singulair), which violate more than 
one of Lipinski’s rules.15 Therefore, we sought to investigate the anti-inflammatory 
properties, stability and oral bioavailability of these new PAR2 modulators in both in 
vitro and in vivo models.  
 
 
 151 
Chapter 4 
Pharmacological Evaluation of 
PAR2 Antagonists  
Statement of contributions ...................................................................................... 152 
4.1 Abstract .............................................................................................................. 153 
4.2 Introduction ....................................................................................................... 154 
4.3 Results and Discussion ...................................................................................... 155 
4.3.1 Physiochemical properties of LL13C (133), LL115 (159) AY117 (167) 
and AY265 (192). ..................................................................................... 155 
4.3.2 Pharmacokinetic properties of PAR2 agonists and antagonists. ........ 157 
4.3.3 PAR2 antagonism efficacy in vivo. ......................................................... 159 
4.3.4 Antagonist profile of LL13C (133), AY117 (167) and AY265 (192) in  
 vitro. .......................................................................................................... 161 
4.3.5 PAR2 antagonists inhibited secretion of inflammatory cytokines ...... 163 
4.4 Summary and Conclusions ............................................................................... 164 
4.5 Experimental Methods ...................................................................................... 165 
4.5.1 Intracellular calcium release assay ........................................................ 165 
4.5.2 Stability studies on PAR2 agonists and antagonists in rat plasma and 
liver homogenate ..................................................................................... 166 
4.5.3 In vivo pharmacokinetics ........................................................................ 167 
4.5.4 In vivo PAR2-agonist induced paw oedema .......................................... 167 
4.5.5 Human Tubule Epithelial Cells (HTEC) isolation and culture ........... 168 
4.5.6.Treatment of Human Tubule Epithelial Cells (HTEC) ....................... 169 
4.5.7 Enzyme-linked immunosorbent assay ................................................... 169 
4.6 References ........................................................................................................... 169 
 
 
 
 
 
 
 
 
 
 
 152 
	  
Statement of contributions 
 
Experiments Contributors 
Stability, pharmacokinetics and 
in vivo experiments 
Mei-Kwan (Annika) Yau (Candidate) – 20% 
Dr. Ligong Liu – 40% 
Dr. Rink-Jan Lohman – 40% 
Intracellular calcium 
mobilisation assay  
Mei-Kwan (Annika) Yau (Candidate) – 100% 
 
ELISA assay Dr. David Vesey – 50% 
Dr. Jacky Suen – 50% 
 
 
Stability, pharmacokinetics and in vivo experiments: 
 
Dr. Ligong Liu and Dr. Rink-Jan Lohman from Institute for Molecular Bioscience 
(IMB) at University of Queensland (UQ) performed the stability, pharmacokinetics 
and in vivo experiments. However, the candidate assisted the collaborators in 
performing these experiments and involved in analysing the data. 
 
Intracellular calcium mobilisation assay: 
 
Candidate performed all intracellular calcium mobilisation assay in this chapter. 
 
ELISA assay: 
 
Dr Jacky Suen (IMB, UQ) and Dr. David Vesey (UQ Department of Medicine at 
Princess Alexandra Hospital) performed the ELISA experiments.  
 
 153 
4.1 Abstract 	  
A number of studies have demonstrated that activation of protease-activated 
receptor 2 (PAR2) was pro-inflammatory. Therefore, development of PAR2 
antagonists could be beneficial for the treatment of these inflammatory disorders 
through inhibition of the above inflammation events. To date, there are limited PAR2 
antagonists reported in the literature. The most potent reported PAR2 antagonist was 
developed in our research group, known as GB88 (110). Through structure activity 
relationships (SAR) and optimisation studies on GB88 (110), two antagonists (LL13C 
(133), LL115 (159)) were developed in this thesis with similar potency to GB88 (110) 
and two antagonists (AY117 (167) and AY265 (192)) with better potency than GB88 
(110), as measured by intracellular calcium release in HT29 human colorectal 
carcinoma cells (Chapters 2 and 3). Some pharmacological properties of these PAR2 
antagonists were investigated in this chapter. Antagonists AY117 (167) and AY265 
(192) were able to inhibit intracellular calcium release in HT29 cells stimulated by 
PAR2 agonists, 2f-LIGRLO-NH2 or endogenous trypsin, and blocked the release of 
pro-inflammatory cytokines (IL6, TNF-α) in primary human tubule epithelial cells 
(HTEC). They were also generally more stable than LL13C (133) and LL115 (159) in 
rat liver homogenate. AY117 (167) was orally bioavailable and effective for the 
treatment of joint inflammation in rats at 10 mg/kg dose. On the other hand, AY265 
(192) was less effective given orally in a rat paw oedema model due to lower oral 
bioavailability. However, AY265 (192) was a more efficient anti-inflammatory agent 
than GB88 (110) and AY117 (167) in the paw oedema model at 5 mg/kg via 
subcutaneous injection. Herein, PAR2 antagonists have been shown to provide 
beneficial effects in the treatment of inflammatory conditions and these newly 
discovered PAR2 antagonists could be utilised for the exploration in vivo of the roles 
of PAR2 in  inflammatory conditions.  
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4.2 Introduction 	  
PAR2 has been shown to be expressed in epithelial cells (e.g. lung, gastro-
intestinal tract),  endothelial cells, smooth muscle cells, fibroblasts, nerves and 
immune and inflammatory cells (T cells, monocytes, macrophages, neutrophils, mast 
cells and eosinophils).1-2 PAR2 also has been reported to participate widely in 
inflammation3-5 and proliferative diseases.6-8 There is evidence indicating that PAR2 
activation is likely to be pro-inflammatory. For example, activation of PAR2 by 
trypsin (10 ng/paw/i.p.) or synthetic PAR2 agonist (SLIGRL-NH2, 1 & 10 
μg/paw/i.p.) triggered thermal and mechanical hyperalgesia.9 PAR2 activation 
induced by SLIGRL-NH2 (1 μg/paw/i.p.) also caused paw oedema in mice.10 It is also 
well established that PAR2 activation is linked to arthritis, since PAR2-deficient mice 
showed reduction in joint inflammation.10 Furthermore, PAR2 knockout mice/PAR2 
inhibition showed a decrease in the expression of inflammatory cytokines such as 
TNF-α and IL8 in arthritis and inflammatory bowel disease models.11-12	   PAR2 
activation is also linked to airway, skin and adipose inflammation. Therefore, a PAR2 
antagonist would be an effective anti-inflammatory agent.  
Through optimisation of a PAR2 antagonist (GB88, 110), four new PAR2 
antagonists have been developed here: LL13C (133), LL115 (159) AY117 (167) and 
AY265 (192). AY265 (192) showed the best antagonist potency in the calcium 
mobilisation assay. First of all, the physiochemical properties of these compounds 
were analysed to predict their drug-likeness or oral bioavailability. Previously it had 
been shown that these antagonists inhibited PAR2 activation induced by 2f-LIGRLO-
NH2 (Chapter 2 and 3). Here, the antagonists were assessed in vitro for the inhibition 
of PAR2 activation by an endogenous agonist, trypsin, and also for the selectivity of 
the compounds in a calcium mobilisation assay. In addition, the stabilities of these 
compounds in rat plasma and rat liver homogenate were also investigated. Last of all, 
the anti-inflammatory properties of these compounds were evaluated in both in vitro 
and in vivo models of inflamamtion.  
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Table 4.1 Physiochemical properties of PAR2 antagonists 133, 159, 167, 192 and GB88. 
Properties LL13C (133) LL115 (159) AY117 (167) AY265 (192) GB88 
Chemical Structure 
N
OH
N
O
N
H
O
N O
H2N
 
N
O
OH
N
O
N
H
O
N O  
N
OH
N
O
N
H
O
N O
 
N
H
OH
N
O
N
H
O
N O
OMe
 
N
OH
N
O
N
H
O
N O  
Molecular weight 561.7 548.7 522.7 498.6 546.7 
Rt (min)a 9.4 9.2 9.4 7.9 9.7 
cLogP b 4.0 3.0 4.2 3.3 4.3 
IC50 (μM)c 1.0 1.0 0.7 0.5 1–2 
Rotatable amide 
bonds 3 3 3 3 3 
Non-amide rotatable 
bonds 9 8 9 12 9 
Hydrogen bond 
donors 4 2 2 3 2 
Hydrogen bond 
acceptors 9 9 8 9 8 
PSA (Å2) b 131 114 105 123 105 
 
a Retention time (Rt, min) on analytical rpHPLC. Method used: 50%–100% MeCN linear gradient in 10 min, 100% MeCN for further 10 min. 
b Values were calculated by Marvin Sketch software. The calculation of LogP is based on a reported method16, PSA is based on a reported 
method.17 
c The half maximal inhibitory concentration (IC50) values of compounds for the inhibition of calcium release induced in HT29 cells by 2f-
LIGRLO-NH2 (1 µM). 
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4.3.2 Pharmacokinetic properties of PAR2 agonists and antagonists  
 
The stability of selected PAR2 agonists (SLIGRL-NH2, 2f-LIGRLO-NH2 and 
GB110) and antagonists (GB88, AY117, AY265, LL13C, LL115) was examined in 
rat plasma and rat liver homogenate over a period of 3 hours at 37°C. In rat plasma, 
all compounds were stable over 3 hours at 37°C (>75% intact, i.e. >75% of the 
desired compound signal was detected on LCMS) except the hexapeptide SLIGRL-
NH2 (t1/2 ≈ 20 min) which was the only test compound that had a free N-terminus and 
might be susceptible to aminopeptidases (Fig. 4.1A). In rat liver homogenate, the t1/2 
of most compounds was around 60 min, except for SLIGRL-NH2 and the 
aminoisoxazole (LL13C) and O-Me-Thr (LL115) analogues of GB88 (110), which 
had completely metabolised by 60 min at 37°C (t1/2 ≈ 20 min, Fig. 4.1B). GB88 (110) 
was slightly more stable than AY117 (167) and AY265 (192) in rat liver homogenate 
(Fig. 4.1B). 
Antagonists (AY117, AY265 and GB88) were administered to rats by oral 
gavage at 10 mg/kg in olive oil. The results from pharmacokinetic studies indicated 
that both the phenylpiperidine (AY117) and the 2-methoxybenzylamine (AY265) 
analogues produced a lower compound plasma concentrations over 6 h compared to 
GB88 (AUC6h 1964 and 444 ng•h/mL respectively, compared to 3420 ng•h/mL for 
GB88, Table 4.2, Fig. 4.1C). AY265 (192) showed a very low plasma concentration 
over 6 h (Fig. 4.1C), likely because of poorer oral bioavailability. A very small 
amount of AY265 (192) was detected by LCMS in the plasma sample collected 60 
min after oral administration. However after 3 h, the compound might be metabolised 
followed by subsequent clearance and thus not detectable by LCMS. AY265 (192) 
and AY117 (167) reached maximum plasma concentrations between 2–3 h after oral 
administration, with maximum concentrations (Cmax)  being between 0.5–2.0 µM.   
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Figure 4.1 Stability and pharmacokinetics of PAR2 agonists and antagonists. (A) ex 
vivo stability in rat plasma. All compounds except peptide SLIGRL-NH2 were stable 
in rat plasma over 3 hours at 37°C. (B) ex vivo stability in rat liver homogenate. The 
t1/2 of most compounds was ~60 min, except for SLIGRL-NH2 and LL13C and 
LL115, which had completely metabolised by 60 min at 37°C (t1/2 ≈ 20 min). (C) 
Plasma concentration–time curves of antagonists in rat after oral dose (10 mg/kg in 
olive oil). AY117 and GB88 showed higher compound plasma concentration over 6 
hours compared to AY265. Each data point represents mean ± SEM.  
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Table 4.2 Pharmacokinetic data after oral dose of GB88, AY265 and AY117 (10 
mg/kg in olive oil). The values were obtained from four independent experiments 
using 4 or 7 male Wistar rats.  
 
Compound 
n Tmax 
(min) 
Cmax 
(µM) 
AUC6h 
(ng•h/mL) 
F% a 
GB88 (110) 7 167 ± 18 1.97 ± 0.38 3420 60 
AY265 (192) 4 158 ± 45 0.51 ± 0.25 444 10 
AY117 (167) 4 173 ± 31 1.45 ± 0.39 1964 40 
a The F% was estimated based on a method reported in the literature.18  
 
4.3.3 PAR2 antagonism efficacy in vivo  	  
To demonstrate the PAR2 antagonist efficacy in vivo, a selected panel of the most 
potent and stable antagonists (AY117, AY265, LL13C and LL115) were tested 
individually in an oedema model induced by PAR2 agonist administered to a rat 
paw.19-20 When administered orally at 10 mg/kg (in olive oil), both AY117 (167) and 
LL13C (133) significantly reduced joint swelling induced 30 minutes later by 
intraplantar injection of PAR2 agonist 2f-LIGRLO-NH2 (350 µg/paw in 100 µL 
saline. p < 0.05 repeated measures ANOVA, bonferroni planned comparison) (Fig. 
4.2A). Efficacy was comparable to that of GB88 (10 mg/kg/p.o.), although AY117 
(167) was significantly less effective at 30 min than GB88 (p < 0.05, Fig. 4.2A). 
AY265 (192)  and LL115 (159) were ineffective at this dose in this oral dose regime 
(Fig. 4.2A). Interestingly, the most potent PAR2 antagonist, AY265 (192), also best 
obeys Lipinski’s13  and Veber’s14 guidelines for oral bioavailability (only one 
violation), but was not effective in reducing severity of paw oedema following oral 
administration (Fig. 4.2A). This correlates well with the apparent oral bioavailability 
determined in the rat (F=10%) (Table 4.2). 
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Figure 4.2 In vivo efficacy of PAR2 antagonists. PAR2 antagonists attenuated 
experimental paw oedema either (A) p.o. or (B) s.c. Each data point represents mean 
± SEM. When administered orally at 10 mg/kg (in olive oil), LL13C, GB88 and 
AY117 were effective in reducing paw swelling induced by intraplantar injection of 
PAR2 agonist 2f-LIGRLO-NH2. When given subcutaneously, AY265 showed greater 
efficacy than GB88 and AY117 at 5 mg/kg dose. The paw oedema experiments were 
performed by Dr. Rink-Jan Lohman (The University of Queensland).  
  
To further investigate the potency of these PAR2 antagonists in vivo, they were 
administered subcutaneously at both 5 and 10 mg/kg (in saline) in similar paw 
oedema experiments (Fig. 4.2B). GB88 (10 mg/kg/s.c.) showed greatest efficacy in 
reducing joint swelling induced by 2f-LIGRLO-NH2. The lower 5 mg/kg dose gave 
an expected reduced efficacy. When given subcutaneously, compound AY265 (192) 
showed efficacy at both doses, but little efficacy when administered orally. 
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Interestingly, both AY265 (192) and AY117 (167) showed maximal efficacy at 5 
mg/kg following subcutaneous administration, with no statistical difference from 
GB88 (110) at 10 mg/kg (s.c.) (Fig. 4.2B). These results confirmed the PK data that 
AY265 (192) was not orally bioavailable (Fig. 4.1C), but had efficacy when given 
subcutaneously as a PAR2 antagonist in vivo and was a potent PAR2 antagonist in the 
in vitro cell-based assay. None of the compounds showed better efficacy than GB88 
(110) at doses above 10 mg/kg, but AY265 (192) showed similar activity at half this 
dose when given subcutaneously. These results showed that the majority of the GB88 
(110) analogues exhibited PAR2 antagonist activity in vivo, albeit with varying 
efficacy and oral bioavailability. In light of our previous data,20-21 they were expected 
to exhibit anti-inflammatory activity in vivo. Most importantly, AY265 (192) was 
most effective at 5 mg/kg/s.c., more so than GB88 (110) and AY117 (167) at the 
same dose via subcutaneous injection. This was consistent with the results obtained 
from the intracellular calcium release assay, where AY265 (192) was also the most 
potent PAR2 antagonist (IC50 = 500 nM). As previously shown, AY265 (192) 
displayed some agonist response at higher concentrations in the calcium release assay. 
This may explain why this compound at 10 mg/kg/s.c. was less efficient than 5 
mg/kg/s.c. Hence, AY265 (192) was a PAR2 antagonist that inhibited PAR2 
activation in a concentration-dependent manner, but it may have biased agonist 
properties which will be investigated further in the future. 
  
4.3.4 Antagonist profile of LL13C (133), AY117 (167) and AY265 (192) in vitro  	  
The in vivo results presented in sections 4.3.2 and 4.3.3 indicated that the most 
promising new PAR2 antagonists were LL13C (133), AY117 (167) and AY265 (192). 
Therefore, the antagonist profiles of these compounds were investigated further in a 
cell-based assay. 
 Similar to GB88 (110), LL13C (133), AY117 (167) and AY265 (192) displayed 
slight agonist activity at higher concentrations in the calcium release assay, which 
may not be due to PAR2 activation. Therefore, the selectivity of the compounds was 
briefly assessed (Fig. 4.3) using  a desensitisation assay (as described in Chapter 2).22 
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Figure 4.3 Desensitisation assays for compounds LL13C, AY117 and AY265. (A) 
Control: HT29 cells were treated with 2f-LIGRLO-NH2 (20 µM) at t0 to desensitise 
the PAR2 receptor. 2f-LIGRLO-NH2 (100 µM) was then injected at t300 (s) to confirm 
PAR2 desensitisation. (B) 2nd Control: HT29 cells were first desensitised with 2f-
LIGRLO-NH2 (20 µM), then a PAR1 agonist (TFLLR-NH2 at 100 µM) was added to 
confirm only PAR2 was desensitised. (C–E) Cells were first desensitised by 2f-
LIGRLO-NH2 (20 µM) at t0, then compound at 100 µM was administered at t300 (s). 
All compounds did not stimulate further release of Ca2+ following desensitisation of 
PAR2 receptor by 2f-LIGRLO-NH2, suggesting the agonist response observed for this 
compounds at higher concentrations was due to the activation of PAR2. 
 
The desensitisation assay demonstrated that all three compounds did not 
stimulate further release of Ca2+ following desensitisation of PAR2 receptor by 2f-
LIGRLO-NH2, whereas an agonist specific for PAR1 did. These results confirmed 
that compounds LL13C (133), AY117 (167) and AY265 (192) were selective for 
PAR2 over PAR1 and that the agonist response at higher concentrations was likely 
due to the activation of PAR2. These results may suggest concentration-dependent 
functional roles for PAR2.  
Apart from inhibition of PAR2 activation induced by a peptide agonist (2f-
LIGRLO-NH2), both AY117 (167) and AY265 (192, the most promising PAR2 
antagonists herein) were able to inhibit trypsin-induced PAR2 activation in HT29 
cells with IC50 3.6 µM (pIC50 5.4 ± 0.1) and 1.9 µM (pIC50 5.7 ± 0.1), respectively, 
which were more potent than GB88 (IC50  7.8 µM, pIC50 5.1 ± 0.2) under the same 
conditions (Fig. 4.4). 
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Figure 4.4 Concentration dependent responses for selected antagonists, AY265 (), 
AY117 () and GB88 (), based on the inhibition of Ca2+ release induced by 100 
nM trypsin (n ≥ 3) in HT29 cells. Each data point represents mean ± SEM. These 
antagonists inhibited activation of PAR2 induced by endogenous trypsin in 
concentration dependent manner.  
 
4.3.5 PAR2 antagonists inhibited secretion of inflammatory cytokines 	  
Activation of PAR2 is known to induce the release of inflammatory cytokines in 
vitro (IL6, IL8 and TNF-α).23-24,25 Given the high abundance of PAR2 in kidney and 
its roles in mediating proinflammatory events,26 the effects of PAR2 agonist and 
antagonists were investigated in ELISA assays on primary human tubule epithelial 
cells (HTEC). Stimulation of HTEC with PAR2 agonist (2f-LIGRLO-NH2) showed 
increases in TNF-α and IL6 secretion. Pre-treatment with PAR2 antagonist (AY117 
or AY265) exhibited dose-dependent inhibition of the secretion of cytokines 
stimulated by 2f-LIGRLO-NH2 (Fig. 4.5). Our collaborators have previously 
examined GB88 in this ELISA assay and showed that GB88 at 10 µM inhibited both 
TNF-α and IL-6 with almost identical potency to AY117. So, in Figure 4.5, AY265 
was directly compared with AY117. AY265 (192) was a more potent inhibitor of IL6 
secretion from HTEC than AY117 (167), consistent with the in vivo results for these 
two compounds in the paw oedema model.  
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Figure 4.5 Analysis of proinflammatory cytokines in primary human tubule epithelial 
cells (HTEC) of the kidney. Controls: compounds alone at 100 µM did not stimulate 
TNF-α or IL6 secretion. PAR2 antagonists (AY117 and AY265) displayed dose-
dependent inhibition of 2f-LIGRLO-NH2-stimulated (A) TNF-α and (B) IL6 
secretion. Each data point represents mean ± SEM (n = 3). This experiment was 
performed by Dr. Jacky Suen (The University of Queensland) and Dr. David Vesey 
(UQ Department of Medicine at Princess Alexandra Hospital). 
 
 
4.4 Summary and Conclusions 	  
PAR2 antagonists (LL13C, LL115, AY117, AY265 and GB88) were stable in rat 
plasma over 3 hours at 37°C, but the first two (LL13C, LL115) were less stable in rat 
liver homogenate, with t1/2 around 20 minutes at 37°C. The anti-inflammatory and 
oral bioavailability properties of these compounds were also investigated in vivo in 
rats, with results indicating that AY117 (167) was able to reduce joint swelling, 
similar to GB88 (110), at 10 mg/kg dose and were orally bioavailable (F = 40%). 
However, AY265 (192), which was a more potent antagonist than GB88 (110) based 
on results from the intracellular calcium assay, was not orally bioavailable and 
therefore it failed to reduce paw inflammation at 10 mg/kg following oral 
administration. Nevertheless, AY265 (192, 5 mg/kg) had superior anti-inflammatory 
activity in the paw oedema model, compared to GB88 (110) and AY117 (167) at the 
same dose, when the compounds were given to rats by subcutaneous injection. It was 
suspected that AY265 (192) was a PAR2 antagonist that inhibited PAR2 activation in 
a concentration-dependent manner. The ELISA experiments had shown that AY117 
(167) and AY265 (192) inhibited the secretion of pro-inflammtory cytokines (TNF-α 
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and IL6) from primary human tubule epithelial cells (HTEC) stimulated by 2f-
LIGRLO-NH2. 
To conclude, two new PAR2 antagonists were successfully developed, AY117 
(167) and AY265 (192), with superior potency than GB88 (110). These compounds 
were able to inhibit in vitro PAR2 activation induced by peptide agonist 2f-LIGRLO-
NH2 and endogenous trypsin with reasonable PK profiles ex vivo in rat plasma and rat 
liver homogenate. Importantly, AY117 (167) and AY265 (192) displayed in vivo 
(reducing rat paw oedema) and in vitro (inhibiting secretion of proinflammatory 
cytokines from human cells) anti-inflammatory activity. Furthermore, AY265 (192) 
was highly efficacious in a PAR2 agonist-induced rat paw oedema model, 
outperforming GB88 (110) at 5 mg/kg via subcutaneous injection. These newly 
discovered potent and selective human PAR2 antagonists may offer new compound 
leads for further investigation of PAR2 functions in cell signaling pathways and 
diverse inflammatory diseases.  
 
4.5 Experimental Methods 	  
4.5.1 Intracellular calcium release assay20, 27 	  
Assay Protocol. Adherent human colon adenocarcinoma cells (HT29) were 
plated at ~2 x 104 cells/well in a 96-well cleared-bottom black-wall assay plate 
(Corning) with equal amounts of medium (Dulbecco’s modified essential serum 
(DMEM from Gibco), penicillin (100 U/mL) and streptomycin (100 U/mL)) added 
and incubated overnight at 37oC. Before assay, the medium was removed and cells 
were incubated with dye-loading buffer (12 mL assay buffer, 4 µM Fluo-3 AM, 25 µL 
Pluronic acid F-127 and 1% fetal bovine serum) for 1 hour at 37oC. Cells were then 
washed once with the same assay buffer (HBSS supplemented with 2.5 mM 
probenecid and 20 mM HEPES, pH 7.4).  
 
Sample Preparation. Stock solutions of compounds were prepared by dissolving 
the compound in DMSO solution to give a 10 mM stock solution. The 10 mM stock 
solutions were then diluted with assay buffer (described in assay protocol) to give the 
concentrations required for the assay.  
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Concentration Dependent Inhibition Assay. A range of concentrations of the 
compound (50 µL) was pre-incubated with the cells for 30 min prior to the addition of 
trypsin (50 µL, 200 nM). Final concentration of trypsin was 100 nM. Fluostar Optima 
(BMG Labtechnologies) and FLIPRTETRA were used to monitor the intracellular 
release of Ca2+ via fluorescence measurements for at least 60 s (excitation 495 nm, 
emission 520 nm). Duplicate measurements were made for each data point, mean ± 
SEM were reported from multiple experiments as indicated. Changes in fluorescence 
(% response) were plotted against logarithmic compound concentrations. The half 
maximal inhibitory concentration (IC50) values were derived from the concentration 
response curve using a nonlinear regression curve in Graphpad Prism v5. 
 
4.5.2 Stability studies on PAR2 agonists and antagonists in rat plasma and liver 
homogenate 	  	  
Blood and whole liver samples were collected from non-drug dosed male and 
female Wistar rats (aged 8–9 weeks, 200–250 g and 250–300 g respectively). Blood 
samples were centrifuged at 8k rpm for 5 min.  Plasma samples were pooled and 
stored at –80 °C for later use.  The rat livers were homogenized, diluted with three 
volumes of PBS and cloth filtered.  The filtrate was used directly for stability studies. 
Each compound was dissolved in DMSO to make 5 mM stock solution. 10 µL of the 
stock was diluted with either rat plasma or liver homogenate (490 µL) to make up a 
starting concentration of 10 µM (performed in triplicate).  The mixtures were 
vortexed and incubated at 37 ºC.  At each time point of 0, 30, 60 and 180 minutes, 
100 µL of the mixture was taken and diluted with 300 µL of acetonitrile.  The mixture 
was vortexed and centrifuged. 350 µL of the liquid was transferred into a microfuge 
tube and concentrated using a rotational vacuum concentrator (Christ Beta-RVC, 
supplied by Quantum Scientific). 100 µL of acetonitrile–water (9:1, v/v) was added to 
the residue, vortexed and immediately analyzed by LCMS/MS. Data from these 
experiments are expressed as percent of peak area recorded from the LCMS/MS trace 
at time zero (t0). 
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4.5.3 In vivo pharmacokinetics 	  
Male Wistar rats were surgically implanted with a jugular vein catheter, as 
previously described.28-29 Twenty four hours later, 300 µL blood samples were 
collected from the indwelling catheter of an unanaesthetised, unrestrained rat, 5 min 
prior to PAR2 antagonist administration (10 mg/kg p.o.) and 30 min, 1−6, 8 h 
post−administration. Volumes collected were replaced intravenously with heparinised 
saline (100 U/mL). 	  
Preparation of fluid samples. Stock solutions of each antagonist were prepared 
in acetonitrile at the concentration of 5.0E-03, 2.5E-03, 5.0E-04, 2.5E-04, 5.0E-05, 
2.5E-05, 5.0E-06 and 2.5E-06 mg/mL. Rat plasma (100 µL) was diluted with stock 
solution (100 µL) and acetonitrile (200 µL), vortexed, sonicated (10 min) and 
centrifuged (13 K rpm, 5 min). The stock solutions (of known concentrations) were 
analysed by LCMS/MS and a standard curve was generated for each antagonist. 
Similar to the preparation of stock solutions, the blood samples (100 µL) from rats, 
collected at different time points, were diluted with acetonitrile (300 µL), vortexed, 
sonicated (10 min) and centrifuged (13 K rpm, 5 min). Supernatants were diluted in 
deionised Millipore water (1.2 mL) and tert-butyl methyl ether (1.2 mL), vortexed, 
sonicated, centrifuged and frozen on dry ice. The supernatant was decanted, 
concentrated using RVC, acetonitrile (100 µL) was added to the residue, vortexed, 
centrifuged and analysed by LCMS/MS (ABSCIEX 4000 QTRAP Triple Quadrupole, 
Linear Ion-Trap LC/MS/MS mass spectrometer). Chromatography was carried out on 
a C18 column (Phenomenex Luna, 5 µm, 2.1 × 50 mm) using a linear gradient (5–
80% Buffer B in 8 minutes, flow rate 0.35 mL/min). Buffer A was 0.1% formic acid 
in deionised Millipore water and Buffer B was 9:1 acetonitrile:water with 0.1% 
formic acid. The concentration of compound in blood samples was determined by 
reference to the compound standard curve.  
 
4.5.4 In vivo PAR2-agonist induced paw oedema  	  
The methods used were based on those previously described.19, 30-31 Male Wistar 
rats (n = 3–5 per group) were used. Briefly, rats were given 10 mg/kg of a compound 
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orally (p.o. via gavage in olive oil, approx. 500 µL, weight adjusted), or 
subcutaneously at 5 mg/kg or 10 mg/kg (s.c. in 500 µL saline, weight adjusted). 
Control animals received only olive oil or saline (500 µL p.o. or s.c. respectively). 
After a relevant absorption period (2 h for oral, 15 min for s.c.), the PAR2 agonist 2f-
LIGRLO-NH2 (350 µg/paw in saline, 100 µL) was injected into the plantar surface 
(i.pl.) of the right paw pad using a 30 G needle. The left paw acted as a control, 
receiving saline only. Paw thickness and width were measured at given time points 
(30 min, 60 min, 2 h, 3 h) thereafter using digital calipers (World Precision 
Instruments, USA) and paw swelling was calculated by area (mm2; thickness 
multiplied by width). Data was expressed as a percentage change from baseline of 
each individual paw, mean ± SEM. Statistical tests performed were repeated measures 
ANOVA with Bonferroni planned comparisons, using GraphPad Prism software 
(v5.0). 
 
4.5.5 Human Tubule Epithelial Cells (HTEC) isolation and culture  	  	  
Segments of macroscopically and histologically normal renal cortex (5–10g) 
were obtained aseptically from the non-cancerous pole of adult human kidneys 
removed surgically because of small renal cancers. Patients were otherwise healthy. 
Informed consent was obtained prior to each operative procedure and the use of 
human renal tissue for primary culture was reviewed and approved by the Princess 
Alexandra Hospital Research Ethics Committee. The method for isolation and 
primary culture of human tubule epithelial cells (HTEC) is described in detail in the 
literature.26, 32 Briefly, the cortical tissue was minced finely, washed several times and 
agitated for 20 minutes at 37°C in a Hank Balanced Salt Solution (HBSS) with Ca2+ 
& Mg2+ containing collagenase type II (1 mg/mL). Cold HBSS was added and the 
solution was passed through a 297 µm sieve (stainless-steel tissue dissociation sieve, 
50 Mesh, Sigma). After washing three times, the tubular fragments were resuspended 
in 45% percoll – Krebs-Henseleit Solution (KHB) and centrifuged at 25000 xg. A 
high density band, previously shown to be tubule fragments, was removed and 
cultured in a serum free, hormonally defined media (DMEM/F12 containing 10 
ng/mL epidermal growth factor, 5 µg/mL insulin, 5 µg/mL transferrin, 50 nM 
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hydrocortisone, 50 µM prostaglandin E1, 50 nM selenium and 5 pM 
triiodothyronine).  
 
4.5.6.Treatment of Human Tubule Epithelial Cells (HTEC) 	  
All experiments were performed on confluent passage 2 HTEC, (in 48 well 
plates), made quiescent by two washes with serum and growth factor free DMEM/F12 
media followed by incubation for 24 h in the same media. Compounds diluted in 
DMEM/F12 were added to the cells at the concentrations shown. Antagonists were 
added 30 min prior to addition of 2f-LIGRLO-NH2 (2 µM). Conditioned medium was 
collected from the cells at 24 h and stored at -80°C until assayed. 
 
4.5.7 Enzyme-linked immunosorbent assay 	  	  
Cytokines (IL6, TNF-α) were measured either using BD Pharmingen ELISA set 
or R&D Duoset according to the manufacturers protocols. Briefly, each plate was 
coated with anti-IL6 or anti-TNF-α antibody at 4°C overnight before being blocked 
with 10% serum or 1% BSA for 1 h at room temperature. Samples and standards were 
diluted in blocking buffer, added to each well and incubate for 2 h at room 
temperature. The horseradish peroxidase	   (HRP) conjugated detection antibody was 
added and incubated for a further 1–2 h at room temperature. K-blue substrate (Elisa 
Systems, Brisbane Australia) was allowed to develop for 30 min in the dark and the 
reaction was stopped by 2 M sulfuric acid. A Polarstar spectrofluorimeter (BMG 
Labtechnologies) was used to measure the absorbance at λ = 450 nm. 	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5.1 Abstract 
 
The crystal structure of C3a showed that the C-terminus adopts a turn-like 
conformation that may be important for receptor binding. This chapter is based on the 
hypothesis that presenting a ligand, already pre-organised in a conformation 
recognised by the receptor for C3a (C3aR), may confer high affinity receptor binding 
and potent ligand functions. Modification of the C-terminus of C3a led to the 
development of a C3aR hexapeptide agonist, FLTLAR, with EC50 of 0.37 µM in 
calcium release assays using Bt2-cAMP differentiated human U937 cells. The NMR 
structure of this peptide also displayed a similar turn-like conformation in DMSO 
solution. A 5-membered aromatic heterocycle (oxazole) was previously utilised by 
our group (unpublished results) as a scaffold on which to develop mimics of various 
turn conformations and some of these were shown to be potent C3aR ligands. 
However the oxazole scaffold was not optimal and thus we sought to replace the 
oxazole with various different heterocycles. It was demonstrated herein that 
heteroatoms in a range of heterocyclic rings possessed different hydrogen bonding 
strengths that affected the C3aR-binding affinity as well as the functions of the 
heterocyclic ligands. In addition, a linear correlation was generated between binding 
affinity for C3aR and the calculated hydrogen bond interaction energy of different 
heterocycles. Increasing the strength of the hydrogen bond acceptor in the heterocycle 
increased the C3aR binding affinity of the ligand. Incorporation of an imidazole ring 
as scaffold yielded a potent C3aR agonist (242, EC50 24 nM) with comparable 
efficacy to native C3a. On the other hand, when thiazole (234) or thiophene (233) 
were introduced, the ligands displayed antagonist activity, with IC50 of 600 nM and 
80 nM, respectively. The thiophene (233) was the most potent C3aR antagonist 
reported in the calcium release assay. These non-peptidic, potent and selective C3aR 
agonists and antagonists could be beneficial for interrogating the roles of C3aR in 
inflammatory and other disorders.  
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5.2 Introduction 
 
Human anaphylatoxin C3a is a 77-amino acid helix bundle protein produced 
through activation of the complement cascade, and is an important immune regulator 
in innate and adaptive immunity.1-2 This small protein binds to a single G protein 
coupled receptor in man (two in guinea pigs), known as C3a receptor (C3aR), and 
triggers downstream signaling.3 Similar to PAR2, activation of C3aR is pro-
inflammatory and associated with a number of inflammatory diseases such as 
arthritis,4-5 asthma6-7 and renal inflammation.8-9 In addition, C3a protein (or C3aR 
agonist) has been shown to have antibacterial activities.10 Therefore, developing 
potent and selective agonists and antagonists for C3aR will bring new molecular and 
mechanistic insights to the roles of C3a in inflammatory disorders and infectious 
diseases.  
It has been demonstrated that a minimum C-terminal sequence of 5 amino acid 
residues of C3a (LGLAR) is essential for activity.11 However the agonist activity of a 
synthetic 5-residue peptide (LGLAR) was only ~0.5% that of C3a and it was not 
stable in vivo as a molecular probe of C3a/C3aR functions.3, 12 In addition, the last 
residue (arginine) in particular had proven to be crucial for activity. Both the 
carboxylic acid and guanidine groups of arginine are thought to make strong 
interactions with the C3a receptor and to be important for function, since C3a-desArg 
(without the Arg) had no agonist activity at C3aR.3, 13-15  
The crystal structure of C3a has been reported.16-17 It showed that a turn-like 
structure was adopted by the six C-terminal residues (Fig. 5.1) and this may 
correspond to the bioactive conformation required for receptor binding, since many 
peptides that activate GPCRs tend to be recognise in a turn conformation.12, 18 The top 
5 lowest energy conformations of the solution structure of the backbone of 6-residue 
peptide at the C-terminus were compared with the C-terminus of C3a and all of them 
showed similar turn-like conformation (Fig 5.1 right).  
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C-terminus 
 
 
 
Figure 5.1 Crystal structure of C3a ligand displaying a turn-like conformation at the 
C-terminus.  
 
Recently, our group reported that a synthetic hexapeptide, FLTLAR, was a C3aR 
agonist (EC50 0.37 µM) in an intracellular calcium release assay using Bt2-cAMP 
differentiated human U937 cells. Similar to the C-terminus of C3a, this peptide 
showed a turn-like or a bend structure as defined by NMR spectral parameters in 
DMSO-d6 solution (Fig. 5.2). That result supported the idea that a turn conformation 
might be favoured by this peptide sequence and therefore might also be important for 
binding to the C3a receptor.19 Hence, we sought to incorporate heterocycles such as 
oxazole, imidazole and thiophene as rigid templates to mimic the turn conformation 
observed for C3a and hexapeptides. 
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Figure 5.2 1H NMR-derived solution structure of FLTLAR in DMSO-d6.19 
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A non-peptidic oxazole compound (TR12, 228) was previously synthesised in our 
group and it superimposed quite well with the peptide (GLAR) in a type II beta turn 
conformation, demostrating that oxazole can be used as a scaffold to project the side 
chains to the desired positions, thus mimicking a beta turn conformation (Fig. 5.3).  
 
 
Figure 5.3 Superimposition of oxazole compound TR12 (228, blue) with GLAR 
(green) set in a type II beta turn conformation. The C-terminus of C3a is GLAR. 
Openeye software – Omega2 and ROCS were used. 
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The oxazole compound (TR12, 228) was found to be a potent C3aR agonist 
(EC50 60 nM, binding affinity IC50 5 nM, tested on human monocytes derived 
macrophages – HMDM, Tony Reed, Hons Thesis 2009).20 It was the first potent, non-
peptidic and selective C3aR agonist created prior to current studies. Due to the 
promising results obtained from the oxazole compound, we sought to incorporate 
other 5-membered aromatic heterocycles to seek improved agonist/antagonist 
potency. Different heterocycles were expected to behave differently due to different 
relative hydrogen bond donor/acceptor strengths and ring aromaticity. Therefore the 
aims here were to investigate the optimal hydrogen bond donor or acceptor in the 5-
membered ring and to determine how they affected agonist vs antagonist function and 
receptor affinity. 
Previously, Denonne et al 21 introduced a furan ring (114a) to constrain the ether 
chain of the most potent C3aR antagonist, SB290157 (113) in an effort to improve 
potency. However, they gave no indication of what specific conformation was 
preferred and potency was not greatly improved. Therefore, to begin our study on 
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heterocycles, the furan ring in compound 114a (reported by Denonne et al) was 
replaced with other heterocycles. These replacements had not been reported by 
Denonne et al, but the diphenylmethyl substituent and arginine residue had been 
maintained as also used by Denonne. This approach was more synthetically accessible 
and faster compared to inserting an oxazole into a chiral dipeptide, such as in TR12 
(228). The synthesised compounds were dissolved in DMSO to make stock solutions 
for assays to evaluate the function and binding affinity of the ligands at the C3a 
receptor. The two biological assays conducted for this research were intracellular 
calcium mobilisation (to measure agonist/antagonist function) and extracellular 125I-
C3a competitive ligand binding (to measure affinity for C3aR), both using a primary 
immune cell type – human monocyte derived macrophages (HMDM). The calcium 
mobilisation assay is a fluorescence agonist based assay that uses a cell permeable 
dye to capture Ca2+ released (upon C3aR activation) from the endoplasmic reticulum 
into the cytosol, whereupon it becomes fluorescent. The 125I-C3a competitive binding 
assay measures competitive radioligand binding with test ligands at variable 
concentrations to the cell surface of C3aR.19  
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Figure 5.4 The ether linker in SB290157 (113) was replaced with various 5-
membered heterocycles.  
 
5.3 Results and Discussion 
5.3.1 Importance of the ether oxygen of SB290157 (compound 113) 
 
SB290157 (113) was the first C3aR antagonist reported to block the calcium 
response induced by 1 nM C3a (using membranes from rat basophilic leukemia cells 
(RBL 2H3) expressing the human C3aR) with IC50 of 28 nM.4 In the calcium release 
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and binding assays used in our group, with HMDM, compound 113 bound to C3aR 
with IC50 of 10 nM and inhibited the calcium response induced by 100 nM C3a with 
IC50 of 1.3 µM (Table 5.1). This µM antagonist potency is more representative of the 
reported properties of this compound in whole cells, instead of membranes. 
 
X
O
N
H
COOH
H
N NH2
NH  
 
Table 5.1 Biological activities of C3aR ligands 113, 229–231, as determined from  
calcium mobilisation assay and 125I-C3a competitive binding assay in HMDM.  
a logD values were determined experimentally (refer to section 5.5.13).  
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding. 
c concentrations causing 50% inhibition of calcium response induced by 100 nM C3a agonist.  
 
To prove that the ether oxygen was making a significant contribution to receptor 
binding affinity, the oxygen was replaced with a methylene group (229), a sulfur atom 
(230) and an amine NH (231). It was found that the binding affinity for human C3aR 
reduced significantly by 10-fold when the ether oxygen (113) was replaced by a 
methylene group (229), suggesting that the ether oxygen in 113 was likely acting as a 
hydrogen bond acceptor. However, when the ether oxygen was replaced by a sulfur 
atom, 230 showed comparable binding affinity to 113 (Fig. 5.5 A), consistent with the 
calculated ability of a thioether sulfur to be reasonable H-bond acceptor.22 Based on 
the H-bond interaction energy calculations (performed by ab initio methods using 
Gaussian 09 software),23 the H-bond interaction energy between a water molecule and 
thioether is -26.5 kJmol-1, similar to -25.7 kJmol-1 for a H-bond between water and the 
alkyl ether oxygen atom. The secondary amine in 231 was most likely charged at 
physiological pH, and therefore can function as a H-bond donor but not a H-bond 
acceptor. Thus, it was not surprising that binding affinity was reduced by 15-fold. 
Moreover, the antagonist potency was also reduced by 3-fold (Table 5.1, Fig. 5.5 B).  
Compound X LogD a 
Binding 
IC50 
(nM) b 
Binding 
pIC50 ± 
SEM 
n 
Ca2+ 
IC50 
(µM) c 
Ca2+ 
pIC50 ± 
SEM 
n 
113 SB290157 O 0.01 10 8.0 ± 0.2 6 1.3 5.9 ± 0.2 9 
229 BR02 CH2 0.64 96 7.0 ± 0.2 3 6 5.2 ± 0.3 3 
230 AY03 S 0.38 8 8.1 ± 0.3 5 0.8 6.1 ± 0.2 3 
231 AY10 NH -0.23 149 6.8 ± 0.3 3 4.0 5.4 ± 0.2 3 
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Figure 5.5 Concentration dependent responses for compounds 113, 229–231. (A) 
Binding affinities of C3aR ligands measured by displacement of 125I-C3a (80 pM) on 
HMDM (n ≥ 3). (B) Concentration dependent responses of C3aR ligands based on the 
inhibition of Ca2+ release in HMDM induced by 100 nM C3a (n ≥ 3). Each data point 
represents mean ± SEM. 
 
In summary, oxygen or sulfur atoms were preferred at position X in the linker 
likely due to a hydrogen bonding interaction with the receptor, which improved 
receptor binding affinity by at least 10-fold. All four compounds were still full 
antagonists (no agonist activity up to 100 µM, data not shown) with activity (IC50) in 
the range of 1–6 µM, suggesting that a H-bond acceptor can improve ligand affinity 
for C3aR but this was not essential for conferring antagonist function. 
 
5.3.2 Replacing an ether linker with a 5-membered aromatic heterocycle 
 
 
The furan compound (232) was re-synthesised from the literature21 to evaluate its 
biological activity in our assays. A new compound number was given to the furan 
analogue (232, also called BR88, Table 5.2).  
Constraining the ether linker of SB290157 (113) with 5-membered heterocycles 
reduces the flexibility of the ligand. When the linker was replaced with a furan ring, 
the compound (232, Table 5.2) displayed similar antagonist potency to 113 in the 
calcium mobilisation assay (Fig. 5.6 A), with negligible agonist activity below 100 
µM (Fig. 5.6 B). When assessed at 100 µM, some Ca2+ release was observed, 
suggesting partial agonist activity but only equal to about 10% that of 100 nM C3a 
(Fig. 5.6 B). However, the binding affinity for the furan compound (232) was 5-fold 
lower than for 113 (Table 5.2, Fig. 5.6 C).  
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Table 5.2 Biological activities of C3aR ligands 113, 232–234, as determined from 
calcium mobilisation assay and 125I-C3a competitive binding assay in HMDM.  
Compound X Y Z LogD a 
Binding 
IC50 
(nM) b 
Binding 
pIC50 ± 
SEM 
n 
Ca2+ 
IC50 
(µM) c 
Ca2+ 
pIC50 ± 
SEM 
n 
232 BR88 O CH CH 1.10 55 7.3 ± 0.4 3 1.8 5.7 ± 0.4 3 
233 BR111 S CH CH 1.50 65 7.2 ± 0.3 3 0.08 7.1 ± 0.3 7 
234 AY11 S N CH 0.97 3.8 8.4 ± 0.3 4 0.6 6.2 ± 0.2 3 
113 SB290
157 N.A. 
0.01 10 8.0 ± 0.2 6 1.3 5.9 ± 0.2 9 
a logD values were determined experimentally (refer to section 5.5.13).  
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding. 
c concentrations causing 50% inhibition of calcium response induced by 100 nM C3a agonist.  
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Figure 5.6 Concentration dependent responses for compounds 113, 232–234 and C3a. 
(A) Concentration dependent responses of C3aR antagonists based on the inhibition 
of Ca2+ release in HMDM induced by 100 nM C3a (n ≥ 3). (B) Residual partial 
agonist activity of C3aR ligands in HMDM at various concentrations up to 100 µM, 
relative to 100% for C3a at 100 nM (n ≥ 3). (C) Binding affinities of C3aR ligands 
measured by displacement of 125I-C3a (80 pM) on HMDM (n ≥ 3). Each data point 
represents mean ± SEM. 
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The reduction in binding affinity was most likely due to the poor H-bonding 
capability of the oxygen atom in the furan (232) compared to the ether oxygen in 113, 
which is a better H-bond acceptor. Based on the H-bond interaction energy 
calculations (performed by ab initio methods using Gaussian 09 software23) and 
information from the literature,24 the theoretical H-bond interaction energy calculated 
for a water molecule binding to the oxygen of an aliphatic ether is -25.7 kJmol-1, 
compared to only -16.2 kJmol-1 for a H-bond between water and the furan oxygen 
atom (Fig. 5.7).  
O
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-25.7
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Figure 5.7 Calculated H-bond interaction energy (kJmol-1) between water and 
heteroatom. N/A = Not applicable – a stable model could not be generated therefore a 
H-bond interaction energy cannot be calculated. The calculation was done by Dr. 
Robert Reid (University of Queensland). 
 
 
On the other hand, the thiophene compound 233 (IC50 80 nM, calcium 
mobilisation assay), containing a ring sulfur atom that does not participate in H-
bonding (Fig. 5.7), surprisingly was a more potent antagonist than compounds 113 
and 232 (Table 5.2). Compound 233 bound to C3aR with comparable affinity to the 
furan analogue (232), but with less affinity than the aliphatic ether 113. This 
suggested that neither the furan (232) nor thiophene (233) compounds gain any 
additional affinity through H-bonding interactions originating from the heterocyclic 
ring atoms. This is most likely due to the presence of competing H-bonds to the bulk 
water where the energy required to disrupt solvation was not adequately compensated 
for by the formation of alternate H-bonds to these ligands. A furan ring is less 
aromatic than a thiophene because the electron lone pair on the more electronegative 
oxygen atom does not delocalise over the 5-membered ring to the same degree as the 
sulfur lone pair.25 Therefore, thiophene 233 may have stronger π-stacking interactions 
with the receptor than furan 232. Given that the sulfur atom of thiophene does not 
make any H-bond interactions, it was surprising that the thiophene compound (233) 
was a more potent antagonist than 113 and the furan analogue 232. However, it has 
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been reported in the literature that a divalent sulfur atom is able to form a weak non-
bonded hypervalent interaction with neighbouring oxygen atoms (such as C=O of the 
protein backbone), where the interaction energy was around -13.2 kJmol-1, as well as 
nitrogen or sulfur atoms.26-28 Therefore, it was speculated that the antagonist potency 
of the thiophene compound may have resulted from the S-O hypervalent interactions.  
The thiazole analogue (234), with a nitrogen atom at the Y position, bound to the 
receptor with about 17-fold higher affinity compared to both thiophene (233) and 
furan (232), but there was not a corresponding improvement in antagonist potency. 
The thiazole 234 was a slightly better (~3×) antagonist than the furan 232, but the 
thiophene 233 was a more potent antagonist (~8×) than the thiazole 234 (Table 5.2). 
These results support the H-bond energy calculations, consistent with the nitrogen 
atom from thiazole forming a strong H-bond with the receptor, leading to a 17-fold 
improvement in binding affinity. However, this interaction did not influence the 
function of the receptor. It appears that the arginine and diphenylmethyl substituents 
alone provided the essential features for antagonism and that the heterocycle functions 
only as a spacer and template to correctly orient these groups within the receptor. 
Consistent with the trends observed for compounds 113, 229–231 (Table 5.1), this 
finding confirmed that a H-bond acceptor was not required for antagonist function 
although it may improve receptor binding affinity. Thiazole 234 was a slightly better 
antagonist than compound 113 in terms of function and binding affinity. In addition, 
the thiazole compound 234 was less flexible and possessed a more drug-like logD 
than 113 (Table 5.2), which together potentially make it more useful than 113 as an 
antagonist for C3aR.  
 
5.3.3 Introducing heterocycles containing N as H-bond acceptor at position X 
 
It has long been known that both oxygen and nitrogen atoms act as hydrogen 
bond acceptors, however their relative effectiveness is very context dependent. For 
example, recent studies have shown that carbonyl oxygens and ether oxygens are 
much better hydrogen bond acceptors than oxygen atoms adjacent to sp2 hybridised 
atoms such as in furan.29 When two potential H-bond acceptors were present together, 
such as in an oxazole ring, the nitrogen atom was always found to be the preferred H-
bond acceptor (Fig. 5.8), with a calculated H-bond interaction energy with a water 
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molecule of -28.4 kJmol-1. This is consistent with the results observed for the oxazole 
and oxadiazole compounds shown in Table 5.4. 
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Figure 5.8 Calculated H-bond interaction energy (kJmol-1) of water with a 
heteroatom in oxazoles and oxadiazoles. The calculation was done by Dr. Robert Reid 
(University of Queensland). 
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Table 5.3 C3aR ligands 235–240 and their logD values.  
Compound X Y Z LogD a 
235 BR112 N O C-Me 0.98 
236 BR90 O N C-Me 0.70 
237 BR101 N O N 0.50 
238 BR105 O N N 0.15 
239 BR87 N O CH 0.63 
240 BR104 N N O 0.53 
a logD values were determined experimentally (refer to section 5.5.13).  
 
Table 5.4 Biological activities of C3aR ligands 235–240, as determined from calcium 
mobilisation assay and 125I-C3a competitive binding assay in HMDM.  
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding. 
c concentrations causing 50% inhibition/stimulation of calcium response induced by or relative to 100 
nM C3a agonist.  
d 235 and 239 were partial agonists. 
  
Introduction of a better H-bond acceptor, a nitrogen atom, at the X position 
instead of oxygen, improved the binding affinity about 10-fold (235 vs 236 and 237 
Compound 
Binding 
IC50 
(nM) b 
Binding 
pIC50 ± 
SEM  
n 
Ca2+ 
IC50 / EC50 
(µM) c 
Ca2+ 
pIC50 / pEC50 ± SEM   
n 
235 BR112 11 8.0 ± 0.2 3 EC50 0.09 d pEC50 7.0 ± 0.3 5 
236 BR90 100 7.0 ± 0.2 5 IC50 2.9 pIC50  5.4 ± 0.3 3 
237 BR101 54 7.3 ± 0.3 3 IC50 1.2 pIC50 6.0 ± 0.2  3 
238 BR105 967 6.0 ± 0.3 3 IC50 19 pIC50 4.7 ± 0.2  3 
239 BR87 19 7.7 ± 0.3 3 EC50 0.02 d pEC50 7.6 ± 0.4  5 
240 BR104 12 7.9 ± 0.3 3 IC50 1.3 pIC50 6.0 ± 0.2  3 
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vs 238, Table 5.4). In the calcium functional assay, compound 235 was a partial 
agonist (Fig. 5.8 B) while 236 (having oxygen at the X position) acted as an 
antagonist. It was speculated that there might be a H-bonding interaction between N 
at position X with the receptor and this interaction may have induced a 
conformational change of the receptor that led to receptor activation. In addition, 
compound 237 was  a 16-fold more potent antagonist than 238 with IC50 of 1.2 µM 
and 19 µM, respectively (Table 5.4, Fig. 5.9 A). Having a weaker H-bond acceptor 
(oxygen) at  position X, however, may not allow the conformational change for 
agonist function and therefore the compounds (236, 238) behaved as antagonists. This 
may also apply to the 1,2,4-oxadiazole antagonist (237), where the nitrogen at the X 
position has lower H-bond interaction energy than the oxazole nitrogen atom (235).29 
Also, a CH or C-Me at position Z showed better binding affinity than nitrogen at the 
same location, e.g. 235 vs 237 and 236 vs 238 (Table 5.4, Fig. 5.9 C). Introduction of 
a nitrogen atom at position Z seemed to reduce the H-bond ability of other 
heteroatoms at positions X and Y. 
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Figure 5.9 Concentration dependent responses for compounds 235–240. Compound 
113 and C3a were used as controls. (A) Concentration dependent responses of C3aR 
ligands based on the inhibition of Ca2+ release in HMDM induced by 100 nM C3a (n 
≥ 3). (B) Residual partial agonist activity of C3aR ligands in HMDM at various 
concentrations, relative to 100% for C3a at 100 nM (n ≥ 3). (C) Binding affinities of 
C3aR ligands measured by displacement of 125I-C3a (80 pM) on HMDM (n ≥ 3). 
Each data point represents mean ± SEM. 
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The oxadiazole 240, having oxygen at the Z position, evidently weakens the H-
bonding strengths of both nitrogens at the X and Y positions (Fig. 5.8) and so the 
compound was not capable of triggering receptor activation. However this compound 
does bind well to the receptor, which could be due to the combined binding modes 
contributed by the two nitrogens, one at position X and one at position Y. All of the 
above results demonstrated that compounds possessing a heterocyclic ring, containing 
a good H-bond acceptor nitrogen atom at position X, bound to C3aR with higher 
affinity than heterocycles with oxygen or sulfur at that position. Also, polar atoms and 
a H-bond acceptor at position Z were less favoured.  
 
5.3.4 Introduction of imidazole and N-methylated imidazole rings 
 
In the previous section (5.3.3), it was demonstrated that introduction of a nitrogen 
atom at the X position, as shown by compounds 239 and 235, led to high binding 
affinity and induced partial agonist activity up to about 50% that of C3a. The 
imidazole ring has two nitrogens either of which is a good H-bond acceptor than the 
oxazole nitrogen, and so should improve the binding potency. The H-bonding 
interaction energy for imidazole with water was calculated to be -34.0 kJmol-1 
compared to that for oxazole of -28.4 kJmol-1. Therefore, imidazole analogues of the 
oxazoles reported above should bind with high affinity to C3aR. As predicted, the 
imidazole compound (242) did bind with high affinity and was a more potent agonist 
than oxazole (235). In fact 242 displayed comparable agonist potency to the native 
protein ligand, C3a. It is important to note that the imidazole of compound 242 exists 
in two tautomeric forms (as shown in Fig. 5.10), and thus it is important to determine 
which tautomer was the active form responsible for receptor activation. To investigate 
this question, the imidazole nitrogen was separately methylated regiospecifically at 
the X and Y positions and the isomers were isolated.  
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Figure 5.10 Tautomerisation of the imidazole ring of compound 242 interchanges the 
position of the H-bond acceptor/donor atoms.  
 
Ethyl 2-benzhydryl-4-methyl-1H-imidazole-5-carboxylate (intermediate A, 2.9:1 
ratio of tautomers, scheme 5.1) was treated with methyl iodide, in the presence of 
base, to yield two N-methylated intermediates (B and C). These intermediates were 
isolated by flash column chromatography and were separately coupled to arginine to 
give the desired N-methylated compounds 243 and 244.   
 
Scheme 5.1 Synthesis of N-methylated imidazole intermediates and compounds 243–
244.  
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Reagents and conditions: a) NaH, MeI, DMF; b) NaOH, H2O, EtOH, 100°C; c) H-
Arg-OEt, HBTU, DIPEA, DMF; d) NaOH, H2O, EtOH, RT. 
 
The structures of the isolated intermediates B and C were determined using 2D 
NMR experiments (HMBC). The HMBC experiments confirmed that the N-Me group 
of intermediate B was at position X while the N-Me group of intermediate C was at 
position Y. The HMBC spectrum for intermediate B (Fig. 5.11) showed that N-Me 
protons at position X coupled to the quaternary carbon (119.3 ppm, arrow 2, Fig. 
5.11) located adjacent to the carbonyl but did not couple to the quaternary carbon at 
147.0 ppm. On the other hand, the HMBC spectrum for intermediate C (Fig. 5.12) 
indicated that the N-Me protons at position Y coupled to quaternary carbon at 136.7 
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ppm (arrow 2, Fig. 5.12), to quaternary carbon at 148.0 ppm (arrow 3, Fig. 5.12) and 
did not couple to the quaternary carbon (127.9 ppm) that next to the carbonyl.  
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Figure 5.11 HMBC spectrum of imidazole intermediate B indicating that the methyl 
group was located at position X of the imidazole ring.  
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Figure 5.12 HMBC spectrum of imidazole intermediate C indicating that the methyl 
group was located at position Y of the imidazole ring.  
 
Compound 244 (N-Me at position Y) was a full agonist, while 243 (N-Me at 
position X) bound very weakly to the C3aR and was inactive as an agonist (Table 
5.6). This suggested that it is important to have nitrogen as a H-bond acceptor at the X 
position. Thus, the tautomer B of 242 (Fig. 5.10), with NH at the Y position and N at 
the X position was likely to be the active isomer responsible for C3aR activation. 
 
 
 
 
 
 
	   192 
General structure:  
X
ZY
H
N
O COOH
N
H
NH
NH2
 
 
Table 5.5 C3aR ligands 235, 239, 241–244 and their logD values.  
Compound X Y Z LogD a 
239 BR87 N O CH 0.63 
235 BR112 N O C-Me 0.98 
241 AY19 NH N CH -0.10 
242 BR103 N NH C-Me 0.15 
243 BR09 N-Me N C-Me 0.07 
244 BR10 N N-Me C-Me -0.13 
a logD values were determined experimentally (refer to section 5.5.13).  
 
Table 5.6 Biological activities of C3aR ligands 235, 239 and 241–244, as determined 
from calcium mobilisation assay and 125I-C3a competitive binding assay in HMDM. 
Compound 
Binding 
IC50 
(nM) b 
Binding 
pIC50 ± 
SEM 
n 
Ca2+ 
EC50 (µM) 
c 
Ca2+ 
pEC50 ± SEM 
n 
239 BR87 19 7.7 ± 0.3 3 0.02 d 7.6 ± 0.4  5 
235 BR112 11 8.0 ± 0.2 3 0.09 d 7.0 ± 0.3 5 
241 AY19 7 8.2 ± 0.3 3 0.13 e 6.9 ± 0.2 3 
242 BR103 10 8.0 ± 0.2 8 0.02 e 7.6 ± 0.1  5 
243 BR09 1144 5.9 ± 0.3 5 Inactive Inactive 2 
244 BR10 31 7.5 ± 0.2 4 0.04 e 7.4 ± 0.2  3 
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding. 
c concentrations causing 50% release of calcium response induced by 100 nM C3a agonist.  
d 235 and 239 were partial agonists.  
e 241, 242, 244 were full agonists.  
 
The methyl group at the 5-position was also found to be important for agonist 
activity in some compounds. For example, removal of the methyl group from 242 to 
give compound 241 reduced the agonist potency by ~7-fold (Table 5.6, Fig. 5.13 B), 
but the binding affinity was unchanged (Table 5.6, Fig. 5.13 A). The structure-activity 
relationship studies for the 5-position of the heterocycles will be discussed in section 
5.3.6. 
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Figure 5.13 Concentration dependent responses for compounds 235, 239 and 241–
244 compared to C3a. (A) Binding affinities of C3aR ligands measured by 
displacement of 125I-C3a (80 pM) on HMDM (n ≥ 3). (B) Agonist activity of C3aR 
ligands in HMDM at various concentrations, relative to 100% for C3a at 100 nM (n ≥ 
3).Each data point represents mean ± SEM.  
 
 
5.3.5 Comparison of three heterocycles: oxazole, thiazole and imidazole  
 
As mentioned previously, the presence of a nitrogen atom at the X position gave 
better binding affinity than having oxygen at the same location and triggered receptor 
activation. The imidazole compound (242), containing an agonist-triggering nitrogen 
(via tautomerisation) at position X, activated the receptor with high potency (EC50 24 
nM). On the other hand, oxazole compound 235 was just a partial agonist. In addition, 
compounds 236 and 245 were antagonists, since they did not contain a H-bond 
acceptor nitrogen at position X. Thiazole (245) showed 10-fold better binding affinity 
and 3-fold greater antagonist potency than the analogous oxazole (236, Table 5.8). 
The S-C bond is longer than N-C or O-C bond so the bond angles and lengths in the 
thiazole ring are slightly different to oxazole.30 Due to the longer S-C bond length, the 
thiazole nitrogen of 245 may have a closer interaction with the receptor (shorter H-
bond length) and this may improve the binding affinity. Additionally, thiazole may 
exhibit greater aromaticity since the delocalisation of the π-electrons in thiazole 245 is 
greater than for oxazole 236, which may confer greater binding affinity.  
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Table 5.7 C3aR ligands 235, 236, 242 and 245 and their logD values.  
Compound X Y Z LogD a 
235 BR112 N O C-Me 0.98 
236 BR90 O N C-Me 0.70 
245 BR91 S N C-Me 1.10 
242 BR103 N NH C-Me 0.15 
a logD values were determined experimentally (refer to section 5.5.13).  
 
Table 5.8 Biological activities of C3aR ligands 235, 236, 242 and 245, as determined 
from calcium mobilisation assay and 125I-C3a competitive binding assay in HMDM.  
 
Compound 
Binding 
IC50 
(nM) b 
Binding 
pIC50 ± 
SEM 
n 
Ca2+ 
IC50 / EC50 
(µM) c 
Ca2+ 
pIC50 / pEC50 ± 
SEM   
n 
235 BR112 11 8.0 ± 0.2 3 EC50 0.09 d pEC50 7.0 ± 0.3 5 
236 BR90 100 7.0 ± 0.2 5 IC50 2.9 pIC50  5.4 ± 0.3 3 
245 BR91 11 7.9 ± 0.2 4 IC50 1.0 pIC50  5.7 ± 0.3 3 
242 BR103 10 8.0 ± 0.2 8 EC50 0.02 e pEC50 7.6 ± 0.1  5 
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding. 
c concentrations causing 50% inhibition/stimulation of calcium response induced by or relative to 100 
nM C3a agonist.  
d 235 was a partial agonist.  
e 242 was a full agonist.  
 
Both imidazole and thiazole compounds possess a strong H-bond acceptor at 
either the X or Y position (Fig. 5.14) and thus they bound to C3aR with good affinity 
(Table 5.8, Fig. 5.15 C). However, they had completely different functions, the 
imidazole 242 was an agonist (Fig. 5.15 B) and the thiazole 245 was an antagonist 
(Fig. 5.15 A). The imidazole nitrogen at position X could act as H-bond acceptor and 
may be responsible for the agonist activity. On the contrary, thiazole 245, which 
lacked a H-bond acceptor at the same position of the 5-membered heterocyclic ring, 
retained antagonist activity. Thus, the nitrogen at position Y of the ring (as seen in 
thiazole 245) may only contribute to binding affinity, without affecting the function of 
the ligands.  
 
 
 
 
 
	   195 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 Calculated H-bond interaction energy (kJmol-1) between water and the 
heteroatom. The calculation was done by Dr. Robert Reid (University of Queensland). 
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Figure 5.15 Concentration dependent responses for compounds 235, 236, 242 and 
245. Compound 113 and C3a were used as controls. (A) Concentration dependent 
responses of C3aR ligands based on the inhibition of Ca2+ release in HMDM induced 
by 100 nM C3a (n ≥ 3). (B) Agonist activity of C3aR ligands in HMDM at various 
concentrations, relative to 100% for C3a at 100 nM (n ≥ 3). (C) Binding affinities of 
C3aR ligands measured by displacement of 125I-C3a (80 pM) on HMDM (n ≥ 3). 
Each data point represents mean ± SEM.  
 
5.3.6 Substituents at Z position influenced the function and binding affinity of 
the heterocyclic compounds 
 
Superimposition of oxazole-containing ligands with the peptide GLAR, in a type 
II beta turn conformation (Fig. 5.3), showed that the alanine residue of the peptide 
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was located close to the 5-position of the oxazole ring. Therefore, addition of a 
methyl group at the 5-position of oxazole was considered to be able to potentially 
mimic the side chain methyl of alanine and may thus improve potency. There have 
been many cases in medicinal chemistry where adding a single methyl group to a 
compound dramatically improved potency.31 However, this phenomenon was not 
observed in our heterocyclic compounds, except for the imidazole analogues (Table 
5.10).  
General structure:  
X
ZY
H
N
O COOH
N
H
NH
NH2
 
Table 5.9 C3aR ligands and their logD values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a logD values were determined experimentally (refer to section 5.5.13).  
 
Table 5.10 Biological activities of some C3aR ligands, as determined from calcium 
mobilisation assay and 125I-C3a competitive binding assay in HMDM. 
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding. 
c concentrations causing 50% inhibition/stimulation of calcium response induced by or relative to 100 
nM C3a agonist.  
d 241 and 242 were full agonists.  
e 239 and 235 were partial agonists.  
Compound X Y Z LogD a 
241 AY19 N NH CH -0.10 
242 BR103 N NH C-Me 0.15 
246 BR110 N NH C-Ph 1.07 
234 AY11 S N CH 0.97 
245 BR91 S N C-Me 1.10 
247 BR108 S N C-Ph 1.44 
239 BR87 N O CH 0.63 
235 BR112 N O C-Me 0.98 
236 BR90 O N C-Me 0.70 
248 BR109 O N C-Ph 1.90 
Compound 
Binding 
IC50 (nM) 
b 
Binding 
pIC50 ± 
SEM 
n 
Ca2+ 
IC50 / EC50 
(µM) c 
Ca2+ 
pIC50 / pEC50 ± 
SEM   
n 
241 AY19 7 8.2 ± 0.3 3 EC50 0.13 d pEC50 6.9 ± 0.2 3 
242 BR103 10 8.0 ± 0.2 8 EC50 0.02 d pEC50 7.6 ± 0.1  5 
246 BR110 87 7.1 ± 0.3 3 IC50 0.6 pIC50  6.2 ± 0.1 4 
234 AY11 3.8 8.4 ± 0.3 4 IC50 0.6 pIC50 6.2 ± 0.2 3 
245 BR91 11 7.9 ± 0.2 4 IC50 1.0 pIC50  5.7 ± 0.3 3 
247 BR108 433 6.4 ± 0.3 4 IC50 75 pIC50  4.1 ± 0.7 5 
239 BR87 19 7.7 ± 0.3 3 EC50 0.02 e pEC50 7.6 ± 0.4  5 
235 BR112 11 8.0 ± 0.2 3 EC50 0.09 e pEC50 7.0 ± 0.3 5 
236 BR90 100 7.0 ± 0.2 5 IC50 2.9 pIC50  5.4 ± 0.3 3 
248 BR109 110 7.0 ± 0.3 7 IC50 2.0 pIC50  5.7 ± 0.1 3 
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Results showed that, in general, adding a methyl group to the 5-position of 
heterocycles, such as thiazole and oxazole, did not alter the binding affinity or 
function to a great extent. The exception was the imidazole compound (242), which 
was a potent C3aR agonist. Compound 242, with a methyl group at the 5-position of 
the imidazole ring, was 7-fold more potent than the unsubstituted imidazole 241 in the 
calcium release assay, while both had similar binding affinities. Homology modeling 
(Fig. 5.16) suggested that the methyl group of 242 at the 5-position occupied a small 
receptor binding pocket, and this may explain the greater agonist potency observed 
for the 5-methyl imidazole compound (242). The homology model of C3aR was 
generated by Dr. Martin Stoermer (University of Queensland) based on the crystal 
structure of CXCR4 chemokine receptor. C3aR shares just 20% sequence similarity 
with CXCR4, but there is much higher similarity within the 7TM helices. The 
extracellular loop 2 (ECL2) of C3aR is large, containing ~170 amino acid residues, 
and thus very flexible, making it impossible to predict the location of the loop. 
Therefore, ECL2 was not included in this homology model.  
 
Figure 5.16 Homology model of C3aR with docked C3aR agonist 242. The methyl 
group at the 5-position of agonist 242 occupied a small receptor binding pocket. (This 
figure was generated by Drs. Martin Stoermer and Robert Reid, University of 
Queensland). 
 
Adding a bulkier group, like 5-phenyl, at the 5-position of compound 242 (giving 
compound 246) switched the function of the imidazole ligand to an antagonist, but 
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some agonist activity was still observed at high concentrations (Table 5.10, Fig. 5.17 
E). The phenyl group also dramatically reduced the binding affinity of the imidazole 
ligand 242 by almost 10-fold (Table 5.10, Fig. 5.17 C). A similar pattern was 
observed for the thiazole analogues, where the phenyl-substituted thiazole (247) 
showed more than a 100-fold reduction in affinity (Table 5.10, Fig. 5.17 D) and ~70-
fold reduction in function, in comparison to the unsubstituted thiazole (234, Table 
5.10, Fig. 5.17 A). Surprisingly, the binding affinity of the phenyl-substituted oxazole 
(248) was similar to the methyl-substituted analogue (236). In addition, they also 
displayed similar antagonist activity in the intracellular calcium release assay (Fig. 
5.17 A & D).  
In summary, addition of a phenyl group at the 5-position of the heterocyclic ring 
generally was not tolerated. However, smaller groups or more flexible substituents 
might be tolerated at this position, but further SAR investigation is needed to answer 
this question.  
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Figure 5.17 Concentration dependent responses of C3aR ligands. Compound 113 and 
C3a were used as controls. (A) Concentration dependent responses of C3aR ligands 
based on the inhibition of Ca2+ release in HMDM induced by 100 nM C3a (n ≥ 3). (B) 
Agonist activity of C3aR ligands in HMDM at various concentrations, relative to 
100% for C3a at 100 nM (n ≥ 3). (C & D) Binding affinities of C3aR ligands 
measured by displacement of 125I-C3a (80 pM) on HMDM (n ≥ 3). (E) Agonist and 
antagonist responses for compound 246. 246 started to release calcium at 
concentrations above 1 µM reaching 20% partial agonist activity at 10 µM and 50% 
partial agonist activity at 100 µM (n ≥ 3). Each data point represents mean ± SEM.  
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5.3.7 Receptor mutagenesis and C3aR homology model 
 
Site-directed mutagenesis studies on the C3a receptor had demonstrated that three 
charged residues (Arg161, Arg340, Asp417) in C3aR were pivotal for C3a binding 
and receptor activation.32 Recently, a homology model of C3aR, based on the crystal 
structure of CXCR4 chemokine receptor, was generated by Dr. Martin Stoermer 
(University of Queensland) and docking of agonist 242 suggested a possible binding 
mode for this potent small molecule C3aR agonist (Fig. 5.18).   
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Figure 5.18 Proposed interactions between agonist 242 and C3aR. 
 
The arginine group of compound 242 may possess a similar binding mode to the 
arginine group of native C3a, where the carboxylic acid group was thought to form a 
bimodal interaction with Arg161. In this model, the phenolic OH of Tyr392 was H-
bonded to the amide carbonyl oxygen as well as interacting with Arg340. The Arg340 
also interacted with the carboxylate group of 242. In addition, the guanidine side 
chain of 242 formed a divalent interaction with Asp417. The NH at position Y of the 
imidazole ring interacted with the H-bond acceptor His418 and the other imidazole 
nitrogen at position X may act as a H-bond acceptor by interacting with an unknown 
residue in the receptor. Also, one of the phenyl rings could form a T-shaped π-
interaction with His81. Since the large extracellular loop 2 of C3aR was not included 
in this model, it was difficult to predict which residue formed H-bond interaction with 
the imidazole nitrogen at position X. This proposed model gave support for the 
requirement of the arginine residue for binding to C3aR through a tight network of H-
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bonds. Superimposition of the lowest energy conformations of 242 and GLAR 
showed that the conformation of compound 242 was consistent with the turn 
conformation of GLAR (Fig. 5.19). However, it is uncertain whether 242 actually 
adopts a turn conformation when it interacts with C3aR because the crystal structure 
of C3aR bound with compound 242 is not available.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19 Superimposition of imidazole compound 242 (cyan) with GLAR (green) 
set in a type II beta turn conformation. The C-terminus of C3a is GLAR. Openeye 
software – Omega2 and ROCS were used. 
 
5.3.8 Replacement of oxazole from TR16 with imidazole 
 
Prior to the SAR studies on heterocycles, our group had previously developed a 
potent C3aR agonist with oxazole as the scaffold. The structure of one such agonist, 
known as TR16, is shown in scheme 5.2.  
Instead of attaching a diphenylmethyl group onto oxazole, a leucine residue was 
introduced to mimic the leucine residue of LAR at the C-terminus of C3a. An indole 
ring was linked to the leucine to fill possible space in the receptor binding pocket. 
TR16 was a full agonist that activated C3aR with EC50 of 7.5 nM and with binding 
affinity IC50 of 10 nM (Tony Reed, Hons Thesis 2009).20 From the SAR studies 
performed on the diphenylmethyl analogues, it was found that substitution of oxazole 
(which was a partial agonist) with imidazole resulted in the compound becoming a 
full agonist. Therefore, it was expected that replacing the oxazole ring in TR16 with 
imidazole (giving compound 249) might improve the agonist activity of the 
compound. The synthesis of 249 is depicted in scheme 5.2.    
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Scheme 5.2 Synthesis of compound 249. 
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Reagents and conditions: a) (i) NaNO2, AcOH/H2O; (ii) H2, EtOH, 10% Pd/C, 15 psi; 
b) Cbz-L-Leu-OH/Boc-L-Leu-OH, HBTU, DIPEA, DMF; c) NH4OAc, AcOH, 
microwave 150°C, 30 min; d) H2, 10% Pd/C, MeOH, 40 psi; e) N-Boc-indole-3-
carboxylic acid, HBTU, DIPEA, DMF; f) NaOH, H2O, EtOH, 100°C; g) H-Arg-OEt, 
HBTU, DIPEA, DMF; h) NaOH, H2O, EtOH, RT.  
 
 
To synthesise compound 249, Boc-protected leucine amino acid was used 
initially, but the Boc-protecting group was removed and generated a range of 
unknown side products during the cyclisation step c. To overcome this problem, Cbz-
protected leucine was used and eventually the final compound 249 was successfully 
synthesised. It was hypothesised that replacing the oxazole ring in TR16 with 
imidazole ring could improve the agonist potency. However, the agonist and binding 
potency of 249 was similar to 242 and TR16 (Table 5.11, Fig. 5.20).  
 
Table 5.11 Biological activities of compounds TR16, 242 and 249, as determined 
from calcium mobilisation assay and 125I-C3a competitive binding assay in HMDM. 
Compound 
Binding 
IC50 
(nM) b 
Binding pIC50 
± SEM n 
Ca2+ 
EC50 (nM) 
c 
Ca2+ 
pEC50 ± SEM   
n 
TR16 4 8.4 ± 0.3 5 7 8.1 ± 0.2 4 
242 10 8.0 ± 0.2 8 22 7.6 ± 0.2 4 
249 12 7.9 ± 0.3 3 15 7.8 ± 0.3 4 
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding. 
c concentrations causing 50% release of calcium response induced by 100 nM C3a agonist.  
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Figure 5.20 Concentration dependent responses for compounds 242, TR16 and 249.  
(A) Binding affinities of C3aR ligands measured by displacement of 125I-C3a (80 pM) 
on HMDM (n ≥ 3). (B) Agonist activity of C3aR ligands in HMDM at various 
concentrations, relative to 100% for C3a at 100 nM (n ≥ 3).Each data point represents 
mean ± SEM. Compound 249 had similar agonist and binding activity to compounds 
242 and TR16. 
 
It was possible that compounds 242 and TR16 bound to the receptor in a 
different manner to each other and therefore the imidazole ring in 242 did not interact 
with the receptor in the same way as the imidazole ring in 249, and no additional 
potency was gained. Alternatively, the role of the H-bond acceptor present in the 
imidazole ring may have been taken by the amide carbonyl that links the indole 
fragment.  
 
5.3.9 Correlation between binding affinity and antagonist/agonist activity for 
selected heterocyclic compounds  
 
The relationship between C3a receptor binding affinity and calcium functional 
activity in HMDM was examined. A linear regression line was generated with the 
calcium functional activities (-LogIC50 or –LogEC50) on the Y-axis and the binding 
affinity (-LogIC50) on the X-axis. As shown in Figure 5.21A, most of the heterocyclic 
C3aR antagonists did not show a good correlation between the binding affinity and 
the antagonist activity, with the correlation coefficient of R2 = 0.4. No correlation 
between binding affinity and agonist activity could be obtained due to insufficient 
data (Fig. 5.21 B). Of all the compounds synthesised, only five compounds were 
agonists and only three of them (241, 242 & 244) were full agonists, with the other 
two (235 & 239) being partial agonists. As the partial agonists did not give the full 
response in the calcium release assay, their respective EC50 could not be compared 
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with the EC50 values obtained from full agonists. In order to generate a good 
correlation between binding affinity and agonist activity, compounds have to be full 
agonists for C3aR and more data is therefore needed to complete such an analysis. It 
was noticed that the binding affinity did not always correlate well with the functions 
of the ligands. The binding affinity of one compound can be improved through H-
bonding or a hydrophobic interaction with amino acid residues in the receptor. Such 
interactions could improve the binding affinity of the ligand, but may or may not be 
able to induce a conformational change in the receptor, and thus the function of ligand 
can be changed or remained unchanged.  
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Figure 5.21 The relationship between C3aR binding affinity and (A) antagonist 
potency, (B) agonist activity of C3aR ligands. C3aR agonists/antagonists did not 
show a good correlation between the binding affinity and the agonist/antagonist 
activity. 
 
5.3.10 Correlation between binding affinity and H-bond interaction energy  
 
One of the main aims of this work was to investigate how H-bonding properties 
of different heterocycles influence the binding affinity of the ligand. It has been 
demonstrated herein that high affinity ligands generally contain a good H-bond 
acceptor like a nitrogen atom in the heterocycle. To determine the strength of H-
bonding of all heterocycles, the H-bond interaction energy (kJmol-1) between the 
heteroatom in the ring and a water molecule was calculated and the calculated values 
were compared with the interaction energy of the water dimer (Fig. 5.22). These were 
calculated using Gaussian 09 software by Dr. Robert Reid (University of 
Queensland).23 
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Figure 5.22 Calculated H-bond interaction energy (kJmol-1) between water and 
heteroatom of different heterocycles compared with the water dimer. The calculation 
was done by Dr. Robert Reid (University of Queensland). The methylated nitrogen in 
imidazole could not form any H-bond interaction.  
 
The calculated H-bond interaction energy was compared with affinity and 
showed a linear relationship with a correlation coefficient of R2 = 0.95 (Fig. 5.23). 
This was consistent with increasing H-bond interaction with the receptor at position X 
of the heterocycle enhancing binding affinity. Additionally, increases in affinity can 
change the function of the receptor. For instance, when the furan ring of antagonist 
232 was replaced with imidazole (242), which possessed a much stronger H-bond 
acceptor, the ligand was transformed to a potent full agonist.  
Compound X Y Z 
232 BR88 O CH CH 
235 BR112 N O C-Me 
236 BR90 O N C-Me 
240 BR104 N N O 
241 AY19 N NH CH 
242 BR103 N NH C-Me 
243 BR09 N-Me N C-Me 
	   206 
Binding Affinity &  H-Bonding correlation
-40 -30 -20 -10 0
5
6
7
8
9
B
in
d
in
g
 A
ffi
n
ity
 (
-L
o
g
IC
5
0
)
calculated H-Bond energy (kJmol-1)
242 232
R2 = 0.95
240
241
235
236
243
 
Figure 5.23 The relationship between binding affinity (-LogIC50) and the calculated 
hydrogen bond interaction energy (kJmol-1). The binding affinity of different 
heterocycles showed a linear correlation with the calculated hydrogen bond 
interaction energy (kJmol-1). 
 
5.3.11 Determination of the selectivity of a potent C3aR agonist (242)  
 
The structure-activity relationship studies on heterocyclic compounds have led to 
the discovery of a potent small molecule C3aR agonist, compound 242. Compound 
242 showed comparable agonist potency to the native ligand C3a in the calcium 
release assay in HMDM. The receptor selectivity of these compounds was then 
examined using receptor desensitisation assays (as described in Chapter 2). Before 
assessing these ligands in the assay, it was important to determine the optimum 
concentration of C3a to fully desensitise the receptor. Three different concentrations 
of C3a were tested: 200 nM, 500 nM and 1 µM. These concentrations of C3a were 
first applied to the cells at t0 (s) and then, to confirm that no further calcium responses 
were possible, a 2nd injection of 1 µM C3a at t920 (s) was administered (Fig. 5.24 A–
C). The absence of a second calcium signal confirmed that C3a receptor 
desensitisation was complete. The results showed that C3a at 500 nM and 1 µM were 
able to fully desensitise the C3a receptor. However 200 nM C3a was not quite 
sufficient to desensitise the receptor as a very small amount of calcium release was 
still detected after the cells first stimulated by 200 nM C3a were subsequently treated 
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with another dose of 1 µM C3a. Thus, 300 nM C3a was used for all future 
desensitisation experiments.  
To assess the selectivity of 242, the C3a receptors in HMDM were desensitised 
with 300 nM human C3a ligand followed by treatment with 10 µM of 242. The assay 
results showed that injection of agonist 242 at 10 µM did not stimulate a second 
calcium response, suggesting that this agonist was selective for C3aR up to 10 µM, a 
concentration that is 500× of its EC50 (Fig. 5.24 F).  
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Figure 5.24 Desensitisation assays. (A-C): Optimisation of the desensitisation assay 
with various concentrations of C3a. (D) Control 1: HMDM was treated with 300 nM 
of C3a ligand at t0 to desensitise the C3a receptor. 1 µM of C3a was then injected at 
t920 (s) to confirm C3aR desensitisation.  (E) Control 2: Cells were first desensitised 
by 300 nM C3a ligand at t0, then 300 nM C5a was injected at t920 (s) to make sure 
only C3aR was desensitised. (F) Cells were first desensitised by 300 nM of C3a 
ligand at t0, then compound 242 at 10 µM were administered at t920 (s). Compound 
242 was selective for C3aR at 10 µM.  
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5.3.12 Competitive assay for compounds 233, 242 and 245 
 
From the above SAR studies, two new C3aR antagonists (233 and 245) and a 
potent full C3aR agonist (242) were developed. Since these three compounds are 
structurally similar to each other, we sought to investigate the mechanism of 
antagonism by 233 and 245 against the agonist 242.  
The results indicated that 233 and 245 were insurmountable antagonists against 
agonist 242, as shown by reduction of the maximal agonist response as concentration 
of the antagonist increases (Fig. 5.25 A & B). Insurmountable antagonism implies that 
the off-rate of antagonist from the receptor binding site was so slow that a true 
equilibrium between the receptor, agonist and antagonist cannot be attained in the 
short timeframe of the calcium mobilisation assay.33-34 Compound 233 was a 
competitive antagonist with slope equal to 0.98 in the Schild plot (Fig. 5.25 D), 
suggesting that 233 most likely bound to the same receptor binding site as agonist 
242. On the other hand, compound 245 was non-competitive against agonist 242, 
indicated by Schild plot (Fig. 5.25 C) with slope <1. The non-competitiveness of 
compound 245 implied that it might not be binding similarly to agonist 242. In 
summary, antagonists 233 and 245, although both possess a sulfur at position X, have 
different binding modes in C3aR resulting in different antagonist potencies (233 is 
~10× more potent than 245). Compound 245 was an insurmountable and non-
competitive antagonist while 233 was an insurmountable and competitive antagonist 
against agonist 242.  
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Figure 5.25 Mechanism of antagonism for 233 and 245 against agonist 242. (A) 
Concentration dependent responses of 242 with treatment of various concentration of 
antagonist 245 (zero, ; 0.03 µM, n; 0.1 µM, ; 0.3 µM, ; 1 µM, ; 3 µM, ; n = 
3). (B) Concentration dependent responses of 242 with treatment of various 
concentration of antagonist 233 (zero, ; 0.03 µM, n; 0.1 µM, ; 0.3 µM, ; 1 µM, 
; 3 µM, ; n = 3). (C–D) Schild plots for antagonist 233 and 245 against 242. 
Calculated pA2 values for 245 and 233 are 7.4 and 7.7 respectively. Each data point 
represents mean ± SEM. Compound 233 was a competitive antagonist against agonist 
242 but compound 245 was non-competitive against agonist 242.  
 
 
5.4 Summary and Conclusions 
 
 
This chapter has demonstrated that heterocycles containing oxygen or sulfur at 
position X were C3aR antagonists, while replacing the oxygen at position X with 
nitrogen (a better H-bond acceptor) improved binding affinity to C3aR and switched 
the function of ligands from antagonist to agonist. In addition, it was speculated that 
heterocycles with greater aromaticity improved potency (thiophene 233 was a better 
antagonist than furan 232, thiazole 234 was a better antagonist than oxazole 236).  
Having a strong H-bond acceptor nitrogen at position Y also improved the 
binding affinity, just like thiazoles compounds (234, 245). Results from the 
competitive studies indicated that thiazole (245) and imidazole (242) compounds 
were not competitive with each other, suggesting possible different binding modes or 
binding sites for these compounds.  
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Figure 5.26 Summary of the SAR around the 5-membered heterocycle. 
 
In general, heterocycles containing 3 heteroatoms (oxadiazoles) were less 
favorable. Also, substitution of the 5-position of the heterocycles with bulky groups 
like phenyl reduced the binding affinity of the ligands and also switched the function 
to an antagonist.  
In this chapter, a small molecule was developed as a C3aR agonist (242, EC50 24 
nM) with comparable potency to the native ligand C3a (EC50 40 nM). In addition, two 
new C3aR antagonists were developed: 233 (thiophene) and 234 (thiazole), with 233 
(IC50 80 nM) being a 15-fold more potent antagonist than the literature reported 
SB290157 (113, IC50 1.3 µM) in the calcium release assay, but it bound 7-fold less 
tightly to C3aR than 113. In contrast, compound 234 showed strong binding affinity 
to the C3aR with IC50 of 4 nM compared to 113 (IC50 10 nM), but its antagonist 
activity was only 2-fold better than 113.  
Most importantly, a linear correlation between binding affinity of heterocycle 
containing ligand and the calculated hydrogen bond interaction energy for different 
heterocyclic heteroatoms was generated. Ligands containing heterocycles that 
possessed a strong H-bond acceptor atom had the highest binding affinity for the 
receptor. In terms of functions, in most cases, heterocycles with a weak H-bonding 
acceptor at position X behaved as antagonists. 
The potent C3aR agonist (242) and antagonist (233) developed in this chapter 
could prove to be useful for investigating functions of the C3a receptor in cell studies 
and, if bioavailable, might also find valuable in vivo applications in studying various 
diseased states. 
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5.5 Experimental Methods 
 
General Methods 
 
All amino acids were purchased from Novabiochem. Diisopropylethylamine 
(DIPEA), DMF and TFA were obtained from Auspep Pty Ltd., Australia. Other 
chemicals were obtained from Aldrich. All reagents were used as received. 
Hydrogenation reactions were conducted using a medium pressure Parr hydrogenator 
apparatus. Preparative-scale rpHPLC separations were performed on a Phenomenex 
Luna C18 15 µm, 250 × 21.2 mm column. Standard conditions were used for elution 
of all compounds unless otherwise indicated at a flow rate of 20 mL/min: 100% A to 
100% B linear gradient over 10 min followed by a further 10 min at 100% B where 
solvent B was 90% MeCN, 10% H2O + 0.1% TFA and solvent A was H2O + 0.1% 
TFA. Detection was by UV and pure fractions were lyophilised. Analytical rpHPLC 
was used to assess compound purity (Phenomenex Luna C18 column, 15 µm, 90 Å, 
4.6 × 250 mm, λ 214, 230 and 254 nm) at three different wavelengths. Standard 
conditions (same as preparative-scale rpHPLC) were used for all compounds unless 
otherwise indicated at a flow rate of 1 mL/min. Solvent conditions were the same as 
for preparative-scale rpHPLC. All final compounds were ≥ 95% pure. 
Electrospray ionization mass spectra (ESI-MS) measurements were obtained on 
Micromass LCT and high-resolution mass spectra (ESI-HRMS) measurements were 
obtained on a Bruker microTOF mass spectrometer equipped with a Dionex LC 
system (Chromeleon) in positive ion mode by direct infusion in MeCN at 100 µL/h 
using sodium formate clusters as an internal calibrant. Data was processed using 
Bruker Daltonics DataAnalysis 3.4 software. Mass accuracy was consistently better 
than 1 ppm error.  
1H and 13C NMR spectra were recorded on Bruker Avance 600 spectrometers at 
298 K in the deuterated solvents indicated. 1H NMR spectra were referenced to the 
residual 1H signals; DMSO-d6 2.50, CD3OD 3.31 ppm except CDCl3 solutions were 
referenced to internal TMS. 13C NMR resonances were referenced to the residual 
solvent peak (DMSO-d6 40.4, CDCl3 77.0 ppm). The exact concentration of the 
compounds was determined by the quantitative NMR integration ‘PULCON’ 
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experiment.35 These settings were used for all PULCON experiments: relaxation delay 
of 30 seconds, 64 scans, 2 dummy scans, 90° pulse and temperature at 298K.  
5.5.1 Chemical synthesis of C3aR heterocyclic compounds 
 
Scheme 5.3 Preparation of C3aR heterocyclic compounds  
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Reagents and conditions: a) DAST, THF -78°C; b) CBrCl3, DBU, DCM 0°C; c) 
NaOH, H2O, EtOH; d) H-Arg-OEt, BOP, DIPEA, DMF; e) NaOH, H2O, EtOH; f) 
pyridine 2 eq. THF, microwave 150°C, 30 min; g) NH4OAc, AcOH, 100°C, 30 min; 
h) NaH, MeI, THF; i) DIPEA, EtOH, 70°C, 30–60 min; j) NH2OH.HCl, K2CO3, 
EtOH, 90°C; k) AlMe3, NH4Cl; l) pyridine 5 eq., THF, RT; m) (i) EtOH, Δ; (ii) 
diphenylether, microwave 180°C, 15 min; n) DIPEA, DCM, RT; o) TsCl, DIPEA, 
DCM.  
 
Compounds 229, 232-233, 235-240 and 242-248 were synthesised and characterized 
by Dr. Robert Reid (University of Queensland) and therefore the synthetic procedures 
for these compounds were not included in this chapter. However, characterization 
data for all final compounds were reported in section 5.5.9. The following refers to 
compounds made by the candidate. 
 
5.5.2 Standard procedures for coupling of H-Arg-OEt 
 
The diphenylmethyl heterocyclic carboxylic acid (1 eq.) was activated with BOP 
(1 eq.) as 0.2–0.5 M solutions in DMF for 10 min before the addition of H-Arg-
OEt.2HCl (1 eq.) and DIPEA (2 eq.). The reaction mixture was stirred at RT 
overnight. After this time, the reaction mixture was diluted with EtOAc and washed 
with sat. NaHCO3 twice. The organic extract was dried over MgSO4, filtered and 
evaporated to dryness.  
 
5.5.3 Standard procedures for ester hydrolysis 
 
The ester was dissolved in EtOH/H2O/2M NaOH (4:1:1) and stirred until the 
reaction went to completion. The EtOH in the reaction was evaporated in vacuo and 
the aqueous solution was acidified with 2 M HCl and extracted with EtOAc (3 ×). 
Combined organic extracts were dried over MgSO4, filtered and evaporated to 
dryness.  
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5.5.4 Synthetic procedures for compound 230 
 
Scheme 5.4 Synthesis of compound 230 
OH I
HS COOH
S OH
O
S N
H
O COOH H
N NH2
NH
230
a
b
c, d
28 29 30  
Reagents and conditions: a) PPh3, I2, imidazole, DCM; b) NaOH/MeOH; c) H-Arg-
OEt, BOP, DIPEA; d) NaOH, H2O, EtOH. 
 
Synthesis of 2,2-Diphenylethyl iodide (29). Triphenylphosphine (1.97 g, 7.51 
mmol) and iodine (1.91 g, 7.51 mmol) were dissolved in DCM (15 mL) and stirred at 
room temperature for 10 min. To this reaction mixture, imidazole (0.85 g, 12.5 mmol) 
was added and the mixture was stirred for 10 min. After that, 2,2-diphenylethanol (28, 
1.01 g, 5.09 mmol) in DCM (3 mL) was added and the reaction mixture was stirred at 
room temperature overnight. The reaction was evaporated to dryness and the crude 
product was purified by flash column chromatography (SiO2, 10% EtOAc in 
petroleum ether, Rf product 0.5) to yield desired product as a white crystalline solid 
(1.20 g, 78%). Rt = 13.8 min (20–100% B 10 min gradient plus 100 % B for 10 min);  
ESI-MS: product 29 did not ionise on MS; 1H NMR (600 MHz, CDCl3), δ 3.78 (d, 2 
H, J = 7.8 Hz), 4.38 (t, 1 H, J = 7.8 Hz), 7.26–7.29 (m, 6 H), 7.34–7.37 (m, 4 H).  
 
Synthesis of 2-((2,2-diphenylethyl)thio)acetic acid (30). To a NaOH (52 mg, 
1.30 mmol) solution in MeOH (3 mL), 2-mercaptoacetic acid (50 µL, 0.71 mmol) was 
slowly added followed by addition of (2-iodoethane-1,1-diyl)dibenzene 29 (0.20 g, 
0.65 mmol) in portions. The reaction was stirred at room temperature for 1 h. The 
reaction mixture was treated with H2O (5 mL) and washed with Et2O (2 × 5 mL). The 
aqueous layer was acidified with 2 M HCl (5 mL) to pH 2 and extracted with Et2O (2 
× 5 mL). The organic phase was dried over MgSO4, filtered and evaporated to dryness 
in vacuo. Compound 30 was used for the next step without further purification. ESI-
MS: m/z 273.2 [MH]+. 
 
Coupling for H-Arg-OEt and ester hydrolysis. To synthesise compound 230, 
30 (50 mg, 0.18 mmol) was coupled to H-Arg-OEt (as described in section 5.5.2) 
followed by ester hydrolysis (section 5.5.3). The crude product was purified by 
semipreprative HPLC (0–100% B for 15 min) to give compound 230 (4 mg, 5%). Rt 
	   215 
= 11.9 min (0–100% B 15 min gradient); HRMS: [MH]+ 429.1955 (calc. for 
C22H29N4O3S+) 429.1955 (found); 1H NMR (600 MHz, DMSO-d6), δ 1.44–1.53 (m, 2 
H, Arg-γ-CH2), 1.55–1.64 (m, 1 H, Arg-β-CH), 1.71–1.79 (m, 1 H, Arg-β-CH), 3.04–
3.11 (m, 2 H, Arg-δ-CH2), 3.17 (d, 2 H, J = 2.0 Hz, S-CH2-C=O), 3.31 (d, 2 H, J = 
7.9 Hz, Ph2-CH-CH2-S), 4.17–4.27 (m, 2 H, Arg-α-CH, Ph2CH), 7.16 (t, 2 H, J = 7.2 
Hz, guanidine-NH), 7.25–7.33 (m, 10 H, Ar), 7.76 (t, 1 H, J = 5.8 Hz, guanidine-NH), 
8.32 (d, 1 H, J = 7.9 Hz, Arg-α-NH). 13C NMR (150 MHz, DMSO-d6), δ 25.6 (Arg-γ-
CH2), 28.7 (Arg-β-CH2), 34.6 (S-CH2-CO), 37.2 (Ar-CH-CH2-S), 40.7 (Arg-δ-CH2), 
50.3 (Ph2CH), 52.2 (Arg-α-CH), 126.7 (2 × Ar-CH), 128.1 (2 × Ar-CH), 128.2 (2 × 
Ar-CH), 128.8 (2 × Ar-CH), 144.2 (2 × Ar-C), 157.3 (guanidine-C), 169.7 (HNCO), 
173.7 (COOH).  
 
5.5.5 Synthetic procedures for compound 231 
 
 
Scheme 5.5 Synthesis of compound 231 
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Reagents and conditions: a) NaBH(OAc)3, MeOH; b) Boc2O, Et3N, THF; c) NaOH, 
H2O, EtOH; d) H-Arg(Pbf)-Wang resin, HBTU, DIPEA, DMF; e) TFA/TIPS/H2O, 
95:2.5:2.5. 
 
Synthesis of 32. To a solution of glycine methyl ester (1.30 g, 10.2 mmol) in 
MeOH (30 mL) was added AcOH (60 µL, 2.00 mmol) and diphenylacetaldehyde (31, 
0.9 mL, 5.10 mmol) at 0°C followed by slow addition of NaBH(OAc)3 (2.20 g, 10.2 
mmol) at 0°C. The reaction was stirred at 0°C for 45 min. The reaction was quenched 
with sat. NaHCO3 (10 mL) and extracted with EtOAc (1 × 30 mL). The organic phase 
was dried over MgSO4, filtered and evaporated to dryness in vacuo to give 32 as a 
yellow syrup. ESI-MS: m/z 270.2 [MH]+. The crude product was used for the next 
step without further purification. 
 
Boc protection for 32. To the crude product above (32, 1.20 g, 4.40 mmol) in 
THF (15 mL) was added Et3N (0.8 mL, 5.70 mmol) and the reaction mixture was 
stirred at 0°C. To this stirred solution, Boc2O (1.2 g, 5.60 mmol) in DCM (5 mL) was 
added dropwise at 0°C. The reaction mixture was slowly warmed up to room 
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temperature and stirred overnight. After this time, the reaction mixture was 
evaporated, re-dissolved in EtOAc (20 mL) and washed with H2O (1 × 15 mL), 10% 
citric acid (1 × 15 mL) and brine (1 × 15 mL). The organic phase was dried over 
MgSO4, filtered and evaporated to dryness in vacuo. The crude product was purified 
by flash column chromatography (SiO2, 10% EtOAc in petroleum ether, Rf product 
0.3) to yield desired product (135 mg, 7%). Rt = 13.5 min (20–100% B 10 min 
gradient plus 100% B for 10 min); ESI-MS: m/z 370.2 [MH]+; 1H NMR (600 MHz, 
CDCl3), 1:1.2 ratio of rotamers, δ 1.38 & 1.42 (2 sets of s, 9 H), 3.65–3.67 (m, 5 H), 
3.90 & 3.93 (2 sets of d, 2 H, J = 7.8 Hz), 4.23 & 4.33 (2 sets of t, 1 H, J = 7.8 Hz), 
7.18–7.31 (m, 10 H).  
 
Ester hydrolysis of Boc-protected 32. Standard ester hydrolysis procedures 
(section 5.5.3). The Boc-protected 32 (135 mg, 0.36 mmol) was dissolved in 
EtOH/H2O/2M NaOH (4:1:1, 2 mL). The resulting crude product 33 (ESI-MS: m/z 
356.2 [MH]+) from this reaction was used for the next step without further 
purification. 
 
Solid phase amino acid coupling. The acid 33 (121 mg, 0.34 mmol) was 
activated with HBTU (129 mg, 0.34 mmol) and DIPEA (60 µL, 0.34 mmol) in DMF 
(1 mL) for 15 min and then added to H-Arg(Pbf)-Wang resin (250 mg, 0.67 mmol/g). 
The resin was mixed in solution for 2 h and then the solution was drained, and the 
resin was washed with DMF (3 × 5 mL), MeOH (3 × 5 mL) and DCM (3 × 5 mL), 
and dried in vacuo.  
 
Cleavage of Wang-resin. The resin was cleaved with 95% TFA: 2.5% TIPS: 
2.5% H2O (5 mL) for 1 hour and the resin was filtered off and the cleavage solution 
was evaporated under N2. The residue was re-dissolved in ACN/H2O and purified by 
semipreparative HPLC (0–100% B for 15 min) to give compound 231 (10 mg, 10%). 
Rt = 10.1 min (0–100% B 15 min gradient plus 100% B for 10 min); HRMS: [MH]+ 
412.2343 (calc. for C22H30N5O3+) 412.2342 (found); 1H NMR (600 MHz, DMSO-d6), 
δ 1.44–1.51 (m, 2 H), 1.54–1.62 (m, 1 H), 1.70–1.77 (m, 1 H), 3.08 (q, 1 H, J = 6.9 
Hz), 3.70–3.78 (m, 4 H), 4.19–4.25 (m, 1 H), 4.42 (t, 1 H, J = 7.6 Hz), 7.22–7.27 (m, 
2 H), 7.29–7.37 (m, 9 H), 7.76 (t, 1 H, J = 6.0 Hz), 8.80 (d, 1 H, J = 7.52 & br s).  
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5.5.6 Synthetic procedures for compound 234 
 
Scheme 5.6 Synthesis of compound 234 
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Reagents and conditions: a) KOtBu, THF, 0°CRT; b) DIPEA, EtOH, microwave 
100°C, 60 min; c) NaOH, H2O, EtOH; d) H-Arg-OEt, BOP, DIPEA, DMF; e) NaOH, 
H2O, EtOH, 5 min.  
 
Synthesis of ethyl 2-chloro-3-oxopropanoate (36). Potassium tert-butoxide 
(1.13 g, 10.1 mmol) in anhydrous THF (10 mL) was stirred at 0°C under N2. To this 
cooled solution, a mixture of solution of ethyl chloroacetate (34, 1.11 mL, 10.1 mmol) 
and ethyl formate (35, 0.81 mL, 10.1 mmol) in anhydrous THF (4 mL) was added 
dropwise at 0°C over 30 min. After addition, the reaction mixture was stirred at 0°C 
for 2 h and then warmed to room temperature and stirred overnight. After stirring 
overnight, H2O (10 mL) was added to the reaction mixture and extracted with diethyl 
ether (2 × 15 mL). The aqueous layer was acidified to pH 4–5 with 2 M HCl solution 
and then extracted with ether (3 × 25 mL). All organic phases were combined, dried 
over MgSO4, filtered and evaporated to dryness in vacuo. The crude product 36 (ESI-
MS: m/z 151.1 [MH]+) was used immediately for the next reaction without 
purification.  
 
Synthesis of thiazole 38. Ethyl 2-chloro-3-oxopropanoate (36, 135 mg, 0.89 
mmol) and 2,2-diphenylethanethioamide (37, 102 mg, 0.45 mmol) were dissolved in 
EtOH (4 mL) and then DIPEA (78 µL, 0.45 mmol) was added. The reaction mixture 
was heated in microwave at 100°C for an hour and then evaporated to dryness in 
vacuo. The residue was re-dissolved in ACN/H2O and purified by preparative HPLC 
to yield 20 mg of 38 (14%). Rt = 16.4 min (20–100% B 15 min gradient plus 100 % B 
for 10 min); HRMS: [MH]+ 324.1053 (calc. for C19H18N1O2S+) 324.1053 (found); 1H 
NMR (600 MHz, CDCl3), δ 1.34 (t, 3 H, J = 7.1 Hz), 4.33 (q, 2 H, J = 6.9 Hz), 5.82 
(s, 1 H), 7.24–7.36 (m, 10 H), 8.36 (s, 1 H).  
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Ester hydrolysis of 38. Standard ester hydrolysis procedures (section 5.5.3). The 
thiazole 38 (20 mg) was dissolved in EtOH/H2O/2M NaOH (4:1:1, 0.6 mL). The 
resulting crude product (ESI-MS: m/z 296.2 [MH]+) from this reaction was used for 
the next step without further purification. 
 
Coupling for H-Arg-OEt and ester hydrolysis. To synthesise compound 234, 
the thiazole acid (30 mg, 0.10 mmol) was coupled to H-Arg-OEt (as described in 
section 5.5.2). The crude product was purified by semipreparative HPLC (20–100B 
for 15 min).  HRMS: [MH]+ 480.2064 (calc. for C25H30N5O3S+) 480.2065 (found); Rt 
= 10.7 min (20–100% B 15 min gradient). The purified compound was treated with 
NaOH solution (as described in section 5.5.3) to hydrolyse the ethyl ester group. The 
residue was re-dissolved in ACN/H2O and purified by semipreparative HPLC (20–
100B for 15 min) to give compound 234 (3 mg, 12%). Rt = 9.4 min (20–100% B 15 
min gradient); HRMS: [MH]+ 452.1751 (calc. for C23H26N5O3S+) 452.1751 (found); 
1H NMR (600 MHz, DMSO-d6), δ 1.49–1.59 (m, 2 H), 1.67–1.73 (m, 1 H), 1.82–1.88 
(m, 1 H), 3.08–3.15 (m, 2 H), 4.32–4.35 (m, 1 H), 6.00 (s, 1 H), 7.29–7.37 (m, 10 H), 
7.61 (t, 1 H, J = 5.5 Hz), 8.43 (s, 1 H), 8.84 (d, 1 H, J = 7.8 Hz).  
 
5.5.7 Synthetic procedures for compound 241 
 
Scheme 5.7 Synthesis of compound 241  
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Reagents and conditions: a) NH2OH.HCl, K2CO3, EtOH, 90°C; b) (i) EtOH, Δ; (ii) 
diphenylether, microwave 180°C, 15 min; c) NaOH, H2O, EtOH, 100°C; d) H-Arg-
OEt, BOP, DIPEA, DMF; e) NaOH, H2O, EtOH.  
 
Synthesis of N-hydroxy-2,2-diphenylacetimidamide (40).36 A solution of 
diphenylacetonitrile (39, 5.01 g, 26.0 mmol), hydroxylamine hydrochloride (3.10 g, 
45.0 mmol) and K2CO3 (4.97 g, 36.0 mmol) in EtOH (100 mL) was refluxed 
overnight. The reaction mixture was filtered and the filtrate was evaporated to dryness 
in vacuo. The crude product was purified by flash column chromatography (SiO2, 
50% EtOAc in petroleum ether, Rf product 0.3) to yield product as a white solid (3.2 
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g, 54%). Rt = 6.8 min (20–100% B in 10 min gradient); ESI-MS: m/z 227.2 [MH]+; 
1H NMR (600 MHz, CDCl3), δ 4.55 (s, 2 H), 4.94 (s, 1 H), 7.25–7.27 (m, 6 H), 7.31–
7.33 (m, 4 H), 7.65 (br s, 1 H). 
  
Synthesis of 41. The purified compound 40 (2.01 g, 8.91 mmol) together with 
ethyl propiolate (1.0 mL, 9.80 mmol) in EtOH (40 mL) was refluxed overnight. The 
reaction mixture was evaporated to dryness and then re-dissolved in diphenylether (6 
mL). The mixture was transferred to a microwave reactor and heated up to 180°C in 
microwave for 15 min. After that, the reaction mixture was loaded on silica flash 
column for purification (50% EtOAc in petroleum ether, Rf product 0.4) to yield 
product (41) as a brownish yellow solid (0.7 g, 26%). Rt = 8.0 min (20–100% B 10 
min gradient); ESI-MS: m/z 307.2 [MH]+; 1H NMR (600 MHz, CDCl3), 2:1 ratio of 
tautomers, δ 1.33–1.38 (m, 3 H), 4.30 & 4.37 (2 sets of q, 2 H, J = 7.2 Hz), 5.65 & 
5.76 (2 sets of s, 1 H), 7.11 & 7.16 (2 sets of d, 2 H, J = 7.2 Hz), 7.27–7.35 (m, 10 H), 
7.62 & 7.68 (2 sets of s, 1 H).  
Reaction conditions listed below were also tried for this synthesis step but none 
were successful: 
Intermediate 
40 (eq.) 
ethyl 
propiolate 
(eq.) 
Solvent 
Reaction 
Temperature 
(°C) 
Yield (%) & 
comments 
1.0 1.1 EtOH 25 0, reaction did not progress 
1.0 1.1 EtOH 100 (in microwave) 
0, produced 
unknown side 
products 
 
Ester hydrolysis of compound 41. Compound 41 (150 mg, 0.50 mmol) obtained 
from previous step was dissolved in EtOH/H2O/2M NaOH (4:1:1, 6 mL) and refluxed 
until reaction went to completion. It was noted that base hydrolysis of imidazole ester 
was very slow at room temperature. Therefore the reaction was heated at high 
temperature. The EtOH in the reaction was evaporated in vacuo and the aqueous 
solution was acidified with 2 M HCl (2 mL) and extracted with EtOAc (3 × 5 mL). 
The organic extract was dried over MgSO4, filtered and evaporated to dryness in 
vacuo. The crude product (ESI-MS: m/z 279.2 [MH]+, Rt = 7.1 min (20–100% B 10 
min gradient) was used for the next step without further purification.  
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Coupling for H-Arg-OEt and ester hydrolysis. To synthesise compound 241, 
the imidazole acid (128 mg, 0.46 mmol) was coupled to H-Arg-OEt (as described in 
section 5.5.2) followed by ester hydrolysis (section 5.5.3). The residue was re-
dissolved in ACN/H2O and purified by semipreparative HPLC to give compound 241 
(20 mg, 10%). Rt = 9.3 min (0–100% B 15 min gradient); HRMS: [MH]+ 435.2139 
(calc. for C23H27N6O3+) 435.2139 (found); 1H NMR (600 MHz, DMSO-d6), δ 1.47–
1.55 (m, 2 H), 1.68–1.76 (m, 1 H), 1.81–1.88 (m, 1 H), 3.06–3.14 (m, 2 H), 4.36–4.41 
(m, 2 H), 5.78 (s, 1 H), 7.24–7.29 (m, 7 H), 7.33–7.36 (m, 5 H), 7.68–7.70 (t, 1 H, J = 
5.3 Hz), 7.88 (s, 1 H), 8.35 (br s, 1 H).  
 
5.5.8 Synthetic procedures for compound 249 
 
Scheme 5.8 Synthesis of compound 249 
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Reagents and conditions: a) (i) NaNO2, AcOH/H2O; (ii) H2,10% Pd/C, EtOH, 15 psi; 
b) Cbz-L-Leu-OH/Boc-L-Leu-OH, HBTU, DIPEA, DMF; c) NH4OAc, AcOH, 
microwave 150°C, 30 min; d) H2, 10% Pd/C, MeOH, 40 psi; e) N-Boc-indole-3-
carboxylic acid, HBTU, DIPEA, DMF; f) NaOH, H2O, EtOH, 100°C; g) H-Arg-OEt, 
HBTU, DIPEA, DMF; h) NaOH, H2O, EtOH.  
 
Synthesis of ethyl 2-amino-3-oxobutanoate hydrochloride (43). A solution of 
NaNO2 (1.40 g, 20.0 mmol) in H2O (3 mL) was added dropwisely to a mixture of 
ethyl acetoacetate (42, 2 mL, 15.4 mmol) in glacial AcOH (3 mL) at room 
temperature. The reaction mixture was stirred for 1 h, then H2O (11 mL) was added 
and stirred for 2 h. The reaction mixture was then extracted with Et2O (3 × 15 mL). 
The combined organic extracts were washed with H2O (1 × 20 mL), sat. NaHCO3 (1 
× 20 mL) and brine (1 × 20 mL). The organic phase was dried over MgSO4, filtered 
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and evaporated to dryness in vacuo to give 2.4 g of yellow oil. This was dissolved in 
EtOH (25 mL) and to this solution, acetyl chloride (1.5 mL) was added dropwise. 
After that, the reaction mixture was diluted with 15 mL EtOH and then 10% Pd/C (50 
mg) was added. The mixture was hydrogenated at 15 psi for 3 h. The Pd/C catalyst 
was removed by filtering the mixture through celite and the filtrate was evaporated to 
dryness to give product (43) as a yellow syrup. ESI-MS: m/z 146.1 [MH]+. It was 
used for the next step without purification. 
 
Synthesis of 44. Boc- (1.02 g, 4.09 mmol, 1.2 eq.) or Cbz-protected L-leucine 
amino acid (1.20 g, 4.51 mmol, 1.2 eq.) was first activated with HBTU (1.2 eq.) and 
DIPEA (1.2 eq.) for 15 min in DMF (18 mL). After that, the ethyl 2-amino-3-
oxobutanoate hydrochloride (43, 1 eq.) was added and the reaction mixture was 
stirred at RT for 2 h. The reaction mixture was concentrated in vacuo and the residue 
was dissolved in EtOAc (20 mL) and washed with sat. NaHCO3 (3 × 20 mL). The 
combined organic extracts were dried over MgSO4, filtered and evaporated to dryness 
in vacuo. The crude product was purified by flash column chromatography (SiO2, 
30% EtOAc in petroleum ether, Rf product 0.2) to give product (44) as a yellow syrup  
Compound 44 (with Boc group), ESI-MS: m/z 359.2 [MH]+, Rt = 9.51 min (20–100% 
B in 10 min gradient). Compound 44 (with Cbz group), ESI-MS: m/z 393.2 [MH]+, Rt 
= 9.51 min (20–100% B in 10 min gradient). These compounds were ~70% pure by 
LCMS.  
 
Synthesis of compound 45 (R = Cbz). The product (44, 0.5 g, 1.27 mmol) from 
step (b) was treated with a large excess of NH4OAc (0.98 g, 12.7 mmol) in AcOH (5 
mL) and microwave heated at 150°C for 30 min. Reaction using the Boc-protected 
starting material failed with the formation of unknown products. After 30 min, the 
Cbz compound reaction mixture was diluted with EtOAc (35 mL) and washed with a 
mixture of H2O/28% aq. NH3 solution (4:1, 30 mL) once and brine (1 × 30 mL). The 
organic phase was dried over MgSO4, filtered and evaporated to dryness in vacuo. 
The crude product was purified by flash column chromatography (SiO2, 50% EtOAc 
in petroleum ether, Rf product 0.4) to give 0.24 g of product (51%). Rt = 8.0 min (20–
100% B 10 min gradient); ESI-MS: m/z 374.1 [MH]+; 1H NMR (600 MHz, CDCl3), 
2:1 ratio of tautomers, δ 0.80–0.82 (m, 3 H), 0.87–0.88 (m, 3 H), 1.34–1.37 (m, 3 H), 
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1.50–1.57 (m, 1 H), 1.66–1.70 (m, 1 H), 1.97–2.01 (m, 1 H), 2.56 (s, 3 H), 4.30–4.38 
(m, 2 H), 5.04–5.07 (m, 1 H), 5.12–5.16 (m, 2 H), 7.24–7.30 (m, 5 H), 8.51 (t, 1 H, J 
= 8.3 Hz).   
 
Cbz deprotection. The product from above (45, 0.24 g, 0.60 mmol) was 
dissolved in MeOH (20 mL), treated with 10% Pd/C (30 mg) and hydrogenated at 40 
psi for 5 h. The Pd/C catalyst was removed by filtering the mixture through celite and 
the filtrate was evaporated to dryness in vacuo. The crude product (ESI-MS: m/z 
240.1 [MH]+) was used for the next step without further purification. 
 
Synthesis of compound 46. The amine from step (d) (170 mg, 0.71 mmol) was 
added to the pre-activated N-Boc-indole-3-carboxylic acid (222 mg, 0.85 mmol;  
activated by HBTU (0.85 mmol), DIPEA (0.85 mmol)) and stirred overnight at RT. 
The reaction mixture was diluted with EtOAc (5 mL) and washed with sat. NaHCO3 
(2 × 3 mL). The combined organic extracts were dried over MgSO4, filtered and 
evaporated to dryness in vacuo. The crude product (ESI-MS: m/z 482.3 [MH]+) was 
used for the next step without further purification. 
 
Ester hydrolysis of 46. The intermediate 46 (0.17 g, 0.70 mmol) obtained from 
the previous step was dissolved in EtOH/H2O/2M NaOH (4:1:1, 12 mL) and refluxed 
until the reaction went to completion. The EtOH in the reaction was evaporated in 
vacuo and the aqueous solution was acidified with 2 M HCl (4 mL) and extracted 
with EtOAc (3 × 5 mL). The combined organic extracts were dried over MgSO4, 
filtered and evaporated to dryness in vacuo. Note: The Boc group on the indole ring 
was removed under this basic condition. The crude product (ESI-MS: m/z 355.2 
[MH]+) was used for the next step without further purification. 
 
Coupling for H-Arg-OEt and ester hydrolysis. The acid (124 mg, 0.35 mmol) 
from step (f) in DMF (0.7 mL) was activated with HBTU (133 mg, 0.35 mmol) and 
DIPEA (61 µL, 0.35 mmol) for 10 min before the addition of H-Arg-OEt.2HCl (80 
mg, 0.29 mmol) and DIPEA (122 µL, 0.70 mmol). The reaction mixture was stirred at 
RT. Upon completion, the reaction mixture was diluted with EtOAc (5 mL) and 
washed with sat. NaHCO3 (2 × 4 mL). The organic extract was dried over MgSO4, 
filtered and evaporated in vacuo to dryness. The crude product was purified by 
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semipreparative HPLC (Rt = 8.3 min, 0–100% B 10 min gradient). The product was 
then dissolved in EtOH/H2O/2M NaOH (4:1:1, 3 mL) and stirred for 5 min then the 
reaction mixture was neutralised with 2 M HCl and evaporated in vacuo to remove 
the organic solvent. The residue was re-dissolved in ACN/H2O and purified by 
semipreparative HPLC to give compound 249 (30 mg, 20%). Rt = 7.9 min (0–100% 
B 10 min gradient); HRMS: [MH]+ 511.2776 (calc. for C25H35N8O4+) 511.2774 
(found); 1H NMR (600 MHz, DMSO-d6), δ 0.94 (dd, 6 H, J = 6.6, 15.5 Hz), 1.49–
1.56 (m, 2 H), 1.63–1.80 (m, 3 H), 1.82–1.96 (m, 2 H), 2.43 (s, 3 H), 3.08–3.17 (m, 2 
H), 4.39–4.44 (m, 1 H), 5.24–5.29 (m, 1 H), 7.10 (t, 1 H, J = 7.6 Hz), 7.15 (t, 1 H, J = 
7.8 Hz), 7.43 (d, 1 H, J = 7.7 Hz), 7.59 (br s, 1 H), 8.02 (br s, 1 H), 8.11 (d, 1 H, J = 
7.7 Hz), 8.17 (t, 1 H, J = 3.0 Hz), 8.25 (br s, 1 H).  
 
5.5.9 Characterization data for C3aR heterocylic compounds. 
 
The following compounds were synthesised by Dr. Robert Reid (University of 
Queensland). 
 
General structure: 
X
ZY H
N
O COOH
N
H
NH
NH2
 
 
Compound X Y Z Analytical data 
232 BR88 O CH CH Rt = 11.8 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 435.2027 (calc. for C24H27N4O4+) 435.2025 
(found). 1H NMR (600 MHz, DMSO-d6), δ 1.43-
1.57 (m, 2 H), 1.71 (m, 1 H), 1.84 (m, 1 H), 3.04-
3.14 (m, 2 H), 4.33 (m, 1 H), 5.65 (s, 1 H), 6.15 (d, 
1 H, J = 3.4 Hz), 7.18 (d, 1 H, J = 3.4 Hz), 7.21-
7.28 (m, 6 H), 7.34 (t, 4 H, J =7.6 Hz), 7.51 (t, 1 H, 
J = 5.6 Hz), 8.41 (d, 1 H, J = 8.0 Hz).  
233 BR111 S CH CH Rt = 10.7 min (0–100% B 15 min gradient); HRMS:  
[MH]+ 451.1798 (calc. for C24H27N4O3S+) 451.1798 
(found); 1H NMR (600 MHz, DMSO-d6), δ 1.46-
1.61 (m, 2 H, Arg-γ-CH2), 1.70 (m, 1 H, Arg-β-
CH), 1.85 (m, 1 H, Arg-β-CH), 3.04-3.16 (m, 2 H, 
Arg-δ-CH2), 4.32 (m, 1 H, Arg-α-CH), 5.83 (s, 1 H, 
Ph2CH), 6.79 (dd, 1 H, J = 0.8, 3.8 Hz, thiophene-
CH), 7.22-7.37 (m, 10 H, Ar-CH), 7.58 (t, 1 H, J = 
5.5 Hz, guanidine-NH), 7.73 (d, 1 H, J = 3.8 Hz, 
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thiophene-CH), 8.60 (d, 1 H, J = 8.0 Hz, Arg-α-
NH). 13C NMR (150 MHz, DMSO-d6): δ 25.4, 27.7, 
40.3, 51.2, 51.9, 126.9, 128.5, 128.6, 137.8, 143.2, 
153.0, 156.7, 161.2, 173.4.   
235 BR112 N O C-
Me 
Rt = 11.9 min (0–100% B 15 min gradient; HRMS: 
[MH]+  450.2136 (calc. for C24H28N5O4+) 450.2136 
(found); 1H NMR (600 MHz, DMSO-d6): δ 1.44-
1.54 (m, 2 H), 1.77 (m, 1 H), 1.86 (m, 1 H), 2.54 (s, 
3 H), 3.10 (m, 1 H), 4.38 (m, 1 H), 5.79 (s, 1 H), 
7.39-7.55 (m, 10 H), 7.59 (t, 1 H, J = 5.6 Hz), 8.02 
(d, 1 H, J = 8.1 Hz).  
236 BR90 O N C-
Me 
Rt = 11.5 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 450.2136 (calc. for C24H28N5O4+) 450.2132 
(found); 1H NMR (600 MHz, DMSO-d6): δ 1.40-
1.56 (m, 2 H), 1.74 (m, 1 H), 1.85 (m, 1 H), 2.36 (s, 
3 H), 3.04-3.13 (m, 2 H), 4.33 (m, 1 H), 5.75 (s, 1 
H), 7.20-7.39 (m, 13 H), 7.52 (t, 1 H, J = 5.6 Hz), 
8.46 (d, 1 H, J = 8.0 Hz). 
237 BR101 N O N Rt = 11.7 min (0–100% B 15 min gradient); HRMS:  
[MH]+ 437.1932 (calc. for C22H25N6O4+) 437.1934 
(found); 1H NMR (600 MHz, DMSO-d6): δ 1.47-
1.58 (m, 2 H), 1.77 (m, 1 H), 1.88 (m, 1 H), 3.05-
3.14 (m, 2 H), 4.38 (m, 1 H), 6.19 (s, 1 H), 7.29-
7.42 (m, 10 H), 7.58 (t, 1 H, J = 5.6 Hz), 9.19 (d, 1 
H, J = 7.9 Hz). HRMS:  [MH]+ 437.1932 (calc. for 
C22H25N6O4+) 437.1934 (found).  
238 BR105 O N N Rt = 11.4 min (0–100% B 15 min gradient); HRMS:  
[MH]+ 437.1932 (calc. for C22H25N6O4+) 437.1932 
(found); 1H NMR (600 MHz, DMSO-d6): δ 1.46-
1.60 (m, 2 H), 1.79 (m, 1 H), 1.88 (m, 1 H), 3.05-
3.14 (m, 2 H), 4.35 (m, 1 H), 6.08 (s, 1 H), 7.28-
7.41 (m, 11 H), 7.61 (t, 1 H, J = 5.6 Hz), 9.53 (d, 1 
H, J = 7.8 Hz).  
239 BR87 N O CH Rt = 11.5 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 436.1979 (calc. for C23H26N5O4+) 436.1979 
(found); 1H NMR (600 MHz, DMSO-d6): δ 1.44-
1.55 (m, 2 H), 1.77 (m, 1 H), 1.86 (m, 1 H), 3.04-
3.14 (m, 2 H), 4.39 (m, 1 H), 5.87 (s, 1 H), 7.26-
7.40 (m, 10 H), 7.51 (t, 1 H, J = 5.6 Hz), 8.25 (d, 1 
H, J = 8.1 Hz), 8.64 (s, 1 H).  
240 BR104 N N O Rt = 11.8 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 437.1932 (calc. for C22H25N6O4+) 437.1932 
(found); 1H NMR (600 MHz, DMSO-d6): δ 1.46-
1.59 (m, 2 H), 1.78 (m, 1 H), 1.89 (m, 1 H), 3.04-
3.15 (m, 2 H), 4.37 (m, 1 H), 5.88 (s, 1 H), 7.26-
7.31 (m, 2 H), 7.33-7.38 (m, 8 H), 7.61 (t, 1 H, J = 
5.6 Hz), 9.62 (d, 1 H, J = 7.9 Hz). 
242 BR103 N NH C-
Me 
Rt = 9.5 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 449.2296 (calc. for C24H29N6O3+) 449.2295 
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(found); 1H NMR (600 MHz, DMSO-d6), δ 1.48–
1.53 (m, 2 H, Arg-γ-CH2), 1.69–1.76 (m, 1 H, Arg-
β-CH), 1.81–1.87 (m, 1 H, Arg-β-CH), 2.41 (s, 3 H, 
imidazole-5-CH3), 3.06–3.15 (m, 2 H, Arg-δ-CH2), 
4.37–4.41 (m, 1 H, Arg-α-CH), 5.65 (s, 1 H, 
Ph2CH), 7.26–7.28 (m, 6 H, Ar-CH), 7.33–7.36 (m, 
4 H, Ar-CH), 7.61 (t, 1 H, J = 5.6 Hz, guanidine-
NH), 7.84 (d, 1 H, J = 7.8 Hz, Arg-α-NH).  
243 BR09 N-
Me 
N C-
Me 
Rt = 9.8 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 463.2452 (calc. for C25H31N6O3+) 463.2447 
(found); 1H NMR (600 MHz, DMSO-d6), δ 1.54–
1.59 (m, 2 H, Arg-γ-CH2), 1.67–1.73 (m, 1 H, Arg-
β-CH), 1.82–1.88 (m, 1 H, Arg-β-CH), 2.31 (s, 3 H, 
imidazole-5-CH3), 3.08–3.16 (m, 2 H, Arg-δ-CH2), 
3.60 (s, 3 H, imidazole-N-CH3), 4.32–4.36 (m, 1 H, 
Arg-α-CH), 6.07 (s, 1 H, Ph2CH), 7.23 (d, 4 H, J = 
7.8 Hz, Ar-CH), 7.30–7.35 (m, 2 H, Ar-CH), 7.37–
7.40 (m, 4 H, Ar-CH), 7.70–7.73 (m, 1 H, Arg-α-
NH). 
244 BR10 N N-
Me 
C-
Me 
Rt = 10.3 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 463.2452 (calc. for C25H31N6O3+) 463.2447 
(found); 1H NMR (600 MHz, DMSO-d6), δ 1.45–
1.50 (m, 2 H, Arg-γ-CH2), 1.68–1.74 (m, 1 H, Arg-
β-CH), 1.81–1.87 (m, 1 H, Arg-β-CH), 2.45 (s, 3 H, 
imidazole-5-CH3), 3.06–3.15 (m, 2 H, Arg-δ-CH2), 
3.39 (s, 3 H, imidazole-N-CH3), 4.37–4.41 (m, 1 H, 
Arg-α-CH), 5.79 (s, 1 H, Ph2CH), 7.22–7.26 (m, 2 
H, Ar-CH), 7.29–7.33 (m, 8 H, Ar-CH), 7.37–7.40 
(m, 4 H, Ar-CH), 7.70–7.73 (m, 1 H, Arg-α-NH). 
13C NMR (150 MHz, DMSO-d6), δ 9.5 (imidazole-
5-CH3), 25.2 (Arg-γ-CH2), 28.8 (Arg-β-CH2), 30.2 
(imidazole-N-CH3), 40.3 (Arg-δ-CH2), 47.5 
(Ph2CH), 50.8 (Arg-α-CH), 126.7 (Ar-CH), 128.29 
(imidazole-5-C), 128.36 (Ar-CH), 128.7 (Ar-CH), 
128.8 (Ar-CH), 132.9 (imidazole-1-C-CO), 141.0 
(Ar-C), 141.1 (Ar-C), 146.7 (imidazole-3-C-CH), 
156.6 (guanidine-C), 162.9 (HNCO), 173.4 
(COOH). 
245 BR91 S N C-
Me 
Rt = 11.6 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 466.1907 (calc. for C24H28N5O3S+) 466.1907 
(found); 1H NMR (600 MHz, DMSO-d6): δ 1.44-
1.57 (m, 2 H), 1.67 (m, 1 H), 1.81 (m, 1 H), 2.52 (s, 
3 H), 3.04-3.13 (m, 2 H), 4.29 (m, 1 H), 5.94 (s, 1 
H), 7.26-7.39 (m, 10 H), 7.52 (t, 1 H, J = 5.6 Hz), 
8.41 (d, 1 H, J = 7.8 Hz).  
246 BR110 N NH C-
Ph 
Rt = 10.8 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 511.2452 (calc. for C29H31N6O3+) 511.2453 
(found); 1H NMR (600 MHz, DMSO-d6): δ 1.46-
1.55 (m, 2 H), 1.74 (m, 1 H), 1.85 (m, 1 H), 3.17-
3.05 (m, 2 H), 4.38 (m, 1 H), 5.64 (s, 11 H), 7.26 
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(m, 2 H), 7.34 (m, 5 H), 7.40 (m, 6 H), 7.55 (t, 1 H, 
J = 5.6 Hz), 7.78 (d, 2 H, J = 7.8 Hz), 7.98 (d, 1 H, 
J = 7.9 Hz).   
247 BR108 S N C-
Ph 
Rt = 12.7 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 528.2064 (calc. for C29H30N5O3S+) 528.2065 
(found); 1H NMR (600 MHz, DMSO-d6): δ 1.40-
1.50 (m, 2 H), 1.60 (m, 1 H), 1.76 (m, 1 H), 3.01-
3.11 (m, 2 H), 4.25 (m, 1 H), 6.05 (s, 1 H), 7.27-
7.32 (m, 2 H), 7.34-7.41 (m, 11 H), 7.55 (t, 1 H, J = 
5.6 Hz), 7.75 (m, 2H), 8.82 (d, 1 H, J = 7.5 Hz). 
248 BR109 O N C-
Ph 
Rt = 12.9 min (0–100% B 15 min gradient); HRMS: 
[MH]+ 512.2292 (calc. for C29H30N5O4+) 512.2292 
(found); 1H NMR (600 MHz, DMSO-d6): δ 1.47-
1.58 (m, 2 H), 1.76 (m, 1 H), 1.88 (m, 1 H), 3.06-
3.14 (m, 2 H), 4.36 (m, 1 H), 5.85 (s, 1 H), 7.27-
7.33 (m, 2 H), 7.35-7.51 (m, 12 H), 7.57 (1 H, t, J = 
5.6 Hz), 8.11 (m, 2 H), 8.69 (d, 1 H, J = 7.7 Hz). 
 
5.5.10 Isolation of human monocyte derived macrophages (HMDM) 
 
Human monocyte derived macrophages (HMDM) were isolated using Ficoll-
paque density centrifugation (GE healthcare Bio-Science, Uppsala, Sweden) from 
buffy coat of anonymous human donors provided by Australian Red Cross Blood 
Service, Brisbane. CD14+ monocytes were positively selected using CD14+ MACS 
magnetic beads (Miltenyi Biotech, Auburn, CA, USA) after successive magnetic 
sorting and washings. The CD14+ monocytes were then cultured at 37°C, with 5% 
CO2 and differentiated to HMDM using 100 ng/mL of recombinant human 
macrophage colony stimulating factor (M-CSF) (PeptroTech Inc, Rocky Hill, New 
Jersey, USA) at 1.5 × 106 cells/mL. HMDM were kept in IMDM supplemented with 
10% FBS, penicillin (10 U/mL), streptomycin (10 U/mL) and L-glutamine (2 mM) 
(Invitrogen). HMDM were supplemented after 5 days with fresh medium containing 
100 ng/mL M-CSF. HMDM were harvested by gentle scraping in saline solution on 
day 7. 
 
5.5.11 Intracellular calcium release assay  
 
Assay Protocol. HMDM were plated at 5 × 104 cells/well in a 96-well cleared-
bottom black-wall assay plate (Corning) kept in IMDM supplemented with 10% FBS, 
penicillin (10 U/mL), streptomycin (10 U/mL) and L-glutamine (2 mM) (Invitrogen) 
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and incubated overnight at 37oC. Before assay, the medium was removed and cells 
were incubated with dye-loading buffer (12 mL assay buffer, 4 µM Fluo-3 AM, 25 µL 
Pluronic acid F-127 and 1% FBS) for an hour at 37oC. After an hour, cells were 
washed once with the same assay buffer (HBSS supplemented with 2.5 mM 
probenecid and 20 mM HEPES, pH 7.4).  
 
Sample Preparation. Stock solutions of compounds were prepared by dissolving 
the compound in DMSO solution to give a 10 mM stock solution. The 10 mM stock 
solutions were then diluted with assay buffer (described in assay protocol) to give the 
concentrations required for the assay.  
 
Concentration Dependent Inhibition Assay. A range of concentrations of the 
compound (50 µL) was pre-incubated with the cells for 30 min prior to the addition of 
agonist C3a (50 µL, 100 nM). After addition of agonist, the intracellular release of 
Ca2+ was monitored on fluorescence plate reader (FLIPRTETRA) at least 60 s 
(excitation 495 nm, emission 520 nm). Duplicate measurements were made for each 
data point, mean ± SEM were reported from multiple experiments as indicated. 
Changes in fluorescence (% response) were plotted against logarithmic compound 
concentrations. The half maximal inhibitory concentration (IC50) values were derived 
from the concentration response curve using a nonlinear regression curve in Graphpad 
Prism v5. 
 
Concentration Dependent Response Curves. A range of concentrations of the 
compound (50 µL) was added to the cells containing 50 µL assay buffer. The 
intracellular Ca2+ release was monitored for at least 60 s (excitation 495 nm, emission 
520 nm) immediately after the injection of the desired concentration of the 
synthesised compounds. Duplicate measurements were made for each data point, 
mean ± SEM were reported from multiple experiments as indicated. Changes in 
fluorescence (% response) were plotted against logarithmic compound concentrations. 
The half maximal effective concentration (EC50) values were derived from the 
concentration response curve using a nonlinear regression curve in Graphpad Prism 
v5. 
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5.5.12 125I-C3a radioligand binding assay 
 
Receptor binding was performed by ligand competition with 80 pM [125I]-C3a 
(2200 Ci/mmol; Perkin Elmer, Torrance, CA, USA), HMDM (1.2 × 106 cells/mL), 80 
pM [125I]-C3a with/without various concentrations of unlabeled C3a or C3a non-
peptidic agonist/antagonist, were mixed with Tris buffer (50 mM Tris, 3 mM MgCl2, 
0.1 mM CaCl2, 0.5% (w/v) bovine serum albumin, pH 7.4) for 60 min in a 96-well 
Nunc round bottom plate at room temperature. Unbound [125I]-C3a was removed by 
filtration through glass microfiber filter GF/B (Whatman Iner. Ltd, England) which 
had been soaked in 0.6% polyethyleneimine to reduce non-specific binding. The filter 
was washed 3 times with cold buffer (50 mM Tris-HCl) pH 7.4 and bound [125I]-C3a 
was assessed by scintillation counting on Microbeta counter. Specific [125I]-C3a 
binding was defined as the difference between total binding and non-specific binding 
as determined in the presence of 1 µM unlabeled C3a. The IC50 value was derived 
from the concentration of agonist/antagonist required to inhibit 50% of [125I]-C3a 
binding. 
 
5.5.13 Experimental determination of LogD 
 
Test compound (10 µL, 10 mM stock in DMSO) was added to a 10 mM 
phosphate buffer solution (0.5 mL, pH 7.4) and then 1-octanol (0.5 mL) was added. 
The mixture was vortexed for 5 minutes followed by centrifugation. The organic and 
aqueous layers were separated and dried in a rotational-vacuum-concentrator (Beta-
RVC CMC-2, Christ). The residues were re-dissoved in ACN/H2O (1:1, 100 µL) and 
the UV absorbance of the organic and aqueous layers were measured on analytical 
HPLC (UV 214, 230 and 254 nm). The logD values were calculated as follows: 
 
log D = log (A / B) ; A = integrated signal area in octanol phase 
           B = integrated signal area in aqueous phase 
Note: Compound in solid form was analysed in the same way and the measured logD 
was comparable to the one obtained from compound in DMSO stock. This confirmed 
that the partition coefficients were not affected by the trace amount (1%) of DMSO 
solution. 
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5.5.14 Calculations of H-bond interaction energy using Gaussian software 
 
The geometry of the water-heterocycle hydrogen bonded complex was optimised 
at the MP2/6-311++G(3d,3p) level using Gaussian 09. The H-bond interaction energy 
was the difference in energy of the complex from the sum of energies of water and 
heterocycle calculated in isolation by the same method.23  
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6.1 Abstract 
 
Removal of the C-terminal arginine residue from C3a has been reported to 
abolish agonist potency. The basic arginine group is also known to contribute to a 
poor pharmacokinetic profile. Therefore replacing the guanidine group with less basic 
moieties or replacing the carboxylate group with carboxylic acid bioisosteres could 
lead to more drug-like compounds. In this chapter, we sought to replace the guanidine 
moiety with a variety of other less basic moieties, to replace the carboxylate group 
with carboxylic acid bioisosteres, and to investigate how these changes affected the 
function and binding affinity of the ligands. Compared to other mimetics assessed 
herein, the cyanoguanidine analogue showed the most promising results. However, 
the binding affinity for C3aR was reduced 8-fold relative to the parent arginine-
containing compound. In addition, the carboxylate group can be substituted with an 
N-phenylsulfonamide moiety, which mimics the acid but adds much needed 
hydrophobicity, without significant loss of binding affinity. Although none of the 
arginine mimetics reported herein was able to reproduce the antagonist or agonist 
potency contributed by the arginine group in C3aR ligands, it was shown that linear 
arginine mimetics were more tolerated than constrained mimetics. Future studies on 
optimisation of arginine mimetics are required to improve the pharmacokinetic 
profiles of current C3aR ligands, without reducing agonist/antagonist potency and 
binding affinity. 
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6.2 Introduction 
 
C3aR is expressed on various inflammatory cells such as monocytes, neutrophils, 
macrophages, T cells, mast cells and eosinophils 1-2 and it has been implicated as 
being important in a number of inflammatory disorders.3-6 Hence, development of 
potent and selective C3aR ligands would be valuable for investigating the roles of 
C3aR in vivo in a variety of inflammatory diseases.  
It has been demonstrated that the last 5 amino acid residues (LGLAR) at the C-
terminus of C3a were vital for binding to C3a receptor, especially the arginine 
residue.7 The C-terminal arginine residue (Arg77) of C3a was particularly important 
since cleavage of this basic residue by carboxypeptidase N to give C3a-desArg, 
completely abolished the activity of C3a.8-9 Site directed mutagenesis studies had 
suggested that the guanidine group on Arg77 of C3a may make a charge interaction 
with the carboxylate group of Asp417 (from helix 6), while the carboxylate group of 
Arg77 may interact with the guanidine group of both Arg161 and Arg340.10 
Both the carboxylate and guanidine groups on arginine were important for 
receptor recognition of C3a. Although ligands containing arginine presented good 
potency, the high pKa and low logD of the protonated guanidine moiety (pKa ~12) at 
physiological pH can lead to poor absorption through the gastro-intestinal tract, thus 
resulting in poor oral bioavailability.  
The aims of Chapter 6 were to replace the arginine group of potent C3aR ligands 
with less basic (pKa <12) side chains, to substitute the carboxylate group with 
carboxylic acid bioisosteres, and to investigate how these modifications affect the 
function and binding affinity of the ligands.  
 
6.3 Results and Discussion 
 
In order to facilitate the synthesis and allow evaluation of just the effects of 
various arginine mimetics, without complications introduced by structural changes to 
other parts of the molecule, all mimetics were attached to a common oxazole scaffold 
(Fig. 6.1) and the resulting compounds were assayed in comparison to a control 
compound called TR12 (228). TR12 (228) was a potent unpublished C3aR agonist 
developed in our research group (Tony Reed, Hons Thesis 2009), with an EC50 of 60 
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nM (in intracellular calcium release assays) and a binding affinity IC50 of 5 nM 
(competition with 125I-C3a, 80 pM) in human monocyte derived macrophages 
(HMDM).11  
N
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BocHN
H
N
O
O
OH
NH
NH2HN
TR12, 228
 
N
O
BocHN
O
OH
H2N R2
R1 N
O
BocHN
O
H
N R2
R1250  
Figure 6.1 Chemical structure of TR12 (228) and the synthesis of oxazole compounds 
containing different guanidine (R1) and carboxylate (R2) mimetics.  
 
The guanidino side chain of the arginine residue was to be substituted with 
various guanidine mimetics and the carboxylate group was to be replaced with 
carboxylic acid isosteres (Fig. 6.1), in order to improve the agonist or antagonist 
potency as well as the binding affinity of the ligand. When a good guanidine or 
carboxylate isostere was successfully developed, this mimetic could then be applied 
to other potent C3aR agonists and antagonists.  
The synthesised compounds were dissolved in DMSO to make stock solutions for 
assays to evaluate the function and binding affinity of the ligands for the C3aR 
receptor. The two biological assays conducted for this research were the calcium 
mobilisation assay and 125I-C3a radioligand binding assay using a primary immune 
cell type, human monocyte derived macrophages (HMDM).  
 
6.3.1 Constrained arginine mimetics 
 
Both benzamidines and benzamidoximes are common moieties for mimicking the 
guanidinoalkyl side chain of arginine. For example, these moieties had been 
successfully incorporated into potent orally bioavailable thrombin inhibitors, 
thrombin being a serine protease that cleaves peptides at a site C-terminal to arginine 
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residues.12-14 Therefore, benzamidines, benzamidoximes, phenyl guanidine and 4-
aminomethylphenylalanine were appended to the oxazole scaffold of TR12 (228) and 
the activities of the compounds were determined by intracellular calcium release and 
125I-C3a competitive binding assays using HMDM. These guanidine mimetics were 
conformationally constrained, possessed a less basic amine moiety and were more 
hydrophobic (higher logD than TR12). Compounds 251–253 were synthesised in 
solution phase by the coupling of Boc-Leu-oxazole carboxylic acid (250) with the 
appropriate arginine mimicking fragment.  
R3 = 
N
O
BocHN
O                               R4 = 
N
HN
O
 
 
 
O
OHR3HN
NHOH
NH
O
OHR3HN
NH2
NH
O
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O
OHR4HN
NH2
251 252 253 254  
 
Compound 254 had diphenylmethylimidazole (R4), rather than Boc-Leu-oxazole 
(R3) common to 251–253, to overcome synthetic difficulties caused by the protecting 
groups present on the commercially available reagents and was synthesised on solid 
phase. Due to the fact that the amino group of 4-aminomethylphenylalanine was 
protected with a Boc group, it was incompatible in the synthesis with the Boc-Leu-
oxazole (R3) scaffold, which also contained a Boc group. Therefore, the Boc group on 
4-aminomethylphenylalanine could not be selectively removed in the synthesis. As a 
result, the Boc protected 4-aminomethylphenylalanine was attached to Wang resin, 
then diphenylmethylimidazole carboxylic acid (R4) was coupled, followed by 
cleavage of the product from resin using TFA. The diphenylmethylimidazole group 
(R4) had also been shown to be a good moiety for C3aR agonist activity (Chapter 5).  
Compound 251 was a weak C3aR antagonist in calcium release assays with an IC50 of 
25 µM (Table 6.1, Fig. 6.2A) and it bound to C3aR with an IC50 of 76 nM (Table 6.1, 
Fig.6.2C). It had a notably negative logD value which was unfavourable for 
membrane permeability. The amidoxime analog (251), which was the least basic 
compound compared to 252–254 with a low pKa value (4.8),15-16 was the only 
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compound that showed some activity in both the functional and binding assays. 
Compounds 252 amidine and 253 guanidine have much higher pKa (12) than 251 and 
are positively charged under the assay conditions (pH 7.4). The loss in activity for 
compounds 252 and 253 suggested that having a positively charged group at the para 
position of the aromatic ring is not tolerated.  
 
Table 6.1 LogD values and biological activities of constrained arginine mimetics 
(251–254), as determined from calcium mobilisation assay and 125I-C3a competitive 
binding assay in HMDM.  
 
Compound LogD 
a 
Binding 
IC50 (nM) 
b 
Binding 
pIC50 ± 
SEM 
n Ca2+ IC50/ 
EC50 (µM) c 
n 
228 TR12 -0.05 5 8.3 ± 0.3 5 EC50 0.06  5 
242 BR103 0.15 10 8.0 ± 0.2 8 EC50 0.02  4 
251 AY095 -1.15 76 7.1 ± 0.3 3 IC50 25.0  2 
252 AY098 0.21 No binding No binding 2 EC50 >100 2 
253 AY042 0.35 No binding No binding 1 EC50 >100 1 
254 AY55 -0.09 No binding No binding 1 EC50 >100 1 
a logD values were determined experimentally at pH 7.4 (refer to section 6.5.9).  
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding in HMDM. 
c concentrations causing 50% inhibition/stimulation of calcium response in HMDM induced by or 
relative to 100 nM C3a agonist.  
 
The other analogs (benzamidine 252, phenylguanidine 253 and 4-
aminomethylphenylalanine 254) did not bind to the receptor at all below 100 µM 
(Fig. 6.2 C), and therefore only very weak agonist activity was observed in the 
calcium release assay (Fig. 6.2 B). To sum up, all of these constrained arginine 
mimetics failed to achieve a level of activity comparable to that observed from the 
original arginine containing analogues (>1000 fold reduction in potency). The 
restricted conformation of these mimetics may not be optimally directing the 
guanidino moiety to the desired position in the receptor-binding site and therefore it 
may be unable to form significant interactions with the receptor. Also, para-
substitution on the phenyl ring may not be the most favorable. Thus, moving the 
guanidino group to other positions on the ring may be worth investigating in the 
future. Alternatively, reducing the basicity of the pendant amine also reduces the H-
bond donor properties of the amine NH, thereby substantially reducing the binding 
affinity for the receptor. 
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Figure 6.2 (A) Concentration dependent responses for 251 and SB250157 (113) 
based on the inhibition of Ca2+ release in HMDM induced by 100 nM C3a (n ≥ 2). (B) 
Agonist activity of C3aR ligands in HMDM at various concentrations, relative to 
100% for C3a at 100 nM. (C) Binding affinities of C3aR ligands measured by 
displacement of 125I-C3a (80 pM) on HMDM. Each data point represents mean ± 
SEM. 
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6.3.2 Linear arginine mimetics 
 
Since constraining the arginine side chain did not give promising results, we 
sought to retain arginine mimetics with flexible aliphatic side chains. The aliphatic 
side chain was modified in an attempt to reduce the basicity of the guanidine group. 
First of all, the arginine was substituted with citrulline, which has a urea group instead 
of guanidine in the side chain. The urea moiety is a known bioisostere of guanidine, 
being structurally similar to guanidine, but urea is neutral (uncharged) at 
physiological pH. Essentially the urea CO is an isoelectronic replacement for C=NH. 
Urea is also a good H-bond donor and acceptor. However the citrulline compound 
(255) showed significantly reduced potency (Table 6.2). This suggested that two NH 
protons (NH=C-NH) may be required to maintain putative bidentate hydrogen bonds 
with a carboxylate group in the receptor.  
It has been reported that introducing an electron-withdrawing substituent into the 
guanidine group reduces the basicity17 as shown by the nitroguanidine (256) and 
cyanoguanidine (257) compounds.18-19 Both of these analogues are much less basic 
than arginine as they are weakly amphoteric and therefore uncharged at physiological 
pH.20 On the other hand, L-canavanine (258) possesses an oxygen atom adjacent to 
the guanidine group that also reduces the basicity of the side chain, the conjugate acid 
having a pKa of 7.0–7.521 and therefore is only partially protonated at physiological 
pH. 
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Table 6.2 LogD values and biological activities of linear arginine mimetics (255–
258), as determined from calcium mobilisation assay and 125I-C3a competitive 
binding assay in HMDM.  
 
Compound LogD 
a 
Binding 
IC50 (nM) 
b 
Binding 
pIC50 ± 
SEM 
n Ca2+  
EC50 (µM)c 
n 
228 TR12 -0.05 5.4 8.27 ± 0.27 5 0.06  5 
255 AY7 -1.84 No binding No binding 1 >100 1 
256 AY21 -1.25 129 6.89 ± 0.05 5 29.2  3 
257 AY77 -1.17 41 7.12 ± 0.30 3 0.25  4 
258 AY64 -0.2 93 7.03 ± 0.26 2 0.37  3 
a logD values were determined experimentally at pH 7.4 (refer to section 6.5.9).  
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding in HMDM. 
c concentrations causing 50% of calcium response in HMDM relative to that induced by 100 nM C3a 
agonist.  
 
The assay results indicated that the nitroguanidine analogue (256) was not very 
active. It was a weak antagonist at low concentration and became an agonist at higher 
concentration (Table 6.2). The functions (agonist/antagonist activity) of the ligands 
are sometimes concentration dependent. The lack of activity of compound 256 could 
be due to electronic effects caused by the nitro group on the side chain. On the other 
hand, compound 257 containing a cyanoguanidine group was an agonist (EC50 0.25 
µM), which corresponds to a 4-fold loss of potency in the calcium release assay and 
8-fold in the binding assay compared to a guanidine substituent (TR12, Table 6.2, Fig. 
6.3). In addition, the canavanine analogue (258) was also tolerated with comparable 
agonist potency to the cyanoguanidine analogue (257), but 2-fold less potent in 
binding.  
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Figure 6.3 (A) Agonist activity of C3aR ligands in HMDM at various concentrations, 
relative to 100% for C3a at 100 nM. (B) Binding affinities of C3aR ligands measured 
by displacement of 125I-C3a (80 pM) on HMDM. Each data point represents mean ± 
SEM. 
 
To sum up, linear arginine mimetics, with more flexibility compared to 
constrained mimetics, were favored as C3aR ligands in this series. Herein, compound 
257 was reported as a C3aR agonist with cyanoguanidine on the side chain. This 
compound has a much less basic than arginine, but the agonist potency and binding 
affinity were also lower than for the parent arginine compound (228, TR12). 
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6.3.3 Carboxylic acid bioisosteres 
 
 
Acyl sulfonamides are the most commonly used group of carboxylic acid 
isosteres, because their pKa’s are very similar to those of carboxylic acids (~4.0).22-23 
N-phenylsulfonamide and methane sulfonamide were used to substitute the carboxylic 
acid group of the arginine in order to improve the potency, but also as a means of 
reducing clearance rates and potential toxicity caused by the carboxylate group. Most 
carboxylic acid drugs are metabolised to acyl glucuronides and excreted. Acyl 
glucuronides have also been implicated in idiosyncratic adverse drug reactions caused 
by protein acylations, as have acyl-CoA thioester derivatives, which are reactive 
acylating species that have also led to in vivo toxicity.24-26 
Two acyl-sulfonamides were investigated: phenylsulfonamide and 
methanesulfonamide. Results indicated that the compound containing a 
phenylsulfonamide moiety (259) bound to the C3aR receptor with better potency than 
the methanesulfonamide analogue (260) (Fig. 6.4A), although they showed similar 
antagonist potencies (Table 6.3).  
 
R3 =   
 
    
 
 
 
 
 
Table 6.3 LogD values and biological activities of compounds 259–260, as 
determined from calcium mobilisation assay and 125I-C3a competitive binding assay 
in HMDM.  
 
Compound LogD 
a 
Binding 
IC50 
(nM) b 
Binding 
pIC50 ± 
SEM 
n Ca2+  
IC50 (µM) c 
± SEM 
n 
228 TR12 -0.05 5.4 8.27 ± 0.27 5 0.06  5 
259 AY99 1.37 7.5 8.12 ± 0.35 3 1.3  3 
260 AY107R 0.24 30 7.52 ± 0.39 3 2.0 3 
a logD values were determined experimentally at pH 7.4 (refer to section 6.5.9).  
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding in HMDM. 
c concentrations causing 50% inhibition of calcium response in HMDM induced by 100 nM C3a 
agonist.  
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Figure 6.4 (A) Binding affinities of C3aR ligands measured by displacement of 125I-
C3a (80 pM) on HMDM. Antagonist and agonist activities of (B) 259 and (C) 260 at 
various concentrations in HMDM. The agonist activity was relative to 100% for C3a 
at 100 nM and the antagonist activity was based on the inhibition of Ca2+ release 
induced by 100 nM C3a in HMDM. Each data point represents mean ± SEM.  
 
The slight improvement of compound 259 in binding compared to 260 could be 
due to a possible π-stacking interaction involving the phenyl ring. Nevertheless, the 
phenylsulfonamide analogue (259) displayed an agonist response when the cells were 
treated with the compound at higher concentration (Fig 6.4B), but the 
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methanesulfonamide analogue (260) did not show any agonist response at high 
concentration (Fig. 6.4C). It is also worth noting that replacement of the carboxylic 
acid group with phenylsulfonamide did not reduce the binding affinity, but the 
function of the ligand was changed from agonist to antagonist. In summary, 
phenylsulfonamide was a better carboxylic acid bioisostere in this case and could be 
used for future development of C3aR antagonists. 
 
6.3.4 Determination of the selectivity of the cyanoguanidine analogue (257)  
 
Amongst all the synthesised arginine mimetics, the cyanoguanidine analogue 
(257) gave the most promising result. This compound was a C3aR agonist and was 4-
fold less potent (EC50 250 nM) than the parent arginine derivative (TR12, EC50 60 
nM) in the calcium release assay on HMDM. It had been demonstrated in a receptor 
desensitisation assay (Tony Reed, Hons Thesis 2009)11 that up to 10 µM TR12 (228) 
was selective for C3aR, and therefore the selectivity of the cyanoguanidine derivative 
(257) was also investigated using the same desensitisation assay. In Chapter 5, it had 
been reported that 300 nM C3a ligand was sufficient to desensitise all C3a receptors 
on HMDM. Therefore, 300 nM C3a was used in this experiment to fully desensitise 
C3aR. Results indicated that agonist 257 at 1 µM and 10 µM was selective for C3aR 
over other calcium-inducing receptors, since it did not stimulate a second calcium 
response after C3aR desensitisation (Fig. 6.5).   
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Figure 6.5 Desensitisation assays. (A) Control 1: HMDM was treated with 300 nM of 
C3a at t0 to desensitise the C3a receptor. C3a at 1 µM was then injected at t920 (s) to 
confirm C3aR desensitisation.  (B) Control 2: Cells were first desensitised by 300 nM 
C3a at t0, then 300 nM of C5a was injected at t920 (s) to make sure only C3aR was 
desensitised. (C–D) Cells were first desensitised by 300 nM of C3a at t0, then 
compound at 1 or 10 µM was administered at t920 (s). Cyanoguanidine compound 257 
was selective to C3aR at 1 µM and 10 µM.  
 
6.3.5 Introducing cyanoguanidine and phenyl sulfonamide groups into a C3aR 
antagonist (233) 
 
The activation of the C3a receptor has been suggested to be pro-inflammatory3-6 
and this GPCR is expressed in a wide range of inflammatory cells.1 As a result, a 
C3aR antagonist may have potential for the treatment of inflammatory diseases. There 
are only a few C3aR antagonists reported in the literature with SB290157 (113) being 
the most potent and most thoroughly studied.27 In Chapter 5, the ether linker of 
SB290157 (113) was replaced with different aromatic heterocycles and a more potent 
antagonist (233) was discovered with an IC50 of 80 nM (10-fold better than 113) in 
the calcium mobilisation assay on HMDM. Therefore, it was planned to replace the 
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arginine side chain of 233 with a cyanoguanidine group (Fig. 6.6) since it was the 
most tolerated guanidine mimetic reported in section 6.3.2.  
O
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with 5-membered 
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SB290157 233 Site 1
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Figure 6.6 The guanidine side chain of C3aR antagonist (233) was replaced with 
cyanoguanidine and the carboxylate group was replaced with phenyl sulfonamide. 
 
As indicated in the previous section (6.3.3), replacement of the carboxylic acid 
group with phenyl sulfonamide in TR12 (228) changed the function of the ligand 
from agonist to antagonist. Therefore, the antagonist potency of thiophene 233 could 
potentially be improved when phenyl sulfonamide was incorporated (Fig. 6.6).  
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The resulting compound (261) was still able to bind reasonably well to the 
receptor, but the antagonist potency was reduced by about 4-fold (Table 6.5, Fig. 
6.7A). In contrast, substitution of guanidine with cyanoguanidine significantly 
reduced the binding affinity, as well as the antagonist potency. Compounds 262 and 
263, although binding to the C3aR more weakly than SB290157 (113, Fig. 6.7B), 
were still equally effective C3a antagonists with IC50 of 1–2 µM (iCa2+, HMDM, 
Table 6.5, Fig. 6.7A).  
In summary, all the mimetics reported herein failed to maintain the antagonist 
potency of compound 233. However, other arginine mimetics might be better 
tolerated or more effective and this requires further structure-activity relationship 
studies.  
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Table 6.4 Chemical properties of thiophene derivatives (233, 261–263). 
O
H
N
COOH
N
H
NH2
NH
S
Site 1
Site 2  
 
 
 
 
 
 
 
 
 
 
 
 
a logD values were determined experimentally at pH 7.4 (refer to section 6.5.9). 
 
Table 6.5 Biological activities of thiophene derivatives (233, 261–263), as 
determined from calcium mobilisation assay and 125I-C3a competitive binding assay 
in HMDM.  
. 
 
 
 
 
 
 
 
 
 
b concentrations of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding in HMDM. 
c concentrations causing 50% inhibition of calcium response in HMDM induced by 100 nM C3a 
agonist. 
 
Compound Group at 
Site 1 
Group at 
Site 2 
LogD 
a 
113 SB290157 – – 0.01 
233 BR111 guanidine COOH 1.50 
261 AY31 guanidine Ph 
sulfonamide 
2.19 
262 AY97 Cyano- 
guanidine 
COOH 0.08 
263 AY98 Cyano- 
guanidine 
Ph 
sulfonamide 
1.03 
Compound Binding 
IC50 (nM) b 
Binding 
pIC50 ± 
SEM 
n Ca2+ IC50 
(µM) c 
Ca2+ pIC50 
± SEM 
n 
113 SB290157 10 8.0 ± 0.2 6 1.3 5.9 ± 0.2 9 
233 BR111 65 7.2 ± 0.3 3 0.08 7.1 ± 0.3 7 
261 AY31 35 7.4 ± 0.3 3 0.30 6.5 ± 0.1 6 
262 AY97 853 6.1 ± 0.4 3 0.91 6.0 ± 0.1 3 
263 AY98 888 6.1 ± 0.4 3 2.0 5.7 ± 0.1 3 
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Figure 6.7 (A) Concentration dependent responses for compounds 233, 261–263 and 
SB290157 (113) based on the inhibition of Ca2+ release in HMDM induced by 100 
nM C3a (n ≥ 3). (B) Binding affinities of C3aR ligands measured by displacement of 
125I-C3a (80 pM) on HMDM (n ≥ 3). Each data point represents mean ± SEM.   
 
 
6.3.6 Compound selectivity towards nitric oxide synthase   
 
 
Nitric oxide synthase (NOS) is an enzyme that catalyses the formation of L-
citrulline and nitric oxide (NO) from L-arginine (scheme 6.1).28-30 Other than L-
arginine, a few other arginine derivatives had been reported to be NOS substrates.31-32 
The C3aR ligands containing arginine and the various mimetics reported in this 
chapter could conceivably act as substrates for NOS leading to the release of nitric 
oxide (NO), which is highly undesirable as excessive release of free NO radicals can 
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result in inflammatory conditions, including tissue damage in arthritis, diabetes, 
multiple sclerosis, ulcerative colitis and stroke.33 Therefore, a commercial NO 
detection kit and fluorescence microscopy were used to detect any release of NO upon 
treatment with synthetic C3aR ligands in HMDM.  
 
Scheme 6.1 Oxidation of L-arginine to L-citrulline and production of NO by NOS. 
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The production of NO in HMDM was monitored by fluorescence microscopy 
using the NO detection reagent cyanine 5 (red fluorescence). This reagent dye is cell-
permeable and reacts with the released NO in the cell, resulting in production of a 
water-soluble red fluorescent product. The positive control with L-arginine showed 
red fluorescing cells (Fig. 6.8A), while much less fluorescence signal was observed 
for the negative control (NO scavenger, Fig. 6.8 B). Compounds 242 (potent C3aR 
agonist) and 233 (potent C3aR antagonist) reported in Chapter 5, each possessing an 
arginine group, were assessed in this assay which confirmed that these compounds did 
not stimulate the production of NO (Fig. 6.8 C–D). Similar results were observed for 
two cyanoguanidine compounds (262–263), where no release of NO was detected 
(Fig. 6.8 E–F), suggesting that our C3aR ligands did not activate NOS, and thus will 
not cause the unwanted side effects associated with production of nitric oxide 
radicals. 
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(A) Positive control (L-Arginine)            (B) Negative control (NO scavenger) 
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Quantification of cell fluorescence was performed using ImageJ software1,2. Fluorescence was measured as integrated 
density and normalised against background. 
Dev Cell. 2010 Apr 20;18(4):533-43. doi: 10.1016/j.devcel.2010.02.013.
1. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis.
Gavet O, Pines J.
ol Biol Cell. 2011 Apr 15;22(8):1191-206. doi: 10.1091/mbc.E10-07-0599. Epub 2011 Feb 16.
2. Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 
and Cdc25 are inhibited.
Potapova TA, Sivakumar S, Flynn JN, Li R, Gorbsky GJ.
 
Figure 6.8 Fluorescence images captured using Nikon Ti-U Inverted Microscope with 
Cyanine 5 (650/670 nm). (A) L-arginine stimulated the release of NO (as indicated by 
the red fluorescence) through activation of NOS. (B–F) Same as the negative control 
(B), C3aR ligands containing arginine and cyanoguanidine group did not trigger the 
release of NO. (G) Quantification of cell fluorescence was performed using ImageJ 
software.34-35 Fluorescence was measured as integrated density and normalised against 
background. All figures were provided by Mr. James Lim (University of Queensland).   
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6.4 Summary and Conclusions 
 
Amongst all the arginine mimetics presently investigated herein, those with linear 
alkyl chains were generally tolerated better than those that incorporated 
conformationally constrained aromatic rings. The cyanoguanidine and canavanine can 
be used to mimic the guanidine group, but with some loss of potency. However, the 
cyanoguanidine analog 257 remained selective for C3aR as shown in the 
desensitisation assays. In addition, the carboxylic acid group of the arginine could be 
substituted with an N-phenylsulfonylamide group while maintaining similar binding 
affinity to the parent arginine compound.  
The most potent C3aR antagonist developed previously (reported in Chapter 5), 
the thiophene compound 233, was chosen to examine whether the arginine residue 
could be modified by incorporating both cyanoguanidine and C-terminal phenyl 
sulfonamide groups, whilst retaining high binding affinity and antagonist potency. 
The resulting compound 263 was found to possess weaker binding affinity for C3aR, 
but had comparable antagonist potency to the literature compound SB290157 (113).  
These arginine or arginine-mimicking C3aR ligands were not substrates for nitric 
oxide synthase, and are thus unlikely to exhibit side effects caused at least by nitric 
oxide radicals.  
Although none of the arginine mimetics reported herein improved the antagonist 
or agonist potency of the C3aR ligands, it was shown that linear arginine mimetics 
were more tolerated than constrained arginine mimetics for this particular series. 
These arginine modified compounds, which conform to the reliable predictors of 
bioavailability such as “Lipinski’s rule of five”, may show improved oral activity, 
however future studies are required to demonstrate this.  
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6.5 Experimental Methods 
 
General Methods 
 
All amino acids were purchased from Novabiochem. Diisopropylethylamine 
(DIPEA), DMF and TFA were obtained from Auspep Pty Ltd., Australia. Other 
chemicals were obtained from Aldrich. All reagents were used as received. 
Hydrogenation reactions were conducted using a medium pressure Parr hydrogenator 
apparatus. Preparative-scale rpHPLC separations were performed on a Phenomenex 
Luna C18 15 µm, 250 × 21.2 mm column. Standard conditions were used for elution 
of all compounds unless otherwise indicated at a flow rate of 20 mL/min: 100% A to 
100% B linear gradient over 10 min followed by a further 10 min at 100% B where 
solvent B was 90% MeCN, 10% H2O + 0.1% TFA and solvent A was H2O + 0.1% 
TFA. Detection was by UV and pure fractions were lyophilised. Analytical rpHPLC 
was used to assess compound purity (Phenomenex Luna C18 column, 15 µm, 90 Å, 
4.6 × 250 mm, λ 214, 230 and 254 nm) at three different wavelengths. Standard 
conditions (same as preparative-scale rpHPLC) were used for all compounds unless 
otherwise indicated at a flow rate of 1 mL/min. Solvent conditions were the same as 
for preparative-scale rpHPLC.  
Electrospray ionisation mass spectra (ESI-MS) measurements were obtained on 
Micromass LCT and high-resolution mass spectra (ESI-HRMS) measurements were 
obtained on a Bruker microTOF mass spectrometer equipped with a Dionex LC 
system (Chromeleon) in positive ion mode by direct infusion in MeCN at 100 µL/h 
using sodium formate clusters as an internal calibrant. Data was processed using 
Bruker Daltonics DataAnalysis 3.4 software. Mass accuracy was consistently better 
than 1 ppm error.  
1H NMR and 13C spectra were recorded on Bruker Avance 600 spectrometers at 
298 K in the deuterated solvents indicated. 1H NMR spectra were referenced to the 
residual 1H signals; DMSO-d6 2.50, CD3OD 3.31 ppm except CDCl3 solutions were 
referenced to internal TMS. 13C NMR resonances were referenced to the residual 
solvent peak (DMSO-d6 40.4, CDCl3 77.0 ppm). The exact concentration of the 
compounds was determined by the quantitative NMR integration ‘PULCON’ 
experiment.36 These settings were used for all PULCON experiments: relaxation 
delay of 30 seconds, 64 scans, 2 dummy scans, 90° pulse and temperature at 298K.  
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6.5.1 Synthesis of N-Boc-L-Leu-Oxazole carboxylic acid, 250 
 
Scheme 6.2 Synthesis of N-Boc-L-Leu-Oxazole carboxylic acid (250) 
 
N
OBocHN
CO2Me
BocHN
O
OH H2N CO2Me
HO
BocHN
O
H
N CO2Me
HO
a b
N
OBocHN
CO2H
c, d
HCl
1 2 3 4  
 
Reagents and conditions: a) BOP, DIPEA, DMF; b) DAST, THF -78°C; c) CBrCl3, 
DBU, DCM -40°C to RT; d) NaOH, MeOH, H2O.  
 
Synthesis of Boc-L-Leu-Ser-OMe (2). The Boc-L-Leu-OH (16.0 g, 64.3 mmol) 
in DMF (130 mL) was activated with BOP (28.4 g, 64.3 mmol) for 15 min before the 
addition of DL-serine methyl ester hydrochloride (10.0 g, 64.3 mmol) and DIPEA 
(22.4 mL, 128 mmol). The reaction mixture was stirred at RT for 1 h. The DMF in the 
reaction mixture was evaporated under high vacuum and the residue was re-dissolved 
in EtOAc (100 mL) and washed with sat. NaHCO3 (2 × 70 mL). The organic extract 
was dried over MgSO4, filtered and evaporated to dryness in vacuo. The crude 
product (2, ESI-MS: m/z 333.2 [MH]+) was used for the next step without 
purification. 
 
Synthesis of N-Boc-L-Leu-Oxazoline methyl ester (3). Boc-L-Leu-Ser-OMe (2, 
9.01 g, 26.9 mmol) was dissolved in anhydrous DCM (100 mL) and stirred under N2 
at -78°C before dropwise addition of DAST (5.3 mL, 40.3 mmol) over about 2 min. 
The reaction mixture was stirred at -78°C for 1 h. After that, solid Na2CO3 (14.2 g, 
134 mmol) was added and the reaction was warmed to RT and stirred for 1 h. The 
solution was diluted with DCM (50 mL) and washed with sat. NaHCO3 (2 × 80 mL). 
The organic phase was dried over MgSO4, filtered and concentrated in vacuo. The 
crude product (3, ESI-MS: m/z 315.2 [MH]+) was used for the next step without 
purification. 
 
Synthesis of N-Boc-L-Leu-Oxazole carboxylic acid (250). To a stirred solution 
of starting material oxazoline, 3 (3.40 g, 10.9 mmol) at -40°C in anhydrous DCM (50 
mL) was added CBrCl3 (3.60 mL, 36.0 mmol) dropwise. After that, DBU (6.2 mL, 
41.4 mmol) was added dropwise and the reaction mixture was slowly warmed to RT 
and stirred overnight. After this time, the reaction mixture was concentrated in vacuo. 
The residue was purified by flash column chromatography (SiO2, 20% EtOAc in 
	   256 
petroleum ether, Rf 0.2) to give the oxazole product as a pale yellow solid (1.60 g, 
46%). Rt = 11.5 min (20–100% B in 10 min gradient plus 100% B for further 10 
min); ESI-MS: m/z 313.2 [MH]+; 1H NMR (600 MHz, CDCl3), δ 0.93 (2 sets of d, 6 
H, J = 6.6 Hz), 1.41 (s, 9 H), 1.59–1.64 (m, 1 H), 1.67–1.75 (m, 2 H), 3.90 (s, 3 H), 
4.95–5.00 (m, 1 H), 5.01–5.08 (m, 1 H), 8.16 (s, 1 H). The resulting ester (1.60 g, 
5.10 mmol) in MeOH (18 mL) was treated with 3 M NaOH (6 mL) solution and the 
reaction mixture was stirred at room temperature for 30 min until the reaction went to 
completion as monitored by MS. The MeOH was evaporated in vacuo and the 
aqueous solution was acidified with 2 M HCl (10 mL) and extracted with EtOAc (2 × 
15 mL). The organic extracts were combined, washed with brine (1 × 20 mL) and 
dried over MgSO4, filtered and evaporated to dryness giving a white powder (250, 
1.50 g, ~100%). Rt = 10.4 min (20–100% B in 10 min gradient plus 100% B for 
further 10 min); ESI-MS: m/z 299.2 [MH]+; 1H NMR (600 MHz, CDCl3), δ 0.91 (2 
sets of d, 6 H, J = 6.6 Hz), 1.39 (s, 9 H), 1.57–1.62 (m, 1 H), 1.65–1.73 (m, 2 H), 
4.93–4.98 (m, 1 H), 5.00–5.06 (m, 1 H), 8.14 (s, 1 H).  
 
6.5.2 Synthesis of constrained arginine mimetics 
 
Scheme 6.3 Synthesis of constrained arginine mimetic containing compounds (251–
254). 
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Reagents and conditions: a) 20% Piperidine, DMF; b) N-Boc-L-Leu-Oxazole 
carboxylic acid 250, BOP, DIPEA, DMF; c) NH2OH.HCl, DIPEA, EtOH, 60°C; d) 
NaOH, MeOH, H2O; e) MeI, Na2CO3, DMF; f) 40% TFA, DCM; g) Wang-resin, 
DIC, 5% DMAP, DCM/DMF (1:1); h) 2-benzhydryl-4-methyl-1H-imidazole-5-
carboxylic acid, HBTU, DIPEA, DMF; i) 95% TFA, 2.5% TIPS, 2.5% H2O; j) H2, 
10% Pd/C, AcOH, EtOH, 50 psi.  
 
Esterification of 6a. To the starting material acid (6a, 0.29 g, 0.46 mmol) in 
DMF (2 mL), Na2CO3 (0.10 g, 0.92 mmol) was added followed by MeI (57 µL, 0.92 
mmol) and the reaction mixture was stirred at RT overnight. The reaction mixture was 
diluted with EtOAc (5 mL) and washed with sat. NaHCO3 (2 × 5 mL) and brine (1 × 
5 mL). The combined organic phases were dried over MgSO4, filtered and evaporated 
to dryness in vacuo. The crude product was used for the next step without 
purification. ESI-MS: m/z 659.2 [MH]+ 
 
Boc deprotection (step f). The product from step e (0.20 g, 0.44 mmol) was 
treated with 40% TFA in DCM (3 mL) and stirred until reaction went to completion. 
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The reaction mixture was evaporated under N2 and the residue (6b, ESI-MS: m/z 
459.2 [MH]+) was used for the next step without purification. 
 
Fmoc-deprotection of 6b and 7a. 6b (0.19 g, 0.43 mmol) or 7a (0.11 mmol on 
resin) was treated with 20% piperidine in DMF solution (1 mL) for 10 min. The 
reaction mixture was evaporated in vacuo. For solid phase synthesis, the piperidine 
DMF solution was drained and resin was washed with DMF (3 × 2 mL). 6c (ESI-MS: 
m/z 237.2 [MH]+) was used for the next step without purification. 
 
Coupling of N-Boc-L-Leu-oxazole acid (250) to 5b and 6c. The N-Boc-L-Leu-
oxazole acid (1 eq.) in DMF (as 0.2–0.5 M solution) was activated with BOP (1 eq.) 
for 15 min before the addition of the amine 5b or 6c (1 eq.) and DIPEA (2–3 eq.). The 
reaction mixture was stirred at RT for a few hours where mass spec indicated all 
starting material had been consumed. The reaction mixture was diluted with EtOAc 
and washed with sat. NaHCO3 (2 ×). The combined organic phases were dried over 
MgSO4, filtered and evaporated to dryness in vacuo. 5c (ESI-MS: m/z 485.2 [MH]+) 
and 6d (ESI-MS: m/z 517.1 [MH]+) were used for the next step without purification. 
 
Synthesis of 5d. To a solution of 5c (83 mg, 0.17 mmol) and hydroxylamine 
hydrochloride (18 mg, 0.25 mmol) in EtOH (0.8 mL), DIPEA (45 µL, 0.25 mmol) 
was added and the reaction mixture was heated at 60°C for 2–3 h. After that, the 
reaction mixture was concentrated in vacuo and the crude product (5d, ESI-MS: m/z 
518.2 [MH]+) was used for the next reaction without purification.  
 
Synthesis of 5e. To the amidoxime 5d (67 mg, 0.13 mmol) in EtOH (10 mL), 
AcOH (5 mL) and 10% Pd/C (10 mg) were added and the reaction mixture was 
hydrogenated at 50 psi for 48 h. The Pd/C catalyst was removed by filtering the 
mixture through celite and the filtrate was evaporated to dryness in vacuo. The crude 
product (5e, ESI-MS: m/z 502.2 [MH]+) was used for the next reaction without 
purification.  
 
Loading of 7a onto Wang-resin. 7a (113 mg, 0.21 mmol) was activated with 
DIC (12 µL), 5% DMAP (1 mg) in DCM/DMF (1:1, 0.4 mL) and then loaded onto 
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Wang-resin (100 mg, 1.10 mmol/g) and mixed with the resin overnight. After this 
time, the solution was drained and resin was washed with DCM (3 × 1 mL).  
 
Synthesis of 7c. 2-benzhydryl-4-methyl-1H-imidazole-5-carboxylic acid (64.3 
mg, 0.22 mmol) was activated with HBTU (83 mg, 0.22 mmol) and DIPEA (38 µL, 
0.22 mmol) in DMF for 15 min and then added to the resin (7b, 100 mg) and mixed 
for 1–2 h. After this time, the solution was drained and the resin was washed with 
DMF (3 × 2 mL), MeOH (3 × 2 mL) and DCM (3 × 2 mL). The resin was dried on 
high vacuum.  
 
Cleavage of Wang resin. The desired product (254) was cleaved from resin by 
treating the resin with 95% TFA, 2.5% TIPS, 2.5% H2O for 2 h. After this time, the 
resin was filtered. The cleavage solution was dried under N2 and the residue was 
purified by HPLC. Compound 254 was fully characterized and the data were reported 
in section 6.6. 
 
Ester hydrolysis of 5d, 5e and 6d.  5d, 5e or 6d (1 eq.) in MeOH was treated 
with 3 M NaOH (3 eq.) and stirred at RT until the reaction went to completion. The 
MeOH was evaporated in vacuo and the aqueous solution was neutralised with 2 M 
HCl and purified by HPLC. Compounds 251–253 were fully characterized and the 
data were reported in section 6.6. 
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6.5.3 Synthesis of linear arginine mimetics. 
 
 
Scheme 6.4 Synthesis of linear arginine mimetic containing compounds (255–258). 
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Reagents and conditions: a) MeI, Na2CO3, DMF; b) 20% TFA, DCM; c) N-Boc-L-
Leu-Oxazole carboxylic acid  250, BOP, DIPEA, DMF; d) NaOH, MeOH, H2O; e) 4 
M HCl in dioxane; f) AcCl, MeOH, Δ.  
 
Scheme 6.5 Synthesis of 9a. 
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O
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Reagents and conditions: a) H2, 10% Pd/C, MeOH, 40 psi; b) Diphenyl N-
cyanocarbonimidate, iPrOH, Δ; c) sat. NH3, EtOH.   
 
Cbz deprotection of 12. The amino acid 12 (6.05 g, 16.4 mmol), 10% Pd/C 
(0.10 g) in MeOH (100 mL) was hydrogenated at 40 psi for 1–2 h. After this time, the 
Pd/C catalyst was removed by filtering the mixture through celite, and the filtrate was 
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evaporated to dryness to give a white powder. The white powder (ESI-MS: m/z 233.1 
[MH]+) was used for the next reaction without further purification.  
 
Synthesis of 13. The amine (2.12 g, 9.29 mmol) from the previous step and 
diphenyl N-cyanocarbonimidate (2.21 g, 9.24 mmol) in iPrOH (20 mL) were refluxed 
for 2–3 h. The reaction mixture was cooled down and concentrated in vacuo. The 
residue was purified by flash column chromatography (SiO2, 80% EtOAc in 
petroleum ether, Rf 0.2) to give a semi crystalline solid (13, 1.40 g, 40%). Rt = 9.2 
min (20–100% B in 10 min gradient); ESI-MS: m/z 377.2 [MH]+; 1H NMR (600 
MHz, CDCl3), δ 1.46 (s, 9 H), 1.80–1.87 (m, 3 H), 1.95–2.03 (m, 1 H), 3.50–3.60 (m, 
2 H), 4.43 (br s, 1 H), 5.56 (br s, 1 H), 7.08 (d, 2 H, J = 7.8 Hz), 7.28 (t, 1 H, J = 7.2 
Hz), 7.40 (t, 2 H, J = 7.8 Hz), 7.54 (br s, 1 H). 
  
Synthesis of 9a. The purified intermediate 13 (1.41 g, 3.73 mmol) was treated 
with sat. NH3 in EtOH (20 mL) and stirred for 36 h at room temperature. The reaction 
mixture was concentrated in vacuo and re-dissolved in H2O (20 mL) and washed with 
EtOAc once (15 mL). The aqueous layer was collected and lyophilised to give 9a as a 
white solid (1.12 g, 90%). ESI-MS: m/z 300.2 [MH]+; 1H NMR (600 MHz, DMSO-
d6), δ 1.40 (s, 9 H), 1.87–1.94 (m, 3 H), 2.02–2.10 (m, 1 H), 3.57–3.67 (m, 2 H), 4.50 
(br s, 1 H), 5.63 (br s, 1 H),  6.71 (br s, 1 H).  
 
Synthesis of 8b and 9b. To the starting acid (8a, 9a, 1 eq.) in DMF (4 mL/mmol 
of starting acid), Na2CO3 (2 eq.) was added followed by MeI (2 eq.) and the reaction 
mixture was stirred at RT overnight. The reaction mixture was diluted with EtOAc 
and washed with sat. NaHCO3 (2 ×) and brine (1 ×). The combined organic phases 
were dried over MgSO4, filtered and evaporated to dryness in vacuo. The crude 
product was used for the next step without purification. 8b, ESI-MS: m/z 334.1 
[MH]+; 9b, ESI-MS: m/z 314.1 [MH]+.   
 
Esterification of L-citrulline (10a). Anhydrous MeOH (37 mL) was added into a 
round-bottomed flask and the flask was attached to a reflux condenser placed under 
N2. Acetyl chloride (1.6 mL, 22.8 mmol) was added dropwise through the condenser 
then the reaction mixture was stirred for 5 min. L-citrulline powder (2.01 g, 11.4 
mmol) was added and then the reaction mixture was refluxed overnight. The MeOH 
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was evaporated in vacuo and the residue was re-dissolved in ACN/H2O and 
lyophilised to give a white sticky solid (10b, 2.41 g, 95%). ESI-MS: m/z 190.2 
[MH]+; 1H NMR (600 MHz, H2O/D2O, 9:1), δ 1.49-1.57 (m, 2 H), 1.85-1.93 (m, 2 H), 
3.04-3.06 (m, 2 H), 3.74 (s, 3 H), 4.06 (t, 1 H, J = 6.6 Hz).  
  
Boc deprotection of 8b. The starting material (8b, 0.34 g, 1.02 mmol) was 
treated with 20% TFA in DCM (3 mL) and stirred until reaction went to completion 
as indicated by MS. The reaction mixture was evaporated under N2 and the crude 
residue (8c, ESI-MS: m/z 234.3 [MH]+) was used for the next step without 
purification.  
 
Boc deprotection of 9b. The Boc group on 9b (0.10 g, 0.31 mmol) was removed 
with 4 M HCl in dioxane (1 mL). When completed, the reaction mixture was 
evaporated in vacuo. H2O (2 mL) was added, the solution was neutralised with 2 M 
NaOH (2 mL), and the mixture was lyophilised. The crude product (9c, ESI-MS: m/z 
214.3 [MH]+) was used for the next step without purification. 
 
Coupling of N-Boc-L-Leu-oxazole acid (250) to 8c, 9c, 10b and 11. The N-
Boc-L-Leu-oxazole acid (250, 1 eq.) in DMF (4 mL/mmol of N-Boc-L-Leu-oxazole 
acid) was activated with BOP (1 eq.) for 15 min before the addition of the amine salt 
(1 eq.) and DIPEA (2–3 eq.). The reaction mixture was stirred at RT for a few hours 
where mass spec indicated all starting material had been consumed. The reaction 
mixture was diluted with EtOAc and washed with sat. NaHCO3 (2 ×). The combined 
organic phases were dried over MgSO4, filtered and evaporated to dryness in vacuo. 
The crude product was used for the next step without purification. 
 
Ester hydrolysis of 8c, 9c and 10b. The crude product (1 eq.) from step (c) in 
MeOH was treated with 3 M NaOH (3 eq.) and stirred at RT until the reaction went to 
completion. The MeOH was evaporated in vacuo and the aqueous solution was 
neutralised with 2 M HCl and purified by HPLC. Compounds 255–257 were fully 
characterized and the data were reported in section 6.6.  
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6.5.4 Synthesis of sulfonamide compounds 
 
Scheme 6.6 Synthesis of compounds 259–260 
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Reagents and conditions: a) CDI, DBU, DMF;  b) H2,10% Pd/C, MeOH, 40 psi; c) 
HgCl2, Et3N, DMF; d) 40% TFA, DCM; e) N-Boc-L-Leu-Oxazole carboxylic acid 
250, BOP, DIPEA, DMF.  
 
17a and 17b were first synthesised via route A (Scheme 6.6). However the coupling 
of Boc-Arg-OH with sulfonamides 14a and 14b (step a) was failed. Conditions listed 
below were tried: 
Boc-Arg-
OH (eq.) 
Sulfonamide 
14a/14b 
(eq.) 
Coupling 
reagent Base Solvent 
Yield & 
comments 
2.0 1.0 BOP (2 eq.) DIPEA (2 eq.) DMF 
0%, produced 
unknown side 
products 
1.0 2.0 CDI (3 eq.) DBU (1.5 eq.) THF 
0%, produced 
unknown side 
products 
2.0 1.0 
EDC (2eq.), 
DMAP (0.5 
eq.) 
- DMF 
10%, produced 
unknown side 
products 
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The reaction was then conducted via route B, using Boc-Orn(Z)-OH (12) for the 
coupling step a and the reaction went well as described below: 
 
Synthesis of 15a and 15b. To a solution of 12 (2.90 g, 7.90 mmol) in anhydrous 
THF (30 mL), CDI was added (3.8 g, 23.7 mmol, 3 eq.) and stirred for 30 min. After 
30 min, a mixture of sulfonamide (14a or 14b, 5 mmol, 2 eq.) and DBU (1.8 mL, 11.8 
mmol, 1.5 eq.) in anhydrous THF (10 mL) was added and stirred at RT for 5 h. The 
reaction mixture was evaporated and re-dissolved in EtOAc (40 mL) and washed with 
5% citric acid (1 × 30 mL), dried over MgSO4, filtered and concentrated in vacuo. 
15a (ESI-MS: m/z 444.3 [MH]+) and 15b (ESI-MS: m/z 506.3 [MH]+) were used for 
the next step without purification.  
 
Cbz deprotection of 15a–b. 16a and 16b were prepared following the procedure 
described for step a in scheme 6.5 using starting material 15a (1.02 g, 2.30 mmol) or 
15b (1.01 g, 2.00 mmol), 10% Pd/C (50 mg) in MeOH (20 mL). 16a (ESI-MS: m/z 
310.1 [MH]+) and 16b (ESI-MS: m/z 372.1 [MH]+) were used for the next reaction 
without further purification. 
 
Synthesis of 17a and 17b. To a mixture of 16a (0.70 g, 2.30 mmol) or 16b (0.70 
g, 2.00 mmol), 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (1.5 eq.), 
Et3N (3 eq.) in DMF (10 mL) was added HgCl2 (1.5 eq.) The reaction mixture was 
stirred at RT overnight. After this time, DMF was evaporated in vacuo and the residue 
was re-dissolved in ether (10 mL), filtered and the filtrate was washed with sat. 
NH4Cl (1 × 10 mL), H2O (1 × 10 mL) and brine (1 × 10 mL). The organic phase was 
dried over MgSO4, filtered and evaporated to dryness to yield product as a white 
solid. The solid was treated with 40% TFA in DCM (10 mL) and stirred until reaction 
went to completion. The reaction mixture was evaporated under N2. 17a (ESI-MS: 
m/z 252.2 [MH]+) and 17b (ESI-MS: m/z 314.2 [MH]+) were used for the next step 
without purification. 
 
Coupling of N-Boc-L-Leu-oxazole acid (250) to 17a–b. The N-Boc-L-Leu-
oxazole acid (250, 1 eq.) in DMF (4 mL/mmol of N-Boc-L-Leu-oxazole acid) was 
activated with BOP (1 eq.) for 15 min before the addition of the amine 17a or 17b (1 
eq.) and DIPEA (2–3 eq.). The reaction mixture was stirred at RT for a few hours 
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where mass spec indicated all starting material had been consumed. The reaction 
mixture was diluted with EtOAc and washed with sat. NaHCO3 (2 ×). The combined 
organic phases were dried over MgSO4, filtered, evaporated to dryness in vacuo and 
purified by HPLC. Compounds 259–260 were fully characterized and the data were 
reported in section 6.6. 
 
6.5.5 Synthesis of thiophene derivatives 
 
Scheme 6.7 Synthesis of compounds 261–263 
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Reagents and conditions: a) 5-benzhydrylthiophene-2-carboxylic acid, BOP, DIPEA, 
DMF; b) Diphenyl N-cyanocarbonimidate, iPrOH, Δ; c) sat. NH3, EtOH; d) 4 M HCl 
in dioxane; e) NaOH, MeOH, H2O.   
 
Synthesis of 18. Compound 18 was prepared following the procedure described 
for compound 12 (step b in scheme 6.5), using starting material 16b (0.88 g, 2.37 
mmol) and diphenyl N-cyanocarbonimidate (0.56 g, 2.37 mmol) in isopropanol (10 
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mL). Rt = 10.6 min (20–100% B in 10 min gradient); ESI-MS: m/z 516.2 [MH]+; 1H 
NMR (600 MHz, CDCl3), δ 1.47 (s, 9 H), 1.80–2.10 (m, 4 H), 3.52–3.62 (m, 2 H), 
4.53 (m, 1 H), 5.62 (br s, 1 H), 7.10 (d, 2 H, J = 7.8 Hz), 7.30 (t, 1 H, J = 7.2 Hz), 
7.40 (t, 2 H, J = 7.8 Hz), 7.59 (t, 2 H, J = 7.8 Hz), 7.66–7.71 (m, 2 H), 7.88–7.90 (m, 
2 H). 
 
Synthesis of 19. Compound 19 (ESI-MS: m/z 439.2 [MH]+) was prepared 
following the procedure described for compound 13 (step c in scheme 6.5), using 
starting material 18 (0.36 g, 0.70 mmol) and sat. NH3 in EtOH (5 mL). The crude 
intermediate was used for the next step without purification. 
 
Boc deprotection of 19. Compound 20 (ESI-MS: m/z 339.1 [MH]+) was 
prepared following the procedure described for compound 9b (step e in scheme 6.4), 
using starting material 19 (120 mg, 0.27 mmol) in 4 M HCl in dioxane (1 mL). The 
crude intermediate was used for the next step without purification. 
 
Coupling of 5-benzhydrylthiophene-2-carboxylic acid to 6c, 17b and 20. The 
5-benzhydrylthiophene-2-carboxylic acid (1 eq.) in DMF (4 mL/mmol of 5-
benzhydrylthiophene-2-carboxylic acid) was activated with BOP (1 eq.) for 15 min 
before the addition of the amine 9c, 17b or 20 (1 eq.) and DIPEA (2–3 eq.). The 
reaction mixture was stirred at RT for a few hours where mass spec indicated all 
starting material had been consumed. The reaction mixture was diluted with EtOAc 
and washed with sat. NaHCO3. The combined organic phases were dried over 
MgSO4, filtered, evaporated to dryness in vacuo. Compounds 261–263 were purified 
by HPLC, fully characterized and the data were reported in section 6.6. 
 
Ester hydrolysis of 21. 21 (24 mg, 0.05 mmol) in MeOH (0.2 mL) was treated 
with 3 M NaOH (50 µL, 0.15 mmol) and stirred at RT until the reaction went to 
completion. The MeOH was evaporated in vacuo and the aqueous solution was 
neutralised with 2 M HCl (75 µL) and purified by HPLC. Compound 262 was fully 
characterized and the data were reported in section 6.6. 
 
6.5.6 Isolation of human monocyte derived macrophages (HMDM) 
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Human monocyte derived macrophages (HMDM) were isolated using Ficoll-
paque density centrifugation (GE healthcare Bio-Science, Uppsala, Sweden) from 
buffy coat of anonymous human donors provided by Australian Red Cross Blood 
Service, Brisbane. CD14+ monocytes were positively selected using CD14+ MACS 
magnetic beads (Miltenyi Biotech, Auburn, CA, USA) after successive magnetic 
sorting and washings. The CD14+ monocytes were then cultured at 37°C, with 5% 
CO2 and differentiated to HMDM using 100 ng/mL of recombinant human 
macrophage colony stimulating factor (M-CSF) (PeptroTech Inc, Rocky Hill, New 
Jersey, USA) at 1.5 × 106 cells/mL. HMDM were kept in IMDM supplemented with 
10% FBS, penicillin (10 U/mL), streptomycin (10 U/mL) and L-glutamine (2 mM) 
(Invitrogen). HMDM were supplemented after 5 days with fresh medium containing 
100 ng/mL M-CSF. HMDM were harvested by gentle scraping in saline solution on 
day 7. 
 
6.5.7 Intracellular calcium release assay 
 
Assay Protocol. HMDM were plated at 5 × 104 cells/well in a 96-well cleared-
bottom black-wall assay plate (Corning) kept in IMDM supplemented with 10% FBS, 
penicillin (10 U/mL), streptomycin (10 U/mL) and L-glutamine (2 mM) (Invitrogen) 
and incubated overnight at 37oC. Before assay, the medium was removed and cells 
were incubated with dye-loading buffer (12 mL assay buffer, 4 µM Fluo-3 AM, 25 µL 
Pluronic acid F-127 and 1% FBS) for an hour at 37oC. After an hour, cells were 
washed once with assay buffer (HBSS supplemented with 2.5 mM probenecid and 20 
mM HEPES, pH 7.4).  
 
Sample Preparation. Stock solutions of compounds were prepared by dissolving 
the compound in DMSO solution to give a 10 mM stock solution. The 10 mM stock 
solutions were then diluted with assay buffer (described in assay protocol) to give the 
concentrations required for the assay.  
 
Concentration Dependent Inhibition Assay. A range of concentrations of the 
compound (50 µL) was pre-incubated with the cells for 30 min prior to the addition of 
agonist C3a (50 µL, 100 nM). After addition of agonist, the intracellular release of 
Ca2+ was monitored on fluorescence plate reader (FLIPRTETRA) at least 60 s 
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(excitation 495 nm, emission 520 nm). Duplicate measurements were made for each 
data point, mean ± SEM were reported from experiments as indicated. Changes in 
fluorescence (% response) were plotted against logarithmic compound concentrations. 
The half maximal inhibitory concentration (IC50) values were derived from the 
concentration response curve using a nonlinear regression curve in Graphpad Prism 
v5. 
 
Concentration Dependent Response Curves. A range of concentrations of the 
compound (50 µL) was added to the cells containing 50 µL assay buffer. The 
intracellular Ca2+ release was monitored for at least 60 s (excitation 495 nm, emission 
520 nm) immediately after the injection of the desired concentration of the 
synthesised compounds. Duplicate measurements were made for each data point, 
mean ± SEM were reported from experiments as indicated. Changes in fluorescence 
(% response) were plotted against logarithmic compound concentrations. The half 
maximal effective concentration (EC50) values were derived from the concentration 
response curve using a nonlinear regression curve in Graphpad Prism v5. 
 
6.5.8 125I-C3a radioligand binding assay 
 
Receptor binding was performed by ligand competition with 80 pM [125I]-C3a 
(2200 Ci/mmol; Perkin Elmer, Torrance, CA, USA), HMDM (1.2 × 106 cells/mL), 80 
pM [125I]-C3a with/without various concentrations of unlabeled C3a or C3a non-
peptidic agonist/antagonist, were mixed with Tris buffer (50 mM Tris, 3 mM MgCl2, 
0.1 mM CaCl2, 0.5% (w/v) bovine serum albumin, pH 7.4) for 60 min in a 96-well 
Nunc round bottom plate at room temperature. Unbound [125I]-C3a was removed by 
filtration through glass microfiber filter GF/B (Whatman Iner. Ltd, England) which 
had been soaked in 0.6% polyethyleneimine to reduce non-specific binding. The filter 
was washed 3 times with cold buffer (50 mM Tris-HCl) pH 7.4 and bound [125I]-C3a 
was assessed by scintillation counting on Microbeta counter. Specific [125I]-C3a 
binding was defined as the difference between total binding and non-specific binding 
as determined in the presence of 1 µM unlabeled C3a. The IC50 value was derived 
from the concentration of agonist/antagonist required to inhibit 50% of [125I]-C3a 
binding. 
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6.5.9 Experimental Determination of LogD 
 
For arginine mimetic compounds, where the mimetics can be either protonated or 
neutral depending on the pKa of the side chain, it could be also partially protonated. 
As a result, the octanol-water partition coefficient of each compound was determined 
experimentally. 
Test compound (10 µL, 10 mM stock in DMSO) was added to a 10 mM 
phosphate buffer solution (0.5 mL, pH 7.4) and then 1-octanol (0.5 mL) was added. 
The mixture was vortexed for 5 minutes followed by centrifugation. The organic and 
aqueous layers were separated and dried in a rotational-vacuum-concentrator (Beta-
RVC CMC-2, Christ). The residues were re-dissolved in ACN/H2O (1:1, 100 µL) and 
the UV absorbance of the organic and aqueous layers were measured on analytical 
HPLC (UV 214, 230 and 254 nm). The logD values were calculated as follows: 
 
log D = log (A / B) ; A = integrated signal area in octanol phase 
           B = integrated signal area in aqueous phase 
Note: Compound in solid form was analysed in the same way and the measured logD 
was comparable to the one obtained from compound in DMSO stock. This confirmed 
that the partition coefficients were not affected by the trace amount (1%) of DMSO 
solution. 
 
6.5.10 Fluorescence microscopy  
 
Detection of nitric oxide was performed using NO Detection Kit (Enzo Life 
Sciences) according to manufacturer’s instructions. Briefly, HMDMs were seeded on 
sterile glass coverslips at 0.5 × 106/mL and allowed to adhere overnight. HMDMs 
were incubated with NO Detection Reagent for 2 h prior to treatment. HMDMs were 
treated with the stated compounds (100 µM), positive and negative controls were 
treated with L-Arginine (1 mM) and NO scavenger (C-PITO, 5 µM) respectively. 
Fluorescence images were captured using Nikon Ti-U Inverted Microscope with 
Cyanine 5 (650/670 nm). Quantification of cell fluorescence was performed using 
ImageJ software.34-35 Fluorescence was measured as integrated density and normalised 
against background.  
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6.6 Characterization data for all final compounds 
 
General Methods  
 
All purified final compounds were characterized by ESI-MS/ESI-HRMS and 1H 
NMR (Bruker Avance 600), and the purities were assessed via analytical rpHPLC 
(Phenomenex C18 column, 15 µm, 90 Å, 4.6 × 250 mm, λ 214, 230 and 254 nm). All 
compounds were ≥95% pure. Four standard HPLC conditions were used for all 
compounds unless otherwise indicated at a flow rate of 1 mL/min. Method I: 100% A 
to 100% B linear gradient over 10 min followed by a further 10 min at 100% B; 
Method II: 100% A to 100% B linear gradient over 15 min followed by a further 5 
min at 100% B; Method III: 20% to 100% B linear gradient over 10 min followed by 
a further 10 min at 100% B; Method IV: 20% to 100% B linear gradient over 15 min 
followed by a further 5 min at 100% B; where solvent B was MeCN + 0.1% TFA and 
solvent A was H2O + 0.1% TFA. HPLC was performed using an Agilent 1200 Series 
with a diode-array detector on a Phenomenex Luna 5 µm, C18 or C8 250 × 4.60 mm 
column. All compounds were analysed on NMR (Bruker Avance 600) at 298 K in the 
deuterated solvents indicated and were referenced to the residual 1H signals; DMSO-
d6 2.50, CD3OD 3.31 ppm except CDCl3 solutions were referenced to internal TMS. 
13C NMR resonances were referenced to the residual solvent peak (DMSO-d6 40.4, 
CDCl3 77.0 ppm). Electrospray ionisation high-resolution mass spectra (ESI-HRMS) 
measurements were obtained on a Bruker microTOF mass spectrometer equipped 
with an Agilent 1100 Series LC/MSD mass detector in positive ion mode by direct 
infusion in MeCN at 100 µL/h using sodium formate clusters as an internal calibrant.  
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251 AY095 O
OHR3HN
NHOH
NH  
Rt = 9.0 min (Method I); HRMS: 
[MH]+ 504.2453 (calc. for 
C24H34N5O7+) 504.2452 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 0.84–
0.91 (m, 6 H), 1.23–1.27 (br s, 1 H), 
1.36 (s, 9 H), 1.55–1.62 (m, 2 H), 
1.68–1.75 (m, 1 H), 3.20–3.31 (m, 3 
H), 4.67–4.76 (m, 2 H), 7.41–7.48 (m, 
2 H), 7.51–7.56 (m, 1 H), 7.56–7.61 
(m, 2 H), 8.28–8.33 (m, 1 H), 8.50 (s, 1 
H).  
252 AY098 O
OHR3HN
NH2
NH  
Rt = 9.0 min (Method I); HRMS: 
[MH]+ 488.2504 (calc. for 
C24H34N5O6+) 488.2505 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 0.84–
0.91 (m, 6 H), 1.22–1.28 (br s, 1 H), 
1.36 (s, 9 H), 1.54–1.63 (m, 2 H), 
1.68–1.75 (m, 1 H), 3.22–3.34 (m, 2 
H), 4.67–4.77 (m, 2 H), 7.46–7.50 (m, 
2 H), 7.51–7.55 (m, 1 H), 7.67–7.71 
(m, 2 H), 8.29–8.34 (m, 1 H), 8.50 (s, 1 
H), 8.98–9.06 (m, 2 H), 9.20 (s, 2 H).  
253 AY042 O
OHR3HN
N
H
NH2
NH
 
Rt = 9.2 min (Method IV); HRMS: 
[MH]+ 503.2613 (calc. for 
C24H35N6O6+) 503.2614 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 0.84–
0.91 (m, 6 H), 1.23–1.28 (br s, 1 H), 
1.36 (s, 9 H), 1.53–1.64 (m, 2 H), 
1.68–1.75 (m, 1 H), 3.14–3.19 (m, 2 
H), 4.62–4.73 (m, 2 H), 7.08–7.14 (m, 
2 H), 7.26–7.32 (m, 2 H), 7.33–7.44 
(m, 4 H), 7.50–7.56 (m, 1 H), 8.18–
8.25 (m, 1 H), 8.52 (s, 1 H), 9.59–9.72 
(m, 1 H).  
254 AY55 O
OHR4HN
NH2  
Rt = 9.4 min (Method II); HRMS: 
[MH]+ 469.2234 (calc. for 
C28H29N4O3+) 469.2234 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 2.34 
(s, 3 H), 3.09–3.17 (m, 2 H), 3.96 (q, 2 
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H, J = 5.52 Hz), 5.50 (s, 1 H), 7.21–
7.35 (m, 14 H), 7.67 (d, 1 H, J = 10.1 
Hz), 8.09 (br s, 2 H). 
255 AY7 
R3HN
O
OH
NH
O NH2  
Rt = 8.3 min (Method III); HRMS: 
[MH]+ 456.2453 (calc. for 
C20H34N5O7+) 456.2457 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 0.86 
& 0.89 (2 sets of d, 6 H, J = 6.0 Hz), 
1.26 (br s, 1 H), 1.36 (s, 9 H), 1.55–
1.65 (m, 2 H), 1.69–1.75 (m, 2 H), 
1.77–1.83 (m, 1 H), 2.91–2.96 (m, 2 
H), 4.34–4.37 (m, 1 H), 4.71–4.75 (m, 
1 H), 5.97 (br s, 1 H), 7.53 (d, 1 H, J  = 
8.4 Hz), 8.08 (d, 1 H, J = 7.8 Hz), 8.55 
(s, 1 H).  
256 AY21 
R3HN
O
OH
NH
HN NHNO2  
Rt = 11.6 min (Method II); HRMS: 
[MH]+ 500.2463 (calc. for 
C20H34N7O8+) 500.2463 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 0.84 
& 0.88 (2 sets of d, 6 H, J = 6.6 Hz), 
1.27 (br s, 1 H), 1.36 (s, 9 H), 1.46–
1.54 (m, 2 H), 1.55–1.66 (m, 2 H), 
1.70–1.81 (m, 2 H), 1.82–1.89 (m, 1 
H), 3.11–3.20 (m, 2 H), 4.34–4.41 (m, 
1 H), 4.71–4.75 (m, 1 H), 7.53 (d, 1 H, 
J = 8.4 Hz), 8.16 (d, 1 H, J = 7.8 Hz), 
8.55 (s, 1 H).  
257 AY77 
R3HN
NH
NH2N
NC
O
OH
 
Rt = 10.1 min (Method IV); HRMS: 
[MH]+ 480.2565 (calc. for 
C21H34N7O6+) 480.2565 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 0.86 
& 0.89 (2 sets of d, 6 H, J = 6.6 Hz, 
Leu-δ-CH3), 1.36 (s, 9 H, Boc-CH3 × 
3), 1.41–1.89 (m, 7 H, Arg-γ-CH2, 
Arg-β-CH2, Leu-γ-CH, Leu-β-CH2), 
3.02 (q, 2 H, J = 6.0 Hz, Arg-δ-CH2), 
4.33–4.39 (m, 1 H, Arg-α-CH), 4.71–
4.75 (m, 1 H, Leu-α-CH), 7.53 (d, 1 H, 
J = 7.8 Hz, Arg-α-NH), 8.11 (d, 1 H, J 
= 7.8 Hz, Leu-α-NH), 8.55 (s, 1 H, 
oxazole-CH). 13C NMR (150 MHz, 
DMSO– d6), δ 21.8 (Leu-δ-CH3), 23.1 
(Leu-δ-CH3), 24.5 (Leu-γ-CH), 26.1 
(Arg-γ-CH2), 28.4 (Arg-β-CH2), 28.6 
(Boc-CH3 × 3), 40.4 (Leu-β-CH2), 41.5 
(Arg-δ-CH2), 47.2 (Leu-α-CH), 51.7 
(Arg-α-CH), 78.8 ((CH3)3C), 135.7 
(oxazole-CH), 142.36 (oxazole-C-CO), 
155.7 (oxazole-C-CHαLeu), 160.4 
(Boc-CO), 161.5 (guanidine-C), 165.2 
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(oxazole-C-CO), 173.5 (COOH). 
258 AY64 
R3HN
O
OH
O NH
H2N NH  
Rt = 9.0 min (Method IV); HRMS: 
[MH]+ 457.2405 (calc. for 
C19H33N6O7+) 457.2407 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 0.88 
(2 sets of d, 6 H, J = 6.6 Hz), 1.27 (br 
s, 1 H), 1.38 (s, 9 H), 1.56–1.66 (m, 2 
H), 1.72–1.76 (m, 1 H), 2.06–2.11 (m, 
1 H), 2.16–2.20 (m, 1 H), 3.83 (t, 2 H, 
J = 6.0 Hz), 4.41–4.45 (m, 1 H), 4.72–
4.76 (m, 1 H), 6.56 (s, 2 H), 7.43–7.57 
(m, 5 H), 8.27 (d, 1 H, J = 6.6 Hz), 
8.56 (s, 1 H).   
259 AY99 O
N
H
S
O OR3HN
HN
H2N NH  
Rt = 10.6 min (Method IV); HRMS: 
[MH]+ 594.2704 (calc. for 
C26H40N7O7S+) 594.2704 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 0.85 
& 0.88 (2 sets of d, 6 H, J = 6.0 Hz), 
1.24–1.30 (br s, 1 H), 1.35 (s, 9 H), 
1.51–1.56 (m, 2 H), 1.64–1.73 (m, 2 
H), 3.04 (q, 2 H, J = 7.2 Hz), 4.39–
4.42 (m, 1 H), 4.69–4.73 (m, 1 H), 
7.52–7.54 (m, 1 H), 7.61 (t, 3 H, J = 
7.8 Hz), 7.69 (t, 1 H, J = 7.2 Hz), 7.90 
(d, 2 H, J = 7.2 Hz), 8.13 (d, 1 H, J = 
7.8 Hz), 8.55 (s, 1 H). 
260 AY107
R  
O
N
H
S
O OR3HN
HN
H2N NH  
Rt = 11.4 min (Method II); HRMS: 
[MH]+ 532.2548 (calc. for 
C21H38N7O7S+) 532.2548 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 0.86 
& 0.89 (2 sets of d, 6 H, J = 6.0 Hz), 
1.27 (br s, 1 H), 1.36 (s, 9 H), 1.54–
1.65 (m, 2 H), 1.70–1.80 (m, 2 H), 
3.09 (q, 2 H, J = 7.2 Hz), 3.24 (s, 3 H), 
4.44–4.48 (m, 1 H), 4.71–4.75 (m, 1 
H), 7.50–7.53 (m, 2 H), 8.21 (d, 1 H, J 
= 7.8 Hz), 8.59 (s, 1 H), 12.01 (s, 1 H).  
261 AY31 O
N
H
S
O OR5HN
HN
H2N NH  
Rt = 13.1 min (Method II); HRMS: 
[MH]+ 590.1890 (calc. for 
C30H32N5O4S2+) 590.1890 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 1.32–
1.39 (m, 1 H), 1.41–1.48 (m, 1 H), 
1.54–1.60 (m, 1 H), 1.65–1.70 (m, 1 
H), 3.04 (q, 2 H, J = 7.2 Hz), 4.31–
4.35 (m, 1 H), 5.81 (s, 1 H), 6.75 (d, 1 
H, J = 3.6 Hz), 7.21–7.25 (m, 6 H), 
7.31 (t, 4 H, J = 7.2 Hz), 7.55 (t, 1 H, J 
= 6.0 Hz), 7.59 (t, 2 H, J = 8.4 Hz), 
7.67–7.70 (m, 2 H), 7.88–7.90 (m, 2 
H), 8.53 (d, 1 H, J = 7.2 Hz). 
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262 AY97 O
OHR5HN
HN
H2N NCN  
Rt = 10.7 min (Method I); HRMS: 
[MH]+ 476.1751 (calc. for 
C25H26N5O3S+) 476.1751 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 1.41–
1.42 (m, 2 H, Arg-γ-CH2), 1.62–1.69 
(m, 1 H, Arg-β-CH), 1.75–1.80 (m, 1 
H, Arg-β-CH), 3.03 (q, 2 H, J = 6.6 
Hz, Arg-δ-CH2), 4.25–4.29 (m, 1 H, 
Arg-α-CH), 5.81 (s, 1 H, Ph2CH), 6.76 
(d, 1 H, J = 3.6 Hz, thiophene-CH), 
7.22–7.25 (m, 6 H, Ar-CH), 7.31–7.34 
(m, 4 H, Ar-CH), 7.71 (d, 1 H, J = 3.6 
Hz, thiophene-CH), 8.54 (d, 1 H, J = 
7.8 Hz, HNCO). 13C NMR (150 MHz, 
DMSO–d6), δ 26.4 (Arg-γ-CH2), 28.3 
(Arg-β-CH2), 40.5 (Arg-δ-CH2), 51.6 
(Ph2CH), 52.6 (Arg-α-CH), 
127.27/127.34 (thiophene-CH × 2), 
128.9/129.0 (Ar-CH), 138.3 
(thiophene-C-CO), 143.6/143.7 (Ar-
C), 153.4 (thiophene-C-CH-Ph2), 
161.58 (guanidine-C), 161.65 
(HNCO), 173.9 (COOH).  
263 AY98 O
N
H
S
O OR5HN
HN
H2N NCN  
Rt = 11.6 min (Method I); HRMS: 
[MH]+ 615.1843 (calc. for 
C31H31N6O4S2+) 615.1839 (found); 1H 
NMR (600 MHz, DMSO– d6), δ 1.27–
1.34 (m, 1 H), 1.37–1.43 (m, 1 H), 
1.50–1.56 (m, 1 H), 1.60–1.65 (m, 1 
H), 2.98 (q, 2 H, J = 6.6 Hz), 4.28–
4.31 (m, 1 H), 5.80 (s, 1 H), 6.74 (d, 1 
H, J = 3.6 Hz), 7.21–7.25 (m, 6 H), 
7.30–7.33 (m, 4 H), 7.59 (t, 2 H, J = 
7.8 Hz), 7.67–7.70 (m, 2 H), 7.87–7.89 
(m, 2 H), 8.49 (d, 1 H, J = 7.2 Hz), 
12.34 (s, 1 H).  
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7.1 Introduction 
 
Protease-activated receptor 2 (PAR2) and human anaphylatoxin C3a receptor 
(C3aR) are both class A G-protein coupled receptors that are implicated in a large 
range of inflammatory diseases, such as arthritis and asthma, as well as other 
diseases.1-6 Anti-inflammatory drugs on the market have limited effectiveness or are 
associated with a variety of side effects. Targeting PAR2 and C3aR could have great 
potential for the development of new and more effective drugs for the treatment of 
inflammatory disorders based on information to date about these receptors.  
Ligand development for PAR2 and C3aR has relied heavily on synthetic peptide 
agonists that mimic shorter fragments of the native ligands, which often lack potency 
and have uncertain selectivity and poor pharmacokinetic profiles. The main aims of 
this thesis were to utilise rational drug design approaches to develop potent, receptor-
selective and orally bioavailable non-peptidic compounds for human PAR2 and 
human C3aR. Successfully developed new PAR2 or C3aR agonists/antagonists were 
to be evaluated in vitro for their potential to regulate inflammation in cells and, in 
selected cases, in vivo to validate their pharmacokinetic profiles. 
7.2 Results for PAR2 
 
It has been reported that PAR2 activation can lead to inflammatory diseases such 
as arthritis3-4, 7-8 and inflammatory bowel diseases.9-11 Developing drugs that 
antagonize this receptor could thus be an important objective to realise a potential 
treatment for these diseased states. Recently, a PAR2-selective antagonist  (GB88, 
Fig. 7.1) was reported by our group and found to be effective at low micromolar 
concentrations against both protease and peptide agonists of PAR2 in vitro, while also 
being orally bioavailable and anti-inflammatory in rodent models of paw oedema, 
collagen-induced arthritis, and TNBS-induced colitis. This sets it apart as the most 
potent and useful PAR2 antagonist reported to date.12-14 
To develop more potent and selective ligands for PAR2, the first challenge was to 
investigate optimisation of agonist and antagonist potency against PAR2 by 
investigating structure-activity relationships (SAR). Changes were made to each of 
the component fragments (isoxazole, cyclohexylalanine, isoleucine) of the PAR2 
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antagonist GB88, followed by optimisation of the C-terminal spiroindene piperidine 
fragment (Chapter 2).   
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Figure 7.1 Sites of modification (A, B, C and D) for optimisation of PAR2 lead 
antagonist GB88 and the chemical structure of a non-peptidic PAR2 agonist 
(GB110). 
 
A second approach was to evaluate the SAR around a non-peptidic PAR2 agonist 
(GB110, Fig. 7.1), with the aim of transforming it into a PAR2 antagonist. GB110 
was truncated by removing the piperidine and replacing the aromatic ring with ~40 
different benzylamines which were attached to the C-terminus of isoxazolyl-Cha-Ile 
(Chapter 3).  
Through these SAR studies on GB88 and GB110, the smallest known PAR2 
agonist (isoxazole-Cha-Chg-NH2, 132, EC50 0.4 µM; iCa2+, HT29 cells) and the two 
most potent known PAR2 antagonists (AY117, IC50 0.7 µM and AY265, IC50 0.5 µM; 
iCa2+, HT29 cells) were developed and characterized by intracellular calcium 
mobilization assay (Chapter 2).  
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 132           AY117       AY265 
Biological studies further demonstrated that antagonists AY117 and AY265 
inhibited intracellular calcium release in HT29 cells stimulated by PAR2 agonists, 2f-
LIGRLO-NH2 or endogenous trypsin, and blocked the release of pro-inflammatory 
cytokines (IL6, TNF-α) in a primary kidney cell, human tubule epithelial cells 
(HTEC). These compounds were also stable in rat plasma and rat liver homogenates. 
AY117 was orally bioavailable and effective for the treatment of joint inflammation 
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in rats at 10 mg/kg single dose, while AY265 was much less orally bioavailable (F = 
10%) than AY117 (F = 40%). However, AY265 was a more efficient anti-
inflammatory agent than GB88 and AY117 in the rat paw oedema model at 5 mg/kg 
via subcutaneous injection (Chapter 4).  
PAR2 antagonists have been shown to provide beneficial effects in the treatment 
of inflammatory conditions in both in vitro and in vivo studies. The  rat paw oedema 
studies reported in Chapter 4 also confirmed that PAR2 activation is pro-
inflammatory and that PAR2 antagonism is anti-inflammatory. These newly 
discovered PAR2 antagonists could be used to examine the roles of PAR2 in 
inflammatory conditions.  
7.3 Results for C3aR 
 
Similar to PAR2, the C3a receptor (C3aR) has been implicated in a number of 
inflammatory diseases such as arthritis,2, 5 asthma6, 15 and renal inflammation.16-17 The 
natural ligand for C3aR (C3a protein) has been suggested to be either pro-
inflammatory18-19 or anti-inflammatory20-21 or it might be context and cell dependent. 
Therefore, the biological roles of C3a in diseases remain to be fully elucidated due, in 
part, to the absence of selective and potent C3aR agonists and antagonists. The most 
potent synthetic agonist for C3aR prior to current studies was a six-residue peptide 
(FLTLAR, EC50 0.37 µM, iCa2+ in human dU937 cells)22 and the most potent, non-
peptidic C3aR antagonist was SB290157 (113, IC50 1.3 µM, iCa2+ in human 
monocyte-derived macrophage cells (HMDM)), the latter being reported in the 
literature a decade ago.2 All C3aR ligands developed so far possess an arginine 
residue at the C-terminus, which is known to be crucial for C3aR binding.23-24 The 
protonated-arginine group is a poorly druggable motif that is often associated with 
low oral bioavailability. Therefore, developing potent, selective and orally 
bioavailable agonists and antagonists for C3aR could bring new molecular and 
mechanistic insights to the roles of C3aR in vivo in inflammatory disorders.  
The first goal was to synthesise compounds possessing a turn-like conformation 
that mimicked the turn structure observed at the C-terminus of the crystal structure of 
C3a protein. The C-terminal turn structure of C3a was proposed to be the key 
structural component for potency.25 A few different five-membered heterocycles, with 
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varied hydrogen bonding properties, were incorporated into the ether linker region of 
SB290157 (113) as rigid templates to mimic the turn conformation observed for C3a 
(Fig. 7.2). The aims were to investigate the optimal hydrogen bonding site in the 5-
membered ring, their strengths in H-bonding and how these would affect their 
functions (agonist vs antagonist activity) as well as binding affinities (Chapter 5).  
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Figure 7.2 Replacement of the ether linker region of C3aR antagonist (SB290157, 
113) with different 5-membered heterocycles.  
 
Results have indicated that ligands containing heterocycles that possess a strong 
H-bond acceptor atom generally have very high binding affinity for the receptor. A 
small molecule C3aR agonist (242, EC50 24 nM), possessing an imidazole ring, was 
developed with comparable agonist potency to the native peptide ligand C3a (EC50 40 
nM). In addition, two new C3aR antagonists were developed: 233 (thiophene) and 
234 (thiazole), where 233 (IC50 80 nM) was a 15-fold more potent antagonist than 
reported for SB290157 (113, IC50 1.3 µM) in a calcium release assay on HMDM. In 
contrast, the thiazole compound 234 showed strong binding affinity for the C3aR with 
IC50 4 nM compared to SB290157 (113, IC50 10 nM), but its antagonist activity was 
only 2-fold better.  
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The second goal was to improve the drug-likeness of the current potent C3aR 
ligands through replacement of the guanidine group of arginine (Arg) with different 
guanidine mimetics and substitution of the C-terminal carboxylate group of Arg with 
carboxylic acid bioisosteres (Chapter 6). Amongst all the arginine mimetics presently 
investigated herein, those with linear alkyl chains (especially cyanoguanidine 
analogue) were generally tolerated better than those that incorporated 
conformationally constrained aromatic rings. In addition, the carboxylic acid group of 
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the arginine could be substituted with an N-phenylsulfonamide group while 
maintaining similar binding affinity to the parent arginine compound.  
7.4 Conclusions and future directions 
 
Structure-activity relationships around the PAR2 lead antagonist (GB88) were 
investigated and two new PAR2 antagonists (AY117, AY265) were successfully 
developed. However, these compounds were only 2–5 fold more potent than GB88 in 
a calcium release assay in HT29 cells. Overall, it was suspected that the failure to 
substantially enhance antagonist potency further, despite hundreds of analogues made, 
may be due to an inherent stereochemical constraint imposed in all of these ligands by 
the three central planar amide bonds (isoxazole-Cha-Ile-NH2) linking the four 
fragments (isoxazole, Cha, Ile and the C-terminal moiety). These amides should 
perhaps be removed or replaced with alternative scaffolds in future studies aimed at 
increasing conformational space occupied by the ligand and enhancing antagonist 
potency. Also, the binding sites of these PAR2 ligands in the receptor remain 
uncertain and which receptor residues are crucial for agonist/antagonist activity are 
not known. Future studies could therefore be focused on receptor mutagenesis studies 
and refining the PAR2 homology model using the recently published PAR1 crystal 
structure to gain better understanding of the ligand-receptor interactions that are 
beneficial or detrimental for future drug development. 
The most promising result was the successful development of a non-peptidic and 
selective C3aR agonist (242), which had comparable potency to the 77-residue C3a 
protein. In addition, a potent C3aR antagonist (233, IC50 80 nM, iCa2+ assay in 
HMDM) was also developed. Herein, the heterocyclic part of the compound was 
optimised but future research could be focused on the optimisation of the 
diphenylmethylene group and substitution of different groups at the 5-position of 
heterocycle to improve the agonist or antagonist potency further. Also, further 
structure-activity relationships on arginine mimetic analogues are needed to achieve 
better pharmacokinetic profiles for C3aR agonists and antagonists. The pro- and anti-
inflammatory properties of the most potent C3aR agonists and antagonists reported in 
this thesis will also be evaluated in future in both in vitro and in vivo inflammatory 
models. 
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Discovered in the 1990s, protease activated receptors1 (PARs) are membrane-spanning cell surface proteins
that belong to the G protein coupled receptor (GPCR) family. A deﬁning feature of these receptors is their
irreversible activation by proteases; mainly serine. Proteolytic agonists remove the PAR extracellular amino
terminal pro-domain to expose a new amino terminus, or tethered ligand, that binds intramolecularly to
induce intracellular signal transduction via a number of molecular pathways that regulate a variety of cellular
responses. By these mechanisms PARs function as cell surface sensors of extracellular and cell surface
associated proteases, contributing extensively to regulation of homeostasis, as well as to dysfunctional
responses required for progression of a number of diseases. This review examines common and distinguishing
structural features of PARs, mechanisms of receptor activation, trafﬁcking and signal termination, and
discusses the physiological and pathological roles of these receptors and emerging approaches for modulating
PAR-mediated signaling in disease.
© 2011 Elsevier Inc. All rights reserved.
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1. Introduction
The four PAR family members (designated PAR1, PAR2, PAR3 and
PAR4 (Hollenberg & Compton, 2002)2) belong to the broader G
protein coupled receptor (GPCR) super family. In contrast with other
GPCRs, PARs are not activated in vivo by binding of a soluble ligand
but, instead, are triggered by proteases which cleave extracellularly
within the PAR amino terminus. This cleavage exposes a new amino
terminus that binds intramolecularly to activate the receptor and
induce intracellular signal transduction. As described below, although
Pharmacology & Therapeutics 130 (2011) 248–282
Abbreviations: AP, activating peptide; APC, activated protein C; ECL, extracellular
loop; EGFR, epidermal growth factor receptor; EPCR, endothelial protein kinase C
receptor; GPCR, G protein coupled receptor; HRS, hepatocyte growth factor-regulated
tyrosine kinase substrate; ICL, intracellular loop; MMP, Matrix metalloprotease; PAR,
protease activated receptors; PKC, protein kinase C; TGF, transforming growth factor;
TL, tethered ligand.
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1 The term “protease activated receptor” is used in preference to “proteinase
activated receptor”.
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the PARs are homologous and have overlapping tissue expression
patterns, the functions of each receptor, and their roles in physiology
and disease, are distinct and coordinated by an intricate array of
binding proteins and post-translation modiﬁcations that regulate PAR
trafﬁcking, sub-cellular localization, signal transduction and termina-
tion, and receptor degradation.
2. Structural features and activation mechanisms
The PARs are encoded by genes thatmap to either a gene cluster on
chromosome 5q13 (F2R encoding PAR1, F2RL1 encoding PAR2 and
F2RL2 encoding PAR3) or chromosome 19p12 (F2RL3 encoding PAR4;
Schmidt et al., 1997; Kahn et al., 1998a). Each gene spans two exons,
the ﬁrst encoding the signal peptide and the second the mature
protein (Kahn et al., 1998a). As shown in Fig. 1, the PARs contain seven
transmembrane (TM) helices, an extracellular amino terminal domain
encompassing a signal peptide of between 17 and 26 residues and a
pro-domain of between 11 and 30 amino acids, three intracellular
loops (ICL1-3), three extracellular loops (ECL1-3) and an intracellular
carboxy terminal domain of between 13 and 51 residues. As well as
connecting TM4 and TM5, ECL2 also makes a disulﬁde bond with TM3
that is conserved amongst GPCRs and contributes to receptor
structural stability ((Hamm, 2001) Fig. 1). To facilitate thrombin
binding and proteolysis, PAR1 and PAR3 each contain a hirudin-like
binding domain within the amino terminus ((Vu et al., 1991;
Macfarlane et al., 2001) Fig. 1). In contrast, the third thrombin
responsive receptor, PAR4, while lacking a hirudin-like binding
domain contains a dual proline motif, P45APR, that provides a low
afﬁnity thrombin binding site and a cluster of anionic residues, D57,
D59, E62 and D65, which serves to slow thrombin dissociation ((Jacques
& Kuliopulos, 2003; Nieman, 2008) Fig. 1). Consensus motifs for post-
translational modiﬁcations present on the PARs (N-glycosylation,
ubiquitination, phosphorylation and palmitoylation) are also shown
in Fig. 1.
PAR activation via proteolytic cleavage results in irreversible
removal of the amino terminal pro-peptide and unmasking of a
neoepitope termed the tethered ligand (TL; Vu et al., 1991;
Macfarlane et al., 2001) Fig. 1). The TL is thought to interact
intramolecularly with ECL2, which is glycoslyated on asparagine
residues for PAR1 and PAR2 (Fig. 1), and possibly also with other
regions of the PAR, to initiate a conformational change in the receptor
eliciting downstream intracellular signaling (Macfarlane et al., 2001).
Soon after PAR1 was cloned it was established that, in addition to
activation by intramolecular binding of the proteolytically exposed TL,
this receptor could also be activated by a short synthetic peptide
mimicking the sequence of the revealed TL (Vu et al., 1991;
Scarborough et al., 1992). It is now known that PAR subtype-selective
short synthetic peptides, called activating peptides (APs), can mimic
the TL to activate PAR1, PAR2 and PAR4 and possibly PAR3. These
reagents have been valuable probes for understanding the roles that
PARs play in physiology and disease (Macfarlane et al., 2001;
Ramachandran & Hollenberg, 2008). Use of PAR APs is particularly
informative in settings where more than one PAR is expressed and
activated by the same protease, such as in human platelets where
Fig. 1. PAR structural features. Sequence alignments are shown of the signal (green lettering) and pro-peptide (orange lettering) regions, the mature amino terminus, extracellular
loop (ECL) regions 1, 2 and 3, intracellular loop (ICL) regions 1, 2 and 3, and the carboxy terminal domain of the four human PAR family members. These are overlayed on the seven
transmembrane (TM) domain structure characteristic of GPCRs. Underlined amino terminal sequences represent the tethered ligand for each respective receptor. Boxed residues in
the mature amino terminus represent the hirudin-like domains of PAR1 and PAR3. Cysteines which form a disulﬁde linkage between TM3 and ECL2 are highlighted in purple.
Consensus sites for N-glycosylation are highlighted yellow. Red highlighted residues denote putative palmitoylation sites of PAR1 and PAR2. Highlighted grey and blue residues
represent post-translational modiﬁcation sites for ubiquitination and phosphorylation. The boxed residues in the PAR1 carboxyl terminal indicate the tyrosine-based motif involved
in regulation of receptor trafﬁcking.
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both PAR1 and PAR4 are expressed and activated by thrombin (Kahn
et al., 1999).
3. Agonists and antagonists
The various cellular effects stimulated in vivo via the PAR family
are most often mediated by trypsin-like serine proteases that cleave
on the carboxyl terminal side of arginine and lysine residues (Hansen
et al., 2008; Ramsay et al., 2008b). Cleavage by these proteases, other
than at this activation site, results in receptor inactivation (or
disarming). In this section we describe the proteases so far known
to function as PAR agonists and those that disarm these receptors. The
general features of protease-mediated activation and disarming of
PARs are shown in Fig. 2. In addition, we describe progress that has
been made to deﬁne the APs that induce signaling via PARs and the
peptide mimetics (Barry et al., 2006) designed to activate or
antagonize these receptors, thereby providing opportunities to
modulate PAR actions in disease.
3.1. Protease agonists and dis-armers
Proteolytic activation of human PAR1 occurs on the carboxyl side
of residue R41 to yield the TL sequence S42FLLRN (Fig. 1) and is
mediated by a number of trypsin-fold serine proteases (Table 1)
including thrombin (Vu et al., 1991) and pro-thrombin intermediates
(Kaufmann et al., 1998, 2000), granzyme A (Suidan et al., 1994),
plasmin (Kuliopulos et al., 1999), activated protein C (APC (Riewald
et al., 2002)), factor Xa (FXa (Riewald et al., 2001; Camerer et al.,
2002)), trypsin IV (Knecht et al., 2007) andmembers of the kallikrein-
related peptidase (KLK) family, including tissue kallikrein/KLK1 (Gao
et al., 2010a, 2010b), KLK4 (Mize et al., 2008; Ramsay et al., 2008a;
Gratio et al., 2010), KLK5, 6 and 14 (Oikonomopoulou et al., 2006).
Cathepsin G which displays both chymotryptic and tryptic substrate
speciﬁcity (i.e. it hydrolyzes peptide bonds on the carboxyl side of
aromatic and strongly positively charged residues (Tyr, Phe, Lys, Arg;
Fig. 2. Aspects of PAR-mediated signal transduction. As shown in the left panel proteolysis of the PAR amino terminal, by proteases such as thrombin and trypsin, within a deﬁned
activation site reveals a neo-amino terminal termed the tethered ligand with binds intramolecularly within the receptor enabling an allosteric change to elicit signal transduction
from coupled heterotrimeric G-proteins. The PARs are known to couple with several Gα subunits including Gαi, Gα12/13 and Gαq to activate downstream signaling messengers to
induce a myriad of cellular and physiological effects. PAR2 is also able to signal through the scaffolding protein β-arrestin which also functions to desensitize PAR2 by uncoupling the
receptor from G-proteins. Although β-arrestin does not contribute to PAR1 signaling it does participate in desensitization of this receptor. As shown in the right panel proteolytic
cleavage of the PAR amino terminal outside the activation motif by proteases such as cathepsin G leads to receptor inactivation or “disarming”.
Table 1
Protease agonists and dis-armers of PARs.
Activating protease Disarming protease
PAR1 Thrombin KLK1, 14
Meziothrombin/meziothrombin desF1 ADAM17 or MMP
Granzyme A Protease 3
Plasmin Trypsin
APC-EPCR Cathepsin G
Trypsin IV Elastase
Factor Xa Plasmin
KLK1, 4, 5, 6, 14
MMP-1
Cathepsin G
Proatherocytin
Pen C 13
PAR2 Trypsin Plasmin
Mast cell tryptase Protease 3
TF:Factor Xa: Factor VIIa Calpain
Acrosin Cathepsin G
Matriptase/MT-SP1 Elastase
HAT
Trypsin IV
Granzyme A
TMPRSS2
Chitinase
KLK2, 4, 5, 6, 14
Bacterial gingipains
Der P1, Der P2, Der P3
Pen C 13
PAR3 Thrombin Cathepsin G
PAR4 Thrombin KLK14
Trypsin
Cathepsin G
Trypsin IV
MASP-1
Plasmin
Factor Xa
Bacterial gingipains
KLK1, 14
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(Wysocka et al., 2007)), has also been shown to activate PAR1 (Wilson
et al., 2009b). In addition to these mammalian enzymes, non-
mammalian PAR1 activating serine proteases include proatherocytin
from snake venom (Laing et al., 2005) and mold allergen Pen c 13
which can also signal via PAR2 (Chiu et al., 2007).
A signiﬁcant insight from these studies is the identiﬁcation of quite
different mechanisms by which proteolytic activation of PAR1 occurs.
Whereas thrombin activation of this receptor requires direct binding
of the protease at a hirudin-like binding domain located after the
PAR1 activation site (Fig. 1), APC must be tethered to the plasma
membrane via its receptor endothelial protein C receptor (EPCR
(Riewald et al., 2002)), while a ternary complex at the cell surface
consisting of tissue factor (TF)/factor VIIa (FVIIa)/FXa is required for
efﬁcient FXa signaling via PAR1 and PAR2 (Riewald & Ruf, 2001). As
we will discuss, mechanisms of cell surface localization can impact on
the intracellular signaling pathways initiated by PAR cleavage. In
addition, it is clear that further work is required to understand the
mechanisms by which other PAR activating proteases, particularly
those that lack extended α chains, localize at the cell curface to cleave
and signal via these receptors.
Human PAR2 is activated by cleavage on the carboxyl side of R36
revealing the TL sequence S37LIGKV ((Nystedt et al., 1995) Fig. 1). In
addition to being activated by trypsin (Nystedt et al., 1994), PAR2
activation is mediated by mast cell tryptase (Molino et al., 1997),
directly by TF/FVIIa and indirectly by TF/FVIIa-generated FXa
(Camerer et al., 2000), acrosin (Smith et al., 2000), matriptase/MT-
SP1 (Takeuchi et al., 2000), human airway trypsin-like protease (HAT
(Miki et al., 2003)), trypsin IV (Cottrell et al., 2004), Granzyme A
(Hansen et al., 2005), TMPRSS2 (Wilson et al., 2005), KLK2 (Mize
et al., 2008), KLK4 (Mize et al., 2008; Ramsay et al., 2008a), KLK5,
KLK6 and KLK14 (Oikonomopoulou et al., 2006) and themold allergen
serine protease Pen c 13 (Chiu et al., 2007).
Human PAR3 is cleaved primarily by thrombin on the carboxyl side
of K38 to reveal the TL sequence T39FRGAP ((Hauck et al., 1999) Fig. 1).
Interestingly, unlike other PAR family members other proteases that
target PAR3 have not been identiﬁed (Ishihara et al., 1997). Human
PAR4, activated by proteolytic cleavage on the carboxyl side of R47 to
reveal the TL sequence G48YPGQV (Fig. 1), is responsive to comparable
concentrations of trypsin and thrombin (Xu et al., 1998) and also
responds to a number of other proteases including cathepsin G
(Sambrano et al., 2000), trypsin IV (Cottrell et al., 2004), complement
pathway protease MASP-1 (Megyeri et al., 2009), plasmin (Quinton
et al., 2004), FXa (Camerer et al., 2000, 2002), KLK1 (Houle et al.,
2005) and KLK14 (Oikonomopoulou et al., 2006).
In a challenge to the dogma that PARs function exclusively as cell
surface receptors for trypsin-like serine proteases and that cleavage
outside the activation site recognized by these enzymes results in
receptor disarming, it has been reported thatmatrixmetalloproteinase
(MMP)-1 signals via cleavage of PAR1 promoting invasion and
tumorigenesis of breast cancer cells (Boire et al., 2005). MMP-1
cleaves at basic or hydrophobic amino acids and is best known for its
collagenase activity (Pardo & Selman, 2005). This initial report has
been followed by several others demonstrating a role for the PAR1/
MMP-1 axis in breast cancer cell migration (Nguyen et al., 2006),
endothelial cell activation (Goerge et al., 2006), angiogenesis
(Blackburn & Brinckerhoff, 2008) and melanoma invasion and
metastasis (Blackburn et al., 2009). Perhaps most surprisingly, it
has recently been shown that MMP-1 cleavage occurs at D39/P40 and
that this cleavage event can drive platelet aggregation, activation of
Rho-GTP pathways, cell shape changes and motility and p38 MAPK
signaling (Trivedi et al., 2009).
It is also noteworthy that enzymes from other protease classes
activate PARs including bacterial cysteine gingipains that signal
via PAR2 (Uehara et al., 2005) and PAR4 (Lourbakos et al., 2001)
and the PAR2 activators, house dust mite cysteine protease Der P1,
which activates PAR2 in selected settings (Asokananthan et al., 2002b;
Adam et al., 2006), the mite serine proteases, Der P2 and Der P3
(Sun et al., 2001) and chitinase from Streptomyces griseus (Hong et al.,
2008).
In addition to these PAR activating proteases, many proteases also
act as negative PAR regulators, preventing downstream signaling by
proteolytically inactivating (or dis-arming) the receptor via one of
two mechanisms; ﬁrst, by cleavage of the receptor within the
extracellular amino terminal domain C-terminal of the activation
site to disarm the receptor by removal of the tethered ligand; and,
second, by cleaving elsewhere within the receptor to disable signaling
(Kawabata et al., 1999b; Hansen et al., 2008; Ramachandran &
Hollenberg, 2008). Examples include KLK14 mediated disarming of
both PAR1 and PAR4 (Oikonomopoulou et al., 2006), and disarming of
PAR1 by ADAM17 (Ludeman et al., 2004), trypsin (Kawabata et al.,
1999b), cathepsin G (Molino et al., 1995), elastase (Renesto et al.,
1997) and plasmin (Kuliopulos et al., 1999). Plasmin, protease 3 and
calpain (Loew et al., 2000) and elastase and cathepsin G (Dulon et al.,
2003, 2005) also disarm PAR2. While elastase and cathepsin G have
also been shown to disarm PAR3, there appears to be a level of species
speciﬁcity as cathepsin G is able to disarm both human and mouse
PAR3, whereas elastase inactivates only the human receptor (Cumashi
et al., 2001). Interestingly, although able to cleave within the amino-
terminus, the authors speculated that the primary cleavage site for
both cathepsin G and elastase lies elsewhere within the receptor.
3.2. Peptide and peptide mimetic agonists
Most non-proteinaceous PAR agonists identiﬁed to date have been
peptides corresponding to, or derived from, the TL sequence unique to
each PAR. For example, the synthetic peptide corresponding to the TL
sequence (SFLLRN-NH2) generated following cleavage of PAR1
between residues R41 and S42 activates this receptor with an EC50 of
0.53±0.02 μM (Maryanoff et al., 2001). Structure-activity studies
using synthetic peptide agonists with C-terminal amide caps have
identiﬁed key components important for potency and selectivity of
these APs. For example, a minimum of 5 amino acids (e.g. SFLLR-NH2)
are required to activate PAR1, with truncation to tetrapeptides (e.g.
SFLL-NH2) greatly reducing potency while dipeptides (e.g. SL-NH2)
were inactive (Feng et al., 1995; Ceruso et al., 1999). In addition,
acetylation or removal of the N-terminal amino group results in very
low potency, while removing the serine completely abolishes
potency, even when replaced with hydrophilic, charged or aromatic
residues (Feng et al., 1995). Also, replacing phenylalanine at the
second position with small residues, saturated rings, or aromatic
groups other than those bearing electron-withdrawing substituents,
also reduces agonist potency (Feng et al., 1995). Furthermore,
substitution of the ﬁfth residue arginine with acidic amino acids
sharply decreases potency. Mao et al. (2008) and Vassallo et al. (1992)
also reported that phenylalanine instead of leucine at position 2 and
arginine at position 5 are the most important for platelet activation,
presumably by triggering PAR1, while residues at positions 3 and 4 are
only moderately important and can be replaced by other amino acids
including arginine (Mao et al., 2008). Interestingly, N-methylated
amides or D-amino acids reduces potency, suggesting that amide NH
protons and L-amino acids are important for receptor binding afﬁnity
(Mao et al., 2008). In summary, PAR1 APs require a free amine group
at the N-terminal, a small amino acid at position 1 (eg. serine, alanine,
proline), an aromatic group at position 2 (preferably with an electron-
withdrawing group) and a basic residue (arginine/lysine) at position
5. Consistently, one of the most potent reported PAR1 APs, with
an EC50 of ~10 nM, is A-p-fFR-Cha-homoR-Y-NH2 (where p-fF is p-
ﬂuorophenylanine, Cha is cyclohexylalanine and HomoR is homo-
arginine) (Feng et al., 1995).
Using similar approaches, PAR2 APs have been designed to mimic
the natural TL sequence from the human (SLIGKV) and mouse
(SLIGRL) receptors (Macfarlane et al., 2001). As for PAR1, a
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pentapeptide is the minimum sequence for low μM agonist potency
via PAR2 (Hollenberg et al., 1996), and only 3 peptides have
comparable activity to the mouse TL sequence (SLIGRL-NH2), namely
S-p-fFIARL-NH2, SLIARK-NH2 and SL-Cha-ARL-NH2. However, the ﬁrst
of these also shows PAR1 activity with p-fF at position 2 and Arginine
at position 5 favoring PAR1 (Maryanoff et al., 2001). Substitution of
serine at the N-terminal with basic, acidic or large hydrophobic
residues reduces agonist activity. These studies also showed that the
N-terminal amino group is important, because acetylation decreases
activity N25 fold (Maryanoff et al., 2001). In addition, although
introduction of charged or small amino acids (e.g. glycine, alanine) at
position 2 abolished activity, Cha or phenylalanine gives similar
potency, this last amino acid is not selective for PAR2 over PAR1.
Isoleucine and Cha at position 3 give optimal agonist activity, while
substitution with alanine or phenylalanine reduces the potency. At
position 4, glycine could be replaced with alanine and Cha, but Cha
also activates PAR1. Instead of having arginine or positive-charged
residues at position 5, it was surprising that this position also tolerates
large hydrophobic groups, suggesting that a hydrophobic pocket with
an acidic residuemight be located at the corresponding position in the
receptor. It was also demonstrated that leucine at position 6 is less
important, as substitution with other amino acids like small/large
aliphatic chain, aromatic, charged residues and amides does not show
a signiﬁcant change in potency (Maryanoff et al., 2001).
Although these results support a requirement for only 5 amino
acids in a PAR2 agonist, a signiﬁcant decrease in potency is observed
when L2, I3 or G4 is replaced with a D-amino acid, indicating that
stereochemistry is also important for binding to the receptor
(Maryanoff et al., 2001). This requirement is similar to results
obtained for PAR1 APs. Interestingly, Kawabata et al. reported that a
2-furoyl moiety in place of serine at the N-terminal substantially
increases PAR2 AP potency by about 10-fold (Kawabata et al., 2004).
In addition, 2-furoyl-LIGRLO-NH2 (where O is ornithine) is 10–15
times more potent than SLIGRL-NH2 at inducing intracellular calcium
release in both cultured human and rat PAR2-expressing cells, some
300 times more potent in a murine-isolated blood vessel assay, and is
selective for PAR2 over PAR1 (McGuire et al., 2004).
More recently, it has been reported that addition of a seventh and
even eighth residue, such as isoleucine or leucine to the C-terminus of
SLIGRL-NH2, increases potency by ~6–8 fold, while replacing the sixth
residue leucine with aromatic groups increases potency further (Barry
et al., 2007; Devlin et al., 2007). In addition, heptapeptides with
aromatic amino acids at the sixth residue and peptides with 4-
nitrophenylalanine, 3,4-dichlorophenylalanine or 3-benzothienylala-
nine at the sixth position are equipotent with 2-furoyl-LIGRLO-NH2.
Interestingly, structure-activity studies suggest that other hetero-
cycles and aromatic groups could be used as alternatives for 2-furoyl
without much loss of potency, and that these structures are better
than aliphatic groups, suggesting possible pi–pi interactions of the
aromatic/heterocyclic ring with PAR2 (Barry et al., 2007).
In summary, these key potency and selectivity ﬁndings for PAR2
APs (Barry et al, 2006) indicate that in terms of the activity of the
mouse TL sequence (SLIGRL-NH2): S1 or small replacements like a
small heterocycle enhance PAR2 AP potency; L2 is optimally replaced
with Cha, while aromatic residues give similar potency but with
diminished selectivity for PAR2 over PAR1; either isoleucine or Cha at
the third position is optimal; G4 and L6 are not crucial for potency and
can be substituted; R5 is possibly binding to a negatively-charged
residue in PAR2, although substitution with large hydrophobic groups
does not signiﬁcantly reduce agonist potency, suggesting that this
may be for afﬁnity rather than agonist activity per se; and addition of a
seventh residue to the C-terminal may or may not improve potency,
depending on the moiety at the N-terminus.
Although some potent PAR2 APs have been developed, the
typically poor bioavailability of these molecules is still a major
limitation for in vivo studies. To overcome this shortcoming, recent
studies have attempted to develop non-peptidic PAR2 agonists (Barry
et al., 2006). For example, non-peptidic PAR2 agonists 1 to 3 were
reported in 2008 from a screen of over 250,000 drug-like compounds
using a high-throughput functional approach (Seitzberg et al., 2008).
While compound 1 is a full agonist (EC50 200–1000 nM) of PAR2
(Gardell et al., 2008), compound 2 is a partial agonist. Further studies
on the more potent agonist 1 suggested that the methyl substituent
on the hydrazone is crucial for agonist activity, since replacing it with
hydrogen or larger alkyl groups signiﬁcantly reduces activity.
Although this compound possesses good metabolic stability in
human and rat microsomes, it is highly insoluble in aqueous
phosphate buffer as well as organic solvents (Seitzberg et al., 2008).
Superposition of compounds 1 and 2 led to identiﬁcation of the more
potent PAR2 agonist 3 with an EC50 of 30–100 nM. Structure-activity
studies on 3 indicated that meta substitution of the bromine is
prefered, since ortho and para substitutions reduce activity 50-fold.
Also, the N-methylated hydrazone does not show any activity,
suggesting that the NH proton may act as hydrogen bond donor to
PAR2. Importantly, Both 1 and 3 are more potent agonists than the
PAR2 AP SLIGRL, and are selective for PAR2 over other PARs. These
molecules demonstrate good stability, but poor solubility (Gardell
et al., 2008; Seitzberg et al., 2008) and the hydrazone is not a drug-like
moiety as it is readily metabolized.
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To improve drug-like properties, a new class of non-peptidic PAR2
agonists and antagonists has been developed from hexapeptides
through a heterocyclic replacement of the N-terminal serine,
truncation from the C-terminus, and by appending C-terminal non-
peptidic fragments (Barry et al., 2007; Suen, 2009; Barry et al., 2010).
Using intracellular Ca2+ release as a measure of PAR2 activation,
agonist GB110 (compound 4, EC50 0.28 μM) selectively activates PAR2
expressed by a range of cell lines. It is equipotent with themost potent
synthetic peptide agonists reported for PAR2 as well as being selective
for PAR2 over PAR1, and has no effect on PAR1 activation by thrombin
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or on intracellular Ca2+ release in cells desensitized to PAR2 activation
(Suen, 2009; Barry et al., 2010).
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For PAR3, most studies have used APs resembling the TL to tease
out physiological roles. For example, several receptor APs such as
T39FRGAP and T39FRGAPPNSF have been used, although these are
non-speciﬁc with poor selectivity. Also, it has been shown that PAR3
TL sequences TFRGAP-NH2 (human) and SFNGGP-NH2 (murine)
activate PAR1 and PAR2, but not PAR3 in both Jurkat and over-
expressing HEK-293 cells, probably due to the identity of the T/S-F
residues of PAR1 and PAR3 APs (Hansen et al., 2004). TFRGAP-NH2
also induces MAPK signaling by interacting with hPAR1 (Kaufmann
et al., 2005). The authors speculated that this may be a function of the
PAR3 TL serving as a cofactor to modulate PAR1 signaling. These data
indicate that caution is warranted when interpreting data using PAR3
APs.
As for PAR1 and PAR2, mouse and human PAR4 are sensitive to APs
resembling TL sequences. Both murine (GYPGKF-NH2) and human
(GYPGQV-NH2) PAR4 APs are selective and do not activate PAR1 or
PAR2 (Hollenberg et al., 1999). These APs, but not a reverse peptide
(VQGPYG), also induce rat platelet aggregation (Hollenberg &
Saifeddine, 2001). Furthermore, APs with greater sensitivity have
been developedwith the peptide AYPGFK proving 10 foldmore potent
than GYPGKF (Faruqi et al., 2000). Interestingly, these authors report
that substitution of tyrosinewith phenylalanine or p-ﬂurophenylanine
within AYPGKF induces PAR1 and PAR4 activation with potential for
this peptide to serve as a backbone for dual-receptor antagonists.
3.3. Antagonists and pepducins
Once it was established that PARs regulate a number of cellular
responses, it became clear that antagonists of these receptors could
potentially be useful in clinical settings. In this section we discuss
antagonists that bind extracellularly to inhibit PAR activities as well as
a recently identiﬁed class of intracellular antagonists, pepducins
(palmitoylated peptides based on ICL3 of PARs), that function by
interfering with signal transduction (Covic et al., 2002a).
3.3.1. Antagonists for PAR1
Developing an antagonist for PAR1 was particularly attractive,
since the impact of thrombin on platelets and endothelial cells could
in principle be blocked without affecting essential coagulation
properties of thrombin. Even before the ‘thrombin receptor’ (PAR1)
had been cloned, synthetic peptide analogues were synthesized that
blocked the action of thrombin on platelets, without inhibiting its
proteolytic activity and essential coagulation properties (Ruda et al.,
1988, 1990). Although not very potent (Ki 140–450 μM (Ruda et al.,
1990)), these compounds pointed a way forward for developing PAR1
antagonists (Barry et al., 2006). It was the pharmacology of PAR1 APs,
including a substantial amount of structure-activity work in this area
(Hollenberg et al., 1992; Sabo et al., 1992; Scarborough et al., 1992;
Vassallo et al., 1992; Hollenberg et al., 1993; Rasmussen et al., 1993;
Laniyonu & Hollenberg, 1995; Hollenberg et al., 1997), that led to the
synthesis of the ﬁrst thrombin antagonists, which were of low
potency but set the stage for antagonist development (Barry et al.,
2006).
Studies of the amino acid ‘side-chain’ requirements for the potent
PAR1 agonist S-p-fF-p-guanidinoFLR-NH2 (EC50 0.04 μM) (Natarajan
et al., 1995) led to the synthesis of relatively potent peptide
antagonists such as compound 5 with an IC50 of 20 nM (Bernatowicz
et al., 1996). Substitution of serine with a trans-cinnamoyl or 3-
phenyl-2-propynoyl group further increases potency. In addition, the
antagonist potency is improved by introducing a positive charge at the
third residue and extending the C-terminal with another arginine
residue. However, it was not fully appreciated at the time that the
PAR1-targeted APs could also be PAR2 agonists (Kawabata et al.,
1999b).
The ﬁrst potent peptidomimetic PAR1 antagonists to be described
were RWJ-56110 (6a) and RWJ-58259 (6b) (Andrade-Gordon et al.,
1999, 2001; Zhang et al., 2001; Maryanoff et al., 2003). These
compounds were devevoped de novo using a ‘three-point pharma-
cophore model’ based on distances between 3 important functional
groups, i.e. the N-terminal ammonium group, the centre of the
benzene ring of the second residue, and the guanidino group of R5.
These three key residues were attached to rigid scaffolds like 6-
aminoindole to constrain the peptide backbone. RWJ-56110 (6a) is a
potent and selective PAR1 antagonist (IC50 0.34 μM against thrombin;
IC50 0.16 μM against SFLLRN-NH2). It inhibits platelet aggregation
stimulated by both thrombin and SFLLRN-NH2, but causes moderate
hypotensive responses in guinea pigs at an intravenous (iv) dose of
7 mg/kg, possibly because of the bulky substituent at position 2 of the
indole. Therefore, indazole was used to replace the indole moiety to
give RWJ-58259 (6b) (Zhang et al., 2001), which shows similar
selectivity and potency in inhibiting platelet aggregation as RWJ-
56110, but higher binding afﬁnity and no side effects in guinea pigs at
a dose of 7 mg/kg. RWJ-58259 was further shown to have anti-
restenotic activity in vivo in a rat balloon angioplasty model
(Andrade-Gordon et al., 2001) and antithrombotic activity in a
cynomolgus monkey arterial injury model (Derian et al., 2003).
These compounds so far have met with limited use in human clinic
settings (see below).
Some non-peptidic PAR1 antagonists were developed with IC50
values of 100–600 nM, including compounds 7 (FR17113), 8, 9 and 10
(Kato et al., 1999; Barrow et al., 2001; Nantermet et al., 2002).
Antagonist 8, discovered from screening of a combinatorial library and
optimized by reducing the piperidine ring size and introduction of an
oxygen atom to the ring (to morpholine) has strongly reduced
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potency, suggesting that the hydroxyl group on the piperidine ring in
9 could be a hydrogen bond donor or acceptor with PAR1 (Barrow
et al., 2001).
A very potent PAR1 antagonist, ER129614-06 (11) with an IC50 of
14 nM and 28 nM against thrombin and SFLLRN-induced platelet
aggregation, respectively, was reported in 2004 (Kawahara et al.,
2004). This compound shows a dose-dependent antithrombotic effect
in a guinea pig thrombosis model and is orally bioavailable. Two small
piperazine compounds (12, 13) were discovered as PAR1 antagonists
at 10 μM concentrations that inhibit N90% of Ca2+ release induced by
1 μM SFLLR-NH2, with a potent antithrombotic effect in a rat shunt
model. However, F16357 (12) shows even better activity after oral
administration at 40 mg/kg (59%) compared to 1.25 mg/kg iv (28%),
while compound F16618 (13) gives similar results (58% iv vs 54%
orally (p.o.)). These compounds are highly selective for PAR1 against
other PARs (Perez et al., 2009). However, these small molecules may
also target other non-PAR G protein-coupled receptors, as piperazines
are common moieties in GPCR ligands (Blakeney et al., 2007).
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High throughput screening of thioether compounds recently
identiﬁed a lead compound which is a 96% antagonist in a Ca2+
assay (at 10 μM induced by 1 μM SFLLR peptide in CHO cells).
Further lead optimisation disovered two compounds (14, 15) that
show strong antithrombotic activity in vivo. These two compunds
are not metabolically stable against rat microsomes but relatively
stable against human liver microsomes (Planty et al., 2010). Another
class of drugs that has shown very promising results as antagonists
of PAR1 are based on the alkaloid himbacine that can be naturally
isolated from the bark of Australian magnolias. The most advanced
compound SCH530348 (16) is a synthetic tricyclic 3-phenylpyridine
that inhibits PAR1 on platelets with an IC50 of 47 nM and is selective
over a number of other GPCRs including the PARs (Chackalamannil
et al., 2008). Other compounds in clinical development include
compound E5555 (17), chemically identiﬁed as 1-(3-tert-Butyl-4-
methoxy-5-morpholinophenyl)-2-(5,6-di-ethoxy-7-ﬂuoro-1-imino-
1,3-dihydro-2 H-isoindol-2yl)ethanone hydrobromide which in ad-
dition to inhibiting PAR1, also inhibits platelet function through
actions on PECAM-I, GP IIb/IIIa antigen, and activity with PAC-1,
GPIb, thrombospondin, vitronectin receptor expression, and forma-
tion of platelet-monocyte aggregates (Serebruany et al., 2009; Cirino
& Severino, 2010).
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Another innovative strategy for the inhibition of PAR1 has
involved the use of pepducins. These compounds are N-palmitoylated
peptides, derived from the sequences of the ICL3 domains of GPCRs
that traverse or integrate into the plasma membrane in association
with the PARs or other targeted GPCRs (Miller et al., 2009). In this way
the pepducies act as ‘dominant negative’ antagonists to disrupt
interactions between ICL3 of the PARs and cognate interacting G-
proteins or other effectors. This approach has proven successful for a
number of GPCRs including the PARs. For example, the PAR1-targeted
pepducin P1pal-12 (pal-RCLSSSAVANRS-NH2) is a potent, selective
inhibitor of this receptor (IC50 1 μM, stimulated by SFLLRN) without
any agonist activity (Covic et al., 2002a, 2002b). In addition, inhibition
of PAR1 with P1pal-12 protects against sepsis lethality, lung vascular
damage and disseminated intravascular coagulation (Kaneider et al.,
2007). Also, in a recent study the PAR1 pepducin P1pal-7 (pal-
KKSRALF-NH2) blocked MMP-1 induced PAR1-activation of the Akt
survival pathway in breast cancer cells resulting in apoptosis in tumor
xenografts and inhibition of metastasis to the lungs by up to 88%
(Yang et al., 2009).
3.3.2. Antagonists for PAR2 and PAR4
In contrast with the advances in PAR1 antagonism, progress in
development of potent PAR2 antagonists has been slower (Barry et al.,
2006). For example, while the peptides FSLLRY-NH2 and LSIGRL-NH2
block trypsin-mediated activation, AP-mediated activation of this
receptor is unaffected (Al-Ani et al., 2002). Also, while N1-3-
methylbutyryl-N4-6-aminohexanoyl-piperazine (ENMD-1068, 18)
at very large dosages attenuates acute inﬂammation in mice (Kelso
et al., 2006), it is not a PAR-speciﬁc ligand at these concentrations.
More successfully, Plevin and colleagues have reported a number of
peptide antagonists of PAR2 that inhibit calcium signaling and NFκB
activity induced by peptide agonists (though not by serine proteases)
and compete with a high afﬁnity PAR2 radioligand with low micro
molar Ki values (Kanke et al., 2009). One of these compounds, N-[1-
(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-5-
yl]aminocarbonyl]-glycinyl-L-lysinyl-L-phenylalanyl-N-benzhydryla-
mide (K-14585, 19) inhibits intracellular calcium release induced by a
PAR2 AP without affecting ERK signaling (Goh et al., 2009) and also
inhibits p65 NFκB phosphorylation and DNA binding. Furthermore,
although a natural diterpenoid from Tripterygium wilfordii Hook F,
triptolide (20), used in Chinese medicine, inhibits (IC50 14 nM) NFκB
activated by 10 μM 2f-LIGRLO-NH2 (Hoyle et al., 2010), it also reduces
substance P-induced neurokinin receptor 1 (NK1)-mediated produc-
tion of IL-8 (IC50 23 nM) (Hoyle et al., 2010). It should also be noted
that although proposed as a natural product for the treatment of
arthritis and other inﬂammatory diseases (Lipsky & Tao, 1997; Tao
et al., 2001, 2002; Jiao et al., 2008), compound 20 shows toxicity after
oral administration to rats (Shao et al., 2007).
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GB88 (21) is a novel PAR2 antagonist derived from the agonist
GB110 (4), with the same N-terminus but with a bulky C-terminal
spiroindenepiperidine (Suen, 2009). It is the ﬁrst PAR2 antagonist to
reversibly inhibit activation of this receptor by endogenous (e.g.
trypsin), synthetic peptide (e.g. 2f-LIGRLO-NH2) and nonpeptide (4)
agonists at low concentrations (IC50 ~2 μM). In addition, GB88 is a
pathway-speciﬁc antagonist, inhibiting PAR2-induced intracellular Ca2+
release, cAMP stimulation, receptor internalization, and proinﬂamma-
tory cytokine release, without affecting PAR2 mediated ERK phosphor-
ylation (Suen, 2009). It is also a surmountable (competitive) antagonist
of 2f-LIGRLO-NH2, but an insurmountable antagonist of both trypsin and
GB110, making it a valuable PAR2 silencing tool for mechanistic studies
(Suen, 2009). Furthermore, GB88 is serum stable and orally active and
has been investigated for PAR2 modulation in vivo in a range of animal
models of human inﬂammatory and proliferative diseases. In addition,
given orally at 5 mg/kg/p.o. GB88 inhibits rat paw oedema illicited by
PAR2agonists but not PAR1 agonists, and substantially inhibits collagen-
induced arthritis in rats. This compound is likely to be of beneﬁt in
further characterization of PAR2 as a therapeutic target in inﬂammatory
and other diseases (Suen, 2009).
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PAR4 antagonist development has lagged behind PAR1 and PAR2.
Trans-cinnamoyl-YPGKF (tc-YGPKF), a TL derived peptide, blocks
platelet aggregation induced by AYPGKH-NH2, GYPGKF-NH2 and
thrombin at concentrations up to 400 μM (Hollenberg & Saifeddine,
2001). The most promising PAR4 antagonist developed, YD-3 (22) [1-
benzyl-3(ethoxycarbonylphenyl)-indazole], inhibits thrombin-stim-
ulated platelet aggregation in mice (IC50 21 μM). However, in human
platelets, which also express PAR1, it blocks aggregation induced by
GYPGKF-NH2 but not thrombin-induced aggregation (Wu et al., 2000,
2002). Inhibition of PAR4 using pepducins has also been reported. The
PAR4 antagonist pepducin P4pal10 (pal-SGRRYGHALR-NH2) com-
pletely inhibits platelet aggregation, prolongs bleeding time and
prevents systemic platelet activation in mice. However, this pepducin
also inhibits PAR1, possibly due to the similarity of the C-terminal
sequence of ICL3 of human PAR1 and PAR4 (Covic et al., 2002b).
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4. Molecular aspects of PAR function
PAR-mediated signal transduction occurs via ‘conventional’ intra-
cellular coupling to speciﬁc G protein subunits and, also for PAR2, via
G-protein independent pathways involving β-arrestin scaffolding
(Sun et al., 2007; Defea, 2008). It is now apparent that these pathways
are modulated at multiple levels including receptor translocation to,
and localisation within, the plasma membrane, the properties of the
agonist, molecular events following receptor activation including
signal termination, internalisation and degradation, and mechanisms
controlling recycling of uncleaved PAR to the plasma membrane. In
this section we describe features of these signal transduction path-
ways including mechanisms modulating signaling and those govern-
ing receptor trafﬁcking.
4.1. Signal tranduction
Signal transduction mediated by GPCRs such as the PARs is
sustained intracellularly via heterotrimeric G proteins consisting of an
α-subunit (Gα) associated with a Gβγ dimer that couple directly with
GPCR intracellular domains. Ligand activation of GPCRs induces GDP
exchange for GTPwithin Gα and disassociation from the Gβγ dimer to
evoke signal transduction by interacting with and regulating
downstream effectors. It is apparent that downstream of the cell
surface receptor, PAR-mediated signaling is similar to that of other
GPCRs. For example, PAR1 and PAR2 induce classical signal transduc-
tion pathways by coupling directly with G proteins Gαq, Gαi and
Gα12/13 (Macfarlane et al., 2001; Steinhoff et al., 2005; Soh et al.,
2010), while PAR4 also signals conventionally by coupling with Gαq
(Faruqi et al., 2000) and Gαi/o (Momota et al., 2006; Hirano et al.,
2007). However, it remains uncertain whether proteolysis of PAR3
transduces signals intracellularly via G proteins. On the one hand early
reports indicated that PAR3 on its own is unable to induce signal
transduction in a murine system, instead appearing to function as a
co-factor localizing thrombin for efﬁcient signaling via activation of
PAR4 (Nakanishi-Matsui et al., 2000). However, more recently it has
been reported that PAR3 may be able to autonomously generate
intracellular calcium signals and activate ERK in overexpressing
HEK293 cells and in human lung epithelial and astrocytoma cell
systems that endogenously express this receptor (Ostrowska & Reiser,
2008). Similarly, it has also been reported that in A549 lung epithelial
cells, PAR3 activation by thrombin induces ATP release dependent on
RhoA and calciummobilisation (Seminario-Vidal et al., 2009). Thus in
selected settings, it appears that PAR3 indeed may be able to signal on
its own. However, autonomous signaling via PAR3 clearly requires
further attention.
PAR-initiated G protein-mediated signaling activates a complex
array of downstream pathways. Coupling with Gαq activates
phospholipase C which generates diacyl glycerol and inositol 1,4,5-
triphosphate (IP3) from phosphatidylinositol 4,5-bisphophate to
mobilize Ca2+ from the endoplasmic reticulum into the cytosol.
PAR1 and PAR2 activation of this pathway has been demonstrated in a
range of cell types including platelets (Benka et al., 1995), kidney and
intestinal epithelial cells (Bohm et al., 1996a, 1996b), rat hippocampal
neurons, astrocytes (Bushell et al., 2006), myocytes and ﬁbroblasts
(Ossovskaya & Bunnett, 2004).
Other effector pathways downstream of PAR activation include the
mitogen-activated protein kinase (MAPK) pathway that links these
receptors with proliferative cellular responses, and the nuclear factor-
κB (NF-κB) pathway which links PARs with inﬂammation. G protein
dependent PAR1- and PAR2-mediated activation of ERK signaling
through the MAPK signaling cascade has been demonstrated in many
cell types including smooth muscle and kidney epithelial cells
(Belham et al., 1996; Yu et al., 1997), astrocytes (Wang et al.,
2002a) and dermal ﬁbroblasts (Wang et al., 2006). In astrocytes, PAR1
AP activates the MAPK pathway via both the pertussis toxin-sensitive
Gβγ, PI-3 kinase and Ras pathway and the pertussis toxin-insensitive
PKC and Raf pathway (Wang et al., 2002a). In smooth muscle cells,
trypsin and PAR2 APs stimulate components of the MAPK pathway,
including MAPK kinase 1 and 2 and c-Raf-1, but not the MAPK
homologue p38 or c-Jun N-terminal kinase (JNK (Belham et al.,
1996)). In contrast, in other cell-types PAR2-mediated p38 MAPK and
JNK activation is robust (Sabri et al., 2000; Kanke et al., 2001).
The NF-κB family of transcription factors is recognized as a primary
regulator of pro-inﬂammatory mediator genes (Lenardo & Baltimore,
1989). Although not completely understood, a growing literature
suggests important roles for PAR2 and, to a lesser extent, PAR1 in
inﬂammatory responses. In a number of cell types, PAR2 agonists
stimulate the DNA binding activity of NF-κB and activation of
upstream inhibitory kinase κB (IKK) α and IKKβ (Bretschneider
et al., 1999; Kanke et al., 2001; Shpacovitch et al., 2002; Buddenkotte
et al., 2005). It appears from studies using selective PKC isoform
inhibitors that PAR signaling via the NF-κB/IKK pathway is PKC
dependent (Kanke et al., 2001). Interestingly, both PKC dependent
and independent mechanisms regulate PAR2-mediated signaling via
p38 and JNK (Kanke et al., 2001) and it has been shown that PAR2-
mediated NF-κB p65 subunit phosphorylation is also PKC and Gαq/11
dependent (Goon Goh et al., 2008). Downstream of these events, NF-
κB activation by PAR2 stimulation with trypsin and PAR2 APmediates
expression and secretion of many inﬂammatory mediators including
the cytokines CXCL1 and CXCL8 (Rudack et al., 2007; Niu et al., 2008).
NF-κB activation has also been demonstrated through the cooperative
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action of PAR2 and Toll-like receptor-4 (TLR4 (Rallabhandi et al.,
2008; Nhu et al., 2010)). The ectopic co-expression of both receptors
resulted in increased PAR2 AP induced NF-kB signaling culminating in
enhanced interleukin (IL)-8 production. Interestingly, synergism
between these receptors appears dependent on direct PAR2 and
TLR4 physical interaction (Rallabhandi et al., 2008). Consistently,
receptor cooperativity between PAR2 and the TLR4 related receptors,
TLR2 and TLR3, results in NF-κB activation occurs inmucosal epithelial
cells (Nhu et al., 2010).
Signaling via PAR1 is also thought to activate NF-κB through Gαq
and Gβγ dependent pathways with Gαq signaling involving PKCδ and
the Gβγ mediated pathway requiring PI-3 kinase (Rahman et al.,
2002). Of functional relevance, it has been shown that PAR1
dependent activation of NF-κB p65 promotes survival of prostate
cancer PC3 and DU145 cells and elevates expression of the pro-
inﬂammatory cytokines IL-6 and IL-8 (Tantivejkul et al., 2005).
It is also apparent that PARs transactivate other receptor systems.
For example, activation of PAR1 transactivates ErbB2/HER2/EGFR2 in
breast carcinoma cells (Arora et al., 2008) and EGFR in cardiomyocytes
(Sabri et al., 2002), HT-29 human colon cancer cells (Darmoul et al.,
2004b), renal carcinoma cells (Bergmann et al., 2006), breast
carcinoma cells (Arora et al., 2008) and human keratinocytes (Gao
et al., 2010a). Activated PAR2 also transactivates EGFR in the gastric
cancer cell lines AGS and MKN28 (Caruso et al., 2006) and in human
intestinal epithelial cells (Jarry et al., 2007; van derMerweet al., 2008).
Of note, PAR2-mediated EGFR transactivation in HaCaT keratinocytes
induces ERK signaling and leads to secretion of transforming growth
factor-beta-1 (TGF-β1 (Rattenholl et al., 2007)). Furthermore, a recent
study has shown that synergistic signaling involving PAR1 and ErbB2/
HER2/EGFR2 enhances induction of the atherosclerosis-associated
protein MAPK phosphatase-1 in an ERK1/2 independent, JNK and
VEGFR-2 dependent process (Chandrasekharan et al., 2010).
Other PAR1 and PAR2 signaling pathways are emerging. PAR1
signaling via Gα12/13-induced cytoskeletal reorganisation is mediated
by RhoA GTPase activation in several cell types including ﬁbroblasts
(Hatziapostolou et al., 2008), prostate cancer cells (Greenberg et al.,
2003), kidney and colonic epithelial cells (Nguyen et al., 2002) and
endothelium (Russo et al., 2009a) and induces focal adhesion kinase
(FAK) tyrosine phosphorylation dependent cell migration (Steinhoff
et al., 2005). However in ﬁbroblasts, PAR1-mediated cytoskeletal
reorganisation occurs independent of RhoA but dependent on Rac1
and FAK activation by tumor progression locus 2 (Hatziapostolou et
al., 2008). For PAR2, AP agonism activates RhoA in respiratory
epithelial (Yagi et al., 2006), umbilical vein endothelial (Klarenbach
et al., 2003) and prostate cancer cells (Greenberg et al., 2003) to
induce FAK tyrosine phosphorylation and formation of stress ﬁbers,
contributing to cell adhesion and migration (Steinhoff et al., 2005). In
endothelial cells, PAR2 AP stimulation concomitantly induces RhoA
activation and transient phosphorylation of the Rac effector, p21-
activated kinase, whereas treatment with PAR1 APs oppose this
response by inhibiting Rac (Vouret-Craviari et al., 2003). PAR2 is also
thought to regulate downstream transcriptional activation through
cut-like homeobox-1 (CUX1), a transcription factor involved in tissue
homeostatis (Wilson et al., 2009a). Consistently, treatment of both
epithelial and ﬁbroblastic cells with trypsin induces a rapid increase in
the DNA binding activity of CUX1 which speciﬁcally enhances the
expression of IL-1α, MMP-10 and cyclo-oxygenase-2 downstream of
PAR2 (Nepveu, 2001; Sansregret & Nepveu, 2008).
Similar to PAR1 and PAR2, PAR4 couples with G proteins to
mediate intracellular signal transduction in a number of cells from
various tissues with G protein subunit coupling displaying cell type
selectivity. For example, thrombin and the PAR4 AP AYPGKF induce
calciummobilisation via Gαq in primary cultured mouse lung alveolar
epithelial cells (Ando et al., 2007), primary rat brain capillary
endothelial cells (Vajda et al., 2008), microglial cells (Suo et al.,
2003), human vascular smooth muscle cells (Bretschneider et al.,
2001) and human platelets (Coughlin, 2000; Faruqi et al., 2000). In
these cells, thrombin and AYPGKF induce calcium mobilisation,
whereby Gαq and phospholipase C-β2 are required for effective
signaling (Vaidyula & Rao, 2003). Recently, PAR4 coupling with Gαq
has been shown to modulate platelet aggregation and secretion via
phosphorylation of hematopoietic lineage cell speciﬁc protein 1
(Kahner et al., 2007, 2008). In contrast to the above cell types, PAR4
is thought to couple predominantly with Gαi/o in bovine aortic
endothelial cells (Momota et al., 2006), porcine aortic endothelial cells
and HUVECs (Hirano et al., 2007) and this receptor also transactivates
EGFR in cardiomyocytes (Sabri et al., 2003) and ErbB2/HER2/EGFR2 in
HT29 colon cancer cells (Gratio et al., 2009).
Other PAR4-mediated signaling effectors such as ERK, p38
activation (Mazharian et al., 2007) and Akt phosphorylation (Resendiz
et al., 2007; Grenegard et al., 2008) also contribute to human platelet
function. PAR4-mediated ERK (Shankar et al., 2006) and PKCδ
(Murugappan et al., 2005) signaling in human platelets induces
thromboxane A2 production, which activates and causes aggregation
of new platelets. Supporting the role of PAR4 in this process, the PAR4
antagonist YD-3 inhibits agonist-induced thromboxane A2 production
(Wu et al., 2003). Both PAR1- and PAR4-mediated platelet signaling
events are modulated by intracellular levels of cAMP and cGMP;
particularly PAR4 dependent calcium mobilisation and dense granule
release (Bilodeau & Hamm, 2007). Interestingly, the bradykinin
breakdown product, bradykinin 1–5 (RPPGF) also regulates PAR4-
mediated platelet function. This peptide has been shown to inhibit
murine and humanplatelet aggregation via amechanism that involves
binding with the PAR4 amino terminal to inhibit thrombin cleavage
(Nieman et al., 2005).
In addition to these G protein dependent signaling events, it is
clear that G protein independent signal transduction pathways are
also initiated by proteolytic activation of PARs. The most completely
characterized of these pathways involves PAR2 interactions with the
scaffolding proteins β-arrestin 1 and 2, which bind to the phosphor-
ylated carboxyl terminal of the receptor. In addition to mediating G
protein independent signaling, these interactions uncouple PAR2
from downstream heterotrimeric G protein signal transduction and
link the receptor with internalisation machinery (Dery et al., 1999;
DeFea et al., 2000; Defea, 2008). By this mechanism β-arrestins
participate in G-protein signal termination and also mediate down-
stream signaling by acting as scaffolds permitting complex formation
with multiple components including ERK1/2 to modulate G protein
independent signal transduction. Interaction of PAR2 with β-arrrestin
1 and 2 (Jacob et al., 2005b; Stalheim et al., 2005) prolongs
intracellular receptor-mediated signaling via ERK1/2 activation
(DeFea et al., 2000; Ge et al., 2003; Stalheim et al., 2005; Defea,
2008). Interestingly, PAR2-mediated ERK1/2 activation is also
possible in the absence (Stalheim et al., 2005) or prevention of β-
arrestin binding (DeFea et al., 2000) but this activation is not
prolonged and activity rapidly declines. Of pathophysiological
relevance, prolonged ERK1/2 activation mediated by PAR2 interaction
with β-arrestin1 and 2 elicits a direct cellular response by regulating
intestinal paracellular permeability (Jacob et al., 2005b). In addition,
in MDA-MB-231 breast cancer cell activation of this pathway requires
β-arrestin1 and 2 induction of actin cytoskeletal reorganisation in
conjunction with polarised pseudopodia extension and chemotaxis
(Ge et al., 2004). PAR2 also mediates G-protein independent
chemotaxis by another β-arrestin dependent pathway involving
β-arrestin complex formation with coﬁlin and its activator chronophin
to modulate actin assembly within membrane protrusions (Zoudilova
et al., 2007, 2010).
In addition to β-arrestin mediated signaling, a recent report has
identiﬁed Jun activation domain-binding protein 1 (Jab1), a compo-
nent of the COP9 signalosome complex, as a PAR2 interacting and
signal modulating protein. Post PAR2 activation, Jab1 dissociates from
the receptor to bind and activate c-Jun and further activate the
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transcription factor activator protein-1. This novel signal transduction
pathway highlights the diversity of cellular processes mediated by
PAR2 and further links this receptor with regulation of gene
expression (Luo et al., 2006).
In contrast with PAR2, G protein independent signaling pathways
transduced via PAR1 evidently do not involve β-arrestins. Rather, it
has been suggested that PAR1 directly interacts with both creatine
kinase and heat shock protein 90 to regulate receptor mediated RhoA
signaling and cytoskeletal reorganisation independent of G proteins
(Mahajan et al., 2000; Pai et al., 2001). Interestingly, PAR1 is also
capable of inducing cytoskeletal reorganisation independent of G
proteins and RhoA activation by interacting directly with the zinc-
binding phosphoprotein zyxin (Han et al., 2009). The ability of PAR3
and PAR4 to transduce intracellular signals independent of G proteins
has not been investigated.
4.2. Modulation of signal transduction
The mechanisms regulating PAR-mediated signaling via both G
protein dependent and independent pathways are complex and, as
described in this section, involve modulation via post-translational
modiﬁcations, receptor co-factoring and dimerisation, and differential
localization within plasma membrane domains.
4.2.1. Post-translational modiﬁcations
Post-translational modiﬁcations that affect PAR signaling include
N-glycosylation, phosphorylation, ubiquitination and, potentially,
palmitoylation. Phosphorylation of serine and threonine amino acids
and ubiquitination of lysine residues have primarily been investigated
in the context of PAR signal termination and receptor desensitization,
internalization and trafﬁcking. Therefore, in this section we focus on
the role of N-glycosylation and, to a limited extent, palmitoylation, in
PAR signaling, while the roles of phosphorylation and ubiqutinylation
in receptor trafﬁcking are discussed in later sections.
PAR1 has ﬁve N-glycosylation sites, three in the amino terminal
(N35, N62 and N75, Fig. 1) and two in ECL2 (N240 and N258, Fig. 1).
Although glycosylation of PAR1 at these sites does not inhibit receptor
inactivation by plasmin (Kuliopulos et al., 1999), this modiﬁcation
does appear to have a role in regulation of this receptor. For example,
mutation of the amino terminal consensus glycosylation sites reduces
PAR1 cell surface expression, whereas mutation of ECL2 glycosylation
sites impairs agonist-triggered internalisation, highlighting differen-
tial roles for glycosylation in receptor trafﬁcking to and from the cell
surface (Soto & Trejo, 2010). Moreover, removal of ECL2 glycosylation
sites improves the maximal receptor signaling response, not by
impacting on proteolysis, but by enhancing G protein signaling,
potentially by stabilizing active receptor conformations to modulate
the coupling of G proteins (Soto & Trejo, 2010).
In contrast to PAR1, N-glycosylation of PAR2 can impact on
receptor proteolytic activation. Mast cell tryptase displays variation in
PAR2 activation dependent on glycosylation at the two N-glycosyla-
tion sites of the receptor. Mutants lacking site N30, located within the
PAR2 amino terminal (Fig. 1) are more responsive to tryptase-
mediated activation relative to the wildtype receptor. However,
receptor devoid of N222, located within ECL2, signal as efﬁciently as
wildtype PAR2 in response to tryptase (Compton et al., 2001). In
contrast, trypsin signaling via PAR2 is unaffected bymutation of either
site (Compton et al., 2002). As is the case for PAR1, N-glycosylation of
PAR2 is necessary for its efﬁcient cell surface expression (Compton
et al., 2002). Although PAR3 and PAR4 also display consensus N-
glycoslyation sites (Fig. 1), the glycan content of each receptor and the
role of this modiﬁcation in receptor function is unknown.
Addition of a palmitatemoiety (a 16 carbon saturated fatty acid) to
one or more cysteine residues via a thioester bond generally occurs in
the cytoplasmic tail of GPCRs 10 to 14 residues after the ﬁnal
transmembrane domain (Probst et al., 1992). This modiﬁcation is
thought to act as a targeting signal for cell surface localisation and
formation of signaling complexes within plasma membrane micro-
domains (Chini & Parenti, 2004; Escriba et al., 2007). While the role of
palmitoylation in regulation of PAR signaling is largely unexplored, it
is known that PAR1 contains a di-cysteine motif and PAR2 a single
cysteine residue located down stream of the last transmembrane
domain (Fig. 1) at sites conserved in and functionally important for
many palmitoylated GPCRs (Qanbar & Bouvier, 2003). Although,
palmitoylation of PAR1 and PAR2 at these cysteines has not been
directly demonstrated, PAR1mutants lacking the di-cysteinemotif fail
to couple efﬁciently with Gαq (Swift et al., 2006).
4.2.2. PARs as co-factors and heterodimerisation partners
PAR-mediated signal transduction is also modulated by interac-
tions with other PARs functioning either as a cofactor to facilitate
localization of the activating protease or as a dimerization partner. For
example, PAR3 functions as a cofactor for thrombin-mediated
activation of PAR4. In murine platelets, thrombin binds to the PAR3
hirudin-like domain (Fig. 1) cleaving the amino terminus of this
receptor thereby functioning to localise bound thrombin within
proximity of the PAR4 activation site (Nakanishi-Matsui et al., 2000).
An X-ray crystallographic study has conﬁrmed that by thismechanism
PAR3 functions as a co-factor facilitating thrombin-mediated activa-
tion of PAR4 (Bah et al., 2007). There is now also good evidence that
PAR1 transactivates PAR2 in sepsis. Kaneider and coworkers demon-
strated that PAR1 switches from a vascular disruptive to a vascular-
protective receptor during progression of sepsis in mice. The
mechanism involves re-localization of PAR1-PAR2 complexes to the
plasma membrane, where PAR1 switches to protective signaling by
transactivation of PAR2-Gαi-Rac pathways that mediate endothelial
barrier repair (Kaneider et al., 2007). In support of this proposal,
transactivation of PAR2 by PAR1 has also been demonstrated in COS-7
cells coexpressing PAR2 and a mutant PAR1 that can be cleaved but
cannot signal (O'Brien et al., 2000).
PAR heterodimerization also accentuates protease-mediated sig-
naling in certain situations. For example, PAR3 heterodimerised with
PAR1 in human endothelial cells yields greater Gα13 coupling
comparedwith PAR1 homodimers in response to thrombin, indicating
that PAR3 may act as an allosteric regulator of thrombin mediated
PAR1 signaling (McLaughlin et al., 2007). PAR1 also heterodimerizes
with PAR4 in human platelets to enhance thrombin cleavage of PAR4
and calciummobilization (Leger et al., 2006). This heterodimerisation
mechanism enables thrombin to function as a bivalent agonist and
this perhaps contributes to the biphasic response previously observed
in human platelets in response to thrombin (Covic et al., 2000;
Shapiro et al., 2000).
4.2.3. Differential plasma membrane localization of PARs
GPCRs can localize to distinct plasmamembrane structures known
as membrane rafts and caveolae. These are lipid rich regions
composed of heterogeneously and laterally segregated classes of
freely ﬂowing lipid and cholesterol variants assembled via van der
Waals interactions, that provide an organizational platform for GPCR-
mediated signal transduction from the cell surface (Xu et al., 2006;
Hanzal-Bayer & Hancock, 2007; Kubale et al., 2007; Morris et al., 2008;
Patel et al., 2008). Several recent reports have demonstrated
differential localization of PARs in these plasmamembrane structures.
PAR1 expressed on the surface of ﬁbroblasts localizes to caveolae by
direct interaction with the caveolae scaffold protein caveolin-1
(CAV1) and it is only this caveolae localized PAR1 that induces
CAV1 tyrosine phosphorylation in a Src and p38 MAPK dependent
manner (Lu et al., 2006). Also of interest, membrane raft, but not
caveolae localized, PAR1 modulates bovine endothelial cell cytoskel-
etal reorganization by stimulating the RhoA/Rho kinase signaling
pathway (Carlile-Klusacek & Rizzo, 2007). In addition, efﬁcient
induction of TF in human endothelial cells is dependent on caveolae
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localized PAR1 and interaction with CAV1 (Banﬁ et al., 2007).
Interestingly, localization of PAR2 within caveolae is cell type
dependent. While PAR2 cell surface localization is independent of
caveolae in endothelial cells (Banﬁ et al., 2007), this receptor
colocalizes with TF in membrane rafts and caveolae in breast cancer
MDA-MB-231 cells. Disruption of lipid rafts and silencing of CAV1 can
disrupt the ability of TF/FVIIa to activate signaling through PAR2 in
these cells (Awasthi et al., 2007).
The ability of different agonists to induce different signaling
responses via the same PAR (a process known as biased signaling
(Kenakin, 2007; Urban et al., 2007; Kenakin & Miller, 2010) is related,
at least in part, with differential membrane localization of PAR
receptors and is disucussed in the following sections.
4.2.4. Biased signaling
Biased signaling, or agonist-directed trafﬁcking of responses, is a
recently recognized phenomenon describing how different extracel-
lular stimulii can initiate multiple cellular responses via the one GPCR
(Kenakin, 2007; Galandrin et al., 2008; Shukla et al., 2008; Kenakin &
Miller, 2010; Rajagopal et al., 2010; Zheng et al., 2010). When ﬁrst
identiﬁed GPCRs were thought to be capable of switching between
only two states, on and off. It is now realized that this model is
insufﬁcient to explain the complexity of GPCR signaling, and several
new models have been put forward to characterize GPCR-mediated
signaling, including biased signaling, receptor dimerization, allosteric
interaction, inverse agonist and G protein independent signaling
(Rajagopal et al., 2010). Biased signaling is associated with GPCRs
switching between different conformational states, each state
triggering different downstream signaling pathways. Structurally
different agonists or antagonists are thought to be able to stabilise
the targeted receptor in one of these states. Thus, two agonists of the
same receptor may actually trigger quite different cellular responses
due to different activated conformational states of the membrane-
imbedded GPCR. In addition, the extent of cell surface GPCR
expression and the nature of the cell/tissue type have both been
reported to alter downstream signaling proﬁles (Cussac et al., 2002).
This new understanding has created both opportunities and dilemmas
for GPCR research. It promises the potential to use different ligands to
ﬁne tune control over receptor signaling and more efﬁciently dissect
the role of speciﬁc pathways in particular physiological processes or
disease states. However, it also implies that mass screening of
compound libraries in one or a few assays will be insufﬁcient to
characterize agonist or antagonist activity.
The recent proposal that PAR1 forms preassembled complexes
with Gαi1, but not with Gα12, supports the proposal that multiple
conformational states exist for PARs. In this report by Ayoub and
colleagues, it appears that rapid Gαi1 activation (t1/2 4.13 s) occurs
because of the existence of preassembled PAR1/Gαi1 complexes that
recruit β-arrestin 1 following receptor activation. In contrast, PAR1/
Gα12 complex assembly is much slower (t1/2 8.8 min) and occurs well
after receptor activation and in parallel with β-arrestin 1 recruitment
(t1/2 7.5 min) (Ayoub et al., 2010). These differential mechanisms
of PAR1 complex formation with Gα proteins are indicative that
the receptor can take up multiple conformations and it is these
conﬁrmations that may support biased signaling.
A functionally important example of biased signaling has come
from a comparison of thrombin- and APC-induced PAR1 signaling in
endothelium. This differential signaling is summarized in Fig. 3. In this
study, biased agonism involving divergent responses of PAR1 to these
serine proteases was shown to modulate endothelial barrier integrity
(Feistritzer & Riewald, 2005; Finigan et al., 2005; Riewald & Ruf, 2005;
Russo et al., 2009a). In this system, the pro-inﬂammatory mediator
thrombin signals via PAR1 resulting in activation of the GTPase RhoA,
but not the related protein Rac1 (Russo et al., 2009a); a reaction
cascade known to disrupt endothelial barrier integrity (Komarova
et al., 2007). In contrast, the cytoprotective agonist APC strongly
activates Rac1 but not RhoA via PAR1 (Russo et al., 2009a) enhancing
barrier integrity (Feistritzer & Riewald, 2005; Finigan et al., 2005).
Signiﬁcantly, whereas APC signaling and endothelial barrier protec-
tion is abolished in CAV1 deﬁcient cells, thrombin signaling is
unaffected (Russo et al., 2009a). These data demonstrate that
compartmentalization of PAR1 in lipid rafts and localization to
Fig. 3. PAR1 biased signaling.Membrane raft localized PAR1modulates endothelial cell cytoskeletal reorganization to disrupt endothelial barrier integrity by stimulating the RhoA/Rho
kinase signaling pathway following thrombin-mediated activation (left panel). PAR1 expressed on the surface of ﬁbroblast cells localizes to caveolae by direct interaction with the
caveolae scaffold protein caveolin-1 (CAV1) and it is only this caveolae localized PAR1 that induces CAV1 tyrosine phosphorylation in a Src and p38 MAPK dependent manner (right
panel). The cytoprotective agonist APC bound to EPCR activates Rac1 but not RhoA via PAR1 to enhance barrier integrity. Compartmentalization of PAR1 in lipid rafts and localization to
caveolae are critical for APC biased agonism of PAR1 and enhanced barrier integrity.
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caveolae were critical for the APC biased agonism of PAR1 required for
enhanced barrier integrity (Russo et al., 2009a).
Based on the difference in PAR1 sites cleaved by MMP-1 (D39/P40)
and thrombin (R41/S42) to induce signaling, it would be reasonable to
expect that these proteases will also demonstrate biased signaling via
this receptor. However, as reported by Trivedi et al. (2009), collagen
induced MMP-1 activation of PAR1 drives the same cellular responses
in platelets as thrombin; aggregation, activation of RhoA, cell shape
changes and motility, and p38 MAPK signaling. However, it is possible
that responses may indeed be biased in other processes involving
endotheial cells and in other cell types as it has previously been
shown that, although both MMP-1 and thrombin are pro-angiogenic
and signal via MAPK, activation of this pathway happens with
different kinetics and each protease induces expression of different
subsets of pro-angiogenic genes (Blackburn & Brinckerhoff, 2008).
Although PAR2 can also be activated by a range of proteases
including the complexed coagulation proteases TF-VIIa or TF-VIIa-Xa,
as well as mast cell tryptase, KLKs and trypsin, it has not been directly
established whether PAR2 activation by these proteases results in
biased agonism. However, recent molecular pharmacological studies
have shown that PAR2 has different determinants for receptor
coupling to signaling, depending on whether agonists are presented
to the receptor as a proteolytically revealed TL or as soluble peptides,
suggesting indirectly that this receptor can exhibit biased signaling
(Al-Ani et al., 2004). Furthermore, it has been shown that whereas
mutations within the ﬁrst two amino acids of the proteolytically
revealed tethered ligand of PAR2 (S37L38) render the receptor unable
to couple to the Gαq calcium signaling pathway, the mutated receptor
retains the ability to trigger other distinct signaling pathways such as
the MAPK pathway. In this system, signaling to MAPK and coupling to
Gα12/13 is independent of β-arrestin recruitment but dependent on
Rho-associated protein kinase activity, suggesting that PAR2 can
signal tomultiple pathways that are differentially triggered by distinct
agonists (Ramachandran et al., 2009).
In fact, there is other evidence, from studies employing APs and
proteases to induce PAR signaling, that suggest that biased agonism in
PARs has been known for many years. In 1993, it was observed that TL
derived peptide agonists stimulate signaling responses that are
distinct from those triggered by protease activated PAR1 receptors.
While both thrombin and the TL peptide agonist SFFLRNP stimulate a
transient ERK activation, only thrombin activated PAR1 shows a
second more sustained ERK activation (Vouret-Craviari et al., 1993).
Another study showed that PAR1 activation with APs biases the
signaling response towards Gαq coupling and calcium signaling, while
thrombin-stimulated PAR1 couples preferrentially to Gα12/13. It is
functionally signiﬁcant that coupling to Gα12/13, but not to Gαq,
induces endothelial barrier permeability (McLaughlin et al., 2005).
Similarly, two PAR2 APs differentially signal via rat PAR2 in stably
expressing KNRK cells. While the AP matching the rat PAR2 TL
(SLIGRL-NH2) induces both calcium and ERK signaling, the synthetic
peptide SLAAAA-NH2 fails to induce PAR2-mediated calcium signaling
but does activate ERK (Ramachandran et al., 2009). More recently,
examination of PAR2 activation by trypsin and 2f-LIGRLO-NH2 in
HEK293 cells highlighted extensive differences in expression of
19,000 analysed human genes and also demonstrated that PAR2
regulates expression of genes associatedwith cellularmetabolism, the
MAPK pathway, cell cycle, anti-complement function, HDAC and
sirutuin enzymes and inﬂammatory cytokines (Suen et al., 2010).
4.3. Desensitisation, resensitisation and PAR trafﬁcking
Following signal tranduction, GPCR desensitisation is generally
induced by rapid phosphorylation, usually via GPCR kinases (GRKs
(Krupnick & Benovic, 1998)), followed by arrestin binding, promoting
G protein uncoupling. Receptor endocytosis ensues, removing the
activated receptor from signaling effectors and the plasmamembrane.
For non-PAR GPCRs the internalized receptor is either recycled to
repopulate the cell surface or targeted for lysosomal degradation
(Ritter & Hall, 2009). However for PARs, receptor recycling is
prevented by the proteolysis inherent in the activation mechanism.
In this section we discuss aspects of the speciﬁc mechanisms
controlling processing of PARs following activation with a primary
focus on PAR1 and PAR2.
4.3.1. PAR1
As shown in Fig. 4A PAR1 internalization occurs via two highly
regulated mechanisms: (1) constitutive and (2) agonist-triggered
pathways (Shapiro & Coughlin, 1998). Constitutive internalization of
PAR1 modulates cell surface expression of uncleaved receptor.
Internalized, unactivated PAR1 can resensitize the cell surface
independent of de novo synthesis of nascent receptors by constitu-
tively cycling between the cell surface and intracellular organelles
(Hein et al., 1994; Paing et al., 2006). Protease agonist triggered
internalization prevents sustained agonist mediated signal transduc-
tion (Soh et al., 2010).
It is well established that protease-mediated activation of PAR1
induces its rapid internalization and degradation (Shapiro & Coughlin,
1998). In addition to this agonist-mediated regulation of internaliza-
tion and degradation, it appears that trafﬁcking of PAR1 to the cell
surface also occurs in an agonist-dependent manner. For example,
recently it has been shown that APC-mediated activation of PAR1
results in the accumulation and persistence of the receptor at the
surface of endothelial cells even in the presence of thrombin
(Schuepbach et al., 2008). Furthermore, APC activation of PAR1
induces receptor phosphorylation but does not result in efﬁcient
internalization or degradation (Russo et al., 2009a). When the action
of an agonist does trigger receptor internalization this step is
preceded by rapid phosphorylation of PAR1 which is required for
receptor uncoupling from signaling effectors (Ishii et al., 1993, 1994).
While phosphorylation of the carboxyl terminal of PAR1, which
contains 15 serine and threonine residues, can be mediated by
GRK3 (Ishii et al., 1994), GRK5 (Tiruppathi et al., 2000) and a novel
33 kDa Ser/Thr kinase (Ido et al., 2000), it is likely that other kinases
capable of phosphorylating PAR1 exist. In any case, differential
phosphorylation of the PAR1 carboxyl terminal targets the receptor
either toward desensitisation or internalization (Hammes et al.,
1999).
Activated and phosphorylated PAR1 and unactivated PAR1
internalize through a clathrin and dynamin dependent mechanism
(Trejo et al., 2000) and not via caveolae (Lu et al., 2006). Although
internalisation of activated and unactivated PAR1 does not require β-
arrestin (Paing et al., 2002), receptor desensitization is β-arrestin 1
dependent (Paing et al., 2002; Chen et al., 2004) and this scaffolding
protein physically interacts with both phosphorylated and unpho-
sphorylated PAR1 (Chen et al., 2004). For GPCRs generally, β-arrestins
bind predominantly to the phosphorylated receptor to act as a protein
scaffold linking the receptor with internalisation machinery such as
Fig. 4. PAR desensitization, resensitization and trafﬁcking. A. PAR1 is internalised through constitutive and agonist-triggered internalisation pathways and is dependent on dynamin
and clathrin-coated pits (CCP). Constitutive internalisation of unactivated PAR1 is AP2 dependent and negatively regulated by ubiquitination. Following activation, basally
unbiqutinated PAR1 is deubiqutinated by unknown mechanisms, then phosphorylated and internalised also in a bicaudal D1 (BicD1) dependent mechanism to early endosomes
(EE). Activated PAR1 is then sorted through late endosomes (LE) and targeted to lysosomes for degradation in a process dependent on sorting nexin 1 (SNX1). B. PAR2 internalises
solely through agonist-triggered mechanisms. In contrast with PAR1, activated PAR2 is phosphorylated and binds β-arrestin 1 and 2 (βarr) and internalises to the EE in a
ubiquitination dependent process also requiring GTPase rab5a. Continued sorting of PAR2 also requires hepatocyte growth factor-regulated tyrosine kinase substrate (HRS). PAR2
trafﬁcked through LE is deubiqutinated before lysosomal degradation. PAR2 resensitisation of the cell surface with nascent receptors occurs in a p24a, ARF-1 and rab11a dependent
process from the Golgi. C. Mechanisms contributing to PAR3 and PAR4 internalisation and trafﬁcking remain largely unknown.
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clathrin and adaptor protein-2 (AP2 (Laporte et al., 1999)). In the
absence of β-arrestin, AP2 binds PAR1 through the motif Y383KKL
located in the receptor carboxyl terminal (Paing et al., 2006) to
regulate agonist triggered internalisation (Paing et al., 2004). In
addition, AP2 is critical for both constitutive internalisation and cell
surface resensitisation of the receptor (Paing et al., 2006). The GTPase
Rac1 also modulates constitutive internalization of PAR1 (Yufu et al.,
2005) while the adapter transport protein bicaudal D1 (BicD1) has
recently emerged as a critical regulator of agonist triggered PAR1
internalisation (Swift et al., 2010). BicD1 does this by interacting
directly with the carboxyl terminal of PAR1, independent of
phosphorylation and β-arrestins, to inhibt Gαq-mediated signaling
and suppress PAR1-induced proliferation of breast carcinoma cells
(Swift et al., 2010). In addition to these mechanisms, internalization
of PAR1 is also modulated by post-translational modiﬁcation with
ubiquitin. Traditionally, covalent modiﬁcation of GPCR lysine residues
with ubiquitin directs receptor internalization usually targeting the
receptor for degradation (Marchese et al., 2008). However, PAR1 is
basally ubiquitinated, negatively regulating constitutive receptor
internalization, and is deubiquitinated after receptor activation
(Wolfe et al., 2007).
Complete signal termination of PAR signaling relies on trafﬁcking
of internalized receptor to early and late endosomes and ﬁnally to
lysosomes for degration (Soh et al., 2010). The mechanisms of
trafﬁcking that culminate in PAR degradation are not well deﬁned but
appear to have unique features for each receptor. For example, unlike
PAR2, trafﬁcking of PAR1 for degradation is independent of receptor
ubiquitination (Soh et al., 2010). Also, efﬁcient endocytic trafﬁcking of
PAR1 towards lysosomes requires sorting nexin 1 (SNX1) and SNX2,
mammalian homologues of the yeast Vps5p retromer component that
functions in endosome-to-Golgi trafﬁcking (Wang et al., 2002b;
Gullapalli et al., 2006). SNX1, modulated by SNX2, physically interacts
with PAR1 to directly target the receptor to lysosomes (Gullapalli
et al., 2006).
4.3.2. PAR2
Mechanisms regulating PAR2 signal termination, trafﬁcking and
degradation are summarized in Fig. 4B. Unactivated PAR2, unlike
unactivated PAR1, does not constitutively internalize. Also, proteo-
lytically activated PAR2 is initially phosphorylated not by GRKs, but
rather by PKC isoforms (Bohm et al., 1996a) resulting in receptor
desensitisation. Broad range inhibitors and PKC isoform-selective
inhibitors (against α, β, γ, ε, η and θ) block phosphorylation of PAR2
resulting in increased Ca2+ in response to trypsin and AP, whereas
potent activators of PKC, particularly isoformsα and ε, decrease PAR2-
mediated Ca2+ responses by inducing receptor phosphorylation and
enhancing initiation of signal termination (Bohm et al., 1996a).
Phosphorylation of PAR2 occurs on the 18 serine and threonine
residues located within the receptor carboxy terminal domain (Fig. 1,
(Ricks & Trejo, 2009)), and this is critical for efﬁcient receptor
desensitisation and internalization through dynamin- and clathrin-
dependent mechanisms (Ricks & Trejo, 2009). Furthermore, it is clear
that phosphorylation of this receptor enhances its afﬁnity for β-
arrestin (Seatter et al., 2004; Ricks & Trejo, 2009). It is this interaction
between β-arrestin and PAR2 that is essential for receptor uncoupling
from G protein-dependent signaling cascades via a mechanism
involving redistribution of β-arrestin from the cytosol and interaction
with PAR2 at the plasma membrane. Following receptor activation,
β-arrestin and PAR2 internalize into early endosomes (Dery et al.,
1999), an event that is mediated, at least in part, by the small GTPase
Rab5a (Roosterman et al., 2003) a critical factor in endosome formation
(Bucci et al., 1994).
PAR2 is also regulated by ubiquination with mono-ubiquitination
of activated PAR2 preventing its recycling to the cell surface. This
modiﬁcation is mediated by c-Cbl, a ubiquitin-protein ligase, in a Src-
dependent mechanism (Jacob et al., 2005a). In addition, continued
trafﬁcking of internalized PAR2 from endosomes to lysosomes is
reliant on receptor deubiquitination by the endosomal deubiquitinat-
ing proteases AMSH and UBPY (Hasdemir et al., 2009) and the
endosomal sorting protein hepatocyte growth factor-regulated
tyrosine kinase substrate (Hasdemir et al., 2007).
It is clear from the above summary that proteolytic activation of
PAR2 results in signal transduction followed by receptor internalisa-
tion and degradation to prevent persistent PAR2 signaling. A
consequence of this mechanism is that large cytoplasmic stores of
PAR2 are required to replenish cell surface localized receptor before
PAR-mediated signaling can recommence; a process known as
resensitisation (Steinhoff et al., 2005). Thus, in contrast to other
GPCRs which show abundant cell surface expression and low
cytoplasmic levels, PAR2 can be detected in many cells predominantly
inside the cell, with comparatively lower levels on the cell surface
(Dery et al., 1999). Although the mechanisms involved in receptor
resensitisation are poorly characterized, it is clear that another
GTPase, Rab11a, participates in trafﬁcking of cytoplasmic stores of
pro-PAR2 from the Golgi apparatus to the plasma membrane. During
trafﬁcking to the plasma membrane Rab11a co-localises with
intracellular stores of PAR2 in vesicles and overexpression of this
GTPase accelerates replenishment of intact cell surface-localised
receptor (Roosterman et al., 2003). Recently another Golgi localised
protein, p24a, a type I transmembrane protein, has also been shown to
aid PAR2 exocytic trafﬁcking. This protein interacts with ECL2 of
nascent PAR2 at the Golgi apparatus in a mechanism regulated by
ADP-ribosylation factor 1 (ARF-1; (Luo et al., 2007a)). Finally,
although it is clear that mechanisms controlling PAR2 desensitisation
and resensitisation are incompletely understood, an equilibrium
between these processes is essential for effective PAR2 signal
transduction of extracellular stimuli across the plasma membrane.
4.3.3. PAR3 and PAR4
The limited insights currently available on mechanisms regulating
desensitisation, resensitisation and trafﬁcking of PAR3 and PAR4 are
depicted in Fig. 4C. Unlike PAR1 and PAR2, phosphorylation of the
carboxyl terminal of PAR4 does not appear to regulate receptor
signaling. Shapiro and coworkers have shown that phosphorylation of
PAR4 is undetectable in transfected ﬁbroblasts, and mutation of eight
potential serine/threonine carboxy terminal phosphorylation sites
(Fig. 1) has no effect on signaling by this receptor. A functional
consequence is that activation-dependent internalization of PAR4 is
much slower than that seen for PAR1, a receptor which is known to
depend on activation-induced phosphorylation of its carboxyl tail for
signal termination and internalisation (Shapiro et al., 2000). Inter-
estingly, compared with PAR1 and PAR2, desensitization to PAR4
calcium mobilization in lung epithelial A549 and HBEC cells is two-
fold slower (Asokananthan et al., 2002a), perhaps also suggesting that
in these cells PAR4may not be phosphorylated. As shown in Fig. 1, the
carboxyl terminal of PAR3, spanning 13 amino acids, is much shorter
than the corresponding region of the other PARs. Whether this
structural difference has an impact on regulation of PAR3 trafﬁcking
has not been examined. In addition, the roles of adapter proteins, such
as β-arrestins, and post-translation modiﬁcations in modulation of
PAR3 and PAR4 processing are yet to be examined.
5. Physiological and pathological roles
Soon after PAR1 was cloned Coughlin and colleagues were able to
establish that, in addition to activation by proteolytic cleavage and
exposure and intramolecular binding of the TL, PAR1 could also be
activated by a short synthetic peptide mimicking the sequence of the
revealed TL (Vu et al., 1991; Scarborough et al., 1992). As described
above, subtype-selective short synthetic peptides that activate each
PAR are known (with the possible exception of PAR3) and have
proven to be invaluable in understanding the roles that PARs play in
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Table 2
Summary of PAR knockout mouse studies.
Model/Physiology Phenotype PAR function Reference
Cardiovascular
system
PAR1 Cardiovascular response No hemodynamic response to TFLRRNPNPD.
AP caused hypotension, reduced HR in WT;
enhanced response in PAR2(−/−) mice
Role in cardiovascular pathophysiology;
likely receptor compensation
(Damiano et al.,
1999)
Vascular injury response Comparable endothelial regrowth, increased
carotid cell density, lowered vessel and
lumen diameters
Involved in vascular injury response (Cheung et al.,
1999)
Hypoxia-induced angiogenesis Unaffected revascularisation of TFδCT
(cytoplasmic domain deleted) mice
Angiogenesis mediated primarily by
PAR2
(Uusitalo-Jarvinen
et al., 2007)
Mouse heart-to-rat transplant Reduced MCP-1, -3 and -5 production,
reduced NK and macrophage inﬁltration
Required for inﬂammatory cell
recruitment
(Chen et al., 2008)
Myocardial ischemia/
reperfusion injury
Absence of protective APC effects Regulator of APC mediated protection (Loubele et al.,
2009)
PAR2 Cardiovascular response No hemodynamic response to SLIGRL. AP
caused hypotension and unaffected HR
in WT
Role in cardiovascular pathophysiology (Damiano et al.,
1999)
Hypoxia-induced angiogenesis Impaired revascularisation of TFδCT
(cytoplasmic domain deleted) mice
Signaling by TF-VIIa and PAR2 is
sufﬁcient for angiogenesis
(Uusitalo-Jarvinen
et al., 2007)
Blood pressure phenotype Elevated systolic and pulse pressures, lower
salt-induced systolic and pulse pressures,
unaffected heart reat and locomotor activity
Subtle contributor to blood pressure
regulation
(McGuire et al.,
2008)
Cardiac I/R injury Reduced infarct size and protection from
postinfarction remodelling, attenuated
pro-inﬂammatory gene expression and
MAPK phosphorylation
Contributes to myocardial infarction
and heart remodelling post I/R
(Antoniak et al.,
2010)
PAR3 Thrombosis Protected from chemically induced
thrombosis and pulmonary embolism
Reduced platelet response to thrombin
provides protection from thrombosis
(Weiss et al., 2002)
PAR4 Haemostasis and thrombosis Murine platelets unresponsive to
thrombin, prolonged bleed times and
protection from arteriolar thrombosis
Thrombin activate murine platelets via
PAR4 which contributes to thrombosis
and normal haemostasis
(Sambrano et al.,
2001)
Thrombosis Protected from chemically induced
thrombosis and pulmonary embolism
Reduced platelet response to thrombin
provides protection from thrombosis
(Weiss et al., 2002)
Thrombosis Increased tail bleed and reduced survival
times for (+/+) and (−/−) mice
reconstituted with (−/−) bone marrow
Effective thrombin activation of
platelets and not other cell types
protect against thrombosis
(Hamilton et al.,
2004)
Thrombus assembly Reduced platelet accumulation and
delayed P-selectin expression, indifferent
ﬁbrin deposition
Thrombin platelet activation required
for normal thrombus assembly
(Vandendries et al.,
2007)
Thombus formation – protein
disulﬁde isomerase (PDI)
PDI blocking antibody inhibited ﬁbrin
generation whereas ﬁbrin deposition
is normal in PAR4 KO mice
PDI is required for ﬁbrin generation
and thrombus formation
(Cho et al., 2008)
Atherogenesis – ApoE(−/−)
background
Indifferent plaque coverage and plaque
surface area
Thrombin platelet activation not
required for atherogenesis
(Hamilton et al.,
2009)
Respiratory
system
PAR1 Pulmonary microvascular
permeability
Increased microvessel permeability to
thrombin and PAR1-AP in WT not (−/−)
Mediator of pulmonary microvascular
permeability
(Vogel et al., 2000)
Bleomycin-induced lung injury Attenuated inﬂammatory cell recruitment,
reduced collagen accumulation and levels
of proinﬂammatory and proﬁbrotic
mediators
Mediator of experimentally induced
lung injury
(Howell et al., 2005)
Bleomycin-induced lung injury Reduced TGF-β activity and pulmonary
oedema
Involved in development of acute
lung injury
(Jenkins et al., 2006)
Chronic obstructive
pulmonary disease
Unaffected inﬂammation and emphysema,
protection from goblet cell metaplasia
development
Potential mediator of goblet cell
metaplasia
(Atzori et al., 2009)
Vascular barrier integrity Unaffected vascular barrier function,
no APC protection from pulmonary
ﬂuid accumulation
Key mediator of APC protection (Schuepbach et al.,
2009)
Lung Vagal C-ﬁbre activation No action potential discharge response
to thrombin or AP
Able to evoke vagal C-ﬁbre response (Kwong et al., 2010)
PAR2 Allergic airway inﬂammation Reduced IgE response, eosinophil
inﬁltration and methacholine-induced
airway hyper reactivity
Contributes to immunity development
and inﬂammatory response
(Schmidlin et al.,
2002)
Allergic airway inﬂammation Reduced eosinophil inﬁlatration and
lavage ﬂuid eotaxin content
Linked with eotaxin production and
airway inﬂammation
(Takizawa et al.,
2005)
Pseudomonal infection Increased lung inﬂammation and injury
severity but decreased IFN-γ levels and
P. aeruginosa clearance, reduced bacterial
phagocytosis
Protective role from P. aeruginosa
lung infection
(Moraes et al., 2008)
Allergic airway inﬂammation:
mucosal sensitisation to
German cockroach (GC) faeces
Reduced serum IgE, TH2 and TH17
release and airway hyperresponsiveness
Mediator of mucosa allergen-induced
airway inﬂammation
(Page et al., 2010)
Airway innate immune response Reduced GC faeces-induced immune
response
Regulator of innate immune response (Day et al., 2010)
Nervous
system
PAR1 T-cell mediated
neuroprotection
Increased survival of post-traumatic CNS
neurons, unchanged T cell number post
injury
Toxic thrombin effect mediated by
PAR1 but regulated by T-cell produced
thrombin inhibitors
(Friedmann
et al., 2001)
(continued on next page)
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Table 2 (continued)
Model/Physiology Phenotype PAR function Reference
Astrogliosis Reduced astrocytic response to brain
injury
Involved in astrogliosis following glial
scar formation post injury
(Nicole et al., 2005)
Nicotine reward Reduced dopamine release and nicotine-
induced place preference
Target for therapeutic development (Nagai et al., 2006)
Learning and memory Reduced cued fear conditioning, passive
avoidance
Potentially involved in emotionally
motivated learning
(Almonte et al.,
2007)
MPTP-induced Parkinson's
disease
Increased domapine, reduced microgliosis Target for therapeutic development (Hamill et al., 2007)
Trypsin IV- and p23-induced
inﬂammation and nociception
Reduced oedema or granulocyte inﬁltration
in reponse to trypsin IV, unaffected thermal/
hyperalgesia or mechanical allodynia
Mediate trypsin IV- and p23-induced
inﬂammation
(Knecht et al., 2007)
Methamphetamine (METH)-
induced neurotoxicitiy
Similar TH and DAT reduction to WT mice Not required for METH-induced
dopaminergic neurotoxicity
(Fukakusa et al.,
2008)
APC transport across
blood-brain barrier
Unaffected APC brain uptake Not required for APC transport (Deane et al., 2009)
Intracerebral hemorrhage-
mediated neurotoxicity
Reduced blood-induced brain damage Contributes to thrombin neurotoxicity (Xue et al., 2009)
Neuronal injury and
inﬂammation
Reduced NMDA-induced neuronal injury PAR1 mediated damage requires
NMDA receptor
(Hamill et al., 2009)
Inﬂammatory pain Increased inﬂammatory hyperalgesia
formalin- or carrageenan-induced
Regulator of analgesia (Martin et al., 2009)
PAR2 Transient middle cerebral
artery occlusion
Increased infarct volume and TUNEL
positive cells, reduced neuronal p-ERK,
inhibited astroglial activation
Protective role from acute focal
ischemic brain injury
(Jin et al., 2005)
Neuroinﬂammation during
HIV infection
Severe Tat induced neuroinﬂammation
and neuronal loss; TNF-α cytotoxicity
Expression increased by
neuroinﬂammation and protects
against neuronal death
(Noorbakhsh et al.,
2005)
Alzheimer's disease Upregulated IL-4, reduced
neuroinﬂammation, improved
neurobehavior after Ab1-42 implantation
Pathogenic role in alzheimer's disease (Afkhami-Goli et al.,
2007)
Trypsin IV- and p23-induced
inﬂammation and nociception
Reduced oedema or granulocyte inﬁltration
in reponse to trypsin IV and p23, reduced
thermal/hyperalgesia and mechanical
allodynia
Mediate trypsin IV- and p23-induced
inﬂammation and hyperalgesia
(Knecht et al., 2007)
Intrathecal administered
PAR2-AP-induced
pronociception
No SLIGRL induced allodynia or
hyperalgesia compared with WT
Involved in pronociception (Alier et al., 2008)
Mouse paw Inﬂammation
and nociception
Reduced tyrpsin-induced paw oedema,
myeloperoxidase activity and nociception,
Mediator of trypsin-induced pain
and acute inﬂammation
(Paszcuk et al.,
2008)
Cancer pain No human carcinoma cell supernatant-
induced mechanical allodynia
Involved in pathogenesis of
cancer pain
(Lam & Schmidt,
2010)
PAR3 Neuronal apoptosis Reduced APC modulated protection from
neuronal apoptosis by chemically induced
endotoxicity
PAR1 and PAR3 mediate activated
protein C anti-apoptotic signaling
(Guo et al., 2004)
PAR4 Visceral pain and nociception Intracolonic mustard oil administration
induces Increased pain behaviour
Regulator of colonic nociception,
inhibit hypersensitivity
(Auge et al., 2009)
Gastrointestinal
tract
PAR1 TH2-mediated colitis Exacerbated colitis Anti-inﬂammatory role in TH2
cytokine colitis
(Cenac et al., 2005)
Colon inﬂammation Reduced tissue damage, granulocyte
inﬂitration and bacterial translocation
Contributor to acute colonic
inﬂammatory response
(Cenac et al., 2002)
Acetaminophen (APAP)-
induced hepatotoxicity
Reduced injury and hepatic ﬁbrin deposits Contributes to APAP-induced
liver injury
(Ganey et al., 2007)
Induced liver ﬁbrosis Protection from ﬁbrosis, reduced area of
ﬁbrogenic cells, T lymphocyte inﬁltration
decrease
Involved in thrombin mediated
proﬁbrogenic effects independent
of coagulation
(Rullier et al., 2008)
PAR2 Infectious colitis Reduced Citrobacter rodentium-induced
inﬂammatiory indices
Participant in acute inﬂammatory
response
(Hansen et al.,
2005)
Irritable bowel syndrome:
visceral pain
No colonic biopsy supernatants-induced
hyperalgesia or allodynia
Involved in sensory neuron
hypersensitivity to IBS proteases
(Cenac et al., 2007)
Insulin secretion Moderate blood insulin decrease, unaffected
blood glucose levels
Inhibitor of insulin release in a
Gαi/o dependent manner
(Regard et al., 2007)
Musculoskeletal
system
PAR1 Peritonitis model Diminished inﬂammatory response but
PAR1 independent macrophage adhesion
and cytokine/chemokine accumulation
Potential mediator of pleotropic
effects
(Szaba & Smiley,
2002)
Skeletal myoblast
physiology
Indifferent myoblast fusion and apoptotic
response, no thrombin stimulated proliferation
PAR1 dependent and independent
myoblast functions
(de Niese et al.,
2002)
Bone repair Reduced wound invasion by bone marrow
cells, increased osteoclast number, reduced
early stage new mineralised bone area
Involved in early bone healing (Song et al., 2005)
Cytokine expression
in osteoblasts
Growth factor and cytokines not induced
by thrombin
Mediator of growth factor and
cytokine expression
(Pagel et al., 2009)
PAR2 Alveolar peridontitis Reduced inﬂammatory response and
alveolar bone loss
Contributor to chronic inﬂammation (Holzhausen et al.,
2006)
Osteoblast function Reduced collagen Type I expression and
enhanced osteoblast survival
Regulation of osteoblast function (Georgy et al., 2010)
Nervous PAR1
system
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Table 2 (continued)
Model/Physiology Phenotype PAR function Reference
Chronic periodontitis No periodontal bone resorption post
infection, decreased T-cell activation,
TH1 inﬂammation
Involved in pathogenesis of disease (Wong et al., 2010)
Renal system PAR1 Crescentic
glomerulonephritis (GN)
Protection from GN, reduced crescent
formation, inﬂammatory cell inﬁltration,
serum creatinine
Mediator of thrombin
proinﬂammatory effects
(Cunningham et al.,
2000)
Renal ischemia reperfusion
injury
Renal failure protection and reduced
mortality, chemokine levels
Deﬁciency is protective (Sevastos et al.,
2007)
Bladder inﬂammation Reduced inﬂammatory response to PAR1-AP Modulator of bladder inﬂammation (Saban et al., 2007)
PAR2 Crescentic
glomerulonephritis (GN)
Reduced crescent formation, proteinuria,
serum creatinine and ﬁbrin deposition
Proinﬂammatory role in GN (Moussa et al.,
2007)
Renal ischemia reperfusion
injury
No protection from renal failure No involvement in renal ischemic
injury protection
(Sevastos et al.,
2007)
Embryogenesis PAR1 Emybryonic development Half of embryos die at embryonic day 9–10,
half survive to adulthood with no bleeding
diathesis, ﬁbroblasts but not platelets
unresponsive to thrombin
Contributes to embryonic development (Connolly et al.,
1996)
Embryonic development Midgestation exsanguination in about half
the embryos
Endothelial cells require PAR1
expression for normal development
(Grifﬁn et al., 2001)
PAR1 and
PAR2
Neural tube closure Defective hindbrain and neuropore closure –
developing exencephaly and spina biﬁda
Modulators of epithelial integrity
during development, particularly PAR2
(Camerer et al.,
2010)
PAR2 Antiphospholipid (aPL)
antibody induced miscarriages
aPL antibody-treatment: reduced neutrophil
activation, normal pregnancy
Contributor to aPL-induced fetal injury (Redecha et al.,
2008)
PAR4 Hemostatsis – PAR4(−/−)
and Fibrinogen (Fib)( −/−)
Individual(−/−) mice survive to adulthood;
combined(−/−) mice exsanguiate at birth
like prothrombin(−/−) mice
Platelet activation and ﬁbrinogen
sufﬁce for thrombin during hemostatsis
but not embryonic development
(Camerer et al.,
2004)
Fetal loss in factor V Leiden
(FVL) mothers
Maternal PAR4 disrupts normal placentation
likely via platelet activation but independent
of thrombosis
Fetal loss is mediated by maternal
platelet activation
(Sood et al., 2007)
Fetal loss of thrombomodulin
(thbd)( −/−) mice
Maternal PAR4(−/−) or platelet absence
partially rescues thbd(−/−) mice
Thrombin platelet activation involved
in placental malfunction
(Sood et al., 2007)
Inﬂammation PAR1 Wound healing No notable difference between WT
and (−/−)
PAR1 not necessary for normal
wound healing
(Connolly et al.,
1997)
Antigen induced arthritis Reduced arthritis severity, cytokine
expression and antigen speciﬁc IgG
response
Involved in this model of arthritis (Yang et al., 2005)
Endoxemia and sepsis Increased mortality Mediator of APC cyroprotection (Kerschen et al.,
2007)
Tissue factor (TF) induced
extravasculature inﬂammation
Unaffected inﬂammatory response to
soluble TF
Not required for TF-induced acute
inﬂammation
(Busso et al., 2008)
Response to Heliocobacter
pylori
Reduced H. pylori levels, inceased serum
antibody response and proinﬂammatory
cytokine MIP-2.
Protection from disease induced
H. pylori infection
(Wee et al., 2010)
Diet-induced steatohepatitis Unaffected triglyceride accumulation,
reduced inﬂammation
Contribute to hepatic inﬂammation
and injury
(Luyendyk et al.,
2010)
PAR2 Surgical trauma of cremaster
muscle
Reduced leukocyte rolling ﬂux but
increased leukocyte rolling velocity in
cremaster venules
Contributes to microvascular
inﬂammation
(Lindner et al.,
2000)
Inﬂammatory hyperalgesia Reduced oedema formation, mechanical
and thermal hyperalgesia
Mediator of joint acute inﬂammatory
response
(Vergnolle et al.,
2001)
Allergic dermatitis of mouse
ear
Reduced ear swelling, attenuated
inﬂmmatory cell inﬁltration, unaffected
vascular permeability
Crucial contributor to type IV allergic
dermatitis
(Kawagoe et al.,
2002)
Dendritic cell (CD)
development
No spontaneous in vitro DC development
from bone marrow but can be induced
Participant in stimulation of DC
development
(Fields et al., 2003)
Allergic contact dermatitis
and toxic contact dermatitis
Attenuated ear swelling response,
plasma extravasation and leukocyte
adherance
Reduced acute inﬂammatory response (Seeliger et al.,
2003)
Chronic arthritis Reduced joint swelling, heterozygotes
displayed intermediate phenotype
Key role in chronic joint inﬂammation (Ferrell et al., 2003)
Endotoxemia Unaffected inﬂammation and survival,
adjunct thrombin inhibition reduced
inﬂammation and mortality
Multiple PARs modulate link between
coagulation and inﬂammation
(Pawlinski &
Mackman, 2004)
IL-18 production Reduced IL-18 production following
Propionibacterium acnes and LPS
treatment
Cruicial contributor to IL-18 induction (Ikawa et al., 2005)
Acute pancreatitis Increased acinar cell vaculoisation,
pacreatic oedema and acinar cell
necrosis
Increased acute inﬂammation (Sharma et al.,
2005)
Joint inﬂammation Reduced joint swelling Reduced acute joint inﬂammation (Kelso et al., 2006)
T-lymphocyte function Reduced serum IgE and IL-4 produced
T cells, increased IFN-g and JNK1
phosphorylation in T cells
Regulator of T cell cytokine production (Shichijo et al.,
2006)
Antigen-induced arthritis
(methylated BSA)
Reduced synovial thickness and
cartilage damage and lymph node
proliferation
Contributor to immune-mediated
joint inﬂammation
(Busso et al., 2007)
(continued on next page)
Musculoskeletal PAR2
system
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physiology and disease. Use of PAR APs is particularly informative in
settings where more than one PAR is expressed and activated by the
same protease, such as PAR1 and PAR4 in human platelets, where both
can be activated by thrombin (Kahn et al., 1999). PAR APs have also
been employed in structure activity studies demonstrating the
existence of distinct receptor subtypes (Vergnolle et al., 1998;
Saifeddine et al., 2007).
In vitro and in vivo studies using pharmacological reagents such as
APs have been greatly enhanced by those employing genetically
engineered mice to address PAR function. In this section we
summarize how these approaches have been used to assess the
roles of PARs in physiological processes and disease and also
summarize data from clinical trials using PAR1 antagonists. The
results of studies using PAR-null KO mice and transgenic mice are
summarized in Tables 2 and 3, respectively.
5.1. Insights from in vitro studies and experiments in animal models
5.1.1. Cardiovascular and respiratory systems
A large number of studies have now demonstrated the importance
of PARs in cardiovascular and respiratory systems. For example,
activation of endothelial cell expressed PAR1 and PAR2 from rat and
human systems regulates vascular tone by inducing vascular
relaxation (al-Ani et al., 1995; Hamilton et al., 2001a, 2001b, 2002)
and vasodilation (Robin et al., 2003; Gudmundsdottir et al., 2008).
PAR activation also induces vascular smoothmuscle (McNamara et al.,
1993; Chaikof et al., 1995; Bretschneider et al., 1999; Koo et al., 2002)
and endothelial cell proliferation (Mirza et al., 1996). Studies in the rat
aorta and the human internal mammary artery have shown that PAR1
but not PAR2 activation causes nitric oxide (NO) and endothelium
dependent relaxation of arterial rings (Laniyonu & Hollenberg, 1995;
Ballerio et al., 2007). Human coronary arteries with minimal to mild
intimal proliferation also show an endothelium and NO dependent
relaxation to the PAR1 AP SFLLRN, which is completely absent in
coronary arteries with severe atherosclerotic lesions where this
peptide elicits a contractile response (Ku & Dai, 1997). Similarly in
the rat aorta, mechanical disruption of the endothelium unmasks a
contractile reponse to PAR1 activation (Laniyonu & Hollenberg, 1995).
Thus, in both rat and human studies, endothelial PAR1 activation leads
to vaso-relaxation while endothelial damage or dysfunction shifts the
PAR1-mediated response to vasoconstriction. Similarly, studies in rat
pulmonary artery preparations have shown that low concentrations
of the PAR2 AP SLIGRL-NH2 (b10 μM) cause a NO dependent
endothelium dependent relaxation while higher concentrations
(N10 μM) initiate a contractile response (Roy et al., 1998). In human
pulmonary arteries PAR1 but not PAR2 or PAR4 cause relaxation
Table 2 (continued)
Model/Physiology Phenotype PAR function Reference
Clostridium difﬁcile toxin A
(TxA)-induced enteritis
Decreased ileitis, tissue and ﬂuid
myeloperoxidase and lowered
epithelial tissue damage, oedema
and neutrophil inﬁltration
Pro-inﬂammatory role in TxA-induced
enteritis
(Cottrell et al.,
2007)
Tissue factor (TF) induced
extravasculature inﬂammation
Unaffected inﬂammatory response to
soluble TF
Not required for TF-induced acute
inﬂammation
(Busso et al., 2008)
Inﬂuenza virus type A (IAV)
pathogenesis
Increased susceptibility to IAV infection
and lung inﬂammation severity
Protective role in IAV infection –
IFN-g dependent
(Khoufache
et al., 2009)
MMTL section-induced
osteoarthritis
Reduced cartilage erosion and
subchondral bone formation. Reduced
long-term joint degradation
Involved in osteoarthritis (Ferrell et al., 2010)
PAR3 Tissue factor (TF) induced
extravasculature inﬂammation
Unaffected inﬂammatory response
to soluble TF
Not required for TF-induced acute
inﬂammation
(Busso et al., 2008)
PAR4 Endotoxemia – individual and
combine PAR1,-2&-4(−/−)
No survival beneﬁt or reduced cytokine
response; unaffected thrombocytopenia
Endotoxemia induced platelet
decrease independent of PARs
(Camerer et al.,
2006)
Tissue factor (TF) induced
extravasculature inﬂammation
PAR4(−/−) and hirudin and factor
VIIa inhibitors reduced paw swelling/
inﬂammation
PAR4 is crucial for platelet mediated
TF induced acute inﬂammation
(Busso et al., 2008)
Cancer PAR1 Tumor progression Apoptosis of immature vasculature Survival factor for tumor progression (Salah et al., 2007)
Breast cancer development Unaffected tumor development Not required for mammary tumor
development
(Versteeg et al.,
2008)
PAR2 Skin carcinogenesis Increased skin tumour number Tumor protective role through TGF-β1
secretion
(Rattenholl et al.,
2007)
Breast cancer development Reduced disease development,
reduced CXCL1 production
Contribute to mammary tumor
development
(Versteeg et al.,
2008)
MMTV-PyMT breast cancer
model
No TF cytoplasmic domain Tyr
phosphorylation
Link TF phosphorylation and PAR2
signaling, indicator of breast cancer
prognosis
(Ryden et al., 2010)
PAR4 Hematogenous metastasis –
SCID PAR4(−/−)
Reduced lung tumor count and total
tumor burden
Deﬁciency confers protection against
metastisis
(Camerer et al.,
2004)
Inﬂammation PAR2
Table 3
Summary of PAR transgenic mouse studies.
Model/physiology Phenotype PAR function Reference
PAR1 Embryonic development Endothelial-speciﬁc transgene expression prevented
KO embryo death
Endothelial cells and not platelets require
PAR-1 expression for normal development
(Grifﬁn et al., 2001)
Transgenic overexpression
in mammary gland
Prococious hyperplasia: increased wnt-4, wnt-7b,
stabilised beta-catenin
Involved in tumor progression through
beta-catenin stabilisation
(Yin et al., 2006)
Mammary gland overexpression Wnt independent stabilised beta-catenin levels via Gα13 Novel signalling cascade in cancer (Turm et al., 2010)
PAR2 Allergic airway inﬂammation Increased eosinophil inﬁltration, increased
methacholine-induced airway hyperreactivity
Contributes to immunity development and
inﬂammatory response
(Schmidlin et al., 2002)
Arterial vasodilation in diabetes AP induced aorta vasorelaxation, COX-1 upregulation Modulator of arterial response in diabetes (Roviezzo et al., 2005)
Pulmonary hypertension (PH)
in smokers
Cigarette smoke exposure: develop small intrapulmonary
vessel muscularisation and vasodilator and vasoconstrictor
imbalance, enhanced PDGF and TGFβ production
Overexpression participates in PH
development by inﬂuencing growth
factor production and secretion
(De Cunto et al., 2010)
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responses, while in rat aorta PAR4 APs stimulate an endothelium
dependent, NO-mediated relaxation (Hollenberg et al., 1999). In
human coronary arteries PAR4 does not appear to be required for
regulation of vessel tone under normal conditions. However,
inﬂammatory insult induces expression of PAR4 and PAR4 APs relax
arterial tone under these conditions (Hamilton et al., 2001a).
Similarly, the inﬂammatory mediator TNF-α induces PAR2 expression
and AP responsiveness in mammary and coronary arteries (Hamilton
et al., 2001a; Ballerio et al., 2007).
KO mice have been important in elucidating the in vivo roles of
PARs in cardiovascular responses. Deletion of the PAR1 gene protects
mice from hypotension and heart rate decreases induced by treatment
with the PAR1 AP TFLLRNPNDK (Damiano et al., 1999). PAR1 deletion
also protects against hypertension induced by the NO synthesis
inhibitor L-NAME. Similarly, deletion of the PAR2 gene protects mice
from hypotension decreases induced by treatment with the PAR2
selective AP SLIGRL (Damiano et al., 1999). These data from Damiano
and colleagues highlight the hemodynamic roles of PAR1 and PAR2.
Data demonstrating that PAR2 KO mice display elevated blood
pressure but unaffected heart rate and locomotor activity compared
with wildtype mice, also suggest that this receptor contributes to
blood pressure regulation (McGuire et al., 2008).
In addition to roles in cardiovascular pathologies, protective roles
for the PARs are also emerging. As described above, whereas thrombin
mediates harmful effects via PAR1, APC-mediated signaling via this
receptor inhibits apoptosis and initiation of inﬂammatory signals
(Russo et al., 2009b). In addition, in a murine model of myocardial
ischemia reperfusion injury, genetic deletion of PAR1 ablates APC-
mediated protection (Loubele et al., 2009). Similarly, several reports
have demonstrated cardioprotective effects for PAR2 (Napoli et al.,
2000, 2002; Jiang et al., 2007). In a murine ischaemia reperfusion
injury model, administration of a PAR2 AP reduces infarct size and
delay ischemic pre-conditioning in wildtype but not PAR2 KO mice
(Lim et al., 2009). In addition, the PAR4 antagonists tc-YPGKF and
P4pal-10 provide protective effects in rat models of experimentally
induced myocardial ischaemia reperfusion injury (Strande et al.,
2008).
As summarized above PARs have well established roles in platelet
biology. Studies using KO mice have established that thrombin-
triggered activation of PAR1 and PAR4 in humans and PAR3 and PAR4
in rodents is essential for platelet aggregation (Ishihara et al., 1998;
Kahn et al., 1998b, 1999) and thrombus formation (Sambrano et al.,
2001; Weiss et al., 2002). In addition, PAR3 and PAR4 deﬁcient mice
have been used to show that thrombin-mediated platelet activation is
an important contributor to arterial thrombosis and normal haemos-
tasis (Sambrano et al., 2001; Weiss et al., 2002). Examination of PAR4
KO mouse bone marrow indicated that thrombin signaling in
hematopoietic derived platelets, but not other cell types, accounts
for the observed phenotype (Hamilton et al., 2004). A PAR4 KOmouse
model of laser injury-induced thrombosis also demonstrated that this
receptor is required for continued and stable thrombus growth
(Vandendries et al., 2007). These studies highlight the contribution of
PAR-mediated thrombin signaling to normal haemostasis and
thrombosis and suggest that PAR inhibition represents a viable
therapeutic target for thrombosis prevention (Weiss et al., 2002;
Coughlin, 2005).
Platelets contribute to the formation of vascular plaques by
adhering to injured endothelium and platelet recruitment results in
the formation of platelet plugs and intimal thickening (Marutsuka
et al., 2005). Unlike thrombus formation, thrombin activation of
murine platelets via PAR4 did not appear to be required in this
process. PAR4 KO mice with an atherosclerosis-prone apolipoprotein
E-deﬁcient (ApoE−/−) background, fed a high cholesterol diet,
display unaffected plaque formation and indifferent plaque surface
area coverage (Hamilton et al., 2009). Interestingly, consistent with
the observation that PAR1 does not mediate murine platelet response
to thrombin, a recent report has indicated that it is the action of
thrombin on monocytes via PAR1 that promotes plaque stability
during atherogenesis in mice by inhibiting transendothelial migration
to reduce macrophage accumulation (Seehaus et al., 2009). Further,
use of PAR1 KO mice demonstrated a potential role for PAR1 in
regulation of murine vasculature independent of platelet activation in
response to injury, likely mediated by tissue remodeling and
extracellular matrix synthesis (Cheung et al., 1999).
Studies using selective PAR1 and PAR4 APs have additionally
shown that these two receptors play distinct roles in regulating
platelets through release of factors such as endostatin (angiogenesis
inhibitor) and VEGF (angiogenesis stimulator) (Ma et al., 2001, 2005).
For example, while a PAR4 AP (AYPGKF-NH2) stimulates platelet
aggregation and endostatin release, it also suppresses VEGF release. A
selective PAR1 AP (TFLLR-NH2) on the other hand induces platelet
aggregation and VEGF release but suppresses endostatin release. In
addition, it is known that distinct signaling pathways are activated in
platelets by PAR1 and PAR4 selective peptides (Holinstat et al., 2006,
2007, 2009) and these differences may form the basis of differential
platelet responses to PAR activation.
PARs are widely expressed in cell types of the lung and airways
(Peters & Henry, 2009) and are required for normal respiratory
functions and response to injury and infection. Isolated lungs from
PAR1−/− mice are protected from thrombin- and AP-induced
pulmonary microvascular permeability, indicating that this receptor
is essential for mediating the permeability-increasing and vasocon-
strictor effects of thrombin in pulmonary microvessels (Vogel et al.,
2000). In contrast with this role in pulmonary endothelial barrier
regulation, PAR1 does not appear to be necessary for airway epithelial
barrier permeability but may have an important role in response to
injury to airway epithelium. For example, in vitro data indicate that
PAR1 activation by thrombin and AP in primary rat distal lung
epithelial cultures decreases chloride channel-dependent transepithe-
lial resistance without increasing epithelial permeability (Moraes
et al., 2009). Consistently, in vivo observations demonstrate that
PAR1 activation does not disrupt mouse lung epithelial barrier
function (Moraes et al., 2009). Studies using KO mice have also
shown that PAR1 can cause increased lung oedema resulting from
ventilator-associated injury and that this receptor plays a role in the
induction of acute lung injury in mice by a pathway involving αvβ6
integrin-mediated TGF-β activation in epithelial cells (Jenkins et al.,
2006).
PAR2 also has a role in response to respiratory bacterial infection.
PAR2−/− mice have enhanced inﬂammation, reduced bacterial
clearance and an altered bronchoalveolar lavage cytokine proﬁle in
response to intratracheal administration of P. aeruginosa; an
observation that may be attributable to reduced IFN-γ levels and a
primary defect in phagocytosis (Moraes et al., 2008). The authors
proposed that these observations are relevant to conditions
associated with increased pulmonary levels of extracellular pro-
teases such as cystic ﬁbrsosis, acute lung injury, adult respiratory
distress syndrome and chronic obstructive pulmonary disease,
(Moraes et al., 2008).
PARs, especially PAR1 and PAR2, mediate a number of other
pulmonary disease states (Sokolova & Reiser, 2007). Based on a
bleomycin induced lung injury mouse model PAR1 is a critical
regulator of acute inﬂammation and chronic ﬁbrosis. PAR1 signalling
in this model mediates pulmonary ﬁbrosis, stimulates proinﬂamma-
tory and proﬁbrotic mediators and induces inﬂammatory cell
recruitment (Howell et al., 2005). In addition, in a model of chronic
obstructive pulmonary disease induced by the neutrophil chemoat-
tractant and degranulating agent N-formyl-L-methionyl-L-leucyl-L-
phenylalanine, PAR1 deﬁciency protects goblet cells from metaplasia
whereas PAR1 activation induces epithelial cell transdifferentiation,
suggesting an active role for PAR1 in pulmonary inﬂammation and
modulation of responses to injury (Atzori et al., 2009).
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KO and transgenic mice have also provided evidence of roles for
PAR2 in modulating allergic airway inﬂammation. Challenge of wild-
type mice with ovalbumin (OVA), a model allergen for airway hyper-
responsiveness, stimulates leukocyte inﬁltration into bronchoalveolar
lavage ﬂuid (BALF) and increases methacholine-induced airway
hyperreactivity (Schmidlin et al., 2002). This response is diminished
in PAR2 KO mice but enhanced in transgenic PAR2 overexpressing
mice. OVA-sensitised PAR2 KO mice also display a reduced IgE
response a key immunoglobulin indicator of an immune response to
allergy (Schmidlin et al., 2002). Also, OVA sensitization and challenge
of wild-type, but not PAR2-deﬁcient, mice induces increased levels of
the eosinophil attractant chemokine eotaxin, and eosinophil inﬁltra-
tion into BALF (Takizawa et al., 2005). Similarly, PAR2 is required for
mucosal responsiveness, including IgE response and inﬂammatory
cell inﬁltration, in response to German cockroach (GC) feces (Page
et al., 2010). It would appear that cockroach proteases are essential for
these PAR2-mediated responses as protease depleted cockroach feces
do not induce airway inﬂammation (Page et al., 2010), or inﬂamma-
tory cytokine production and cellular inﬁltration (Day et al., 2010).
APs have been used successfully as probes to show that PARs
regulate inﬂammatory responses in the airways as well as elsewhere
(see below). For example, PAR2 and PAR4 APs relax isolated airway
preparations whereas PAR1 APs stimulate contractile responses
(Chow et al., 2000). In addition, the PARs stimulate release of
cytokines and other mediators of inﬂammation in the airways. In
cultured airway ﬁbroblasts PAR2 activation leads to IL-8 and GCSF
release (Ramachandran et al., 2006)while in epithelial cells PAR1, PAR2
and PAR4 agonists stimulate release of IL-6 and IL-8 (Asokananthan
et al., 2002a). PAR activation is also thought tomodulate airway ﬁbrosis
as indicated by studies showing that PAR1 and PAR2 activation
stimulates proliferation of cultured respiratory ﬁbroblasts (Akers
et al., 2000; Ramachandran et al., 2007), whereas PAR4 activation
suppresses this response (Ramachandran et al., 2007). Consistent with
observations from gut epithelium, PAR2 APs disrupt the airway
epithelial barrier through a mechanism involving the interruption of
E-cadherin-mediated cell to cell adhesion (Winter et al., 2006).
5.1.2. Nervous system
The PARs are widely expressed in the central and peripheral
nervous systems (Luo et al., 2007b) and several studies have indicated
potential roles for this receptor family in these settings. PAR1
activation protects neurons and astrocytes from hypoglycemia and
growth factor deprivation (Vaughan et al., 1995). In addition, PAR1
(Grabham & Cunningham, 1995) and PAR2 (Wang et al., 2002a)
stimulation with APs drives astrocyte proliferation, while PAR4
activation causes a reduction in cell number (Wang et al., 2002a).
PAR1 APs also stimulate astrocytemorphological changes and reversal
of stellation (Cavanaugh et al., 1990; Beecher et al., 1994; Grabham &
Cunningham, 1995). Furthermore, PAR1 and PAR2 activation in rat
astrocytes leads to the release of GRO/CINC-1, the rat orthologue of the
human cytokine IL-8 (Wang et al., 2007). As will be described further
below, sensory nerve activation by PARs can release neurokinins, so as
to augment peripheral inﬂammation (Steinhoff et al., 2000).
PAR activation also promotes neuroprotective properties in a
number of conditions. Use of PAR1 and PAR3 KO mice has shown that
these receptors are required for cytoprotective APC-mediated
signaling in murine neurons by preventing N-methyl-D-aspartate
(NMDA)- and staurosporine-induced apoptosis (Guo et al., 2004).
PAR2 activation also protects the brain from acute focal ischemic
injury (Jin et al., 2005) and, more recently, PAR2 activation has been
shown to protect hippocampal cells from kainate-induced neurotox-
icity via a mechanism involving astrocyte activation, inhibition of
MAPK signaling and participation of the CXCR2 and metabotropic
glutamate receptors (Greenwood & Bushell, 2010).
However, there is also evidence that PAR activation in the brain is
harmful in other situations. For example, striatal implantation of PAR1
AP induced brain inﬂammation and neurobehavioral deﬁcits in mice
(Boven et al., 2003). Recent evidencehas also pointed to a role for PAR1
in the pathogenesis of Parkinson's disease which is characterized by
gliosis, reduced dopamine expression and damage to the neuronal
nigrostriatal pathway (Lee et al., 2010). Using inhibitors of PAR1 and
PAR1 APs these authors showed that α-synuclein, a neuronal protein
associatedwith Parkinson's disease, upregulatesMMPswhich then act
through PAR1 to increase expression of IL1-β and TNF-α as well as NO
and other reactive oxygen species (Lee et al., 2010). In addition, in a
murine chemicalmodel of Parkinson's disease that uses the neurotoxic
agent, 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) to
cause disease, PAR1-deﬁcient mice are protected, with elevated levels
of dopamine and reduced microgliosis compared with wild-type mice
(Hamill et al., 2007).
Protective and pathogenic roles have been suggested for PAR2 in
other neurodegenerative disorders. Whereas a dual protective and
pathogenic role has been reported for PAR2 in a murine model of
Alzheimer's disease (AD), an ailment characterized by the accumu-
lation of misfolded proteins, inﬂammation and neuronal death
(Afkhami-Goli et al., 2007), a patholgical role has been reported for
this receptor in multiple sclerosis (MS (Noorbakhsh et al., 2006)). In
AD patient brains expression of PAR2 and the anti-inﬂammatory
cytokine IL-4 are reduced in neurons while expression of this receptor
and proinﬂammatory cytokines and chemokines are increased in glial
cells (Afkhami-Goli et al., 2007). These workers showed that while
glial cell PAR2 has pathogenic properties resulting in neuronal death,
neuronal PAR2 is protective, preventing β-amyloid toxicity which is a
key component of neurodegenerative AD (Afkhami-Goli et al., 2007).
Hippocampal implantation of β-amyloid into PAR2 KO mice results in
decreased neuroinﬂammation and increased IL-4 induction compared
with the induction of hallmarks of pathogenic AD in wildtype mice
(Afkhami-Goli et al., 2007).
In contrast with its role in AD, a murine experimentally-induced
autoimmune encephalomyelitis (EAE) model, indicates that PAR2 is a
modulator of neuroinﬂammation in MS (Noorbakhsh et al., 2006). In
this model, PAR2 deﬁcient mice but not wild-type mice display
enhanced anti-inﬂammatory cytokine IL-10 expression from macro-
phages and diminished neuroinﬂammation with reduced CNS leuko-
cyte inﬁltration andprotection fromdemyelination (Noorbakhsh et al.,
2006). Furthermore, PAR2 deﬁciency proves neuroprotective during
EAE with reduced severity of neurological disability and disease
relapse, further demonstrating that PAR2 signaling can contribute to
neurodegenerative pathogenesis (Noorbakhsh et al., 2006). Such
neuroprotective evidence for PAR2 has also been shown in an
excitotoxic model of seizure in vivo, where PAR2 AP delivered
centrally has distinct anti-convulsive effects (Lohman et al., 2008).
The authors claimed that PAR2 is important in regulating protease-
dependent neuroplasticity related to both health and disease (Lohman
et al., 2008, 2009).
Other recent studies demonstrating induction of PAR1 and PAR3
microglial expression and augmentation of PAR4 neuronal expression
following experimentally induced brain injury in rat models have
suggested roles for these receptors in neuronal degeneration and
post-ischaemic adaption (Henrich-Noack et al., 2006, 2010). A
PAR1−/− mouse model-based study indicated that this receptor
is involved in triggering astrogliosis following brain injury via a
mechanism involving disruption of the blood-brain barrier allowing
extravasation of systemic PAR1 activators (Nicole et al., 2005).
Interestingly, a role for NMDA receptor signaling mediated by PAR1
has been shown in neuronal damage during transient focal ischemia
(Hamill et al., 2009). As the NMDA receptor contributes to cell death
under ischemic conditions, potentiation of NMDA signaling by PAR1
activation is thought to contribute to harmful neuronal effects. In
addition, although PAR1 contributes to neurotoxicity in a murine
model of blood-induced intracerebral hemorrhage brain injury (Xue
et al., 2009), another PAR1−/− mouse model indicates that this
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receptor is not involved inmethamphetamine-induced neurotoxicity
(Fukakusa et al., 2008).
Roles for PAR2 and PAR4 are also emerging in the non-
histaminergic itch reponse. Although PAR2 APs induce histamine
release from human primary skin mast cells (Moormann et al., 2006),
this receptor has also been shown to act as a histamine-independent
itch mediator (Steinhoff et al., 2003). In atopic dermatitis patients,
intracutaneous injection of PAR2 AP intralesionally provokes a dose-
dependent prolonged itch sensation and increases expression of PAR2
and mast cell tryptase in lesional skin (Steinhoff et al., 2003).
Consistently, intradermal injection of trypsin (Costa et al., 2008)
and PAR2 AP induces scratching behaviour in murine systems
(Shimada et al., 2006; Ui et al., 2006; Akiyama et al., 2009a; Tsujii
et al., 2009; Akiyama et al., 2010). The AP-mediated itch response
is not blocked by histamine H1 receptor antagonists further suggest-
ing a histamine independent PAR2-mediated scratching response
(Shimada et al., 2006). Although less efﬁcacious than PAR2 signaling,
intradermal injections of PAR4 AP also evoke scratching behaviour in
mice (Akiyama et al., 2009b; Tsujii et al., 2009).
5.1.3. Gastrointestinal tract
PAR family members are expressed throughout the gastrointesti-
nal (GI) tract on epithelial, smooth muscle and neuronal elements
(Kong et al., 1997; Ramachandran & Hollenberg, 2008). A range of
model sytems have been used to examine the roles of these receptors
in GI pathophysiology including studies of isolated gastric and colonic
smooth muscle preparations in vitro and an evaluation of the impact
of APs on intestinal inﬂammation in vivo (Kawabata et al., 2008). The
actions of APs on gastric smooth muscle preparations (Al-Ani et al.,
1995; Zheng et al., 1998) established that the PARs as important
regulators of GI motility not only in the stomach but also in the small
intestine (Kawabata et al., 1999a, 2001). The intestinal epithelium is
also a target for PAR regulation. Both PAR1 and PAR2 can affect
intestinal epithelial functions, with activation of these receptors
increasing colonic permeability through the disruption of tight
junctions (Chin et al., 2003; Cenac et al., 2004). Interestingly,
apparently inconsistent data on the role of PAR1 in mucosal hydration
in the GI tract have come from comparison of cell line cultures and
whole organ preparations. While PAR1 AP treatment was shown to
increase chloride secretion by nontransformed human SCBN epithelial
cells in an Ussing chamber assay, the same experimental approach
showed that chloride secretion decreases in whole mouse colon tissue
preparations (Buresi et al., 2001; Buresi et al., 2005). Chloride
secretion by SCBN cells is also triggered by PAR2 APs via a mechanism
involving the production of PGE2which acts on EP2 and EP4 receptors
to stimulate the secretion response (van der Merwe et al., 2008). This
response also involves elevation of cAMP and Ca2+ and the Src-
dependent transactivation of EGFR (van der Merwe et al., 2008). More
recently it has been shown that PAR1 mediated chloride secretion in
the mouse cecum occurs via activation of submucosal secretomotor
neurons whereas the PAR2-mediated response occurs through direct
activation of epithelial cells (Ikehara et al., 2010). It was proposed that
PAR1-mediated secretion likely occurrs by activation of the receptor
on the submucosal secretomotor neurons, resulting mainly in the
release of tachykinin neuropeptides and activation of the NK1
receptor, and partly in the release of the neurotransmitter acetylcho-
line and activation of the muscarinic and nicotinic receptors (Ikehara
et al., 2010).
Recently it has emerged that PARs regulate GI functions through
the enteric neuronal system. PAR2 AP administration increases
abdominal contractions resulting in nociceptor activation in the
superﬁcial laminae of the spinal dorsal horn with this response
blocked by an NK1 receptor antagonist (Coelho et al., 2002).
Interestingly, activation of PAR4 suppresses PAR2 AP stimulated gut
neuronal excitability (Karanjia et al., 2009). These opposing receptor
effects were highlighted in a murine model of diarrhea-predominant
inﬂammatory bowel disease with cathepsin G-mediated PAR4
activation inducing visceral hyposensitivity while PAR2 exerts
pronociceptive effects (Annahazi et al., 2009).
In vivo models and receptor deﬁcient mice also indicate roles for
PAR1 and PAR2 in GI pathophysiology. Intracolonic administration of
PAR2 AP, trypsin and tryptase induces inﬂammation characterized by
granulocyte inﬁltration, tissue damage and elevated T-helper cell type
1 (TH1) cytokine (Cenac et al., 2002). PAR1 activation by an AP or a
serine protease also causes intestinal inﬂammation and enhances
colitis that is ongoing (Nguyen et al., 2003; Vergnolle et al., 2004;
Vergnolle, 2005). In addition, in a murine model of infectious colitis,
PAR2 mediates inﬂammation displaying granulocyte inﬁltration,
tissue damage and bacterial translocation (Hansen et al., 2005). In
each of these inﬂammatory bowel models, PAR2−/− mice display a
reduced inﬂammatory response. In contrast, PAR1 mediates an anti-
inﬂammatory response in a TH2 cytokine colitis model. In this model
in which colitis is induced by intracolonic administration of
oxazolone, increased inﬂammatory cytokine expression is inhibited
by concomitant administration of a PAR1 agonist while oxazolone
treated PAR1−/− mice display reduced colitis (Cenac et al., 2005).
Thus, PARs regulate all elements of intestinal tissue and contribute to
gut pathophysiology.
5.1.4. Muscoloskeletal system
It is known from a small number of studies that PARs are
differentially expressed by a range of cell types in the mammalian
musculoskeletel system (Abraham et al., 1998; Mackie et al., 2008).
For example, in bone PAR1 and PAR2 are expressed by bone marrow
stromal cells including osteoblast precursors while PAR1, PAR2 and
PAR3 are expressed by mature osteoblasts and monocytes including
osteoclast precursors (Abraham et al., 1998; Mackie et al., 2008). In
cartilage all four PARs are expressed by chondrocytes, while in muscle
it is known that PAR1 and PAR2 are expressed bymyoblasts and PAR1,
PAR2 and PAR4 by muscle ﬁbres (Abraham et al., 1998; Mackie et al.,
2008). Although PAR function in the musculoskeletal system remains
to be completely understood, PAR2 can be seen to play an essential
role in rodent models of arthritis (Ferrell et al., 2003; Busso et al.,
2007; Ferrell et al., 2007 and see below). PAR1 and PAR2 also appear
to promote regeneration and provide protective effects (Mackie et al.,
2008). Data from KO mice indicate that in muscle PAR1 mediates
thrombin-induced myoblast mitogenic effects but is not required for
the inhibition of apoptosis or myotube formation induced by this
serine protease (de Niese et al., 2002). In addition, thrombin induced
PAR1 activation in bone mediates cyclooxygenase activity, which in
turn induces osteoblastic expression of a range of factors including
TGF-β, tenascin C, FGF-1 and -2, CTGF and IL-6 which may act to
promote osteoblast involvement in bone healing (Pagel et al., 2009).
Consistently, it has been shown that PAR1 is required for the earliest
stages of bone repair in mice. PAR1 null mice display greater
osteoclast numbers, reduced bone marrow cell inﬁltration and
reduced new mineralized bone area than wildtype mice following
mechanically induced tibiae damage (Song et al., 2005). PAR2 is also
thought to be required for regulation of osteoblast function; in
particular osteoblast survival and the ability of these cells to mediate
bone formation (Georgy et al., 2010).
5.1.5. Renal system
PAR1, PAR2 and PAR4 are expressed in normal kidney (Gui et al.,
2003; Hollenberg et al., 2003), whereas PAR1 and PAR3 are expressed
by primary cultures of human renal cell carcinomas (Kaufmann et al.,
2002). KO mouse studies indicate that these receptors have key roles
in renal pathophysiology, primarily in inﬂammation (Rondeau et al.,
2001; Vesey et al., 2007). For example, a role for PAR1 and PAR2 in
renal ischemic/reperfusion (IR) injury has been examined using
receptor deﬁcient mice (Sevastos et al., 2007). PAR1 deﬁcient mice
and hirudin treated mice are protected from IR with reduced
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mortality, renal injury, neutrophil inﬁltration and lower KC andMIP-2
chemokine expression. Interestingly, genetic deletion of PAR2 does
not afford protection from IR highlighting thrombin-mediated PAR1
signaling as a predominant regulatory pathway of renal function in
this IR model (Sevastos et al., 2007).
PAR1 and PAR2 are also implicated as modulators of renal
inﬂammation in other murine models. In a model of crescentic
glomerulonephritis (CGN), PAR1 deﬁciency provides protection from
thrombin-mediated CGN indices such as glomerula crescent forma-
tion, T cell and macrophage inﬁltration, ﬁbrin deposition and elevated
serum creatinine (Cunningham et al., 2000). Similarly, deletion of
PAR2 also provides protection in an experimentally induced model of
CGN with reduced crescent formation, proteinuria, serum creatinine
levels and ﬁbrin deposition (Moussa et al., 2007). However, unlike
PAR1 deﬁcient mice, macrophage inﬁltration is unaffected in PAR2 KO
mice (Moussa et al., 2007).
5.1.6. Embryogenesis
The importance of PARs in embryonic development ﬁrst became
apparent from attempts to generate PAR1−/− mice since ~50% of
these animals die at embryonic day 9-10 through loss of vascular
integrity, while about half develop into apparently normal adult mice
(Connolly et al., 1996). Signiﬁcantly, the observed in utero death of
PAR1 null embryos is prevented by speciﬁc transgenic expression of
PAR1 in endothelial cells suggesting that thrombin contributes to
embryonic haemostasis through its action on these cells (Grifﬁn et al.,
2001). Initerestingly, it has also been shown that an untranslated RNA
in the PAR1 gene promoter has a role in expression of this gene during
embryonesis (Madamanchi et al., 2002).
Recently it has been proposed that PAR4 is also required for fetal
development. Fetal loss in pregnant women carrying factor V Leiden
(fV-L), who are refractory to inactivating proteolysis by the anti-
coagulant APC, is caused by disruption of placental morphogenesis at
the stage of formation of the platelet labyrinth layer. This fetal loss
occurs in the absence of overt placental thrombosis, infarction or
perfusion defects. Sood et al. (2007) have shown, using KO mice, that
pregnancy failure in this setting is mediated by PAR4-dependent
activation of maternal platelets at the fetomaternal interface. More
recently, the importance of this receptor in embryogenesis has been
further highlighted in a study where it was shown that deletion of
PAR4 partially rescues the fetal arrest of placental morphogenesis
observed in mice genetically deﬁcient in the blood coagulation
inhibitor thrombomodulin (Sood et al., 2008).
It has also been suggested that PAR mediated-signaling is required
for neural tube closure and formation of the central nervous system. A
role for PAR1 and PAR2 in these processes was demonstrated in mice
deﬁcient in both receptors. PAR1/PAR2 null mice show defective
hindbrain and posterior neuropore closure and develop the congenital
anomalies exencephaly and spina biﬁda (Camerer et al., 2010).
Interestingly, the authors proposed that a local serine protease network,
potentially involvingmatriptase, hepsin and prostasin, may be required
for PAR2-mediated roles in epithelial integrity during neural tube
closure (Camerer et al., 2010). It has also been proposed that PAR2
contributes to antiphospholipid (aPL) syndrome, a condition charac-
terized by the presence of aPL antibodies in which women often suffer
pregnancy-related complications, includingmiscarriage (Redecha et al.,
2008). PAR2, but not PAR1, deﬁciency rescues embryos in aPL treated
mice exhibiting reducedneutrophil activation. Consistently, neutrophils
from aPL treated mice express PAR2 and stimulation of this receptor
results in neutrophil activation, trophoblast injury and fetal death. The
data indicate that aPL-induced TF expression on neutrophils and
formation of a TF/FVIIa complex contribute to fetal loss by signaling
through PAR2. Interestingly, the observation that the statins simvastatin
and pravastatin reduce neutrophil expression of TF and PAR2 and
prevent aPL-induced fetal death, potentially indicates that therapeutic
approaches inhibiting TF/FVIIa/PAR2 signaling may be suitable for
treatment of women with aPL-induced pregnancy complications
(Redecha et al., 2008; Girardi, 2009).
5.1.7. Inﬂammation and pain
PARs are important modulators of responses that are the hallmark
of inﬂammation (pain, swelling, redness). Studieswith PAR1 and PAR2
APs were the ﬁrst to establish a link between the PARs and peripheral
inﬂammation and pain (Vergnolle et al., 1999a, 1999b, 2001).
Associated increased blood ﬂow and swelling could be attributed in
part to the effects of the PAR activation of the endothelium.
Subsequently it was found that paw oedema inﬂammation response
also comprises a neurogenic component, involving the release of the
pro-inﬂammatory neuropeptides calcitonin gene-related peptide and
substance P (Steinhoff et al., 2000). Deletion of PAR2 can signiﬁcantly
reduce nociception, hyperalgesia and inﬂammation resulting from
administration of the PAR2 serine protease agonists, trypsin IV, its
rodent homolouge p23 (Knecht et al., 2007) and trypsin I (Paszcuk
et al., 2008). PAR2-null mice also have reduced pain sensation arising
as a result of cancer, heat and chemical agents (Alier et al., 2008; Lam&
Schmidt, 2010). Apart from inﬂammatory pain, the PAR2-dependent
increase in sensitivity to mechanical and thermal pain (hyperalgesia)
requires activation of neurokinin-1 (NK1) receptors (Vergnolle et al.,
2001). In contrast, activation of PAR1 and PAR4 reduces carageenan-
induced hyperalgesis (Asfaha et al., 2002, 2007), while PAR1-induced
plasma extravasation and oedema formation also involves substance P
release and NK1 receptor activation (de Garavilla et al., 2001). In
contrast with PAR2-null mice, PAR1 and PAR4 KO mice demonstrate
heightened sensitivity to pain induced by chemical stimuli (Auge et al.,
2009; Martin et al., 2009).
It is well established that PARs contribute to inﬂammation through
cell and tissue speciﬁc induction of inﬂammatory cytokines and
chemokines. In murine microglia and rat cortex, the PAR4 AP GYPGKF
increases expression of TNF-α (Suo et al., 2003). Trypsin and a PAR2
AP (SLIGKV) and the PAR4 AP GYPGKF also induce expression of this
inﬂammatory mediator in human leukemic mast cells (Kang et al.,
2003). Moreover, PAR1 and PAR2 regulate cytokine release from GI
cells and stimulate transcriptional up-regulation of IL-8 in colonic
epithelial cells through a pathway involving ERK/RSK p90, NF-κB
phosphorylation and histone acetyl transferase activity (Wang et al.,
2010). Other studies have shown that PAR2-stimulated release of IL-
8 from gut epithelial cells is dependent on ERK and PI-3 kinase/AKT
signaling pathways (Tanaka et al., 2008).
In the acute phase of inﬂammation, as well as modulating the
vasculature (endothelium and smooth muscle elements) and sensory
nerves, the PARs contribute to the initial responses through
stimulation of tissue resident inﬂammatory cells such as macro-
phages. For example, activation of macrophage expressed PAR2 is
required for cell-mediated immunity in response to microbial
challenge by induction of the pro-inﬂammatory cytokine IL-18
(Ikawa et al., 2005). PAR activation also contributes to acute
inﬂammation by promoting leukocyte migration and extravasation
(Ossovskaya & Bunnett, 2004). Thrombin- and AP-mediated PAR4
activation, independent of PAR1 and platelet activation, is also
involved in early inﬂammatory responses by modulating leukocyte
rolling, adhesion and recruitment (Vergnolle et al., 2002). A role for
PAR2 in leukocyte trafﬁcking is also indicated by a study showing that
mice deﬁcient in this receptor exhibit a lower leukocyte rolling ﬂux
fraction and a higher mean rolling velocity than wildtype mice, early
in response to surgical trauma. The data demonstrate that PAR2
activation induces microvascular inﬂammation by rapid induction of
P-selectin-mediated leukocyte rolling (Lindner et al., 2000). Interest-
ingly, insulin has recently been shown to act as an anti-inﬂammatory
agent modulating PAR2-induced acute inﬂammatory response by
reducing leukocyte recruitment and inﬂammation in a murine paw
oedema model (Hyun et al., 2010).
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Cells in addition to leukocytes, such as platelets, and cellular
components including platelet derived inﬂammatory factors, also
participate in acute inﬂammatory responses (Ferreira et al., 1976;
Issekutz et al., 1983). Recently, PAR4 has been identiﬁed as a key
modulator of TF-induced acute inﬂammation with PAR4 deﬁcient
mice exhibiting reduced paw oedema following soluble TF injection
(Busso et al., 2008). Similarly, the thrombin inhibitor hirudin and
experimentally-induced thrombocytopenia, a condition of low plate-
let number, also reduce inﬂammation suggesting that in this murine
model, thrombin, platelets and PAR4 participate in inﬂammatory
disorders (Busso et al., 2008).
PARs also contribute to acute systemic inﬂammatory responses
such as sepsis. In a murine model of lipopolysaccharide (LPS) induced
endotoxemia, TF deﬁciency afforded protection and increased
survival, whereas genetic deletion of PAR1 or PAR2 did not inﬂuence
the inﬂammatory response (Pawlinski & Mackman, 2004). Interest-
ingly, inhibition of thrombin increased survival but not inﬂammation
(Pawlinski & Mackman, 2004). However, the observation that
combined PAR2 deﬁciency and inhibition of thrombin-mediated
signaling by hirudin, reduced proinﬂammatory mediators and
improved survival and lowered mortality, indicated that both PAR1
and PAR2 may contribute to pathogenic inﬂammatory responses to
sepsis (Pawlinski & Mackman, 2004). In support of this proposal a
recent report has indicated that although PAR1 activation contributes
to sepsis-induced vascular damage in vivo, protective properties from
sepsis and subsequent vascular damage require receptor cross-talk
and transactivation of PAR2 (Kaneider et al., 2007). PAR1 is also able
to exert protective effects mediated by APC in sepsis. PAR1−/−mice
and mice with lowered transgenic expression of EPCR show an
increase inmortality due to the lack of a protective effect mediated via
APC-activated PAR1 (Kerschen et al., 2007). Moreover, thrombin-
mediated PAR1 signaling in vivo increases inﬂammation-induced
vascular hyperpermeability whereas EPCR/APC-activated PAR1 sig-
naling prevents inﬂammation-induced vascular leakage and, impor-
tantly, lethality (Niessen et al., 2009).
Roles for the PAR family have also been reported in models of
chronic inﬂammation. This was most clearly established using PAR2
null mice and with the use of strategies that diminishes PAR2
activation in an experimental arthritis setting (Ferrell et al., 2003;
Kelso et al., 2006). In this adjuvant model of arthritis, intra-articular
injection of PAR2 agonist ASKH95 induces joint swelling and synovial
hyperemia (Ferrell et al., 2003). In another model of arthritis, joint
oedema induced by intra-articular injection of carrageenan/kaolin
into WT mice is abolished by receptor-blocking antibodies that
prevent protease activation and by the PAR2 antagonist ENMD-1068
(Kelso et al., 2006). In contrast, use of PAR2 KO mice and WT
littermates also identiﬁed a protective effect for PAR2 deﬁciency in an
auto-immune arthritis model, indicating a pathogenic role for PAR2 in
immune-mediated arthritis (Busso et al., 2007). In support of the
proposal that PAR2 contributes to immune-mediated chronic inﬂam-
mation in humans, increased PAR2 expression is present in synovial
biopsies from rheumatoid arthritis patients, compared with osteoar-
thritic (OA) patients (Busso et al., 2007). In addition, the observation
that PAR2 activation in human OA cartilage stimulates pro-inﬂam-
matory pathways supports a role for this receptor in the pathogenesis
of osteoarthritis in humans (Boileau et al., 2007). Further, PAR2
deﬁcient mice display greatly reduced OA indices, such as cartilage
degradation and increased subchondral bone formation, in response
to osteoarthritis induced by sectioning of the medial meniscotibial
ligament (Ferrell et al., 2010). Also, the PAR2 antagonist p520 and the
blocking antibody SAM11, reduce progression of osteoarthritis
(Ferrell et al., 2010). These data suggest that PAR2 may be a suitable
therapeutic target for the treatment of inﬂammatory conditions.
PAR1 also appears to play a role in arthritis. In an antigen-induced
arthritis (AIA) murine model, PAR1 deﬁciency reduces arthritis
severity. Compared with wild-type littermates PAR1-deﬁcient mice
had lowered arthritic indices such as cartilage degradation, bone
damage and synovial exudates (Yang et al., 2005). Antigen-speciﬁc
serum IgG is lowered and expression of proinﬂammatory markers IL-
1, IL-6 and MMP-13 are also greatly reduced whereas serum anti-
inﬂammatory cytokine IL-4 are increased (Yang et al., 2005).
5.1.8. Cancer
Roles are also emerging for the PARs in promoting cancer
progression. PAR1 may play a role in stimulating tumour cell growth
and survival via the recognized mitogenic activity of thrombin (Salah
et al., 2007), and also in tumour invasion (Even-ram et al., 1998, 2001;
Yin et al., 2003a, 2003b). Aberrant PAR1 and PAR2 expression and
signaling have been linked with lung (Jin et al., 2003; Nierodzik et al.,
1998), colorectal (Darmoul et al., 2001, 2004a, 2004b; Heider et al.,
2004), prostate (Black et al., 2007; Ramsay et al., 2008b), breast
(Hernandez et al., 2009; Su et al., 2009; Versteeg et al., 2008) and
ovarian cancers (Agarwal et al., 2008; Grisaru-Granovsky et al., 2005;
Jahan et al., 2007). In addition, PAR4 expression is increased in
prostate cancer (Black et al., 2007) and this receptor has been
reported to contribute to migration of colon cancer (Gratio et al.,
2009) and hepatocellular carcinoma derived cell lines (Kaufmann
et al., 2007, 2009). Also, reduced PAR1 expression in the highly
metastatic melanoma cell line A375SM attenuates in vitro cell
invasion and proliferation and in vivo xenograft tumor formation
and vascularisation (Salah et al., 2007). In addition, transgenic mice
expressing human PAR1 in mammary tissue develop hyperplasia
characterized by a dense network of ductal side branching and
accelerated proliferation that is thought to involve Wnt-mediated
β-catenin nuclear stabilisation (Yin et al., 2006).
Thrombin, generated at the sites of tumour invasion has long been
considered to play a role in tumour metastasis. Consistently, PAR1
activation via tumour-derived thrombin enhances invasion of MDA-
MB-231, BT549 and Hs578T breast carcinoma cell lines in vitro
(Booden et al., 2004) and this receptor is essential for in vivo tumor
growth of mouse mammary fat pad xenografts of MDA-MB-231 cells.
However, data from transgenic mice cast doubt on the in vivo
relevance of these ﬁndings. In the spontaneous mouse mammary
tumor virus-polyoma middle T model (MMTV-PyMT) Versteeg et al.
(2008) showed that deletion of PAR1 has no impact on the appearance
of palpable tumors, tumor expansion and metastasis.
In contrast with PAR1, data indicating a role for PAR2 in mammary
cancer progression are consistent between xenograft and MMTV-
PyMT models. PAR2−/− mice on a MMTV-PyMT background exhibit
delayed tumor onset and reduced metastasis (Versteeg et al., 2008).
Consistently, inhibition of TF-FVIIa-PAR2 signaling, but not PAR1
cleavage, attenuates the growth of highly aggressive human breast
cancer MDA-MB-231mfp cells in a xenograft model (Versteeg et al.,
2008). Other studies have shown that PAR2 signaling also contributes
to angiogenesis and breast cancer progression via TF-VIIa- and TF-Xa-
mediatedmechanisms (Ge et al., 2004; Hjortoe et al., 2004; Jiang et al.,
2004; Morris et al., 2006) and that AP- and TF-VIIa-mediated
activation of MDA-MB-231 cell expressed PAR2 regulates expression
of growth factors, chemokines and cytokines known to contribute to
cancer progression (Albrektsen et al., 2007). Interestingly, PAR2-
mediated angiogenesis appears to be negatively regulated by the
cytoplasmic domain of TF (Belting et al., 2004) and phosphorylation of
this domain, likely by PKC (Dorﬂeutner & Ruf, 2003), liberates PAR2-
mediated angiogenesis whereby constitutive phosphorylation is
demonstrated to contribute to pathogenic states such as breast cancer
(Ruf et al., 2010). Other murine models including PAR2 deﬁcient/
MMTV-PyMT transgenic mice and MDA-MB-231 mouse xenografts
also support a functional role for PAR2 signaling and TF cytoplasmic
domain phosphorylation in breast cancer (Ryden et al., 2010). The
relevance of these data to disease in humans is indicated by
immunohistochemical analysis of patient samples showing that
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PAR2 and TF cytoplasmic domain phosphorylation correlate with
shorter recurrence free breast cancer survival (Ryden et al., 2010).
For some time, platelets activated by tumour-derived thrombin
have been proposed to play a role in tumour invasion (Karpatkin et al.,
1988). The relative contribution of components of the platelet
activation cascade to metastasis has been examined by following the
dissemination to lung of mouse melanoma B16-F10 cells (Camerer
et al., 2004). Metastatsis following intravenous injection was exam-
ined inNf-E2(−/−)mice,whichhave virtually no circulating platelets,
PAR4−/−mice,which have platelets that do not respond to thrombin,
PAR1 and PAR2−/−mice, which have markedly attenuated endothe-
lial responses to coagulation proteases, and in Fib(−/−) mice, which
lack ﬁbrinogen. While PAR4, ﬁbrinogen and platelet deﬁcient mice
display reduced distant lung metastasis and tumor burden, PAR1 and
PAR2 deﬁciency fails to confer protection. These data suggest that
platelets play a key role in hematogenousmetastasis and contribute to
this process by both thrombin-dependent and -independent mecha-
nisms, whereas endothelial function is not required in this model of
metastasis (Camerer et al., 2004).
5.2. Clinical trial results for PAR1 antagonists
As outlined above, considerable effort has gone into the develop-
ment of PAR1 antagonists, like RWJ-56110, RWJ-58259 and
SCH530348, which have proved to be active in vivo and shown
promise for therapeutic use. Recent clinical trial data for PAR1
antagonists have shown that such compounds can indeed be effective
in clinical settings. The most advanced compound, the synthetic
tricyclic 3-phenylpyridine SCH530348, is a himbacine-based antago-
nist of platelet PAR1 (Chackalamannil et al., 2008) which show
promising results in trials assessing safety (Clinical trial registration
number: NCT00684203, NCT00684515, NCT00132912) and is now in
Phase III trials evaluating efﬁcacy in different patient populations.
SCH530348 has been reported to reduce major adverse coronary
events (MACE) without increasing bleeding in patients with non-ST-
segment elevation acute coronary syndrome (Goto et al., 2010;
Macaulay et al., 2010). Phase III studies are ongoing to assess the
efﬁcacy of this drug in improving clinical outcomes for patients with
non-ST-segment elevation myocardial infarction (Thrombin receptor
antagonist for clinical event reduction: TRA-CER Trial; Clinical trial
registration number: NCT00527943; TRA*CER 2009) and to evaluate
the effect of the drug in patients with a documented history of
atherosclerotic disease (TRA 2°P)-TIMI 50 (Clinical trial registration
number: NCT00526474) (Morrow et al., 2009).
Another compound E5555 is in phase II clinical trials in patients
with acute coronary syndrome (Clinical trial registration numbers:
NCT00619164 and NCT00548587), coronary artery disease (Clinical
trial registration numbers: NCT00540670 and NCT00312052) (Cirino
& Severino, 2010; Serebruany et al., 2009). However in addition to
inhibiting PAR1, E5555 also inhibits platelet function through actions
on PECAM-I, GP IIb/IIIa antigen, and activity with PAC-1, GPIb,
thrombospondin, vitronectin receptor expression, and formation of
platelet-monocyte aggregates (Serebruany et al., 2009) and these off
target effects may limit its use in the clinic. These clinical trials results
suggest that PAR1 antagonists, and potentially antagonists of other
PARs, may ﬁnd valuable clinical uses in the treatment of human
disease.
6. Conclusion
Much progress has been made over the last 20 years through
molecular, biochemical, pharmacological and animal based studies in
understanding aspects of the intricate mechanisms regulating PARs
and the roles these receptors have in normal physiology and disease.
This level of understanding has supported the ﬁrst attempts to
generate PAR1-targeted therapeutics designed to treat a number of
cardiovascular ailments. Further effort is required to provide a more
complete understanding of PAR biology so that the unique features of
these receptors can be used to develop antagonists and agonists that
are selective for each PAR, bioavailable and of acceptable toxicity.
Importantly, these studies will also be valuable for dissecting the roles
of proteolytic enzymes as ‘hormone-like’ messengers. This is of
particular relevance as it is very challenging to evaluate the
physiological roles of proteases in vivo and in vitro since there are
so many potential substrates that may account for their biological
effects and because, in any tissue, there can be a number of closely
related proteolytic enzymes or even unrelated proteases with similar
substrate speciﬁcities. There is no doubt, however, that many of the
pathophysiological effects of arginine/lysine speciﬁc proteases and,
potentially MMP-1, will be mediated, at least in part, via PARs
(Ramachandran and Hollenberg, 2008; Steinhoff et al., 2005;
Ossovskaya and Bunnett, 2004). It has been through these insights
to date that the development of the ﬁeld since the early 1990s has
progressed from the bench to now permit advanced clinical trials in
humans. From an evolutionary perspective it should also be noted that
these proteolytically activated receptor systems have been identiﬁed
in all vertebrates. Thus, we can look forward with excitement to the
anticipated developments in the understanding of these receptor
systems at a molecular, phylogenetic and clnical level in the coming
years.
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ABSTRACT: PAR2 has a distinctive functional phenotype among an
unusual group of GPCRs called protease activated receptors, which self-
activate after cleavage of their N-termini by mainly serine proteases. PAR2
is the most highly expressed PAR on certain immune cells, and it is
activated by multiple proteases (but not thrombin) in inﬂammation.
PAR2 is expressed on many types of primary human cells and cancer cells.
PAR2 knockout mice and PAR2 agonists and antagonists have implicated
PAR2 as a promising target in inﬂammatory conditions; respiratory,
gastrointestinal, metabolic, cardiovascular, and neurological dysfunction;
and cancers. This article summarizes salient features of PAR2 structure,
activation, and function; opportunities for disease intervention via PAR2;
pharmacological properties of published or patented PAR2 modulators
(small molecule agonists and antagonists, pepducins, antibodies); and
some personal perspectives on limitations of assessing their properties and on promising new directions for PAR2 modulation.
■ INTRODUCTION
Protease-activated receptor 2 (PAR2; not to be confused with
Par2, pulmonary adenoma resistance 2) is a distinctive member
of an unusual family of four rhodopsin-like, class A G-protein-
coupled receptors (GPCRs) called PARs. They are not
activated directly by endogenous extracellular agonists like
most GPCRs but are instead indirectly activated by proteolytic
enzymes such as thrombin, trypsin, tryptase, tissue factor/
factorVIIa/factorXa, other serine proteases, and possibly certain
metalloproteases.1−4 The four PAR subtypes (designated by
IUPHAR as PAR1, PAR2, PAR3, PAR4 rather than PAR1−4)
are widely expressed in many cell types, including endothelial
and smooth muscle cells of the cardiovascular, respiratory, and
gastrointestinal systems, on cells in blood (including platelets)
and the immune system, in the central nervous system (glial,
astrocytes, neuronal cells), and in the cornea, pancreas, liver,
kidney, synovium, skeletal muscle, and bone.2−7
PAR2 is referred to in older literature as coagulation factor II
(thrombin) receptor-like 1 (F2RL1) or G-protein-coupled
receptor 11 (GPR11). PAR2 is encoded by the F2RL1 gene
containing two exons and is conserved across human, mouse,
rat, dog, Rhesus monkey, chimpanzee, chicken, and zebraﬁsh.8,9
PAR2 is highly expressed in epithelial cells (e.g., lung,
gastrointestinal tract), endothelial cells, smooth muscle cells,
ﬁbroblasts, nerves, and immune and inﬂammatory cells (T cells,
monocytes, macrophages, neutrophils, mast cells, and eosino-
phils).1−4,10 However, the level of PAR2 expression in a given
cell type has recently been found to be heavily inﬂuenced by
environmental stimuli with, for example, dietary fats, LPS,
cytokines, and other proteins11−13 inducing stimulation of
PAR2 expression at both mRNA and cell surface protein levels
observed at least in some immune and other cell types.14−18
Laboratory cultured cells frequently do not appropriately reﬂect
expression levels of human PAR2 in primary cells and especially
in vivo in a disease setting, where there are many diﬀerent
stimuli present. Furthermore, human GPCRs like PAR2 have
traditionally been studied in vitro in isolation, frequently
artiﬁcially overexpressed by transfection in, for example, CHO
cells, but current data suggest that signaling through a GPCR
can be signiﬁcantly inﬂuenced by crosstalk from other GPCRs
and other receptors, such as Toll-like receptors (TLRs). For
example, a PAR2 agonist has been shown to promote
association between PAR2 and TLR4 in HEK293 cells, these
receptors synergizing to promote NF-κB-dependent inﬂamma-
tory responses in these cells and in vivo.19 Additional studies
identiﬁed PAR2-TLR crosstalk using diﬀerent TLR agonists20
and in mouse macrophages.21 Moreover, signaling pathways in
cells can also be diﬀerent for diﬀerent species, and it can be
dangerous to extrapolate modulated signaling in non-human
cells to clinical responses or to use such data in making
deﬁnitive drug development decisions. Despite these in vivo
complications, a great deal has been learned about PAR2
activation in vitro and its physiological and pathological
consequences have been extensively proﬁled.2−4,7,10,22−25
■ PAR2 STRUCTURE AND ACTIVATION
Human PAR2 consists of 397 amino acids with molecular
weight 44 kDa. It has an extracellular N-terminal domain of
∼75 amino acids tethered to a transmembrane (TM) domain
of ∼155 amino acids, assembled in seven pseudo-parallel
helical sequences connected by three extracellular and three
intracellular loops of ∼117 amino acids, with a small eighth
helix within the intracellular C-terminus of ∼50 amino acids
Received: April 30, 2013
Published: July 30, 2013
Perspective
pubs.acs.org/jmc
© 2013 American Chemical Society 7477 dx.doi.org/10.1021/jm400638v | J. Med. Chem. 2013, 56, 7477−7497
(Figure 1).3 Perturbations of the transmembrane helices (e.g.,
helix rotation, kinking, or side chain interactions) by extra-
cellular ligand binding are thought to aﬀect intracellular
coupling of heterotrimeric G proteins, thereby triggering
intracellular signaling cascades that lead to cellular functions.
Unlike other GPCRs that are activated by direct binding of
discrete extracellular ligands to the N-terminus, extracellular
loops (ECLs) and/or 7TM regions of the receptor, PAR2, and
other PAR subtypes are indirectly activated by certain
proteolytic enzymes. The extracellular N-terminus of PAR2 is
cleaved by a (mainly serine) protease at a speciﬁc site, and the
newly exposed N-terminus (known as a tethered ligand) then
folds back and self-activates PAR2 through binding to
conserved regions of ECL2 and/or the PAR2 transmembrane
region (Figure 1).3,7,26 The binding site in PARs for each dis-
tinctive tethered ligand of PAR1−4 has not been unambiguously
identiﬁed to date nor has any speciﬁc function been identiﬁed
for the cleaved and dissociating N-terminal fragment.2 PAR1
and PAR3 also contain a Hirudin-like sequence, resembling the
leech anticoagulant hirudin domain, located in the N-terminus
but away from the cleavage site. The negatively charged hirudin
region on PAR1 and PAR3 was proposed to bind to the
positively charged region of α-thrombin, resulting in localization
of α-thrombin temporarily on the surface of the receptor for its
subsequent activation.10 On the other hand, PAR2 does not
possess this thrombin-binding sequence and is not cleaved by
thrombin. PAR2 is instead activated by a host of other serine
proteases, including trypsin, mast cell tryptase, factors Xa and
VIIa, matriptase, granzyme A, kallikreins (e.g., KLK 2/4/5/6/14),
gingipains, and a number of cockroach and dust mite antigens
(e.g., Der p1-3, p9) (Table 1).1,3,27−31
After trypsin has cleaved the N-terminus of PAR2, the
tethered ligand sequence (SLIGRL- in rodent or SLIGKV- in
human) folds back and binds to a diﬀerent, as yet unknown,
part of PAR2 and activates this receptor. The serine is at the
end of these activating N-termini in rodent and human PARs.
Importantly, synthetic hexapeptides corresponding to these
tethered ligands also activate PARs, albeit at micromolar con-
centrations instead of the low to high nanomolar concen-
trations of activating proteases.33−35 Most pharmacological and
physiological research on PAR2 to date has been conducted
with such synthetic peptides (e.g., SLIGKV-NH2, SLIGRL-NH2)
and their derivatives (e.g., 2-furoyl-LIGRLO-NH2 referred to as 2f-
LIGRLO-NH2 in this review).
36−40 While each synthetic peptide
corresponding to the tethered ligand is selective for the cognate
PAR over other PARs, there is now doubt about how really
selective they are for PAR2 over other receptors.41−44 This can be
particularly problematic when the synthetic peptide is intrinsically
either not very potent (e.g., human PAR2 sequence SLIGKV-NH2)
or not very eﬀective on a particular cell type and needs to be used at
high micromolar concentrations to elicit physiological responses
that may not then be PAR2-mediated.
The activation of GPCRs is generally caused by conforma-
tional changes of transmembrane helices, particularly TM3 and
TM6, which subsequently alter the conformation of the intra-
cellular loops to promote activation of associated heterotrimeric
G proteins.45 The important interacting section of GPCRs with
G proteins has been identiﬁed, in several cases, as the third
intracellular loop (ICL3) and intracellular C-terminus.46 The
Figure 1. Activation of PAR2. The tethered ligand (red), exposed through cleavage by proteases, folds back onto extracellular loop 2 (ECL2) and/or
a speciﬁc 7TM region to activate the receptor.
Table 1. Activators of the Four Subtypes of Protease-Activated Receptors1−3,32,a
property PAR1 PAR2 PAR3 PAR4
activating enzyme thrombin trypsin thrombin thrombin and trypsin
other enzyme
activators
trypsin, mast cell tryptase, factors Xa,
plasmin, granzyme A, cathepsin G,
KLK 1/4/5/6/14, MMP-1, trypsin IV,
Pen C 13, proatherocytin
mast cell tryptase, factors Xa/VIIa, granzyme A, Der p1-3, p9,
KLK 2/4/5/6/14, MMP-1, bacterial gingipains, TMPRSS2,
trypsin IV, acrosin, matriptase/MT-SP1, HAT, chitinase,
Pen C 13
factor Xa,
cathepsin G,
plasmin, KLK 1/14,
bacterial gingipains,
MASP1, trypsin IV
cleavage site
(human)
Arg41-Ser42 Arg36-Ser37 Lys38-Thr39 Arg47-Gly48
tethered ligand
sequences
SFLLRN (h), TFRIFD (x), SFFLRN (m, r) SLIGKV (h), SLIGRL (m, r) TFRGAP (h),
SFNGCP (m)
GYPGQV (h),
GYPGKF (m)
ah = human; m = mouse; r = rat; x = Xenopus.
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activation or deactivation state of PAR2 is thought to be
promoted through ligand capture, small agonists and the
protease-generated tethered ligand promoting an activation
state(s), while antagonists capture and stabilize inactivated states.
The amino acid sequences of PAR2 from diﬀerent species are
listed in Figure 2 for comparison, and this is a useful guide for
design of small molecule, pepducin, and antibody modulators of
PAR2, and for avoiding cross-reactivity with other PARs or for
maintaining PAR2 interactions in diﬀerent species. The struc-
ture and function of PAR2 are further inﬂuenced by post-
translational modiﬁcations, such as glycosylation, ubiquitination,
phosphorylation, and palmitoylation, some of which are critical
for intracellular signaling and internalization of PAR2.3,47,48
The binding site on PARs for the tethered ligand has been
suggested as ECL2, originating from studies on chimeric
receptors. For example, chimeras of the human and Xenopus
PAR1 supported ECL2 as being critical for its constitutive or
agonist-induced activation.49 Further mutagenesis analysis pointed
to Asn260 as the critical residue forming an ionic interaction with
the ﬁfth arginine in PAR1 peptide agonist SFLLRN-NH2.
50,51
Similar analysis with chimeric receptors substituted with individual
mPAR2 domains (N-terminal or each of three ECLs) revealed the
importance of ECL2 in agonist activation. Although lacking
mutagenesis evidence in this case, the authors postulated a similar
binding mechanism for PAR2 conserved residue Asn in ECL2
(E232 in hPAR2, E234 in mPAR2, Figure 2) interacting with
arginine at the ﬁfth position of the PAR2 ligand SLIGRL-NH2.
52
Mutation of Asn-linked glycosylation sites in hPAR2-CHO-Pro5
cells also indicated the importance of residues in ECL2 (N222) and
in the N-terminus (N30) for receptor expression and function.53
PARs can interact with one another to form homo- and
heterodimers.46,54 Mutagenesis studies on hPAR2 indicated that
PAR2 can associate with itself in a homodimer or oligomeric
complex.46 Key residues in the ICL3−TM6 region, such as
M274, R284, and K287, were critical to maintain both
constitutive and agonist-induced activity (SLIGRL-NH2-induced
PLC-β-inositol phosphate formation).46 Furthermore, a PAR2
mutant deleting the eighth helix in the C-terminus completely
abolished this agonist-induced activity.46 The results supported a
dimeric model, using the monomeric homology structure
derived from the X-ray crystal structure of bovine rhodopsin
(sharing 45% identity46 with PAR2, PDB accession 1HZX),
where the ICL3 interacts with an eighth helix within the
C-terminus to form an interface responsible for G protein
interaction.46 This information led to the design and discovery
of selective PAR2 pepducin agonists and antagonists (see
ahead).46 Our group has also created PAR2 homology models
based on bovine rhodopsin and human opioid, chemokine, and
PAR1 crystal structures. This was done to compare sequence
and structural homology to identify the optimal PAR2 structure
Figure 2. Sequence alignment of human (h), bovine (b), rat (r), and mouse (m) PAR2. PAR2 sequences were obtained from the Swiss-Prot Web
site (accession number: human, P55085; bovine, Q2HJA4; rat, Q63645; mouse, P55086). Helix and loop predictions were based on literature.3
Other known species for PAR2 are excluded and can be found at the UniProt Web site (frog, Q5U791; salmon, B5X4N8). Boxed residues are
tethered hexapeptide starting from the proteolytic cleavage site. The number with “∗” refers to hPAR2 sequence. The helix in C-terminus is referred
to as TM8 and marked with “●”. Residues highlighted in bold are critical residues for receptor interactions determined from mutagenesis studies.
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for predicting ligand binding sites and to identify inﬂuences of
PAR2 residues on ligand signaling through mutagenesis studies.
A docking study with PAR2 agonist 2f-LIGRL-NH2 in, for
example, the rhodopsin homology structure (Figure 3)
suggested that the ligand bound to a 7TM region rather than
ECL2 on the receptor surface.11,55 This was supported by
subsequent mutagenesis of hPAR2 transfected CHO cells,11 in
collaboration with the Hooper group (Queensland University
of Technology, Brisbane, Australia). Critical residues that were
important for receptor interactions were determined from
mutagenesis and are alluded to in Figure 2.
Recently, the basic molecular architecture of GPCRs was
reviewed through a systematic analysis of high-resolution
GPCR structures.56 In particular, structures of several binary
complexes of GPCRs with their ligands, such as opioid receptor
(4EA3)57 and CXCR4 chemokine (3ODU)58 were crystallo-
graphically resolved, as well as PAR1 in complex with a natural
product-derived antagonist vorapaxar (3VW7).59 In contrast to
deep, yet solvent-exposed, ligand-binding sites observed in
structures of other peptide-activated GPCRs, the vorapaxar-
binding site of PAR1 is close to the plasma membrane surface
and includes part of ECL2. This may be an atypical structural
mode for ligand binding to PAR1 or PARs generally. It is our
view that the bulky natural product vorapaxar may stabilize an
unusual conformation due to its unusual binding orientation.
Alternative homology models may be more suitable for
structure-based or de novo drug design targeting PARs, since
they do not rely on the unusual vorapaxar-binding pocket in
this PAR1 crystal structure.
■ PAR2 FUNCTIONAL PHENOTYPE
The activation of PAR2 is associated with many inﬂammatory,
respiratory, gastrointestinal, metabolic, cardiovascular, and neuro-
logical diseases, as well as cancers.1,3,4,7,60 One of the ﬁrst PAR2
knockout studies found that the onset of inﬂammation was
delayed in PAR2 deﬁcient mice.61 PAR2 knockout studies in
mice have since given key information on the importance of
PAR2 in diﬀerent pathological conditions, implicating PAR2 in,
for example, the development of inﬂammatory arthritis, colitis,
airways inﬂammation, inﬂammatory and cancer pain, pancreatitis,
diet-induced obesity with associated cardiovascular remodeling
and metabolic dysfunction, ischemia−reperfusion injury, peri-
dontitis, hyperalgesia, and cancers (Table 2). However, in
inﬂammatory diseases where there are many in-built redun-
dancies, data from gene knockout mice can sometimes be
deceiving. Moreover, when a particuar gene has both pro- and
anti-inﬂammatory roles or both disease-causing and protective
eﬀects, this will be missed by merely inspecting knockout data.
Indeed, we and others believe that PAR2 has both protective and
pathogenic roles in human physiology and disease. Transgenic
mouse studies have so far associated PAR2 activation with
allergic airways inﬂammation, pulmonary hypertension and
ﬁbrosis, and arterial vasodilation.62−64 Unfortunately, the
available commercial antibodies for PAR2 have not proven to
be highly selective and/or potent for human PAR2,65 while there
have been few siRNA studies related to PAR2 to date.66−68
It is expected by many reseachers that results from gene
knockout studies in mice can be translated to human conditions.
However, this is often not the case, and recent studies showed
that gene expression responses from mouse models did not
always correlate well with human inﬂammatory conditions.140
This highlights the importance of studying responses in human
cells and against human proteins before investigating animal
models, and the need to interpret gene knockout studies in mice
with caution in considering human physiology and disease.
There has been some controversy about whether PAR2
activation is pro- and/or anti-inﬂammatory. Proteases play
numerous roles, both beneﬁcial and detrimental, in physio-
logical processess associated with inﬂammation, and PAR2 is a
target shared by a number of these proteases. Speciﬁc roles for
PAR2 in resolving inﬂammation are still being investigated, and
details of how PAR2 modulators diﬀerentially aﬀect PAR2-
mediated signaling pathways can help clarify the inﬂammatory
proﬁles of PAR2. In the airways, at least, there appears to be
substantial evidence that PAR2 activation may be protec-
tive.26,141−143 However, it has also been reported that PAR2
activation is protective and anti-inﬂammatory in pancreatitis,
ulcers, and colitis; these ﬁndings need corroborating.3,4,24 Most
studies involving PAR2 activation have identiﬁed induced
expression or release of proinﬂammatory mediators especially
cytokines (IL-1β, IL-6, IL-8, TNFα, GMCSF, MMP1, MMP10,
ICAM1, TRAF1, etc.),144−147 but anti-inﬂammatory mediators
(PGE2, NO, IL-10, etc.)
26,141 have also been detected in some
inﬂammatory, immune, and other primary cells. It is sensible to
consider that some functions of PAR2 may indeed be protective
in response to endogenous proteases, while others are detrimental
in promoting disease progression. Putative therapeutic agents
targeting PAR2 thus need to be examined cautiously for selective
eﬀects on diﬀerent cell signaling pathways, related either to disease
pathogenesis or to normal physiological responses.
PAR2 activation has also been implicated in diﬀerent forms
of cancer. Type II transmembrane-bound serine protease
(TMPRSS2) has been shown to cleave and activate PAR2 in
prostate cancer cells, leading to tumor growth.148 It was also
suggested that trypsin was a potent growth factor for colon
cancer cells by activating PAR2, subsequently transactivating
the epidermal growth factor receptor (EGFR) leading to cell
proliferation.149 Other PAR2 activators like kallikrein 14 (KLK14)
induced cell signaling in colon cancer cells by activating PAR2,
leading to proliferative responses.150 There are also reports
suggesting that TF/FVIIa induced PAR2 activation, leading to
proliferation and migration of SW620 colon cancer cells,151,152 as
well as inducing signaling, migration, and invasion of breast
cancer cells.86,153 In addition, PAR2-induced β-arrestin signaling
has been shown to mediate migration of breast cancer cells,154,155
although it is likely that other pathways are important in
migration.
PAR2 is clearly an important regulator in multiple diseases,
possibly amplifying inﬂammatory and other signaling responses
to infection or injury. Therefore, availability of potent, selective,
Figure 3. Homology model of PAR2 based on bovine rhodopsin
showing key residues (red sticks), examined through mutagenesis,
that deﬁne the putative binding pocket in the 7TM region for
agonist 2f-LIGRL-NH2 (green sticks), docked in PAR2 using
GOLD v3.1.11,55
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and bioavailable PAR2 agonists and antagonists to study PAR2
activation, especially in vivo, can greatly increase our under-
standing of the roles of PAR2 in inﬂammatory, respiratory,
metabolic, and cardiovascular diseases and in cancers, while also
assessing the viability of PAR2 as a drug target.
■ PAR2 SIGNALING AND ASSAY DESIGN
Although this is a medicinal chemistry perspective, it is
important to consider downstream signaling activated by
PAR2 to know how best to evaluate agonists and antagonists.
Most medicinal chemists approach drug discovery for GPCRs
by using a null cell type transfected with the human GPCR
of interest to measure ligand aﬃnity, followed by one or two
functional assays in relevant cells/tissues when available to
identify agonist or antagonist potency. This approach seems
particularly ﬂawed for PAR2, where “biased signaling” (see
below) seems to be a property for a number of ligands assessed
by others and us. In short, a given PAR2-binding ligand may have
few “oﬀ target” eﬀects; however, there may be undesirable “on
target” but “oﬀ pathway” signaling that could compromise ligand
development. On the other hand, designing ligands to selectively
direct such alternative pathway modulation could lead to panels
of PAR2 ligands with distinctly diﬀerent in vivo proﬁles and
potential beneﬁts in diﬀerent disease settings.
PAR2 transduces signals to initiate downstream pathways
through coupling to G proteins Gαq, Gαi, Gαs, and Gα12/13, as
well as triggering G-protein independent pathways, such as
through coupling to β-arrestins 1 and 2.3,5,156−158 Coupling of
PAR2 to diﬀerent G-proteins or β-arrestins varies depending on
the cell type. One of the most widely used biological assays for
screening for PAR2 ligands is intracellular calcium release
(iCa2+) from the endoplasmic reticulum, measured using cell
permeable dyes that ﬂuoresce only upon binding to intracellular
calcium. The Ca2+ pathway is stimulated upon coupling of Gαq
to activated PAR2.3,23,158 PAR2 activation by proteases and
peptide agonists also triggers other signaling pathways, such as
mitogen-activated protein kinase (MAPK) and phosphorylation
of extracellular signal-regulated kinases (ERK1/2), cyclic AMP,
activation of Rho kinase, and nuclear factor κB (NF-κB)
pathways.1,3,158 Some of these pathways have been demon-
strated to be mediated by PAR2 ligands in diﬀerent cell types
and in diﬀerent diseased states. For example, PAR2 activation
by SLIGRL-NH2 increased cAMP levels in neurons and
HEK293 cells,159 activating PKCε and PKA in sensory neurons,
and thus sensitized TRPV1 to induce thermal hyperalgesia.159
Activation of the MAPK or ERK1/2 pathway by SLIGRL-NH2
resulted in release of IL-8 in HT29 cells and in GI epithelial
cells.160,161 Activation of this pathway by diﬀerent PAR2
activating peptides also induced proliferative cellular re-
sponses.3 Activation of ERK1/2 by SLIGKV-NH2 or 2f-
LIGRLO-NH2 through coupling of β-arrestins-1 and -2 also
has been reported to prolong intracellular receptor-mediated
signaling and to promote tumor cell migration.154,157 PAR2
activation through the NF-κB pathway (by SLIGRL-NH2 or
trypsin) promotes expression and secretion of many inﬂam-
matory mediators, including the cytokines IL-8 and CXCL1 in,
for example, human nasal mucosa cells and intestinal epithelial
cells.161,162 Intracellular signaling proﬁles can also change
according to the extent of PAR2 cell surface expression, the
nature of the cell type, and through biased signaling induced
by diﬀerent ligand structures. The capacity of diﬀerent ligands
to act as both an agonist and an antagonist (“biased” ligands
brieﬂy discussed below), thereby diﬀerentially inducing and
blocking PAR2 coupling to diﬀerent G proteins, is an emerging
property that could potentially be usefully harnessed and
exploited to direct PAR2 modulation to control speciﬁc disease
indications.3,163−165
Each of the above pathways is now known to be regulated by
PAR2 activation and diﬀerentially regulated by diﬀerent
ligands.164,165 The phenomenon of biased ligand signaling is
likely to be associated with the ability of certain ligands to
subtly alter the conformational state of PAR2, probably by
slight distortions of the helix orientation, kinking, and side
chain interactions in the 7TM region. Each of these distortions
can, in turn, have knock on eﬀects on the interactions of the
three IC loops and C-terminal domain of PAR2 with
intracellular proteins, including G proteins. This phenomenon
has been known as functional selectivity, biased agonism, or
ligand-induced signaling.166−168 Biased ligands are important for
drug design to selectively target a particular physiological
process or diseased state by inﬂuencing the appropriate signaling
pathway. For example, the synthetic PAR2 agonist, SLIGRL-
NH2, was able to activate both calcium and MAPK pathways but
the peptide analogue SLAAAA-NH2 only activated MAPK.
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Recently, our group discovered that a PAR2 ligand, which acted
as a PAR2 antagonist in the calcium pathway, was instead a
PAR2 agonist in ERK1/2, cAMP, and Rho pathways and did
not have any eﬀect on receptor internalization.163,165
Because of the high sequence similarity between PAR1 and
PAR2, it is important to conﬁrm that new PAR2 ligands do not
interact with PAR1. The conventional approach is to examine,
for example, CHO cells transfected with PAR1 versus PAR2
using an aﬃnity assay. Selectivity can alternatively be evaluated
rapidly and at low cost through an iCa2+ desensitization assay,
using native cell lines that express both PAR1 and PAR2 (e.g.,
HEK293, HT29, or PC3).169−171 To determine whether an
agonist is selective for PAR2 using the latter assay, the cells are
ﬁrst treated with a selective PAR2 agonist (like 2f-LIGRLO-
NH2) at a certain concentration to elicit a calcium signal,
leading to desensitization of PAR2 receptors. After the signal
returns to baseline (a few minutes), the agonist ligand of
interest can then be added. If the agonist ligand is selective for
PAR2, no calcium signal should be observed, since PAR2 was
desensitized after the ﬁrst treatment with PAR2 agonist. For
determination of selectivity of PAR2 antagonists, the iCa2+
assay can be used by testing for inhibition of calcium elicited by
PAR1 agonists (e.g., TFLLR-NH2 or thrombin). PAR2 selective
eﬀects in vivo can also be demonstrated through use of PAR2-
gene knockout mice. A number of PAR2 agonists have been
tested in PAR2 KO models.61,75,89,96,172,173
Development of potent PAR2 ligands has been both
challenging and interesting. The molecular and mechanistic
details of how diﬀerent ligands activate or inhibit PAR2
functions are still under investigation and will aid the design of
ligands that more selectively control PAR2 conformations that
translate into speciﬁc signaling events. Therefore, it is extremely
important to proﬁle each new PAR2 ligand in parallel func-
tional assays to determine eﬀects on multiple signaling events.
An alternative approach for PAR2 ligand screening is to
utilize a competitive ligand-binding aﬃnity assay. The ﬁrst PAR2
aﬃnity assay was performed using tritiated 2f-LIGRL-NH2 in
monolayers of PAR2 expressing NCTC2544 and human
umbilical vein endothelial cells (HUVEC).174 Tritium was
incorporated at the second residue leucine side chain of 2f-
LIGRL-NH2,
174 while later Hollenberg et al. introduced the
tritium at the ornithine side chain of 2f-LIGRLO-NH2 (a potent
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PAR2 peptide agonist).175 The unlabeled 2f-LIGRLO-NH2
competed with these tritiated peptides with similar binding
aﬃnity (IC50 0.1 μM).
174,175 Instead of using radioactive-labeled
peptide, Alexa Fluor 594-2f-LIGRLO-NH2 was synthesized for
ligand binding aﬃnity as well as receptor visualization studies in
KNRK cells expressing PAR2.98 In the assays mentioned
previously, the PAR2-activating peptide SLIGRL-NH2 demon-
strated higher aﬃnity for the receptor than SLIGKV-NH2.
174,175
In addition, peptides with a C-terminal amide were more potent
agonists than with a free C-terminal carboxylic acid, and
2f-LIGRL-NH2 exhibited the highest binding aﬃnity.
174 These
results were consistent with activities observed in an iCa2+
mobilization assay. Also, addition of a ﬂuorophore substituent
at the ornithine side chain of 2f-LIGRLO-NH2 did not
appreciably change the activity or selectivity of the peptide.175
On the other hand, we found that iodinating tyrosine of
SLIGKVY-NH2 or SLIGKVDGY-NH2 did reduce agonist
activity somewhat (Beyer RL, unpublished results), but these
peptides still had activity comparable to SLIGKV-NH2, so it may
be possible to label peptide agonists in general with 125I for
radioligand binding studies. Additionally, the C-terminus of 2f-
LIGRLO-NH2 has been conjugated to ﬂuorescein or rhodamine
via diﬀerent linkers, but the resulting peptide-bound ﬂuoro-
phores internalized into cells via passive diﬀusion because of the
ﬂuorophore rather than via a PAR2-dependent mechanism.11
More recently, a lanthanide-based time-resolved ﬂuorescence-
binding assay was reported.176 Diethylenetriaminepentaacetic
acid (dtpa) was introduced at the ornithine side chain to give 2f-
LIGRLO(dtpa)-NH2, and this peptide was then chelated to
europium(III). This is a highly sensitive assay and can be used
for high-throughput competitive ligand binding, as long as the
test ligand binds in the same or overlapping location in PAR2 as
this ﬂuorophore.176 The lanthanide peptide is straightforward,
convenient, and cheap to make. Ligands that interact with PAR2
may or may not compete with the labeled peptide. Some ligands
can bind to allosteric sites without aﬀecting the binding of a
labeled ligand. Since the assay only detects those ligands that
compete with the labeled ligand for PAR2, allosteric ligands
cannot be identiﬁed in this way.
■ PAR2 AGONISTS
The design of PAR2 ligands started with synthetic peptides,
with sequences corresponding to the native tethered-ligand
sequence from human (SLIGKV) and rodent (SLIGRL)
PAR2.5 The rodent hexapeptide sequence, SLIGRL-NH2, was
reported to be a 2- to 5-fold more potent agonist (EC50
5−30 μM) than the human sequence, SLIGKV-NH2, depend-
ing upon the human cell type or assay used.177−179 In addition,
PAR1 activity was observed when the aliphatic residue (leucine)
at position 2 of SLIGRL-NH2 was replaced with aromatic
residues such as phenylalanine.35 Additionally, D-amino acids
were not tolerated in these peptides and the C-terminal amide
was required at the C-terminal end of the peptides for optimal
agonist activity.35
Later it was reported that replacing the serine residue of
SLIGRL-NH2 (1) with the 2-furoyl (2f) group and adding an
ornithine at the C-terminus (2f-LIGRLO-NH2, 2, Table 3)
signiﬁcantly improved the agonist potency >10-fold and 2 was
selective for PAR2 over PAR1.180 This peptide remains one
of the most potent PAR2 agonists reported to date for cells
(EC50 0.2 μM), as measured by iCa
2+ mobilization.171,180,181
It has also been reported that addition of a seventh residue,
such as isoleucine (3), to the C-terminus of SLIGRL-NH2
increased potency by ∼6-fold182,183 and that replacing the sixth
residue leucine with aromatic groups, such as tyrosine (4),
4-nitrophenylalanine (5), or 3,4-dichlorophenylalanine (6),
increased potency further (Table 3).182 Therefore, it was
expected that substituting the sixth residue leucine of 2f-
LIGRLI-NH2 peptide (7) with a 4-nitrophenylalanine group
(8) could also improve agonist potency. However, no
improvement was observed.182 Instead, this peptide (8) had
similar potency to 2f-LIGRLI-NH2 (7, EC50 0.2 μM) in iCa
2+
release assay on HT29 cells.182 In the same paper, a series of
heterocycles and aromatic substitutents (9) were substituted
for the serine residue of SLIGRLI-NH2 (3), with 4-(2-
methyloxazolyl), 5-isoxazolyl, 2-pyrazoyl, 2-pyridoyl, 3-pyridoyl,
2-benzofuranoyl, 2-naphthoyl, 2-benzothienyl, and others,
all producing potent agonists with EC50 0.1−0.3 μM (iCa2+,
HT29 cells).182
Recently, the serine of SLIGRL-NH2 was similarly replaced
with closely related heterocycles, 2-aminothiazol-4-oyl (2-at)
and 6-aminonicotinoyl (6-an), to also produce agonist
analogues of 2f-LIGRLO-NH2 (2), activating both Ca
2+ and
MAPK signaling with comparable potency to the above.181
Addition of a palmitoyl group linked by three modiﬁed PEG
units (∼60 atoms length) to the ornithine side chain of 2-at-
LIGRLO-NH2 increased PAR2 agonist potency 200-fold (EC50
4 nM, iCa2+; EC50 10 nM, MAPK; 16HBE14o-cells).
173 A few
hydrophobic linkers with diﬀerent chain length were inves-
tigated, and PEG3-Pam was optimal. This lipid peptide, 2-at-
LIGRLO(PEG3-Pam)-NH2, was reported to be selective for
PAR2 over PAR1 in a Ca2+ desensitization experiment, and it
showed minimal Ca2+ response in PAR2−/− cultured cells
compared to wild-type. In addition, it induced allodynia in mice.
Although ligand potency can be improved through the lipidation/
membrane-tethering approach, this huge and highly hydrophobic
molecule may have limited application in drug development.
Small molecule PAR2 agonists (10−12, Figure 4) were
identiﬁed through screening a chemical library.184,185 Com-
pounds 10 and 12 were reported as full PAR2 agonists (EC50
200−1000 and 30−100 nM, respectively) in cellular prolifer-
ation, phosphatidylinositol hydrolysis, and Ca2+ mobilization
assays using human HEK293T cells. On the other hand,
compound 11 was a partial PAR2 agonist. Although these
compounds demonstrated good stability, they had solubility
Table 3. PAR2 Peptide Agonists and Their Comparative Activities in a Calcium Mobilization Assay on HT29 Cells182,183
compd PAR2 peptide agonist
EC50
(μM) compd PAR2 peptide agonist EC50 (μM)
1 SLIGRL-NH2 4.2 6 SLIGR-(3,4-dichloro-Phe)-I-NH2 0.3
2 2f-LIGRLO-NH2 0.2 7 2f-LIGRLI-NH2 0.2
3 SLIGRLI-NH2 0.7 8 2f-LIGR-(4-nitro-Phe)-I-NH2 0.2
4 SLIGRYI-NH2 0.4 9 X-LIGRLI-NH2 X = 4-(2-methyloxazolyl), 5-isoxazolyl, 2-pyrazoyl, 2-pyridoyl, 3-pyridoyl,
2-benzofuranoyl, 2-naphthoyl, 2-benzothienyl
0.1−0.3
5 SLIGR-(4-nitro-Phe)-I-NH2 0.4
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issues.184,185 We evaluated compound 12 in HT29 cells but did
not ﬁnd agonist activity; compound 12 at 1 μM did not stimulate
any Ca2+ release. The biological activity of this compound may
require further investigation to examine if there really is PAR2-
mediated activity in diﬀerent cells and conditions.
Truncation of 2f-LIGRLI-NH2 to two residues, with the
2-furoyl (2f) cap at the N-terminus (“dipeptide”, 13−15,
Figure 4) was found to maintain relatively good potency in the
iCa2+ assay performed using HT29 cells.171 From the furoyl-
dipeptide, optimization of the second and third residues led to
L-phenylalanine (13) or L-cyclohexylalanine (14) at position 2
and L-isoleucine at position 3 with the greatest PAR2 agonist
potencies. However, compound 13 with Phe at position 2 was
not selective for PAR2 over PAR1, whereas 14 did retain PAR2
selectivity.171 The promising dipeptide analogue (2f-Cha-Ile-
NH2, 14) was therefore further elaborated by replacing the
2-furoyl capping group with other small heterocycles. Pyrazole,
isoxazole, and methyloxazole were examined, with the isoxa-
zole being optimal for this fragment, leading to 15 (EC50 1.0−
4.0 μM).171
A potent and selective agonist 16 (GB110, Figure 4, EC50
0.28 μM, iCa2+ in HT29) was derived from dipeptide agonist
15.171 This is the most potent peptidomimetic PAR2 agonist
reported to date. PAR2 agonists reported here were evaluated
in diﬀerent disease models, and a few examples are listed in
Table 4.
■ PAR2 ANTAGONISTS
The development of PAR2 antagonists has not yet progressed
as far as PAR1 antagonists. The structure−activity relation-
ships for PAR2 agonists are not always applicable to PAR2
antagonists, which may bind diﬀerently to the receptor. PAR2
peptide “antagonists”, FSLLRY-NH2 and LSIGRL-NH2,
inhibited PAR2 activation induced by trypsin but not by the
synthetic agonist (SLIGRL-NH2), with IC50 50−200 μM
(iCa2+, PAR2-transfected KNRK cells).192 The ﬁrst reported
nonpeptidic PAR2 antagonist was ENMD-1068 (17, Figure 5),
which was selective for PAR2 over other PARs in vitro but
with only very low potency (IC50, millimolar).
76 Although 17
attenuated carrageenan/kaolin-induced joint swelling in mice
(4 mg, ip),76 the extremely low in vitro potency makes it diﬃcult
to know if PAR2 is the target in vivo where the compound likely
binds a myriad of receptors; thus, any properties attributed to
PAR2 in vivo must be treated warily.
A more potent PAR2 antagonist (K-14585, 18) was reported
in 2009.193 This compound did not antagonize PAR2 activation
Figure 4. Peptide and small molecule PAR2 agonists.
Table 4. Examples of the Many Eﬀects Caused by Diﬀerent PAR2 Agonists in Disease Models
PAR2 agonist eﬀects caused by PAR2 activation in disease models
cardiovascular system PAR2-activating peptides, SLIGRL-NH2 Induced hypotension.
89
Reduced infarct size and delay ischemic preconditioning in murine ischemia reperfusion injury model.172
gastrointestinal tract SLIGRL-NH2, trypsin, tryptase Induced colonic inﬂammation (granulocyte inﬁltration, tissue damage, increases bowel wall thickness and
TH1 cytokine release).97,186
inﬂammation SLIGRL-NH2, Induced leukocyte rolling in mice.
61
2f-LIGRLO-NH2, 16 Induced joint swelling and synovial hyperemia.
75,171,187,188
nervous system SLIGRL-NH2 Induced deﬁcits in experience-dependent learning in rats.
189
Stimulated scratching behavior in murine model.3
Diminished epileptogenic activity in rats.190
2f-LIGRLO-NH2, 2-at-LIGRL-NH2, Induced thermal hyperalgesia.
191
2-at-LIGRLO(PEG3-Pam)-NH2 Induced allodynia in mice.
173
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by proteases like trypsin, but it was a competitive inhibitor
(Ki 0.6 μM) of the binding of radiolabeled
3H-2f-LIGRL-NH2
to NCTC2544-PAR2 cells, and it was selective for PAR2 over
other PARs. The compound inhibited activation of PAR2 in
NCTC2544-PAR2 cells by the weakly potent PAR2 agonist
SLIGKV-NH2, as measured by an NF-κB-luciferase reporter
gene assay (IC50 1.1 μM).
193 Compound 18 had dual eﬀects
on certain signaling events, such as PAR2 mediated phos-
phorylation of ERK, p38 MAPK, and NF-κB pathways. At low
micromolar concentrations, it inhibited distinct signaling
parameters induced by SLIGKV-NH2 but became an agonist
at higher concentrations.194 This PAR2 ligand had solubility
issues due to high molecular weight and bulky hydrophobic
groups. Lack of eﬀects on PAR2 activation by endogenous
proteases (e.g., trypsin) may limit its usefulness.
A natural diterpenoid from Tripterygium wilfordii Hook F,
triptolide (19), inhibited NF-κB activation of PAR2 (IC50 14 nM)
by 2f-LIGRLO-NH2 (10 μM) in A549/NF-κB-luc cells,
195
but it was not selective and also inhibited substance P induced,
neurokinin receptor 1 (NK1) mediated production of IL-8
(IC50 23 nM, A549/Tacr1 cells).
195 This compound 19 was
reported to be toxic after oral administration to rats.196
The morpholine 20 (IC50 57 μM, iCa
2+, HT29 cells),
spiroindane 21 (GB83, IC50 2 μM) and spiroindene 22
(GB88, IC50 1 μM) compounds were derived from the non-
peptidic PAR2 agonist 16 (Figure 4).171,187 Compounds 21 and
22 were novel PAR2 antagonists that shared an N-terminal
structural component (5-isoxazoyl-Cha-Ile) with the PAR2
agonist 16, diﬀering only in the C-terminal spiropiperidine.171,187
It was concluded that the C-terminal fragment dictated ligand
function. Unlike previously reported PAR2 antagonists, 22 was
the ﬁrst potent, nonpeptidic PAR2 antagonist that inhibited
PAR2-induced iCa2+ release by all known agonists, including
synthetic peptides (SLIGKV-NH2, SLIGRL-NH2, 2f-LIGRLO-
NH2), nonpeptidic agonist (16), and endogenous agonists like
trypsin and tryptase. Interestingly, 22 was equipotent (IC50
1 μM, iCa2+) against all three types of PAR2 agonist in seven
diﬀerent human cell types.187 Compound 22 was a surmountable
and competitive antagonist of 2f-LIGRLO-NH2 (with a Schild
plot slope being unity) but a competitive yet insurmountable
antagonist of agonist 16.187 This suggested that 22, 16, and
2f-LIGRLO-NH2 bind at the same, or an overlapping, site on
PAR2. Further evaluation of 22 in vitro identiﬁed it as a biased
PAR2 antagonist, inhibiting release of PAR2-induced intracellular
Ca2+ and proinﬂammatory cytokines from a wide range of cell
types while acting as an agonist in inhibiting cAMP stimulation
and activating ERK phosphorylation and Rho stimulation.11,163,165
Importantly, 22 was selective for PAR2 over PAR1, serum stable
and orally active in rodents.186−188 It has proven to be a very
useful probe for studying eﬀects of PAR2 antagonism in a range
of in vivo disease models, including rat paw edema, colitis,
arthritis, and diet-induced metabolic dysfunction. Antagonist 22
(5−10 mg/kg, po) attenuated PAR2, but not PAR1, agonist-
induced paw edema and acute inﬂammation,187 as well as
inhibited collagen-induced arthritis in rats.188 It also inhibited
PAR2 agonist-induced acute colonic inﬂammation and chronic
TNBS-induced colitis in rats at 10 mg kg−1 day−1, po.186 When
given orally at 10 mg kg−1 day−1, 22 attenuated diet-induced
obesity in rats, inhibiting adipose inﬂammation, cardiovascular
remodeling and cardiac ﬁbrosis, insulin sensitivity and glucose
intolerance, and liver and pancreatic dysfunction, suggesting that
inhibition of PAR2 may be beneﬁcial for both treating and
preventing metabolic dysfunction.12,13
Nordihydroguaiaretic acid (NDGA, 23, Figure 6) was
recently reported as a PAR2 selective antagonist, inhibiting
PAR2-induced calcium release, production of IL-8, and inter-
cellular cell adhesion molecule 1 in HaCat keratinocytes.197 It
showed some anti-inﬂammatory activity, attenuating oxazolone-
induced chronic dermatitis symptoms in hairless mice model.197
Unfortunately, the eﬀective concentrations of this compound
in cell-based assays and animal models were not reported.
NPS-1557 (structure not disclosed) was also reported to have
anti-inﬂammatory activity in oxazolone-induced chronic derma-
titis mice model but inhibited calcium mobilization in HCT-15
Figure 5. Peptidomimetic and small molecule PAR2 antagonists.
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cells with very low potency (IC50 ≈ 125 μM, against 25 μM
SLIGRL-NH2).
198,199 A few other PAR2 antagonists (24−33,
Figure 6) were also reported in patents, and their properties are
summarized in Table 5. All of these PAR2 antagonists were
suggested to be potential anti-inﬂammatory agents, albeit with
little or no in vivo data supplied in most cases.
Among all PAR2 antagonists reported in patents, compounds
32 and 33 were the most potent in vivo. Compounds 32 and
33 were derived from PAR2 antagonist 22 (WO2013013273).
Structure−activity relationships (SAR) derived for 22 identiﬁed
putative roles for each component. Both the nitrogen and
oxygen atoms of the isoxazole are thought to be hydrogen
bond acceptors for residues in PAR2. The cyclohexylalanine
conferred PAR2 selectivity over PAR1; phenylalanine at this
position did not discriminate between PAR1 and PAR2.200 The
isoleucine was important for binding aﬃnity. The C-terminal
component dictated antagonist versus agonist function. In
addition, an aromatic ring at the C-terminus of the ligand helped
to maintain antagonist activity, possibly due to a π-stacking
interaction with the receptor. These two PAR2 antagonists (32
and 33), with enhanced potency over 22, inhibited PAR2
activation induced by either the PAR2 peptide agonist 2f-
LIGRLO-NH2 (IC50 0.7 and 0.4 μM, respectively) or trypsin
(IC50 3.6 and 1.9 μM, respectively) in the calcium mobilization
assay using HT29 cells and also blocked release of
proinﬂammatory cytokines (IL-6, TNFα) in primary human
kidney tubule epithelial cells (HTEC).200 These antagonists
were stable in rat plasma, with 32 being more orally bioavailable
than 33 and more eﬀective in preventing joint inﬂammation in
rats. However, 33 was a more eﬃcient anti-inﬂammatory agent
than 22 and 32 in the rat paw edema model when the com-
pounds were given to rats at 5 mg/kg, sc (WO2013013273).200
In summary, compounds 22, 32, and 33 are the most eﬀective
small molecule PAR2 antagonists published to date with anti-
inﬂammatory properties in vivo. These PAR2 antagonists oﬀer
new insights to PAR2 functions in vitro in signaling pathways
and in vivo in diverse PAR2-mediated diseases.
■ PAR2 PEPDUCINS
Pepducins are lipidated synthetic peptides reported to modulate
GPCR function in diﬀerent cell types or in vivo in rodent
models. Pepducins are composed of amino acid sequences
corresponding to sequences of the tethered intracellular loops
Figure 6. Peptide and small molecule PAR2 antagonists. Compounds 24−33 were reported in patents (Table 5). X = H, OH, Me, CO2H, CO2Et, or
CH2OH. Y = CH or N. R1 = H, F, or Cl. R2 = substituted benzyl ring.
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(ICL) or perhaps the C-terminus of GPCRs.201 These peptide
sequences provide a degree of receptor speciﬁcity, while the
attached lipid (e.g., palmitate) evidently facilitates diﬀusion of
the peptide across the lipid bilayer of cells. The lipid may also
help to anchor the peptide in the lipid bilayer, bringing the
peptide headgroup close to potential targets such as receptor−
G-protein interfaces. As the peptide head mimics the ICL, it
may disrupt cognate receptor−G-protein interactions and
inhibit signaling.202 However, pepducins with wild-type
sequences are generally agonists and modiﬁcations would be
necessary to switch function to antagonism.
Advantages of using pepducins as biological tools or potential
therapeutics lie in high selectivity for their targets and rapid
synthesis with ease of modiﬁcations at speciﬁc amino acid
residues or the lipid moiety. Modiﬁcations could in principle be
tailored to improve both the function of the ligand (target and
pathway selectivity, agonism, or antagonism) and pharmacoki-
netic proﬁles. It is known that, on parenteral delivery,
pepducins become widely distributed throughout animal tissues
(such as liver, kidney, lung, spleen), but not brain because of
limited penetration of the blood−brain barrier, as also usually
observed for peptides.41
In PAR1 pepducins, (1) varying the length of hydrophobic
amino acid residues at the N-terminus reportedly aided cell
penetration but was not suﬃcient for activity, indicating that
the hydrophobic tether must be of suﬃcient length or hydro-
phobicity to transfer its cargo across the membrane; (2) the
presence of the cognate receptor was required for G proteins to
be activated; (3) the receptor was not activated at the extra-
cellular ligand site; rather these compounds localized to the
intracellular membrane surface for activity.202
A few PAR2 pepducins were developed as allosteric
modulators to regulate PAR2 functions (Tables 6 and 7).
P2pal-21 (36, Table 6), mimicking full-length wild-type ICL3
(21-mer from R267 to K287), was a partial agonist for PAR2
(EC50 15 μM, iCa
2+) in SW620 colon adenocarcinoma cells
endogenously expressing PAR2, and at 6 μM it failed to block
the calcium release induced by SLIGRL-NH2 (100 μM).
46,202
However, 36 displayed concentration-dependent biphasic activity
in the PLC-β dependent InsP production pathway, being a partial
agonist (18% maximum) at <100 nM and an antagonist (IC50
1 μM) at higher concentrations against SLIGKV-NH2 (100 μM).
This suggested a two-site mechanism, with a high-aﬃnity binding
site at the intracellular surface of the GPCR, which upon binding
of pepducin agonist either stabilized or induced the activated state
of the receptor and activated the associated G protein(s). When
this ﬁrst site became saturated, higher concentrations of pepducin
may occupy a second lower-aﬃnity inhibitory site that blocked
signal transference to G proteins, perhaps by mimicking or
stabilizing receptor ICL3 ground-state interactions with the
G proteins. Alternatively, exogenous activation or inhibition of
receptors by pepducins could reﬂect a potential dimerization
mode, whereby one receptor donates its intracellular loops to an
adjacent receptor.202
The lack of eﬃcacy of wild-type pepducin 36 may be due to
the presence of a positively charged lysine at the C-terminus of
Table 6. Amino Acid Sequences of Pepducins with Palmitoylation (Omitted) at the N-Terminusa
compd sequence
34 P1pal-19 RCLSSSAVANRSKKSRLF
35 P1pal-13 AVANRSKKSRLF
36 P2pal-21 RMLRSSAMDENSEKKRKRAIK
37 P2pal-21F RMLRSSAMDENSEKKRKRAIF
38 P2pal-18F RSSAMDENSEKKRKRAIF
39 P2pal-18S RSSAMDENSEKKRKSAIK
40 P2pal-18SF RSSAMDENSEKKRKSAIF
41 P2pal-18Q RSSAMDENSEKKRKQAIK
42 P2pal-14GF GDENSEKKRKRAIF
43 P2pal-14GQ GDENSEKKRKQAIK
aResidues highlighted in boldface are mutated.
Table 5. Potential Applications of PAR2 Antagonists Reported in Patents
compd patent number organization PAR2 inhibition activity assay conditions
potential therapeutic
application
24 WO2005030773A1,
JP2003286171A
Sumitomo Phar-
maceuticals Co.,
Ltd.
Up to 98% inhibition of iCa2+ at 10 μg/
mL (∼25 μM); up to 47% inhibition
of PGE2 at 0.25 μg/mL (∼0.6 μM)
iCa2+, HEK293 cells, against trypsin;
PGE2, SW982, against 100 μM
SLIGRL-NH2
Skin inﬂammation
25 KR2010038919A NeoPharm Co.,
Ltd.
Complete inhibition of calcium signal at
2.5 mM
iCa2+, HCT-15 cells, against SLIGKV-
NH2 (2.5 μM)
Undisclosed
26 KR2011118210 Enprani Co., Ltd. IC50 = 0.7 mM iCa
2+, HaCat cells, against SLIGKV-
NH2 (undisclosed concentration)
Hyperpigmentation or in-
ﬂammatory skin diseases
27 KR2011130259A NeoPharm Co.,
Ltd.
IC50 = 34 μM iCa
2+, HCT-15 cells, against SLIGKV-
NH2 (2.5 μM)
Cardiovascular disease,
gastrointestinal disease,
asthma, etc
28 WO2012026766A2 Neopharm Co.,
Ltd.
IC50 = 243 μM iCa
2+, HCT-15 cells, against SLIGKV-
NH2 (2.5 μM)
Skin inﬂammation
29 WO2012026765A2 Neopharm Co.,
Ltd.
IC50 = 77 μM iCa
2+, HCT-15 cells, against SLIGKV-
NH2 (2.5 μM)
Skin inﬂammation
30, 31 WO2012101453 Proximagen Ltd. IC50 < 5 μM, concentration unit missing
in patent
iCa2+, human PAR2-transfected
1321N1 cells, against trypsin (EC50)
Intestinal inﬂammation
and inﬂammatory skin
diseases
32, 33 WO2013013273 University of
Queensland
IC50 = 0.4−4.0 μM iCa2+, HT29 cells, against 2f-LIGRLO-
NH2 (1.0 μM), trypsin (0.1 μM)
Multiple inﬂammatory
diseases
Journal of Medicinal Chemistry Perspective
dx.doi.org/10.1021/jm400638v | J. Med. Chem. 2013, 56, 7477−74977488
the PAR2 ICL3 in a hydrophobic environment. Indeed a single
residue K287F mutation (37) turned pepducin 36 to a potent
full agonist (EC50 25 nM, InsP assay in PAR2-expressed
COS7 cells,202 and 94% in iCa2+ ﬂux assay in SW620 colon
adenocarcinoma cells46). However, 37 also activated PAR1.
Cross-reactivity was also observed for PAR1 ICL3 pepducin
(34), which was not only a full agonist for PAR1 (EC50
180 nM, InsP assay, PAR1-expressed COS7 cells) but also a
full agonist for PAR2 in either InsP production (PAR2-expre-
ssed COS7 cells) or platelet aggregation assays (EC50 8 μM).
However, truncation of six amino acid residues from the
N-terminus (35) retained PAR1 agonist activity and eliminated
PAR2 activity. In contrast to the lack of selectivity observed for
34, truncated pepducin 35 was selective against a panel of seven
GPCRs.202 Therefore, modiﬁcation of key residues of a PAR2
pepducin that mimics the third intracellular loop of the receptor
might improve selectivity for PAR2 pepducin. PAR2 homo-
dimer modeling and mutational analysis suggested that removal
of charged amino acids at a speciﬁc site close to the
C-terminus (e.g., R284/K287 to S/Q or F, respectively), or
truncation of the N-terminus of pepducin, can switch the function
(agonism/antagonism) and/or selectivity over other receptors.202
For example, the agonist potency was reduced when the ﬁrst
three residues were removed (38).46 On the other hand, R284S
mutation led to the most potent pepducin PAR2 antagonist 39.
When the C-terminal lysine of 39 was substituted with
phenylalanine to give 40, it became an agonist.46 In addition,
substitution of R284 with glutamine (41) displayed partial
antagonist activity with no agonist activity observed. Deletion of
seven residues from the N-terminus, along with M274G, K287F
mutations, resulted in an inactive pepducin 42. However, M274G
and R284Q mutations (43) restored 53% antagonist activity
(at 6 μM, iCa2+ in SW620 induced by 100 μM SLIGRL-NH2).
46
In vivo pepducin 39 inhibited PAR2-dependent calcium
signaling (77% inhibition at 6 μM induced by 100 μM SLIGRL-
NH2 in SW620), PLC-β-inositol phosphate formation, and cell
migration (e.g., IC50 0.14 μM, human neutrophil chemotaxis
to 30 nM trypsin and 10 μM SLIGRL-NH2 and 100% inhibi-
tion to 100 nM tryptase) but not proteolytic cleavage or endo-
cytosis. It was speciﬁc for PAR2 over the closely related PAR1,
PAR4, or CXCR1/2 receptors in several assays. It did not cause
membrane disruption or apoptosis up to 30 μM. Unlike other
small molecule antagonists, which had partial agonist activity
(or constitutive activity) observed at higher concentrations, 39
completely ablated residual agonist activity according to the
patent WO2012139137A2.
At 10 mg/kg (sc), 39 exhibited in vivo anti-inﬂammatory
activity in mouse paw edema models induced by several
reagents including PAR2 agonists. Lack of reduced paw edema
in PAR2−/− and mast-cell-deﬁcient mice, compared to control
mice treated with 39, demonstrated speciﬁcity for PAR2 in
vivo. It is notable that, like PAR1 pepducins, 39 required PAR2
to exhibit PAR2 inhibitory activity.46 Recently, 39 was shown to
exert model-speciﬁc eﬀects on the severity of experi-
mental pancreatitis, increasing severity of secretagogue-induced
pancreatitis while reducing severity of bile acid infusion-induced
pancreatitis.203
■ PAR2 ANTIBODIES
Commercially available antibodies with some reactivity/speciﬁcity
for PAR2 are summarized in Table 8. Recently, four commercially
available antibodies from Santa Cruz Biotechnology Inc. (SAM11,
N19, H99, and C17) were evaluated in an academic setting using
Western blot, confocal microscopy, and ﬂow cytometry analysis
for their eﬀectiveness in detecting both ectopic and endogenous
PAR2.65 It was found that for ectopic PAR2 detection, all four
antibodies were eﬀective by immunocytochemical analysis, three
(N19, SAM11, and C17) by Western blot, but only two (SAM11,
N19) by ﬂow cytometry. For endogenous PAR2, N19 was
eﬀective for detection by either ﬂow cytometry or Western blot
analysis but SAM11 was only suitable in ﬂow cytometry, and the
other two failed in all three techniques. These ﬁndings reﬂect
some frustrations of researchers in the ﬁeld and explain problems
that arise through lack of aﬃnity and/or speciﬁcity for PAR2.
It has been recommended that they should be used with
appropriate controls (e.g., materials from vector-transfected cells
and cell fractionation in Western blot analysis) to identify
nonspeciﬁc reactivity.3 SAM11 is the most commonly used PAR2
antibody in vitro to monitor PAR2 expression on cell surfaces,
and recently in vivo eﬃcacy was demonstrated by attenuating
collagen-induced arthritis in mice.204 Three other anti-PAR2
antibodies (3777, 2B, 2D) were also reported to show good
binding aﬃnity for PAR2. These antibodies bound to the
N-terminus of PAR2, preventing proteolytic cleavage and thus
activation of the receptor. They inhibited trypsin-induced iCa2+
release, cytokine secretion, and relaxation of isolated rat aortic
rings. These anti-PAR2 antibodies were also eﬀective in inhibiting
inﬂammatory edema in vivo.205 Table 9 summarizes some PAR2-
binding antibodies reported in patents with potential therapeutic
applications. However, not all antigenic epitopes were disclosed.
In many cases, physiological and disease functions of PAR2
have been identiﬁed by using only peptide agonists or PAR2
antibodies, each with uncertain selectivity for PAR2 in vivo, and it
Table 7. Properties of PAR2-Modulating Pepducinsa
pepducin function
34 P1pal-19 Full agonist (InsP in PAR2-COS7 cells; platelet aggregation); nonselective to PAR1 (full agonist, InsP) and CCKB (partial against, InsP), selective
over PAR4 (iCa2+ and InsP), CCKA, SSTR2, and SubP receptors (InsP in transfected COS7 cells).202
36 P2pal-21 Biphasic eﬀects: partial agonist at <100 nM (InsP in PAR2-COS7 cells) and antagonist at >100 nM (IC50 = 1 μM, induced by 100 μM SLIGKV-
NH2);
202 weak agonist/antagonist (iCa2+ in SW620).46
37 P2pal-21F Full agonist (InsP in PAR2.COS7; iCa2+ in SW620), selective over PAR4, CCKA, CCKB, or SSTR2 but not PAR1 (InsP in transfected COS7).46,202
39 P2pal-18S Antagonist (iCa2+ in SW620 and acinar cells; human neutrophil chemotaxis to trypsin, SLIGRL-NH2, tryptase, and mast cell media; SLIGRL-NH2, but
not caerulein, or TLCS-induced amylase secretion from pancreatic acini; TLCS-induced acinar cell injury/death).46,203
Selective over CXCR1/CXCR2 (human neutrophil chemotaxis), PAR1 (human neutrophil chemotaxis, iCa2+ in SW620, InsP in transfected COS7,
PAR1-dependent aggregation), and PAR4 (human neutrophil chemotaxis, iCa2+ in SW620, and InsP in transfected COS7).46,203
In vivo anti-inﬂammation: paw edema and pancreatitis.46,203
43 P2pal-14GQ Antagonist (iCa2+ in SW620, neutrophil or SW620 migration).46
In vivo anti-inﬂammatory: in paw edema.46
a34 was designed to target PAR1-ICL3, and all the others were designed to target PAR2-ICL3.
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is important for future research that new pure reagents are
developed with greater potency and higher PAR2 selectivity.
■ CONCLUSION AND FUTURE PROSPECTS
PAR2 has a unique activation mechanism and is the common
target of multiple proteolytic enzymes involved in many
biological functions. Given numerous putative roles for PAR2
in inﬂammatory, respiratory, gastrointestinal, metabolic, cardio-
vascular, neurological disorders, and cancers, the development of
PAR2 agonists and antagonists is expected to produce valuable
new therapeutic agents against this novel target. However,
mechanisms for how pathological conditions result from PAR2
signaling still remain uncertain in most cases. Biased-signaling
properties for recently discovered PAR2 ligands3,163−165 may
oﬀer promising opportunities for developing selective agonists/
antagonists that diﬀerentially target PAR2-mediated intracellular
signaling pathways, and in turn these may have impact on
treatment of diﬀerent disease conditions without compromising
beneﬁcial eﬀects of PAR2. Parallel evaluation of PAR2 ligands in
multiple assays is encouraged in order to capture the full
beneﬁts of PAR2 agonists and antagonists in modulating speciﬁc
signaling pathways linked to speciﬁc pathological disorders. We
predict that new ligands for PAR2 that can modulate diﬀerent
signaling pathways could be extremely valuable for interrogating
PAR2 functions and for treating multiple diseases that share
PAR2-dependent inﬂammatory origins.
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■ ABBREVIATIONS USED
2-at, 2-aminothiazol-4-oyl; 2f, 2-furoyl; CHO, Chinese hamster
ovary; COS7, ﬁbroblast-like cells derived from the kidney of the
African green monkey Cercopithecus aethiops; CXCL1, chemo-
kine (C-X-C motif) ligand 1; ECL, extracellular loop; dtpa,
diethylenetriaminepentaacetic acid; GMCSF, granulocyte-
macrophage colony-stimulating factor; HAT, human airway
trypsin-like protease; HCT-15, human colon carcinoma; HT29,
human colonic adenocarcinoma; HTEC, human kidney tubule
epithelial cells; HUVEC, human umbilical vein endothelial
cells; iCa2+, intracellular calcium; ICAM-1, intercellular
adhesion molecule 1; ICL, intracellular loop; IFNγ, interferon
γ; IgE, immunoglobulin E; IL, interleukin; InsP, inositol 1,4,5-
triphosphate; IUPHAR, International Union of Pharmacology,
Committee on Receptor Nomenclature and Drug Classiﬁca-
tion; KLK, kallikrein; KO, knockout; MASP-1, mannose-
associated serine protease 1; mBSA, methylated bovine serum
albumin; OA, ovalbumin; Pam, palmitoyl; PAR2, protease-
activated receptor 2; PC3, human prostate cancer cells; PGE2,
prostaglandin E2; PKCε, protein kinase Cε; PLC, phospholi-
pase C; SSTR2, somatostatin receptor 2; SubP, substance P, a
neuropeptide; SW620, colon adenocarcinoma cells exogenously
expressing PAR2; TF, tissue factor; TH, T helper; TLCS,
taurolithocholic acid 3-sulfate disodium salt, a bile acid; TM,
transmembrane; TMPRSS2, type II transmembrane-bound
serine protease; TNBS, 2,4,6-trinitrobenzenesulfonic acid;
TRAF1, TNF receptor-associated factor 1; TRPV1, transient
receptor potential cation channel subfamily V member 1
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Downsizing a human inﬂammatory protein
to a small molecule with equal potency
and functionality
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A signiﬁcant challenge in chemistry is to rationally reproduce the functional potency of a
protein in a small molecule, which is cheaper to manufacture, non-immunogenic, and also
both stable and bioavailable. Synthetic peptides corresponding to small bioactive protein
surfaces do not form stable structures in water and do not exhibit the functional potencies of
proteins. Here we describe a novel approach to growing small molecules with protein-like
potencies from a functionally important amino acid of a protein. A 77-residue human
inﬂammatory protein (complement C3a) important in innate immunity is rationally trans-
formed to equipotent small molecules, using peptide surrogates that incorporate a turn-
inducing heterocycle with correctly positioned hydrogen-bond-accepting atoms. Small
molecule agonists (molecular weight o500Da) examined for receptor afﬁnity and cellular
responses have the same high potencies, functional proﬁle and speciﬁcity of action as C3a
protein, but greater plasma stability and bioavailability.
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P
rotein–protein interactions underlie most biological
processes deﬁning life, aging, disease and death. However,
the use of proteins in science, industry and medicine is still
signiﬁcantly restricted by their high cost of manufacture, chemical
instability, immunogenicity and poor bioavailability. The need to
overcome these deﬁciencies has driven many chemical efforts, but it
has been extremely challenging to reproduce the exquisitely potent
and speciﬁc actions of proteins1–6. The biological functions of some
proteins are localized in very short polypeptide segments stabilized
in speciﬁc structures (two to four helical turns, isolated b-turns,
strands/sheets, and their combinations) by their protein
environments7,8. Yet, even in these simpler cases, short synthetic
peptides corresponding to bioactive protein components do not
display functional potencies comparable to proteins and are not
thermodynamically stable structures in water, where they instead
adopt random interconverting structures9.
An important example of a protein to functionally mimic is the
human complement protein C3a. This is a 9 kDa helix bundle that
plays key roles in innate immune responses to infection and tissue
injury by interacting with a 100kDa cell surface protein, a G protein-
coupled receptor (GPCR) called C3aR10–12. C3a is a powerful pro-
inﬂammatory agent that recruits immune cells to sites of infection
(chemotaxis) and induces immune cells to secrete bactericidal agents
(via degranulation) as well as inﬂammatory cytokines13,14.
Overexpression of C3a/C3aR or sustained activation of its receptor
can lead to inﬂammatory diseases, including allergies10, asthma15,
arthritis16, sepsis17, lupus18, diabetes19, psoriasis20, nephropathy21,
ischaemia-reperfusion injury22, obesity, and metabolic and
cardiovascular dysfunction23. C3a also reportedly has
antimicrobial24 and antifungal25 activities. Despite these potent
activities, C3a is rapidly degraded in vivo to C3a-desArg26, which
has a different pharmacology from C3a and does not bind to
C3aR27, nor do commercially available antibodies discriminate
between C3a and C3a-desArg22. Synthetic agonists that act through
C3aR, but do not degrade as C3a does, can be expected to have
immunostimulating and degranulating activities, whereas stable
antagonists may be valuable new anti-inﬂammatory therapeutics.
However, despite decades of effort by academia and the
pharmaceutical industry, no small organic molecules have yet been
reported as potent and selective C3aR agonists or antagonists28–32.
The crystal structure of C3a33–35 reveals that its 77 amino acids
adopt a well-deﬁned helix bundle (Fig. 1a), with less structure in
carboxy-terminal residues known to be critical for receptor
activation36. Mutagenesis of C3a and its receptor support a two-
site binding model37. The helical bundle residues 1–69 of C3a
have high afﬁnity for (but do not activate) the receptor, through
multiple positive-charged lysine and arginine residues of C3a
making complementary interactions with negative-charged Asp
residues in the unusually large extracellular loop 2 (ECL2) at one
site of the C3aR38,39. On the other hand, the C-terminal
pentapeptide segment LGLAR of C3a has very low afﬁnity for a
second site on C3aR, leading to activation. Arg77 at the C-
terminus of C3a is critical for agonist activity; on removal, the
resulting C3a-desArg does not bind to C3aR27. Moreover,
mutagenesis of Arg161, Arg340 and Asp417 in the receptor has
shown these residues to be crucial for C3a binding and
activation40. The essential Arg77 residue is the only charged
residue near the C terminus of C3a and is thought to interact with
the above three charged residues of C3aR.
Here we exemplify the approach of growing a functionally
important amino acid of a protein, namely the arginine from the
C-terminus of C3a, into small molecules that can execute
the potent functions of the C3a protein, but are only a fraction
of the size, cheaper to synthesize, and more chemically and
biologically stable. We describe small molecules built from an
amino acid template, incorporating a speciﬁc heterocycle to make
important hydrogen bonds (H-bonds) with the C3a receptor and
to control the shape of the molecule and orientation of its
hydrophobic substituents. The small molecules have similar
afﬁnity for C3aR on human macrophages and comparable agonist
potencies and functional proﬁles to C3a, as measured by
intracellular calcium release and inﬂammatory gene expression
in human macrophages and degranulation of human mast cells.
Importantly, the small molecule agonists are stable in serum,
unlike C3a that rapidly degrades with loss of the C-terminal
arginine that is critical for binding of C3a to its receptor C3aR. If
generally applicable, this template approach could potentially be
useful in creating small molecule surrogates of other proteins for
applications in biology and medicine.
Results
C3aR homology model and ligand evolution. We therefore
created a three-dimensional homology structural model for C3aR
C terminus
TM1 TM7
TM3
TM6
TM5
TM2
TM4
D417
Leu
Ala
ArgR340
R161
Figure 1 | Modelling C3aR interactions with Leu–Ala–Arg. (a) Structure of
human C3a (pdb 4I6O). (b) Side view of seven transmembrane (7TM)
region of C3aR homology model derived from the crystal structure of
human CXCR4 (bound to a cyclic peptide antagonist)41. Ca of D417, R161,
R340, H418 and Y393 rendered as solid spheres. (c) Ac–Leu–Ala–Arg
(3, yellow) placed in the 7TM region of human C3aR, showing putative
interactions with receptor residues D417 (TM7), R161 (TM4) and R340
(TM5) identiﬁed from mutagenesis38–40 to be important for binding to
Arg77 of C3a. (d) A low-energy conformation of Ac–(Leu–Ox)–Arg (6, cyan
carbons; Ox, oxazole) aligned well with Ac–Leu–Ala–Arg (3, green carbons)
modelled in a type IIb turn conformation (fiþ 1  60, ciþ 1 120, fiþ 2 80,
ciþ 2 0), showing the typical (i,iþ 3) H-bond Ac–COyHN–Arg
(Arg side chains omitted for clarity).
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(Fig. 1b) and positioned only an arginine amino acid into C3aR in
the vicinity of those three receptor residues (Fig. 1c). A homology
model of the human C3a receptor was generated, using the Prime
module in the Schro¨dinger molecular modelling suite, based
on aligning its sequence with that of the crystal structure of
human chemokine receptor CXCR4 (bound to a cyclic peptide
antagonist)41 (pdb code 3OE0). Models were created to focus
on the seven transmembrane (7TM) helix domain, without the
ECL2, which in C3aR consists of 170 amino acids and is
inherently ﬂexible and difﬁcult to model (Fig. 1b). An arginine
molecule was speciﬁcally placed in this model, near receptor
residues Arg161, Arg340 and Asp417, to simulate Arg77 of the
C3a ligand. The negatively charged carboxylate terminus of
Arg77 in C3a interacts with cationic side chains of both Arg161
and Arg340, whereas the protonated guanidinium side chain of
Arg77 interacts with the carboxylate side chain of Asp417
(Fig. 1c). These three contact points are consistent with C3aR/
C3a mutagenesis data, indicating complementarity between
Arg77 in C3a and the above three residues of C3aR38–40. On
the basis of this location for Arg77, we identiﬁed space that could
be occupied by attached amino acids Ala76 and Leu75 of C3a,
thereby indicating where a small tripeptide ligand LAR might
bind in C3aR. This was the basis for our strategy to rationally
design and grow novel small molecule ligands from an arginine
point template corresponding to Arg77 of C3a, notwithstanding
the large uncertainties of ligand docking in a three-dimensional
model of a GPCR.
Structure–activity relationships. Tripeptides Leu–Ala–Arg (2),
Ac–Leu–Ala–Arg (3) and Boc–Leu–Ala–Arg (4) did not show
any detectable binding to C3aR or agonist activity at or below
1mM, the highest concentration tested, on human monocyte-
derived macrophages (HMDMs) (Table 1). Next, we sought to
establish whether there were residues present in the 7TM-binding
cavity and/or the ECLs that could potentially form additional
H-bonding interactions with the backbone of Leu or Ala from the
tripeptide Leu–Ala–Arg. Three receptor residues were con-
spicuous as prospective H-bond donors in the proximity of the
Ala attached to Arg, namely Tyr393 from TM6 and His418 from
TM7 (Fig. 1c), and possibly Tyr174 from ECL2, although the
latter position is very uncertain owing to ECL2 ﬂexibility.
Table 1 | Binding afﬁnity and agonist potency of ligands for C3aR on human macrophages.
Compound Binding IC50 (nM)* Binding pIC50±s.e.m. n Agonist EC50 (lM)w Agonist pEC50±s.e.m. n
1 C3a 0.07 10.1±0.2 43 0.04 7.4±0.07 3
2 Leu–Ala–Arg 41,000,000 o4.0 3 41,000 o4.0 3
3 Ac–Leu–Ala–Arg 41,000,000 o4.0 3 41,000 o4.0 3
4 Boc–Leu–Ala–Arg 41,000,000 o4.0 3 41,000 o4.0 3
5 H–(Leu–Oxazole)–Arg 560 6.2±0.4 3 4100 o4.0 3
6 Ac–(Leu–Oxazole)–Arg 30 7.5±0.2 3 0.17 6.8±0.1 3
7 Boc–(Leu–Oxazole)–Arg 12 7.9±0.2 8 0.06 7.2±0.1 3
8 Boc–(Ile–Oxazole)–Arg 34 7.5±0.2 3 0.02 7.7±0.2 3
9 Boc–(Cha–Oxazole)–Arg 99 7.0±0.2 3 0.21 6.7±0.3 3
10 Boc–(Ala–Oxazole)–Arg 4100,000 o4.0 3 4100 o4.0 3
11 Boc–(Leu–Thiazole)–Arg 375 6.4±0.3 3 z z 3
12 Boc–(Leu–Imidazole)–Arg 51 7.3±0.3 3 0.12 6.9±0.1 3
13 Boc–(Leu–N–Me(Y)–Imidazole)–Arg 47 7.3±0.3 3 0.06 7.2±0.1 3
14 Boc–(Leu–N–Me(X)–Imidazole)–Arg 410,000 o5.0 3 9.4 5.0±0.1 3
15 Boc–(Leu–1,3,4-Oxadiazole)–Arg 997 6.0±0.5 3 4100 o4.0 3
16 3-Indole–(Leu–Imidazole)–Arg 12 7.9±0.3 3 0.015 7.8±0.3 4
17 3-Indole–(Leu–Oxazole)–Arg 4 8.4±0.3 5 0.007 8.1±0.2 4
EC50, half maximal effective concentration; HMDM, human monocyte-derived macrophage; IC50, half maximal inhibitory concentration.
*Concentration of ligand required to inhibit 50% of [125I]-C3a (80 pM) binding to HMDMs.
wConcentration of ligand causing 50% of Ca2þ release in HMDMs relative to 100% induced by C3a at 1 mM.
zThis compound showed partial agonist activity at concentrations Z1 mM.
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Figure 2 | Synthesised C3aR ligands. Chemical structures of compounds 5–17, synthesized as detailed in the Methods (16,17) and Supplementary
Methods (5–15).
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Although GPCR models are notoriously ﬂexible and thus of
uncertain accuracy, we decided to test whether H-bond acceptors
strategically placed at the Ala position might increase afﬁnity for
C3aR, thereby conﬁrming the idea that an H-bond donor might
be nearby its binding site in C3aR. Ala in Leu–Ala–Arg was
therefore replaced with oxazole (Ox), which positions a known
H-bond-accepting nitrogen atom of Ox within (Leu–Ox)–Arg for
potential interaction with a putative H-bond donor Tyr393,
His418 or Tyr174. This ligand change from Leu–Ala–Arg (2) to
(Leu–Ox)–Arg (5) resulted in a 41,000-fold increase in afﬁnity
for C3aR and some measurable, albeit weak, agonist activity
(Table 1). Importantly, structure–activity optimization does not
rely on knowing the identity of the interacting H-bond donor in
C3aR. Figure 2 details the chemical structure of ligand 5 and
further modiﬁed ligands 6–17 to be discussed below.
The magnitude of the increase in afﬁnity cannot be accounted
for solely by one H-bond to the Ox, and is in part also attributed
to the known turn-inducing constraint imposed by this hetero-
cycle, conferring some structure in water to an otherwise
unstructured tripeptide unit. Most peptide-activated GPCRs bind
to a b/g-turn conformation of endogenous agonists42, and
incorporation of a turn mimetic often pre-organizes agonists in
a receptor-bound turn conformation. An alignment using ROCS
(rapid overlay of chemical structures, version 3.1.2, OpenEye
Scientiﬁc Software) of low-energy conformers generated with
Omega (version 2.4.3, OpenEye Scientiﬁc Software) of Ac–Leu–
Ala–Arg (3) with Ac–(Leu–Ox)–Arg (6) indicated that a b-turn
conformation of the former was mimicked by the latter (Fig. 1d).
The plane of the Ox ring is perpendicular to the plane of the Leu
amide carbonyl, favourably aligning for making a H-bond
interaction (Fig. 1d). In support of formation of this additional
H-bond, attaching a carbonyl group to the amino terminus of 5
(for example, Ac in Ac–(Leu–Ox)–Arg, 6; Boc in Boc–(Leu–Ox)–
Arg, 7) causedB20- andB50-fold increases in ligand afﬁnity for
C3aR andB103-fold greater agonist activity than for 5 (Table 1).
In combination, these data support both the heterocycle nitrogen
and the N-terminal carbonyl oxygen being important H-bond
acceptors that contribute to the spectacular increase in receptor
binding and agonist function.
Modifying side chains and heterocycles. Further modiﬁcations
of the leucine side chain to isoleucine (8) caused a 3-fold loss of
afﬁnity, to the larger side chain of cyclohexylalanine (9) reduced
binding afﬁnity 8-fold and agonist potency 3-fold, whereas
reducing the size of the side chain to alanine (10) reduced afﬁnity
and agonist activity by over 1,000-fold. Thus, the leucine side
chain is important and essential for binding to C3aR and con-
tributes a factor of at least 103 to agonist binding and function.
On the basis of the promising results for Ox in compound 7,
other ﬁve-membered aromatic heterocycles were incorporated to
identify the contribution of the heterocycle H-bond acceptor to
agonist potency. The theoretical H-bond interaction energy
between a water molecule and each heterocycle was determined
using models minimized by ab initio methods at the MP2/6
311þþ g(3d,3p) level of theory using Gaussian 09 (ref. 43).
Strong interactions were predicted for the trigonal nitrogen atoms
of imidazole and Ox rings, whereas much weaker H-bonds are
likely for the oxygen of oxadiazole and sulphur or p system of
thiazole. N-methylation in the inactive compound 14 precluded
H-bond formation, so the H-bond interaction energy was set at
zero (Fig. 3a). For this small series of heterocycles incorporated
into Boc–Leu–Ala–Arg to produce compounds 7 and 11–15,
there was a linear correlation between H-bond interaction energy
(over a 35 kJmol 1 range), calculated for the respective H-bond
acceptor interacting with water, and the binding afﬁnity (over 4
log units) of the ligand for C3aR (Fig. 3b,c). Positioning of the
H-bond-accepting atom was an important determinant of agonist
potency, the X position being more important than Y or Z
positions (Table 1), highlighted by the N-methyl imidazole
substituents in 13 versus 14.
Having identiﬁed imidazole and Ox as optimal heterocycle
modiﬁcations, the N-terminal Boc group was next replaced to
seek greater agonist potency. The indole-3-carboxamide deriva-
tives 16 and 17 showed approximately threefold greater binding
afﬁnity and almost tenfold greater agonist activity than 12 and 7,
respectively. These observed enhancements may be due to the
indole ring making an additional p-stacking interaction with
His418 and occupying a larger region of hydrophobic space in the
C3a receptor. Concentration–response curves are compared
(Fig. 4a) for C3a versus the most potent small molecule agonist
above, compound 17 (also named TR16), in the intracellular
Ca2þ release assay using HMDMs. It is apparent that 17 shows a
full agonist response comparable to C3a, but that 17 is almost an
order of magnitude more active (EC50 (half maximal effective
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concentration) 7 nM versus 40 nM). Moreover, this agonist
activity for both C3a and 17 was dose-dependently inhibited to
the same degree by a known, albeit weakly potent antagonist of
C3aR (SB290157, IC50 (half maximal inhibitory concentration)
1 mM versus C3a at 1 mM)28,29, consistent with the effect being
mediated in both cases by C3aR (Fig. 4b). The high agonist
potencies of 17 and C3a are, in spite of their quite different
afﬁnities for C3aR (Fig. 4c), the much greater afﬁnity of C3a
being due to its additional large helical domain that binds to an
extracellular region of the receptor. The presence of this high-
afﬁnity receptor-anchoring domain in C3a provides a high
effective molarity for the receptor-activating C-terminus of C3a,
which is otherwise a weakly binding and very feeble agonist
(compound 1, Table 1). Altering concentrations of both 17 and
SB290157 (ref. 29) revealed competition between the compounds,
evidenced by a horizontal shift to the right in agonist plots
(Fig. 4d), with a Schild plot slope B1 (Fig. 4e) consistent with
both compounds binding to the same or overlapping site on
C3aR. An important advantage of compound 17 over C3a is that
17 remains intact after exposure to plasma, whereas the arginine
is cleaved from C3a within minutes in plasma (Fig. 4f) by
carboxypeptidases26. The product of this cleavage is C3a-desArg,
which has quite a different pharmacology and a different
receptor44; thus, C3a is actually of little value as a tool to probe
C3aR-mediated functions induced in vivo by constitutive C3a.
The plasma stability of small molecule agonists such as 17 is likely
to be of enormous beneﬁt for in vivo studies, provided that they
display other comparable functional responses to C3a, and can
therefore be used as small molecule surrogates for C3a (see
ahead).
Proﬁling additional agonist functions. Compound 17 was thus
also compared with recombinant human C3a for other functional
agonist responses using different assays and different cells.
Figure 5a–c shows that C3a and 17 induce comparable proﬁles of
expression of the inﬂammatory genes IL8, CCL3, FOSB, IL6 and
EGR1 in HMDMs. Moreover, IL1b and TNF gene expression
induced by either C3a or 17 was blocked by the known29, but
very weakly potent C3aR antagonist SB290157, by pertussis toxin
that decouples C3aR from Gi, and by the PLCb inhibitor U73122
that blocks C3aR-mediated Ca2þ release (Fig. 5b,c). These effects
are consistent with the actions of 17 being mediated through
C3aR and point to comparable potencies with C3a in the
responses being measured. Finally, in different human immune
cells, both C3a and 17 at nM to mM concentrations induced
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degranulation of human mast cells to the same extent, as
measured by comparable release of hexosaminidase (Fig. 5d).
Further, this agonist response was inhibited to the same extent for
C3a and 17 by SB290157 (Fig. 5e). These data give very strong
support for compound 17 being a viable, equipotent, functional
surrogate for the human C3a protein. We expect
that this compound class can be further developed into valuable
drug-like agonists and antagonists for treating C3aR-mediated
diseases.
Discussion
A method has been described for downsizing a protein to an
equipotent functional small molecule, a method that does not
require a crystal structure for the protein but does rely on some
knowledge of the activating region of the protein. The C3a
protein chosen here for mimicry has its functional activity
localized at its C-terminus, but requires the remainder of the
protein for high afﬁnity binding to the receptor to elicit agonist
activity and high potency. In this study, the high afﬁnity binding
domain of C3a has been removed, but compensated for by
making rational changes to small molecule mimics of the
C-terminal tripeptide segment of C3a, namely Leu–Ala–Arg.
These changes impart H-bond-accepting properties, introduce a
turn-inducing heterocycle and enhance space-ﬁlling properties of
the small molecule analogues. The results convincingly demon-
strate that a number of compounds (7, 8, 13, 16 and 17) have
equipotent agonist activity to the protein C3a, as measured by
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Figure 5 | Inﬂammatory gene expression and degranulation induced by C3a versus 17. (a) C3a or 17 (0.3 mM, 30min) induce expression of
inﬂammatory genes in HMDMs, monitored by quantitative reverse-transcriptase PCR. Relative gene expression data are duplicates normalized to house-
keeping gene 18S. Fold changes were calculated against untreated control. Error bars represent mean±s.e.m. of at least three independent experiments.
*Po0.05; **Po0.01; ***Po0.005. (b,c) Expression in HMDMs of inﬂammatory genes IL1b and TNF induced by C3a or 17 (0.3mM, 30min) alone
or after preincubating cells with C3aR antagonist (10 mM SB290157, 30min), Gai inhibitor (200ngml 1 pertussis toxin (PTX), overnight) or PLCb inhibitor
(10mM U73122, 30min). (d,e) b-Hexosaminidase release mediated by C3a (pEC50 8.0±0.3) and 17 (pEC50 7.8±0.6) in the absence or presence of
SB290157 in LAD2 human mast cells. Cells were pre-sensitized with IgE (100 ngml 1, overnight) before adding C3a (1mM at 1.5 log dilutions) or 17 (10 mM
at 1.5 dilutions) for 30min. In the antagonist assay, cells sensitized overnight with IgE were incubated with SB290157 (100 mM at 1.5 log dilutions,
30min) before adding C3a or 17 (1mM) for 30min. Release of b-hexosaminidase in cell supernatant and lysate was detected by adding p-nitrophenyl
N-acetyl-b-D-glucosamide (PNAG) and reading absorbance at 405 nm. % b-Hexosaminidase release was calculated against response for 1 mM
agonist. Error bars represent mean±s.e.m. of (n¼4) independent experiments.
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induction of intracellular Ca2þ release in human macrophages
(Table 1). The most potent compound (17) was examined in
more detail in other cellular assays, with mimicry of potent C3a
function also extending to C3aR-mediated expression of all seven
selected inﬂammatory genes in human macrophages and to
C3aR-mediated degranulation of human mast cells. These
immunostimulating properties for 17 are the same as for human
C3a, validating successful functional mimicry of a protein by a
small molecule across a range of inﬂammatory and cellular
readouts.
Through structure–activity relationships, it has been shown
that six factors contribute to the spectacular agonist potencies of
these compounds, which are approximately six orders of
magnitude more potent than the Leu–Ala–Arg tripeptide
component of C3a but are not much different in size. (1) These
compounds possess an important arginine, just like the critical
C-terminal arginine of human C3a, which imparts some binding
afﬁnity for C3aR. (2) All compounds possess an Ox or imidazole
heterocycle, which also provides (3) a strong H-bond-accepting
nitrogen atom, as well as (4) subtly altering the position of the
Leu/Ile side chain in the dipeptide surrogate (Leu/Ile–heterocycle)
versus Leu/Ile–Ala. These compounds further share (5) the
presence of an N-terminal carbonyl group that can make an
additional H-bond interaction with C3aR and (6) a Boc/Indole
capping group that can ﬁll additional space in the receptor. The
relative contributions made by each of these components to
ligand afﬁnity and agonist potency were ascertained via
structure–activity relationship studies (Table 1).
Collectively, these features have led to the rational develop-
ment of small molecules (molecular weighto500 Da) with high
afﬁnity and speciﬁcity for the human C3a receptor and
comparable agonist potencies to C3a. The most potent
compound was proﬁled more extensively in multiple additional
assays where it was found to have the same C3aR-mediated
functional proﬁle, selectivity, activities and potencies as human
C3a protein. Compound 17 was shown to be a potent and C3aR-
selective agonist surrogate for C3a (Supplementary Fig. S5), with
the advantage of being plasma stable unlike C3a, which rapidly
loses its C-terminal arginine along with its afﬁnity for and
function through the receptor for C3a. Moreover, all the small
molecules described herein can be made at a fraction of the
thousands of dollars per milligram cost commercially charged
for human C3a.
This approach to potent small molecule protein mimics may
be transferable to the development of highly potent small
molecule mimics of other proteins, including other GPCR-
activating proteins. It is based on a very general premise, that
one may only need to know that an amino acid of a protein
(arginine here) is important for binding at a particular site on a
receptor protein, in this case through known effects on the
donor protein of site-directed mutagenesis of the receptor
protein. This single amino acid can then be grown through a
novel method of appending a H-bond-making entity, hetero-
cycles with graded H-bond acceptor versus H-bond donor
properties being chosen here to illustrate the idea. In principle,
this H-bond making appendage could be placed anywhere, on
one side or the other side, or both sides of the arginine (or other
point template) or further away. On ﬁnding measurable afﬁnity,
the putative H-bond interaction can be rationally optimized by
increasing the H-bonding power, then by modifying the next
position adjacent to the heterocycle–arginine motif to rationally
improve binding and optimize function. Although only
exempliﬁed here for one protein, this is a potentially general
approach. It remains to be determined whether its utility is also
general for developing small molecules with the functional
potencies of other proteins.
Methods
General methods. All reagents were purchased from Sigma-Aldrich or Chem-
Impex International Inc. Solid- and solution-phase chemistry approaches were
used to synthesize all ﬁnal compounds. The purity of each compound investigated
was conﬁrmed by 1H NMR spectroscopy, HPLC and high-resolution mass spectra
(HRMS). All compounds assayed were Z95% pure. The syntheses and char-
acterization of compounds 2–15 are reported in Supplementary Methods and
reaction schemes and spectroscopic data are provided in Supplementary Figs
S2–S20. The production and characterization of the two most potent compounds,
16 and 17, are described below. All ﬁnal compounds were puriﬁed by reversed-
phase HPLC. Preparative-scale reversed-phase HPLC (rpHPLC) separations were
performed on a Phenomenex Luna C18 10 mm, 250 30.0mm column. Standard
conditions were used for elution of all compounds, unless otherwise indicated, at a
ﬂow rate of 40mlmin 1: 100% A to 100% B linear gradient over 15min, followed
by a further 10min at 100% B where solvent B was 90% MeCN, 10% H2O±0.1%
TFA and solvent A was H2O±0.1% TFA. Compounds were detected by ultraviolet
absorption and pure fractions were lyophilized. Analytical rpHPLC was used to
assess compound purity (Phenomenex Luna C18 column, 5 mm, 90Å,
4.6 250mm, at three different wavelengths l¼ 214, 230 and 254 nm). Standard
conditions (same as preparative-scale rpHPLC) were used for all compounds,
unless otherwise indicated, at a ﬂow rate of 1mlmin 1. Solvents were the same as
for preparative-scale rpHPLC. All ﬁnal compounds were Z95% pure by analytical
HPLC. Electrospray ionization mass spectra measurements were obtained on
Micromass LCT. HRMS measurements were obtained on a Bruker microTOF mass
spectrometer equipped with a Dionex LC system (Chromeleon) in positive ion
mode by direct infusion in MeCN at 100 ml h 1 using sodium formate clusters as
an internal calibrant. Data were processed using Bruker Daltonics DataAnalysis 3.4
software. Mass accuracy was consistently better than 1 p.p.m. error. 1H and 13C
NMR spectra were recorded on Bruker Avance 600 or Varian 400 spectrometers at
298 K in the deuterated solvents indicated and were referenced to the residual 1H
signals; DMSO-d6 2.50 p.p.m. and CD3OD 3.31 p.p.m., except CDCl3 solutions
were referenced to internal tetramethylsilane (TMS). The exact concentration of
the compounds was determined by the quantitative NMR integration ‘PULCON’
experiment45. These settings were used for all PULCON experiments: relaxation
delay of 30 s, 64 scans, 2 dummy scans, 90 pulse and temperature at 298 K.
Synthesis of 3-indole-(Leu–Imidazole)–arg (16). Cbz–Leu–5-methylimidazole
ethyl ester (0.24 g, 0.6mmol) in MeOH (20ml) was treated with 10% Pd/C (20mg)
and hydrogenated at 40 psi on a Parr hydrogenator for 5 h. The mixture was ﬁltered
through celite and the ﬁltrate was concentrated in vacuo. The crude product was
added to N-Boc-indole-3-carboxylic acid (0.20 g, 0.70mmol), pre-activated (with
O-(Benzotriazol-1-yl)-N,N,N0 ,N0-tetramethyluronium hexaﬂuorophosphate, diiso-
propylethylamine in dimethylformamide 2ml) and stirred overnight at room
temperature. The reaction mixture was diluted with ethyl acetate and washed with
saturated NaHCO3. The organic extracts were dried over MgSO4, ﬁltered and
concentrated in vacuo. The crude product was dissolved in ethyl alcohol/H2O/2M
NaOH (4:1:1, 3ml) and heated in a microwave at 120 C for 10min. The ethyl
alcohol in the reaction was removed in vacuo and the aqueous solution was
acidiﬁed with 2M HCl and extracted with ethyl acetate. The combined organic
extracts were dried over MgSO4, ﬁltered and concentrated in vacuo. The crude
product was coupled to H–Arg–OEt and then the ester was hydrolysed with
NaOH. The product was puriﬁed by rpHPLC and lyophilized to afford a white
powder (20mg, 7%). 1H NMR (600MHz, DMSO-d6), d 8.25 (br s, 1H), 8.17 (t,
J¼ 3.0Hz, 1H), 8.12 (d, J¼ 7.7Hz, 1H), 8.02 (br s, 1H), 7.59 (br s, 1H), 7.44 (d,
J¼ 7.7Hz, 1H), 7.15 (t, J¼ 7.8Hz, 1H), 7.10 (t, J¼ 7.6Hz, 1H), 5.36 (m, 1H), 4.41
(m, 1H), 3.17–3.08 (m, 2H), 2.43 (s, 3H), 1.96–1.82 (m, 2H), 1.80–1.63 (m, 3H),
1.56–1.49 (m, 2H), 0.96–0.92 (two sets of d, J¼ 6.6Hz, 6H). 13C NMR (150MHz,
DMSO-d6): d 173.3, 164.5, 158.7, 158.5, 158.3, 156.6, 136.3, 128.7, 126.3, 122.0,
120.9, 120.5, 111.9, 51.2, 44.5, 42.0, 40.3, 28.5, 25.3, 24.4, 22.8, 21.6, 10.5. HRMS
(m/z): [MH]þ calcd for C25H35N8O4þ , 511.2776; found, 511.2774; tR¼ 7.9min
(0–100% B in 10min gradient).
Synthesis of 3-indole–(Leu–Ox)–arg (17). This compound was synthesized fol-
lowing the same procedure for compound 16, except that H–Leu–Ox–OMe (0.11 g,
0.46mmol) was used for coupling to N-Boc-indole-3-carboxylic acid and gave 17
(27mg, 12%). 1H NMR (600MHz, DMSO-d6): d 8.59 (s, 1H), 8.39 (d, J¼ 8.6Hz,
1H), 8.22 (d, J¼ 8.6Hz, 1H), 8.16 (d, J¼ 3.0Hz, 1H), 8.11 (d, J¼ 7.9Hz, 1H),
7.55 (t, J¼ 5.8Hz, 1H), 7.43 (d, J¼ 8.2Hz, 1H), 7.15 (t, J¼ 7.4Hz, 1H), 7.09
(t, J¼ 7.6Hz, 1H), 5.36 (m, 1H), 4.40 (m, 1H), 3.14–3.06 (m, 2H), 1.96 (m, 1H),
1.87 (m, 1H), 1.83–1.75 (m, 2H), 1.69 (m, 1H), 1.56–1.45 (m, 2H), 1.00–0.91 (two
sets of d, J¼ 6.6Hz, 6H); 13C NMR (150MHz, DMSO-d6): d 173.5, 165.5, 164.8,
160.5, 157.1, 142.5, 136.5, 135.8, 128.8, 126.7, 122.4, 121.4, 120.9, 112.3, 110.0, 51.6,
45.2, 41.7, 40.8, 28.3, 25.8, 24.7, 23.3, 21.9. HRMS (m/z): [MH]þ calcd for
C24H32N7O5þ , 498.2459; found, 498.2461.; tR¼ 7.3min (20–100% B in 10min
gradient).
Calculations of H-bond interaction energy. The geometry of the water–
heterocycle H-bonded complex was optimized at the MP2/6-311þ þG(3d,3p)
level using Gaussian 09. The H-bond interaction energy was the difference
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in energy of the complex from the sum of energies of water and heterocycle,
calculated in isolation by the same method43.
Intracellular calcium release assay. HMDMs (5 104 cells per well) were added
to a 96-well cleared-bottom black-wall assay plate (Corning) and incubated over-
night at 37 C. Before assay, the medium was removed and cells were incubated
with dye-loading buffer (12ml Hank’s balance salt solution (HBSS) buffer, 4 mM
Fluo-3 AM, 25 ml Pluronic acid F-127 and 1% fetal bovine serum) for 1 h at 37 C.
Cells were then washed once with assay buffer (HBSS supplemented with 2.5mM
probenecid and 20mM HEPES, pH 7.4). Compounds were dissolved in dimethyl
sulphoxide (DMSO) to make a 10-mM stock solution, then further diluted with
HBSS buffer to the desired concentrations for intracellular calcium release assay.
Fluorescence imaging plate reader was used to monitor intracellular release of
Ca2þ via ﬂuorescence measurement (excitation 495 nm, emission 520 nm) for
5min after injection of agonists. Changes in ﬂuorescence (% response) were plotted
against logarithmic concentrations of test compound. The EC50 values were
derived from concentration response curves using nonlinear regression in
Graphpad Prism v5.
125I-C3a radioligand binding assay. Receptor binding was performed by ligand
competition with 80 pM [125I]-C3a (2,200 Cimmol 1; Perkin Elmer, Torrance,
CA, USA), HMDMs (1.2 106 cellsml 1), 80 pM [125I]-C3a±various con-
centrations of unlabelled C3a or test agonist mixed with solvent (50mM Tris,
3mMMgCl2, 0.1mM CaCl2, 0.5% (w/v) BSA, pH 7.4) for 60min in a 96-well Nunc
round-bottom plate at room temperature. Unbound [125I]-C3a was removed by
ﬁltration through glass microﬁbre ﬁlter GF/B (Whatman Iner. Ltd, England),
which had been soaked in 0.6% polyethyleneimine to reduce nonspeciﬁc binding.
The ﬁlter was washed three times with cold buffer (50mM Tris-HCl), pH 7.4, and
bound [125I]-C3a was assessed by scintillation counting on Microbeta counter.
Speciﬁc [125I]-C3a binding was deﬁned as the difference between total binding and
nonspeciﬁc binding as determined in the presence of 1 mM unlabelled C3a. The
IC50 value was derived from the concentration of agonist/antagonist required to
inhibit 50% of [125I]-C3a binding.
Gene analysis. HMDMs were seeded at 1 106 per ml and allowed to adhere
overnight. For inhibition experiments, HMDMs were pretreated with Gai inhibitor
(200 ngml 1 pertussis toxin, overnight) or PLCb inhibitor (10 mM U73122,
30min), or C3aR antagonist (10 mM SB290157, 30min), before adding C3a or 17
(0.3mM, 30min). RNA was extracted from HMDMs according to ISOLATE II
RNA Mini Kit (Bioline). Real-time PCR was measured on a ABI PRISM 7900HT
instrument (Applied Biosystems), each target gene was normalized to house-
keeping 18S rRNA and fold change was calculated relative to untreated control.
Primer sequence is shown in Supplementary Table S1.
Isolation of HMDMs. HMDMs were isolated using Ficoll-paque density centri-
fugation (GE Healthcare Bio-Science, Uppsala, Sweden) from buffy coat of
anonymous human donors provided by the Australian Red Cross Blood Service,
Brisbane. CD14þ monocytes were positively selected using CD14þ MACS
magnetic beads (Miltenyi Biotech, Auburn, CA, USA) after successive magnetic
sorting and washings. The CD14þ monocytes were then cultured at 37 C with 5%
CO2 and differentiated to HMDMs using 100 ngml 1 of recombinant human
macrophage colony-stimulating factor (PeptroTech Inc., Rocky Hill, NJ, USA)
at 1.5 106 cells per ml. HMDMs were kept in Iscove’s modiﬁed Dulbecco’s
media supplemented with 10% fetal bovine serum, penicillin (10Uml 1),
streptomycin (10Uml 1) and L-glutamine (2mM; Invitrogen). HMDMs were
supplemented after 5 days with fresh medium containing 100 ngml 1 macrophage
colony-stimulating factor. HMDMs were collected by gentle scraping in saline
solution on day 7.
b-Hexosaminidase release assay. LAD2 human mast cells (kindly provided by
Dr Dean Metcalfe, National Institute of Allergy and Infectious Diseases, National
Institute of Health) were cultured as previously described46 and b-hexosaminidase
release assay was performed as reported47. Brieﬂy, LAD2 cells were presensitized
with IgE (100 ngml 1) overnight before experiment. In the antagonist assay,
SB290157 was pre-incubated for 30min before the addition of C3a or 17, and
release of b-hexosaminidase was measured at 405 nm using FLUOstar Optima
(BMG LabTechnologies).
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